


No	R ¹	R ²	R ^{3a}	R ^{3b}	R ⁴	R ⁵	R ⁶	X	Y
XXIV-49-6	p-Br-Ph	H	H	CH ₂ -indol-3-yl	Bz	H	H	F	OH
XXIV-49-7	p-Br-Ph	H	H	CH ₂ CH ₂ SCH ₃	Bz	H	H	F	OH
XXIV-49-8	p-Br-Ph	*	H	*	Bz	H	H	F	OH

*R² and R^{3b} joined together by (CH₂)₃ to form five-membered ring.

Table XXIV-50.

No	R ¹	R ²	R ^{3a}	R ^{3b}	R ⁴	R ⁵	R ⁶	X	Y
XXIV-50-1	p-I-Ph	H	H	H	Bz	H	H	F	OH
XXIV-50-2	p-I-Ph	H	H	CH ₃	Bz	H	H	F	OH
XXIV-50-3	p-I-Ph	H	H	CH(CH ₃) ₂	Bz	H	H	F	OH
XXIV-50-4	p-I-Ph	H	H	CH ₂ CH(CH ₃) ₂	Bz	H	H	F	OH
XXIV-50-5	p-I-Ph	H	H	CH ₂ Ph	Bz	H	H	F	OH
XXIV-50-6	p-I-Ph	H	H	CH ₂ -indol-3-yl	Bz	H	H	F	OH
XXIV-50-7	p-I-Ph	H	H	CH ₂ CH ₂ SCH ₃	Bz	H	H	F	OH
XXIV-50-8	p-I-Ph	*	H	*	Bz	H	H	F	OH

*R² and R^{3b} joined together by (CH₂)₃ to form five-membered ring.



XXV

Table XXV-1.

No	R ¹	R ²	R ^{3a}	R ^{3b}	R ⁴	R ⁵	R ⁶	X	Y
XXV-1-1	CH ₃	H	H	H	CH ₃	H	CH ₃	F	OH
XXV-1-2	CH ₃	H	H	CH ₃	CH ₃	H	CH ₃	F	OH
XXV-1-3	CH ₃	H	H	CH(CH ₃) ₂	CH ₃	H	CH ₃	F	OH

N ₂	R ¹	R ²	R ^{3a}	R ^{3b}	R ⁴	R ⁵	R ⁶	X	Y
XXV-1-4	CH ₃	H	H	CH ₂ CH(CH ₃) ₂	CH ₃	H	CH ₃	F	OH
XXV-1-5	CH ₃	H	H	CH ₂ Ph	CH ₃	H	CH ₃	F	OH
XXV-1-6	CH ₃	H	H	CH ₂ -indol-3-yl	CH ₃	H	CH ₃	F	OH
XXV-1-7	CH ₃	H	H	CH ₂ CH ₂ SCH ₃	CH ₃	H	CH ₃	F	OH
XXV-1-8	CH ₃	*	H	*	CH ₃	H	CH ₃	F	OH

*R² and R^{3b} joined together by (CH₂)₃ to form five-membered ring.

Table XXV-2.

N ₂	R ¹	R ²	R ^{3a}	R ^{3b}	R ⁴	R ⁵	R ⁶	X	Y
XXV-2-1	Et	H	H	H	CH ₃	H	CH ₃	F	OH
XXV-2-2	Et	H	H	CH ₃	CH ₃	H	CH ₃	F	OH
XXV-2-3	Et	H	H	CH(CH ₃) ₂	CH ₃	H	CH ₃	F	OH
XXV-2-4	Et	H	H	CH ₂ CH(CH ₃) ₂	CH ₃	H	CH ₃	F	OH
XXV-2-5	Et	H	H	CH ₂ Ph	CH ₃	H	CH ₃	F	OH
XXV-2-6	Et	H	H	CH ₂ -indol-3-yl	CH ₃	H	CH ₃	F	OH
XXV-2-7	Et	H	H	CH ₂ CH ₂ SCH ₃	CH ₃	H	CH ₃	F	OH
XXV-2-8	Et	*	H	*	CH ₃	H	CH ₃	F	OH

*R² and R^{3b} joined together by (CH₂)₃ to form five-membered ring.

Table XXV-3.

N ₂	R ¹	R ²	R ^{3a}	R ^{3b}	R ⁴	R ⁵	R ⁶	X	Y
XXV-3-1	ⁱ Pr	H	H	H	CH ₃	H	CH ₃	F	OH
XXV-3-2	ⁱ Pr	H	H	CH ₃	CH ₃	H	CH ₃	F	OH
XXV-3-3	ⁱ Pr	H	H	CH(CH ₃) ₂	CH ₃	H	CH ₃	F	OH
XXV-3-4	ⁱ Pr	H	H	CH ₂ CH(CH ₃) ₂	CH ₃	H	CH ₃	F	OH
XXV-3-5	ⁱ Pr	H	H	CH ₂ Ph	CH ₃	H	CH ₃	F	OH
XXV-3-6	ⁱ Pr	H	H	CH ₂ -indol-3-yl	CH ₃	H	CH ₃	F	OH
XXV-3-7	ⁱ Pr	H	H	CH ₂ CH ₂ SCH ₃	CH ₃	H	CH ₃	F	OH
XXV-3-8	ⁱ Pr	*	H	*	CH ₃	H	CH ₃	F	OH

*R² and R^{3b} joined together by (CH₂)₃ to form five-membered ring.

Table XXV-4.

N ₂	R ¹	R ²	R ^{3a}	R ^{3b}	R ⁴	R ⁵	R ⁶	X	Y
XXV-4-1	^t Bu	H	H	H	CH ₃	H	CH ₃	F	OH

N ₂	R ¹	R ²	R ^{3a}	R ^{3b}	R ⁴	R ⁵	R ⁶	X	Y
XXV-4-2	^t Bu	H	H	CH ₃	CH ₃	H	CH ₃	F	OH
XXV-4-3	^t Bu	H	H	CH(CH ₃) ₂	CH ₃	H	CH ₃	F	OH
XXV-4-4	^t Bu	H	H	CH ₂ CH(CH ₃) ₂	CH ₃	H	CH ₃	F	OH
XXV-4-5	^t Bu	H	H	CH ₂ Ph	CH ₃	H	CH ₃	F	OH
XXV-4-6	^t Bu	H	H	CH ₂ -indol-3-yl	CH ₃	H	CH ₃	F	OH
XXV-4-7	^t Bu	H	H	CH ₂ CH ₂ SCH ₃	CH ₃	H	CH ₃	F	OH
XXV-4-8	^t Bu	*	H	*	CH ₃	H	CH ₃	F	OH

*R² and R^{3b} joined together by (CH₂)₃ to form five-membered ring.

Table XXV-5.

N ₂	R ¹	R ²	R ^{3a}	R ^{3b}	R ⁴	R ⁵	R ⁶	X	Y
XXV-5-1	Ph	H	H	H	CH ₃	H	CH ₃	F	OH
XXV-5-2	Ph	H	H	CH ₃	CH ₃	H	CH ₃	F	OH
XXV-5-3	Ph	H	H	CH(CH ₃) ₂	CH ₃	H	CH ₃	F	OH
XXV-5-4	Ph	H	H	CH ₂ CH(CH ₃) ₂	CH ₃	H	CH ₃	F	OH
XXV-5-5	Ph	H	H	CH ₂ Ph	CH ₃	H	CH ₃	F	OH
XXV-5-6	Ph	H	H	CH ₂ -indol-3-yl	CH ₃	H	CH ₃	F	OH
XXV-5-7	Ph	H	H	CH ₂ CH ₂ SCH ₃	CH ₃	H	CH ₃	F	OH
XXV-5-8	Ph	*	H	*	CH ₃	H	CH ₃	F	OH

*R² and R^{3b} joined together by (CH₂)₃ to form five-membered ring.

Table XXV-6.

N ₂	R ¹	R ²	R ^{3a}	R ^{3b}	R ⁴	R ⁵	R ⁶	X	Y
XXV-6-1	p-Me-Ph	H	H	H	CH ₃	H	CH ₃	F	OH
XXV-6-2	p-Me-Ph	H	H	CH ₃	CH ₃	H	CH ₃	F	OH
XXV-6-3	p-Me-Ph	H	H	CH(CH ₃) ₂	CH ₃	H	CH ₃	F	OH
XXV-6-4	p-Me-Ph	H	H	CH ₂ CH(CH ₃) ₂	CH ₃	H	CH ₃	F	OH
XXV-6-5	p-Me-Ph	H	H	CH ₂ Ph	CH ₃	H	CH ₃	F	OH
XXV-6-6	p-Me-Ph	H	H	CH ₂ -indol-3-yl	CH ₃	H	CH ₃	F	OH
XXV-6-7	p-Me-Ph	H	H	CH ₂ CH ₂ SCH ₃	CH ₃	H	CH ₃	F	OH
XXV-6-8	p-Me-Ph	*	H	*	CH ₃	H	CH ₃	F	OH

*R² and R^{3b} joined together by (CH₂)₃ to form five-membered ring.

Table XXV-7.

N ^o	R ¹	R ²	R ^{3a}	R ^{3b}	R ⁴	R ⁵	R ⁶	X	Y
XXV-7-1	p-F-Ph	H	H	H	CH ₃	H	CH ₃	F	OH
XXV-7-2	p-F-Ph	H	H	CH ₃	CH ₃	H	CH ₃	F	OH
XXV-7-3	p-F-Ph	H	H	CH(CH ₃) ₂	CH ₃	H	CH ₃	F	OH
XXV-7-4	p-F-Ph	H	H	CH ₂ CH(CH ₃) ₂	CH ₃	H	CH ₃	F	OH
XXV-7-6	p-F-Ph	H	H	CH ₂ Ph	CH ₃	H	CH ₃	F	OH
XXV-7-7	p-F-Ph	H	H	CH ₂ -indol-3-yl	CH ₃	H	CH ₃	F	OH
XXV-7-8	p-F-Ph	H	H	CH ₂ CH ₂ SCH ₃	CH ₃	H	CH ₃	F	OH
XXV-7-20	p-F-Ph	*	H	*	CH ₃	H	CH ₃	F	OH

*R² and R^{3b} joined together by (CH₂)₃ to form five-membered ring.

Table XXV-8.

N ^o	R ¹	R ²	R ^{3a}	R ^{3b}	R ⁴	R ⁵	R ⁶	X	Y
XXV-8-1	p-Cl-Ph	H	H	H	CH ₃	H	CH ₃	F	OH
XXV-8-2	p-Cl-Ph	H	H	CH ₃	CH ₃	H	CH ₃	F	OH
XXV-8-3	p-Cl-Ph	H	H	CH(CH ₃) ₂	CH ₃	H	CH ₃	F	OH
XXV-8-4	p-Cl-Ph	H	H	CH ₂ CH(CH ₃) ₂	CH ₃	H	CH ₃	F	OH
XXV-8-5	p-Cl-Ph	H	H	CH ₂ Ph	CH ₃	H	CH ₃	F	OH
XXV-8-6	p-Cl-Ph	H	H	CH ₂ -indol-3-yl	CH ₃	H	CH ₃	F	OH
XXV-8-7	p-Cl-Ph	H	H	CH ₂ CH ₂ SCH ₃	CH ₃	H	CH ₃	F	OH
XXV-8-8	p-Cl-Ph	*	H	*	CH ₃	H	CH ₃	F	OH

*R² and R^{3b} joined together by (CH₂)₃ to form five-membered ring.

Table XXV-9.

N ^o	R ¹	R ²	R ^{3a}	R ^{3b}	R ⁴	R ⁵	R ⁶	X	Y
XXV-9-1	p-Br-Ph	H	H	H	CH ₃	H	CH ₃	F	OH
XXV-9-2	p-Br-Ph	H	H	CH ₃	CH ₃	H	CH ₃	F	OH
XXV-9-3	p-Br-Ph	H	H	CH(CH ₃) ₂	CH ₃	H	CH ₃	F	OH
XXV-9-4	p-Br-Ph	H	H	CH ₂ CH(CH ₃) ₂	CH ₃	H	CH ₃	F	OH
XXV-9-6	p-Br-Ph	H	H	CH ₂ Ph	CH ₃	H	CH ₃	F	OH
XXV-9-7	p-Br-Ph	H	H	CH ₂ -indol-3-yl	CH ₃	H	CH ₃	F	OH
XXV-9-8	p-Br-Ph	H	H	CH ₂ CH ₂ SCH ₃	CH ₃	H	CH ₃	F	OH
XXV-9-20	p-Br-Ph	*	H	*	CH ₃	H	CH ₃	F	OH

*R² and R^{3b} joined together by (CH₂)₃ to form five-membered ring.

Table XXV-10.

N ^o	R ¹	R ²	R ^{3a}	R ^{3b}	R ⁴	R ⁵	R ⁶	X	Y
XXV-10-1	p-I-Ph	H	H	H	CH ₃	H	CH ₃	F	OH
XXV-10-2	p-I-Ph	H	H	CH ₃	CH ₃	H	CH ₃	F	OH
XXV-10-3	p-I-Ph	H	H	CH(CH ₃) ₂	CH ₃	H	CH ₃	F	OH
XXV-10-4	p-I-Ph	H	H	CH ₂ CH(CH ₃) ₂	CH ₃	H	CH ₃	F	OH
XXV-10-5	p-I-Ph	H	H	CH ₂ Ph	CH ₃	H	CH ₃	F	OH
XXV-10-6	p-I-Ph	H	H	CH ₂ -indol-3-yl	CH ₃	H	CH ₃	F	OH
XXV-10-7	p-I-Ph	H	H	CH ₂ CH ₂ SCH ₃	CH ₃	H	CH ₃	F	OH
XXV-10-8	p-I-Ph	*	H	*	CH ₃	H	CH ₃	F	OH

*R² and R^{3b} joined together by (CH₂)₃ to form five-membered ring.

Table XXV-11.

N ^o	R ¹	R ²	R ^{3a}	R ^{3b}	R ⁴	R ⁵	R ⁶	X	Y
XXV-11-1	CH ₃	H	H	H	Et	H	CH ₃	F	OH
XXV-11-2	CH ₃	H	H	CH ₃	Et	H	CH ₃	F	OH
XXV-11-3	CH ₃	H	H	CH(CH ₃) ₂	Et	H	CH ₃	F	OH
XXV-11-4	CH ₃	H	H	CH ₂ CH(CH ₃) ₂	Et	H	CH ₃	F	OH
XXV-11-5	CH ₃	H	H	CH ₂ Ph	Et	H	CH ₃	F	OH
XXV-11-6	CH ₃	H	H	CH ₂ -indol-3-yl	Et	H	CH ₃	F	OH
XXV-11-7	CH ₃	H	H	CH ₂ CH ₂ SCH ₃	Et	H	CH ₃	F	OH
XXV-11-8	CH ₃	*	H	*	Et	H	CH ₃	F	OH

*R² and R^{3b} joined together by (CH₂)₃ to form five-membered ring.

Table XXV-12.

N ^o	R ¹	R ²	R ^{3a}	R ^{3b}	R ⁴	R ⁵	R ⁶	X	Y
XXV-12-1	Et	H	H	H	Et	H	CH ₃	F	OH
XXV-12-2	Et	H	H	CH ₃	Et	H	CH ₃	F	OH
XXV-12-3	Et	H	H	CH(CH ₃) ₂	Et	H	CH ₃	F	OH
XXV-12-4	Et	H	H	CH ₂ CH(CH ₃) ₂	Et	H	CH ₃	F	OH
XXV-12-5	Et	H	H	CH ₂ Ph	Et	H	CH ₃	F	OH
XXV-12-6	Et	H	H	CH ₂ -indol-3-yl	Et	H	CH ₃	F	OH
XXV-12-7	Et	H	H	CH ₂ CH ₂ SCH ₃	Et	H	CH ₃	F	OH
XXV-12-8	Et	*	H	*	Et	H	CH ₃	F	OH

*R² and R^{3b} joined together by (CH₂)₃ to form five-membered ring.

Table XXV-13.

N ^o	R ¹	R ²	R ^{3a}	R ^{3b}	R ⁴	R ⁵	R ⁶	X	Y
XXV-13-1	ⁱ Pr	H	H	H	Et	H	CH ₃	F	OH
XXV-13-2	ⁱ Pr	H	H	CH ₃	Et	H	CH ₃	F	OH
XXV-13-3	ⁱ Pr	H	H	CH(CH ₃) ₂	Et	H	CH ₃	F	OH
XXV-13-4	ⁱ Pr	H	H	CH ₂ CH(CH ₃) ₂	Et	H	CH ₃	F	OH
XXV-13-5	ⁱ Pr	H	H	CH ₂ Ph	Et	H	CH ₃	F	OH
XXV-13-6	ⁱ Pr	H	H	CH ₂ -indol-3-yl	Et	H	CH ₃	F	OH
XXV-13-7	ⁱ Pr	H	H	CH ₂ CH ₂ SCH ₃	Et	H	CH ₃	F	OH
XXV-13-8	ⁱ Pr	*	H	*	Et	H	CH ₃	F	OH

*R² and R^{3b} joined together by (CH₂)₃ to form five-membered ring.

Table XXV-14.

N ^o	R ¹	R ²	R ^{3a}	R ^{3b}	R ⁴	R ⁵	R ⁶	X	Y
XXV-14-1	^t Bu	H	H	H	Et	H	CH ₃	F	OH
XXV-14-2	^t Bu	H	H	CH ₃	Et	H	CH ₃	F	OH
XXV-14-3	^t Bu	H	H	CH(CH ₃) ₂	Et	H	CH ₃	F	OH
XXV-14-4	^t Bu	H	H	CH ₂ CH(CH ₃) ₂	Et	H	CH ₃	F	OH
XXV-14-5	^t Bu	H	H	CH ₂ Ph	Et	H	CH ₃	F	OH
XXV-14-6	^t Bu	H	H	CH ₂ -indol-3-yl	Et	H	CH ₃	F	OH
XXV-14-7	^t Bu	H	H	CH ₂ CH ₂ SCH ₃	Et	H	CH ₃	F	OH
XXV-14-8	^t Bu	*	H	*	Et	H	CH ₃	F	OH

*R² and R^{3b} joined together by (CH₂)₃ to form five-membered ring.

Table XXV-15.

N ^o	R ¹	R ²	R ^{3a}	R ^{3b}	R ⁴	R ⁵	R ⁶	X	Y
XXV-15-1	Ph	H	H	H	Et	H	CH ₃	F	OH
XXV-15-2	Ph	H	H	CH ₃	Et	H	CH ₃	F	OH
XXV-15-3	Ph	H	H	CH(CH ₃) ₂	Et	H	CH ₃	F	OH
XXV-15-4	Ph	H	H	CH ₂ CH(CH ₃) ₂	Et	H	CH ₃	F	OH
XXV-15-5	Ph	H	H	CH ₂ Ph	Et	H	CH ₃	F	OH
XXV-15-6	Ph	H	H	CH ₂ -indol-3-yl	Et	H	CH ₃	F	OH
XXV-15-7	Ph	H	H	CH ₂ CH ₂ SCH ₃	Et	H	CH ₃	F	OH
XXV-15-8	Ph	*	H	*	Et	H	CH ₃	F	OH

*R² and R^{3b} joined together by (CH₂)₃ to form five-membered ring.

Table XXV-16.

N ^o	R ¹	R ²	R ^{3a}	R ^{3b}	R ⁴	R ⁵	R ⁶	X	Y
XXV-16-1	p-Me-Ph	H	H	H	Et	H	CH ₃	F	OH
XXV-16-2	p-Me-Ph	H	H	CH ₃	Et	H	CH ₃	F	OH
XXV-16-3	p-Me-Ph	H	H	CH(CH ₃) ₂	Et	H	CH ₃	F	OH
XXV-16-4	p-Me-Ph	H	H	CH ₂ CH(CH ₃) ₂	Et	H	CH ₃	F	OH
XXV-16-5	p-Me-Ph	H	H	CH ₂ Ph	Et	H	CH ₃	F	OH
XXV-16-6	p-Me-Ph	H	H	CH ₂ -indol-3-yl	Et	H	CH ₃	F	OH
XXV-16-7	p-Me-Ph	H	H	CH ₂ CH ₂ SCH ₃	Et	H	CH ₃	F	OH
XXV-16-8	p-Me-Ph	*	H	*	Et	H	CH ₃	F	OH

*R² and R^{3b} joined together by (CH₂)₃ to form five-membered ring.

Table XXV-17.

N ^o	R ¹	R ²	R ^{3a}	R ^{3b}	R ⁴	R ⁵	R ⁶	X	Y
XXV-17-1	p-F-Ph	H	H	H	Et	H	CH ₃	F	OH
XXV-17-2	p-F-Ph	H	H	CH ₃	Et	H	CH ₃	F	OH
XXV-17-3	p-F-Ph	H	H	CH(CH ₃) ₂	Et	H	CH ₃	F	OH
XXV-17-4	p-F-Ph	H	H	CH ₂ CH(CH ₃) ₂	Et	H	CH ₃	F	OH
XXV-17-5	p-F-Ph	H	H	CH ₂ Ph	Et	H	CH ₃	F	OH
XXV-17-6	p-F-Ph	H	H	CH ₂ -indol-3-yl	Et	H	CH ₃	F	OH
XXV-17-7	p-F-Ph	H	H	CH ₂ CH ₂ SCH ₃	Et	H	CH ₃	F	OH
XXV-17-8	p-F-Ph	*	H	*	Et	H	CH ₃	F	OH

*R² and R^{3b} joined together by (CH₂)₃ to form five-membered ring.

Table XXV-18.

N ^o	R ¹	R ²	R ^{3a}	R ^{3b}	R ⁴	R ⁵	R ⁶	X	Y
XXV-18-1	p-Cl-Ph	H	H	H	Et	H	CH ₃	F	OH
XXV-18-2	p-Cl-Ph	H	H	CH ₃	Et	H	CH ₃	F	OH
XXV-18-3	p-Cl-Ph	H	H	CH(CH ₃) ₂	Et	H	CH ₃	F	OH
XXV-18-4	p-Cl-Ph	H	H	CH ₂ CH(CH ₃) ₂	Et	H	CH ₃	F	OH
XXV-18-5	p-Cl-Ph	H	H	CH ₂ Ph	Et	H	CH ₃	F	OH
XXV-18-6	p-Cl-Ph	H	H	CH ₂ -indol-3-yl	Et	H	CH ₃	F	OH
XXV-18-7	p-Cl-Ph	H	H	CH ₂ CH ₂ SCH ₃	Et	H	CH ₃	F	OH
XXV-18-8	p-Cl-Ph	*	H	*	Et	H	CH ₃	F	OH

*R² and R^{3b} joined together by (CH₂)₃ to form five-membered ring.

Table XXV-19.

N ^o	R ¹	R ²	R ^{3a}	R ^{3b}	R ⁴	R ⁵	R ⁶	X	Y
XXV-19-1	p-Br-Ph	H	H	H	Et	H	CH ₃	F	OH
XXV-19-2	p-Br-Ph	H	H	CH ₃	Et	H	CH ₃	F	OH
XXV-19-3	p-Br-Ph	H	H	CH(CH ₃) ₂	Et	H	CH ₃	F	OH
XXV-19-4	p-Br-Ph	H	H	CH ₂ CH(CH ₃) ₂	Et	H	CH ₃	F	OH
XXV-19-5	p-Br-Ph	H	H	CH ₂ Ph	Et	H	CH ₃	F	OH
XXV-19-6	p-Br-Ph	H	H	CH ₂ -indol-3-yl	Et	H	CH ₃	F	OH
XXV-19-7	p-Br-Ph	H	H	CH ₂ CH ₂ SCH ₃	Et	H	CH ₃	F	OH
XXV-19-8	p-Br-Ph	*	H	*	Et	H	CH ₃	F	OH

*R² and R^{3b} joined together by (CH₂)₃ to form five-membered ring.

Table XXV-20.

N ^o	R ¹	R ²	R ^{3a}	R ^{3b}	R ⁴	R ⁵	R ⁶	X	Y
XXV-20-1	p-I-Ph	H	H	H	Et	H	CH ₃	F	OH
XXV-20-2	p-I-Ph	H	H	CH ₃	Et	H	CH ₃	F	OH
XXV-20-3	p-I-Ph	H	H	CH(CH ₃) ₂	Et	H	CH ₃	F	OH
XXV-20-4	p-I-Ph	H	H	CH ₂ CH(CH ₃) ₂	Et	H	CH ₃	F	OH
XXV-20-5	p-I-Ph	H	H	CH ₂ Ph	Et	H	CH ₃	F	OH
XXV-20-6	p-I-Ph	H	H	CH ₂ -indol-3-yl	Et	H	CH ₃	F	OH
XXV-20-7	p-I-Ph	H	H	CH ₂ CH ₂ SCH ₃	Et	H	CH ₃	F	OH
XXV-20-8	p-I-Ph	*	H	*	Et	H	CH ₃	F	OH

*R² and R^{3b} joined together by (CH₂)₃ to form five-membered ring.

Table XXV-21.

N ^o	R ¹	R ²	R ^{3a}	R ^{3b}	R ⁴	R ⁵	R ⁶	X	Y
XXV-21-1	CH ₃	H	H	H	ⁱ Pr	H	CH ₃	F	OH
XXV-21-2	CH ₃	H	H	CH ₃	ⁱ Pr	H	CH ₃	F	OH
XXV-21-3	CH ₃	H	H	CH(CH ₃) ₂	ⁱ Pr	H	CH ₃	F	OH
XXV-21-4	CH ₃	H	H	CH ₂ CH(CH ₃) ₂	ⁱ Pr	H	CH ₃	F	OH
XXV-21-5	CH ₃	H	H	CH ₂ Ph	ⁱ Pr	H	CH ₃	F	OH
XXV-21-6	CH ₃	H	H	CH ₂ -indol-3-yl	ⁱ Pr	H	CH ₃	F	OH
XXV-21-7	CH ₃	H	H	CH ₂ CH ₂ SCH ₃	ⁱ Pr	H	CH ₃	F	OH
XXV-21-8	CH ₃	*	H	*	ⁱ Pr	H	CH ₃	F	OH

*R² and R^{3b} joined together by (CH₂)₃ to form five-membered ring.

Table XXV-22.

N ₂	R ¹	R ²	R ^{3a}	R ^{3b}	R ⁴	R ⁵	R ⁶	X	Y
XXV-22-1	Et	H	H	H	ⁱ Pr	H	CH ₃	F	OH
XXV-22-2	Et	H	H	CH ₃	ⁱ Pr	H	CH ₃	F	OH
XXV-22-3	Et	H	H	CH(CH ₃) ₂	ⁱ Pr	H	CH ₃	F	OH
XXV-22-4	Et	H	H	CH ₂ CH(CH ₃) ₂	ⁱ Pr	H	CH ₃	F	OH
XXV-22-5	Et	H	H	CH ₂ Ph	ⁱ Pr	H	CH ₃	F	OH
XXV-22-6	Et	H	H	CH ₂ -indol-3-yl	ⁱ Pr	H	CH ₃	F	OH
XXV-22-7	Et	H	H	CH ₂ CH ₂ SCH ₃	ⁱ Pr	H	CH ₃	F	OH
XXV-22-8	Et	*	H	*	ⁱ Pr	H	CH ₃	F	OH

*R² and R^{3b} joined together by (CH₂)₃ to form five-membered ring.

Table XXV-23.

N ₂	R ¹	R ²	R ^{3a}	R ^{3b}	R ⁴	R ⁵	R ⁶	X	Y
XXV-23-1	ⁱ Pr	H	H	H	ⁱ Pr	H	CH ₃	F	OH
XXV-23-2	ⁱ Pr	H	H	CH ₃	ⁱ Pr	H	CH ₃	F	OH
XXV-23-3	ⁱ Pr	H	H	CH(CH ₃) ₂	ⁱ Pr	H	CH ₃	F	OH
XXV-23-4	ⁱ Pr	H	H	CH ₂ CH(CH ₃) ₂	ⁱ Pr	H	CH ₃	F	OH
XXV-23-5	ⁱ Pr	H	H	CH ₂ Ph	ⁱ Pr	H	CH ₃	F	OH
XXV-23-6	ⁱ Pr	H	H	CH ₂ -indol-3-yl	ⁱ Pr	H	CH ₃	F	OH
XXV-23-7	ⁱ Pr	H	H	CH ₂ CH ₂ SCH ₃	ⁱ Pr	H	CH ₃	F	OH
XXV-23-8	ⁱ Pr	*	H	*	ⁱ Pr	H	CH ₃	F	OH

*R² and R^{3b} joined together by (CH₂)₃ to form five-membered ring.

Table XXV-24.

N ₂	R ¹	R ²	R ^{3a}	R ^{3b}	R ⁴	R ⁵	R ⁶	X	Y
XXV-24-1	^t Bu	H	H	H	ⁱ Pr	H	CH ₃	F	OH
XXV-24-2	^t Bu	H	H	CH ₃	ⁱ Pr	H	CH ₃	F	OH
XXV-24-3	^t Bu	H	H	CH(CH ₃) ₂	ⁱ Pr	H	CH ₃	F	OH
XXV-24-4	^t Bu	H	H	CH ₂ CH(CH ₃) ₂	ⁱ Pr	H	CH ₃	F	OH
XXV-24-5	^t Bu	H	H	CH ₂ Ph	ⁱ Pr	H	CH ₃	F	OH
XXV-24-6	^t Bu	H	H	CH ₂ -indol-3-yl	ⁱ Pr	H	CH ₃	F	OH
XXV-24-7	^t Bu	H	H	CH ₂ CH ₂ SCH ₃	ⁱ Pr	H	CH ₃	F	OH
XXV-24-8	^t Bu	*	H	*	ⁱ Pr	H	CH ₃	F	OH

*R² and R^{3b} joined together by (CH₂)₃ to form five-membered ring.

Table XXV-25.

N ^o	R ¹	R ²	R ^{3a}	R ^{3b}	R ⁴	R ⁵	R ⁶	X	Y
XXV-25-1	Ph	H	H	H	ⁱ Pr	H	CH ₃	F	OH
XXV-25-2	Ph	H	H	CH ₃	ⁱ Pr	H	CH ₃	F	OH
XXV-25-3	Ph	H	H	CH(CH ₃) ₂	ⁱ Pr	H	CH ₃	F	OH
XXV-25-4	Ph	H	H	CH ₂ CH(CH ₃) ₂	ⁱ Pr	H	CH ₃	F	OH
XXV-25-5	Ph	H	H	CH ₂ Ph	ⁱ Pr	H	CH ₃	F	OH
XXV-25-6	Ph	H	H	CH ₂ -indol-3-yl	ⁱ Pr	H	CH ₃	F	OH
XXV-25-7	Ph	H	H	CH ₂ CH ₂ SCH ₃	ⁱ Pr	H	CH ₃	F	OH
XXV-25-8	Ph	*	H	*	ⁱ Pr	H	CH ₃	F	OH

*R² and R^{3b} joined together by (CH₂)₃ to form five-membered ring.

Table XXV-26.

N ^o	R ¹	R ²	R ^{3a}	R ^{3b}	R ⁴	R ⁵	R ⁶	X	Y
XXV-26-1	p-Me-Ph	H	H	H	ⁱ Pr	H	CH ₃	F	OH
XXV-26-2	p-Me-Ph	H	H	CH ₃	ⁱ Pr	H	CH ₃	F	OH
XXV-26-3	p-Me-Ph	H	H	CH(CH ₃) ₂	ⁱ Pr	H	CH ₃	F	OH
XXV-26-4	p-Me-Ph	H	H	CH ₂ CH(CH ₃) ₂	ⁱ Pr	H	CH ₃	F	OH
XXV-26-5	p-Me-Ph	H	H	CH ₂ Ph	ⁱ Pr	H	CH ₃	F	OH
XXV-26-6	p-Me-Ph	H	H	CH ₂ -indol-3-yl	ⁱ Pr	H	CH ₃	F	OH
XXV-26-7	p-Me-Ph	H	H	CH ₂ CH ₂ SCH ₃	ⁱ Pr	H	CH ₃	F	OH
XXV-26-8	p-Me-Ph	*	H	*	ⁱ Pr	H	CH ₃	F	OH

*R² and R^{3b} joined together by (CH₂)₃ to form five-membered ring.

Table XXV-27.

N ^o	R ¹	R ²	R ^{3a}	R ^{3b}	R ⁴	R ⁵	R ⁶	X	Y
XXV-27-1	p-F-Ph	H	H	H	ⁱ Pr	H	CH ₃	F	OH
XXV-27-2	p-F-Ph	H	H	CH ₃	ⁱ Pr	H	CH ₃	F	OH
XXV-27-3	p-F-Ph	H	H	CH(CH ₃) ₂	ⁱ Pr	H	CH ₃	F	OH
XXV-27-4	p-F-Ph	H	H	CH ₂ CH(CH ₃) ₂	ⁱ Pr	H	CH ₃	F	OH
XXV-27-5	p-F-Ph	H	H	CH ₂ Ph	ⁱ Pr	H	CH ₃	F	OH
XXV-27-6	p-F-Ph	H	H	CH ₂ -indol-3-yl	ⁱ Pr	H	CH ₃	F	OH
XXV-27-7	p-F-Ph	H	H	CH ₂ CH ₂ SCH ₃	ⁱ Pr	H	CH ₃	F	OH
XXV-27-8	p-F-Ph	*	H	*	ⁱ Pr	H	CH ₃	F	OH

*R² and R^{3b} joined together by (CH₂)₃ to form five-membered ring.

Table XXV-28.

N ^o	R ¹	R ²	R ^{3a}	R ^{3b}	R ⁴	R ⁵	R ⁶	X	Y
XXV-28-1	p-Cl-Ph	H	H	H	ⁱ Pr	H	CH ₃	F	OH
XXV-28-2	p-Cl-Ph	H	H	CH ₃	ⁱ Pr	H	CH ₃	F	OH
XXV-28-3	p-Cl-Ph	H	H	CH(CH ₃) ₂	ⁱ Pr	H	CH ₃	F	OH
XXV-28-4	p-Cl-Ph	H	H	CH ₂ CH(CH ₃) ₂	ⁱ Pr	H	CH ₃	F	OH
XXV-28-5	p-Cl-Ph	H	H	CH ₂ Ph	ⁱ Pr	H	CH ₃	F	OH
XXV-28-6	p-Cl-Ph	H	H	CH ₂ -indol-3-yl	ⁱ Pr	H	CH ₃	F	OH
XXV-28-7	p-Cl-Ph	H	H	CH ₂ CH ₂ SCH ₃	ⁱ Pr	H	CH ₃	F	OH
XXV-28-8	p-Cl-Ph	*	H	*	ⁱ Pr	H	CH ₃	F	OH

*R² and R^{3b} joined together by (CH₂)₃ to form five-membered ring.

Table XXV-29.

N ^o	R ¹	R ²	R ^{3a}	R ^{3b}	R ⁴	R ⁵	R ⁶	X	Y
XXV-29-1	p-Br-Ph	H	H	H	ⁱ Pr	H	CH ₃	F	OH
XXV-29-2	p-Br-Ph	H	H	CH ₃	ⁱ Pr	H	CH ₃	F	OH
XXV-29-3	p-Br-Ph	H	H	CH(CH ₃) ₂	ⁱ Pr	H	CH ₃	F	OH
XXV-29-4	p-Br-Ph	H	H	CH ₂ CH(CH ₃) ₂	ⁱ Pr	H	CH ₃	F	OH
XXV-29-5	p-Br-Ph	H	H	CH ₂ Ph	ⁱ Pr	H	CH ₃	F	OH
XXV-29-6	p-Br-Ph	H	H	CH ₂ -indol-3-yl	ⁱ Pr	H	CH ₃	F	OH
XXV-29-7	p-Br-Ph	H	H	CH ₂ CH ₂ SCH ₃	ⁱ Pr	H	CH ₃	F	OH
XXV-29-8	p-Br-Ph	*	H	*	ⁱ Pr	H	CH ₃	F	OH

*R² and R^{3b} joined together by (CH₂)₃ to form five-membered ring.

Table XXV-30.

N ^o	R ¹	R ²	R ^{3a}	R ^{3b}	R ⁴	R ⁵	R ⁶	X	Y
XXV-30-1	p-I-Ph	H	H	H	ⁱ Pr	H	CH ₃	F	OH
XXV-30-2	p-I-Ph	H	H	CH ₃	ⁱ Pr	H	CH ₃	F	OH
XXV-30-3	p-I-Ph	H	H	CH(CH ₃) ₂	ⁱ Pr	H	CH ₃	F	OH
XXV-30-4	p-I-Ph	H	H	CH ₂ CH(CH ₃) ₂	ⁱ Pr	H	CH ₃	F	OH
XXV-30-5	p-I-Ph	H	H	CH ₂ Ph	ⁱ Pr	H	CH ₃	F	OH
XXV-30-6	p-I-Ph	H	H	CH ₂ -indol-3-yl	ⁱ Pr	H	CH ₃	F	OH
XXV-30-7	p-I-Ph	H	H	CH ₂ CH ₂ SCH ₃	ⁱ Pr	H	CH ₃	F	OH
XXV-30-8	p-I-Ph	*	H	*	ⁱ Pr	H	CH ₃	F	OH

*R² and R^{3b} joined together by (CH₂)₃ to form five-membered ring.

Table XXV-31.

N ^o	R ¹	R ²	R ^{3a}	R ^{3b}	R ⁴	R ⁵	R ⁶	X	Y
XXV-31-1	CH ₃	H	H	H	ⁿ Bu	H	CH ₃	F	OH
XXV-31-2	CH ₃	H	H	CH ₃	ⁿ Bu	H	CH ₃	F	OH
XXV-31-3	CH ₃	H	H	CH(CH ₃) ₂	ⁿ Bu	H	CH ₃	F	OH
XXV-31-4	CH ₃	H	H	CH ₂ CH(CH ₃) ₂	ⁿ Bu	H	CH ₃	F	OH
XXV-31-5	CH ₃	H	H	CH ₂ Ph	ⁿ Bu	H	CH ₃	F	OH
XXV-31-6	CH ₃	H	H	CH ₂ -indol-3-yl	ⁿ Bu	H	CH ₃	F	OH
XXV-31-7	CH ₃	H	H	CH ₂ CH ₂ SCH ₃	ⁿ Bu	H	CH ₃	F	OH
XXV-31-8	CH ₃	*	H	*	ⁿ Bu	H	CH ₃	F	OH

*R² and R^{3b} joined together by (CH₂)₃ to form five-membered ring.

Table XXV-32.

N ^o	R ¹	R ²	R ^{3a}	R ^{3b}	R ⁴	R ⁵	R ⁶	X	Y
XXV-32-1	Et	H	H	H	ⁿ Bu	H	CH ₃	F	OH
XXV-32-2	Et	H	H	CH ₃	ⁿ Bu	H	CH ₃	F	OH
XXV-32-3	Et	H	H	CH(CH ₃) ₂	ⁿ Bu	H	CH ₃	F	OH
XXV-32-4	Et	H	H	CH ₂ CH(CH ₃) ₂	ⁿ Bu	H	CH ₃	F	OH
XXV-32-5	Et	H	H	CH ₂ Ph	ⁿ Bu	H	CH ₃	F	OH
XXV-32-6	Et	H	H	CH ₂ -indol-3-yl	ⁿ Bu	H	CH ₃	F	OH
XXV-32-7	Et	H	H	CH ₂ CH ₂ SCH ₃	ⁿ Bu	H	CH ₃	F	OH
XXV-32-8	Et	*	H	*	ⁿ Bu	H	CH ₃	F	OH

*R² and R^{3b} joined together by (CH₂)₃ to form five-membered ring.

Table XXV-33.

N ^o	R ¹	R ²	R ^{3a}	R ^{3b}	R ⁴	R ⁵	R ⁶	X	Y
XXV-33-1	ⁱ Pr	H	H	H	ⁿ Bu	H	CH ₃	F	OH
XXV-33-2	ⁱ Pr	H	H	CH ₃	ⁿ Bu	H	CH ₃	F	OH
XXV-33-3	ⁱ Pr	H	H	CH(CH ₃) ₂	ⁿ Bu	H	CH ₃	F	OH
XXV-33-4	ⁱ Pr	H	H	CH ₂ CH(CH ₃) ₂	ⁿ Bu	H	CH ₃	F	OH
XXV-33-5	ⁱ Pr	H	H	CH ₂ Ph	ⁿ Bu	H	CH ₃	F	OH
XXV-33-6	ⁱ Pr	H	H	CH ₂ -indol-3-yl	ⁿ Bu	H	CH ₃	F	OH
XXV-33-7	ⁱ Pr	H	H	CH ₂ CH ₂ SCH ₃	ⁿ Bu	H	CH ₃	F	OH
XXV-33-8	ⁱ Pr	*	H	*	ⁿ Bu	H	CH ₃	F	OH

*R² and R^{3b} joined together by (CH₂)₃ to form five-membered ring.

Table XXV-34.

N ^o	R ¹	R ²	R ^{3a}	R ^{3b}	R ⁴	R ⁵	R ⁶	X	Y
XXV-34-1	^t Bu	H	H	H	ⁿ Bu	H	CH ₃	F	OH
XXV-34-2	^t Bu	H	H	CH ₃	ⁿ Bu	H	CH ₃	F	OH
XXV-34-3	^t Bu	H	H	CH(CH ₃) ₂	ⁿ Bu	H	CH ₃	F	OH
XXV-34-4	^t Bu	H	H	CH ₂ CH(CH ₃) ₂	ⁿ Bu	H	CH ₃	F	OH
XXV-34-5	^t Bu	H	H	CH ₂ Ph	ⁿ Bu	H	CH ₃	F	OH
XXV-34-6	^t Bu	H	H	CH ₂ -indol-3-yl	ⁿ Bu	H	CH ₃	F	OH
XXV-34-7	^t Bu	H	H	CH ₂ CH ₂ SCH ₃	ⁿ Bu	H	CH ₃	F	OH
XXV-34-8	^t Bu	*	H	*	ⁿ Bu	H	CH ₃	F	OH

*R² and R^{3b} joined together by (CH₂)₃ to form five-membered ring.

Table XXV-35.

N ^o	R ¹	R ²	R ^{3a}	R ^{3b}	R ⁴	R ⁵	R ⁶	X	Y
XXV-35-1	Ph	H	H	H	ⁿ Bu	H	CH ₃	F	OH
XXV-35-2	Ph	H	H	CH ₃	ⁿ Bu	H	CH ₃	F	OH
XXV-35-3	Ph	H	H	CH(CH ₃) ₂	ⁿ Bu	H	CH ₃	F	OH
XXV-35-4	Ph	H	H	CH ₂ CH(CH ₃) ₂	ⁿ Bu	H	CH ₃	F	OH
XXV-35-5	Ph	H	H	CH ₂ Ph	ⁿ Bu	H	CH ₃	F	OH
XXV-35-6	Ph	H	H	CH ₂ -indol-3-yl	ⁿ Bu	H	CH ₃	F	OH
XXV-35-7	Ph	H	H	CH ₂ CH ₂ SCH ₃	ⁿ Bu	H	CH ₃	F	OH
XXV-35-8	Ph	*	H	*	ⁿ Bu	H	CH ₃	F	OH

*R² and R^{3b} joined together by (CH₂)₃ to form five-membered ring.

Table XXV-36.

N ^o	R ¹	R ²	R ^{3a}	R ^{3b}	R ⁴	R ⁵	R ⁶	X	Y
XXV-36-1	p-Me-Ph	H	H	H	ⁿ Bu	H	CH ₃	F	OH
XXV-36-2	p-Me-Ph	H	H	CH ₃	ⁿ Bu	H	CH ₃	F	OH
XXV-36-3	p-Me-Ph	H	H	CH(CH ₃) ₂	ⁿ Bu	H	CH ₃	F	OH
XXV-36-4	p-Me-Ph	H	H	CH ₂ CH(CH ₃) ₂	ⁿ Bu	H	CH ₃	F	OH
XXV-36-5	p-Me-Ph	H	H	CH ₂ Ph	ⁿ Bu	H	CH ₃	F	OH
XXV-36-6	p-Me-Ph	H	H	CH ₂ -indol-3-yl	ⁿ Bu	H	CH ₃	F	OH
XXV-36-7	p-Me-Ph	H	H	CH ₂ CH ₂ SCH ₃	ⁿ Bu	H	CH ₃	F	OH
XXV-36-8	p-Me-Ph	*	H	*	ⁿ Bu	H	CH ₃	F	OH

*R² and R^{3b} joined together by (CH₂)₃ to form five-membered ring.

Table XXV-37.

N ^o	R ¹	R ²	R ^{3a}	R ^{3b}	R ⁴	R ⁵	R ⁶	X	Y
XXV-37-1	p-F-Ph	H	H	H	ⁿ Bu	H	CH ₃	F	OH
XXV-37-2	p-F-Ph	H	H	CH ₃	ⁿ Bu	H	CH ₃	F	OH
XXV-37-3	p-F-Ph	H	H	CH(CH ₃) ₂	ⁿ Bu	H	CH ₃	F	OH
XXV-37-4	p-F-Ph	H	H	CH ₂ CH(CH ₃) ₂	ⁿ Bu	H	CH ₃	F	OH
XXV-37-5	p-F-Ph	H	H	CH ₂ Ph	ⁿ Bu	H	CH ₃	F	OH
XXV-37-6	p-F-Ph	H	H	CH ₂ -indol-3-yl	ⁿ Bu	H	CH ₃	F	OH
XXV-37-7	p-F-Ph	H	H	CH ₂ CH ₂ SCH ₃	ⁿ Bu	H	CH ₃	F	OH
XXV-37-8	p-F-Ph	*	H	*	ⁿ Bu	H	CH ₃	F	OH

*R² and R^{3b} joined together by (CH₂)₃ to form five-membered ring.

Table XXV-38.

N ^o	R ¹	R ²	R ^{3a}	R ^{3b}	R ⁴	R ⁵	R ⁶	X	Y
XXV-38-1	p-Cl-Ph	H	H	H	ⁿ Bu	H	CH ₃	F	OH
XXV-38-2	p-Cl-Ph	H	H	CH ₃	ⁿ Bu	H	CH ₃	F	OH
XXV-38-3	p-Cl-Ph	H	H	CH(CH ₃) ₂	ⁿ Bu	H	CH ₃	F	OH
XXV-38-4	p-Cl-Ph	H	H	CH ₂ CH(CH ₃) ₂	ⁿ Bu	H	CH ₃	F	OH
XXV-38-5	p-Cl-Ph	H	H	CH ₂ Ph	ⁿ Bu	H	CH ₃	F	OH
XXV-38-6	p-Cl-Ph	H	H	CH ₂ -indol-3-yl	ⁿ Bu	H	CH ₃	F	OH
XXV-38-7	p-Cl-Ph	H	H	CH ₂ CH ₂ SCH ₃	ⁿ Bu	H	CH ₃	F	OH
XXV-38-8	p-Cl-Ph	*	H	*	ⁿ Bu	H	CH ₃	F	OH

*R² and R^{3b} joined together by (CH₂)₃ to form five-membered ring.

Table XXV-39.

N ^o	R ¹	R ²	R ^{3a}	R ^{3b}	R ⁴	R ⁵	R ⁶	X	Y
XXV-39-1	p-Br-Ph	H	H	H	ⁿ Bu	H	CH ₃	F	OH
XXV-39-2	p-Br-Ph	H	H	CH ₃	ⁿ Bu	H	CH ₃	F	OH
XXV-39-3	p-Br-Ph	H	H	CH(CH ₃) ₂	ⁿ Bu	H	CH ₃	F	OH
XXV-39-4	p-Br-Ph	H	H	CH ₂ CH(CH ₃) ₂	ⁿ Bu	H	CH ₃	F	OH
XXV-39-5	p-Br-Ph	H	H	CH ₂ Ph	ⁿ Bu	H	CH ₃	F	OH
XXV-39-6	p-Br-Ph	H	H	CH ₂ -indol-3-yl	ⁿ Bu	H	CH ₃	F	OH
XXV-39-7	p-Br-Ph	H	H	CH ₂ CH ₂ SCH ₃	ⁿ Bu	H	CH ₃	F	OH
XXV-39-8	p-Br-Ph	*	H	*	ⁿ Bu	H	CH ₃	F	OH

*R² and R^{3b} joined together by (CH₂)₃ to form five-membered ring.

Table XXV-40.

N ^o	R ¹	R ²	R ^{3a}	R ^{3b}	R ⁴	R ⁵	R ⁶	X	Y
XXV-40-1	p-I-Ph	H	H	H	ⁿ Bu	H	CH ₃	F	OH
XXV-40-2	p-I-Ph	H	H	CH ₃	ⁿ Bu	H	CH ₃	F	OH
XXV-40-3	p-I-Ph	H	H	CH(CH ₃) ₂	ⁿ Bu	H	CH ₃	F	OH
XXV-40-4	p-I-Ph	H	H	CH ₂ CH(CH ₃) ₂	ⁿ Bu	H	CH ₃	F	OH
XXV-40-5	p-I-Ph	H	H	CH ₂ Ph	ⁿ Bu	H	CH ₃	F	OH
XXV-40-6	p-I-Ph	H	H	CH ₂ -indol-3-yl	ⁿ Bu	H	CH ₃	F	OH
XXV-40-7	p-I-Ph	H	H	CH ₂ CH ₂ SCH ₃	ⁿ Bu	H	CH ₃	F	OH
XXV-40-8	p-I-Ph	*	H	*	ⁿ Bu	H	CH ₃	F	OH

*R² and R^{3b} joined together by (CH₂)₃ to form five-membered ring.

Table XXV-41.

N ^o	R ¹	R ²	R ^{3a}	R ^{3b}	R ⁴	R ⁵	R ⁶	X	Y
XXV-41-1	CH ₃	H	H	H	Bz	H	CH ₃	F	OH
XXV-41-2	CH ₃	H	H	CH ₃	Bz	H	CH ₃	F	OH
XXV-41-3	CH ₃	H	H	CH(CH ₃) ₂	Bz	H	CH ₃	F	OH
XXV-41-4	CH ₃	H	H	CH ₂ CH(CH ₃) ₂	Bz	H	CH ₃	F	OH
XXV-41-5	CH ₃	H	H	CH ₂ Ph	Bz	H	CH ₃	F	OH
XXV-41-6	CH ₃	H	H	CH ₂ -indol-3-yl	Bz	H	CH ₃	F	OH
XXV-41-7	CH ₃	H	H	CH ₂ CH ₂ SCH ₃	Bz	H	CH ₃	F	OH
XXV-41-8	CH ₃	*	H	*	Bz	H	CH ₃	F	OH

*R² and R^{3b} joined together by (CH₂)₃ to form five-membered ring.

Table XXV-42.

N ^o	R ¹	R ²	R ^{3a}	R ^{3b}	R ⁴	R ⁵	R ⁶	X	Y
XXV-42-1	Et	H	H	H	Bz	H	CH ₃	F	OH
XXV-42-2	Et	H	H	CH ₃	Bz	H	CH ₃	F	OH
XXV-42-3	Et	H	H	CH(CH ₃) ₂	Bz	H	CH ₃	F	OH
XXV-42-4	Et	H	H	CH ₂ CH(CH ₃) ₂	Bz	H	CH ₃	F	OH
XXV-42-5	Et	H	H	CH ₂ Ph	Bz	H	CH ₃	F	OH
XXV-42-6	Et	H	H	CH ₂ -indol-3-yl	Bz	H	CH ₃	F	OH
XXV-42-7	Et	H	H	CH ₂ CH ₂ SCH ₃	Bz	H	CH ₃	F	OH
XXV-42-8	Et	*	H	*	Bz	H	CH ₃	F	OH

*R² and R^{3b} joined together by (CH₂)₃ to form five-membered ring.

Table XXV-43.

N ^o	R ¹	R ²	R ^{3a}	R ^{3b}	R ⁴	R ⁵	R ⁶	X	Y
XXV-43-1	ⁱ Pr	H	H	H	Bz	H	CH ₃	F	OH
XXV-43-2	ⁱ Pr	H	H	CH ₃	Bz	H	CH ₃	F	OH
XXV-43-3	ⁱ Pr	H	H	CH(CH ₃) ₂	Bz	H	CH ₃	F	OH
XXV-43-4	ⁱ Pr	H	H	CH ₂ CH(CH ₃) ₂	Bz	H	CH ₃	F	OH
XXV-43-5	ⁱ Pr	H	H	CH ₂ Ph	Bz	H	CH ₃	F	OH
XXV-43-6	ⁱ Pr	H	H	CH ₂ -indol-3-yl	Bz	H	CH ₃	F	OH
XXV-43-7	ⁱ Pr	H	H	CH ₂ CH ₂ SCH ₃	Bz	H	CH ₃	F	OH
XXV-43-8	ⁱ Pr	*	H	*	Bz	H	CH ₃	F	OH

*R² and R^{3b} joined together by (CH₂)₃ to form five-membered ring.

Table XXV-44.

N ^o	R ¹	R ²	R ^{3a}	R ^{3b}	R ⁴	R ⁵	R ⁶	X	Y
XXV-44-1	^t Bu	H	H	H	Bz	H	CH ₃	F	OH
XXV-44-2	^t Bu	H	H	CH ₃	Bz	H	CH ₃	F	OH
XXV-44-3	^t Bu	H	H	CH(CH ₃) ₂	Bz	H	CH ₃	F	OH
XXV-44-4	^t Bu	H	H	CH ₂ CH(CH ₃) ₂	Bz	H	CH ₃	F	OH
XXV-44-5	^t Bu	H	H	CH ₂ Ph	Bz	H	CH ₃	F	OH
XXV-44-6	^t Bu	H	H	CH ₂ -indol-3-yl	Bz	H	CH ₃	F	OH
XXV-44-7	^t Bu	H	H	CH ₂ CH ₂ SCH ₃	Bz	H	CH ₃	F	OH
XXV-44-8	^t Bu	*	H	*	Bz	H	CH ₃	F	OH

*R² and R^{3b} joined together by (CH₂)₃ to form five-membered ring.

Table XXV-45.

N ^o	R ¹	R ²	R ^{3a}	R ^{3b}	R ⁴	R ⁵	R ⁶	X	Y
XXV-45-1	Ph	H	H	H	Bz	H	CH ₃	F	OH
XXV-45-2	Ph	H	H	CH ₃	Bz	H	CH ₃	F	OH
XXV-45-3	Ph	H	H	CH(CH ₃) ₂	Bz	H	CH ₃	F	OH
XXV-45-4	Ph	H	H	CH ₂ CH(CH ₃) ₂	Bz	H	CH ₃	F	OH
XXV-45-5	Ph	H	H	CH ₂ Ph	Bz	H	CH ₃	F	OH
XXV-45-6	Ph	H	H	CH ₂ -indol-3-yl	Bz	H	CH ₃	F	OH
XXV-45-7	Ph	H	H	CH ₂ CH ₂ SCH ₃	Bz	H	CH ₃	F	OH
XXV-45-8	Ph	*	H	*	Bz	H	CH ₃	F	OH

*R² and R^{3b} joined together by (CH₂)₃ to form five-membered ring.

Table XXV-46.

N ^o	R ¹	R ²	R ^{3a}	R ^{3b}	R ⁴	R ⁵	R ⁶	X	Y
XXV-46-1	p-Me-Ph	H	H	H	Bz	H	CH ₃	F	OH
XXV-46-2	p-Me-Ph	H	H	CH ₃	Bz	H	CH ₃	F	OH
XXV-46-3	p-Me-Ph	H	H	CH(CH ₃) ₂	Bz	H	CH ₃	F	OH
XXV-46-4	p-Me-Ph	H	H	CH ₂ CH(CH ₃) ₂	Bz	H	CH ₃	F	OH
XXV-46-5	p-Me-Ph	H	H	CH ₂ Ph	Bz	H	CH ₃	F	OH
XXV-46-6	p-Me-Ph	H	H	CH ₂ -indol-3-yl	Bz	H	CH ₃	F	OH
XXV-46-7	p-Me-Ph	H	H	CH ₂ CH ₂ SCH ₃	Bz	H	CH ₃	F	OH
XXV-46-8	p-Me-Ph	*	H	*	Bz	H	CH ₃	F	OH

*R² and R^{3b} joined together by (CH₂)₃ to form five-membered ring.

Table XXV-47.

N ^o	R ¹	R ²	R ^{3a}	R ^{3b}	R ⁴	R ⁵	R ⁶	X	Y
XXV-47-1	p-F-Ph	H	H	H	Bz	H	CH ₃	F	OH
XXV-47-2	p-F-Ph	H	H	CH ₃	Bz	H	CH ₃	F	OH
XXV-47-3	p-F-Ph	H	H	CH(CH ₃) ₂	Bz	H	CH ₃	F	OH
XXV-47-4	p-F-Ph	H	H	CH ₂ CH(CH ₃) ₂	Bz	H	CH ₃	F	OH
XXV-47-5	p-F-Ph	H	H	CH ₂ Ph	Bz	H	CH ₃	F	OH
XXV-47-6	p-F-Ph	H	H	CH ₂ -indol-3-yl	Bz	H	CH ₃	F	OH
XXV-47-7	p-F-Ph	H	H	CH ₂ CH ₂ SCH ₃	Bz	H	CH ₃	F	OH
XXV-47-8	p-F-Ph	*	H	*	Bz	H	CH ₃	F	OH

*R² and R^{3b} joined together by (CH₂)₃ to form five-membered ring.

Table XXV-48.

N ^o	R ¹	R ²	R ^{3a}	R ^{3b}	R ⁴	R ⁵	R ⁶	X	Y
XXV-48-1	p-Cl-Ph	H	H	H	Bz	H	CH ₃	F	OH
XXV-48-2	p-Cl-Ph	H	H	CH ₃	Bz	H	CH ₃	F	OH
XXV-48-3	p-Cl-Ph	H	H	CH(CH ₃) ₂	Bz	H	CH ₃	F	OH
XXV-48-4	p-Cl-Ph	H	H	CH ₂ CH(CH ₃) ₂	Bz	H	CH ₃	F	OH
XXV-48-5	p-Cl-Ph	H	H	CH ₂ Ph	Bz	H	CH ₃	F	OH
XXV-48-6	p-Cl-Ph	H	H	CH ₂ -indol-3-yl	Bz	H	CH ₃	F	OH
XXV-48-7	p-Cl-Ph	H	H	CH ₂ CH ₂ SCH ₃	Bz	H	CH ₃	F	OH

N ₂	R ¹	R ²	R ^{3a}	R ^{3b}	R ⁴	R ⁵	R ⁶	X	Y
XXV-48-8	p-Cl-Ph	*	H	*	Bz	H	CH ₃	F	OH

*R² and R^{3b} joined together by (CH₂)₃ to form five-membered ring.

Table XXV-49.

N ₂	R ¹	R ²	R ^{3a}	R ^{3b}	R ⁴	R ⁵	R ⁶	X	Y
XXV-49-1	p-Br-Ph	H	H	H	Bz	H	CH ₃	F	OH
XXV-49-2	p-Br-Ph	H	H	CH ₃	Bz	H	CH ₃	F	OH
XXV-49-3	p-Br-Ph	H	H	CH(CH ₃) ₂	Bz	H	CH ₃	F	OH
XXV-49-4	p-Br-Ph	H	H	CH ₂ CH(CH ₃) ₂	Bz	H	CH ₃	F	OH
XXV-49-5	p-Br-Ph	H	H	CH ₂ Ph	Bz	H	CH ₃	F	OH
XXV-49-6	p-Br-Ph	H	H	CH ₂ -indol-3-yl	Bz	H	CH ₃	F	OH
XXV-49-7	p-Br-Ph	H	H	CH ₂ CH ₂ SCH ₃	Bz	H	CH ₃	F	OH
XXV-49-8	p-Br-Ph	*	H	*	Bz	H	CH ₃	F	OH

*R² and R^{3b} joined together by (CH₂)₃ to form five-membered ring.

Table XXV-50.

N ₂	R ¹	R ²	R ^{3a}	R ^{3b}	R ⁴	R ⁵	R ⁶	X	Y
XXV-50-1	p-I-Ph	H	H	H	Bz	H	CH ₃	F	OH
XXV-50-2	p-I-Ph	H	H	CH ₃	Bz	H	CH ₃	F	OH
XXV-50-3	p-I-Ph	H	H	CH(CH ₃) ₂	Bz	H	CH ₃	F	OH
XXV-50-4	p-I-Ph	H	H	CH ₂ CH(CH ₃) ₂	Bz	H	CH ₃	F	OH
XXV-50-5	p-I-Ph	H	H	CH ₂ Ph	Bz	H	CH ₃	F	OH
XXV-50-6	p-I-Ph	H	H	CH ₂ -indol-3-yl	Bz	H	CH ₃	F	OH
XXV-50-7	p-I-Ph	H	H	CH ₂ CH ₂ SCH ₃	Bz	H	CH ₃	F	OH
XXV-50-8	p-I-Ph	*	H	*	Bz	H	CH ₃	F	OH

*R² and R^{3b} joined together by (CH₂)₃ to form five-membered ring.


**XXVI**

Table XXVI-1.

No	R ¹	R ²	R ^{3a}	R ^{3b}	R ⁴	R ⁵	R ⁶	X	Y
XXVI-1-1	CH ₃	H	H	H	CH ₃	H	F	H	OH
XXVI-1-2	CH ₃	H	H	CH ₃	CH ₃	H	F	H	OH
XXVI-1-3	CH ₃	H	H	CH(CH ₃) ₂	CH ₃	H	F	H	OH
XXVI-1-4	CH ₃	H	H	CH ₂ CH(CH ₃) ₂	CH ₃	H	F	H	OH
XXVI-1-5	CH ₃	H	H	CH ₂ Ph	CH ₃	H	F	H	OH
XXVI-1-6	CH ₃	H	H	CH ₂ -indol-3-yl	CH ₃	H	F	H	OH
XXVI-1-7	CH ₃	H	H	CH ₂ CH ₂ SCH ₃	CH ₃	H	F	H	OH
XXVI-1-8	CH ₃	*	H	*	CH ₃	H	F	H	OH

*R² and R^{3b} joined together by (CH₂)₃ to form five-membered ring.

Table XXVI-2.

No	R ¹	R ²	R ^{3a}	R ^{3b}	R ⁴	R ⁵	R ⁶	X	Y
XXVI-2-1	Et	H	H	H	CH ₃	H	F	H	OH
XXVI-2-2	Et	H	H	CH ₃	CH ₃	H	F	H	OH
XXVI-2-3	Et	H	H	CH(CH ₃) ₂	CH ₃	H	F	H	OH
XXVI-2-4	Et	H	H	CH ₂ CH(CH ₃) ₂	CH ₃	H	F	H	OH
XXVI-2-5	Et	H	H	CH ₂ Ph	CH ₃	H	F	H	OH
XXVI-2-6	Et	H	H	CH ₂ -indol-3-yl	CH ₃	H	F	H	OH
XXVI-2-7	Et	H	H	CH ₂ CH ₂ SCH ₃	CH ₃	H	F	H	OH
XXVI-2-8	Et	*	H	*	CH ₃	H	F	H	OH

*R² and R^{3b} joined together by (CH₂)₃ to form five-membered ring.

Table XXVI-3.

N ^o	R ¹	R ²	R ^{3a}	R ^{3b}	R ⁴	R ⁵	R ⁶	X	Y
XXVI-3-1	ⁱ Pr	H	H	H	CH ₃	H	F	H	OH
XXVI-3-2	ⁱ Pr	H	H	CH ₃	CH ₃	H	F	H	OH
XXVI-3-3	ⁱ Pr	H	H	CH(CH ₃) ₂	CH ₃	H	F	H	OH
XXVI-3-4	ⁱ Pr	H	H	CH ₂ CH(CH ₃) ₂	CH ₃	H	F	H	OH
XXVI-3-5	ⁱ Pr	H	H	CH ₂ Ph	CH ₃	H	F	H	OH
XXVI-3-6	ⁱ Pr	H	H	CH ₂ -indol-3-yl	CH ₃	H	F	H	OH
XXVI-3-7	ⁱ Pr	H	H	CH ₂ CH ₂ SCH ₃	CH ₃	H	F	H	OH
XXVI-3-8	ⁱ Pr	*	H	*	CH ₃	H	F	H	OH

*R² and R^{3b} joined together by (CH₂)₃ to form five-membered ring.

Table XXVI-4.

N ^o	R ¹	R ²	R ^{3a}	R ^{3b}	R ⁴	R ⁵	R ⁶	X	Y
XXVI-4-1	^t Bu	H	H	H	CH ₃	H	F	H	OH
XXVI-4-2	^t Bu	H	H	CH ₃	CH ₃	H	F	H	OH
XXVI-4-3	^t Bu	H	H	CH(CH ₃) ₂	CH ₃	H	F	H	OH
XXVI-4-4	^t Bu	H	H	CH ₂ CH(CH ₃) ₂	CH ₃	H	F	H	OH
XXVI-4-5	^t Bu	H	H	CH ₂ Ph	CH ₃	H	F	H	OH
XXVI-4-6	^t Bu	H	H	CH ₂ -indol-3-yl	CH ₃	H	F	H	OH
XXVI-4-7	^t Bu	H	H	CH ₂ CH ₂ SCH ₃	CH ₃	H	F	H	OH
XXVI-4-8	^t Bu	*	H	*	CH ₃	H	F	H	OH

*R² and R^{3b} joined together by (CH₂)₃ to form five-membered ring.

Table XXVI-5.

N ^o	R ¹	R ²	R ^{3a}	R ^{3b}	R ⁴	R ⁵	R ⁶	X	Y
XXVI-5-1	Ph	H	H	H	CH ₃	H	F	H	OH
XXVI-5-2	Ph	H	H	CH ₃	CH ₃	H	F	H	OH
XXVI-5-3	Ph	H	H	CH(CH ₃) ₂	CH ₃	H	F	H	OH
XXVI-5-4	Ph	H	H	CH ₂ CH(CH ₃) ₂	CH ₃	H	F	H	OH
XXVI-5-5	Ph	H	H	CH ₂ Ph	CH ₃	H	F	H	OH
XXVI-5-6	Ph	H	H	CH ₂ -indol-3-yl	CH ₃	H	F	H	OH
XXVI-5-7	Ph	H	H	CH ₂ CH ₂ SCH ₃	CH ₃	H	F	H	OH
XXVI-5-8	Ph	*	H	*	CH ₃	H	F	H	OH

*R² and R^{3b} joined together by (CH₂)₃ to form five-membered ring.

Table XXVI-6.

N ^o	R ¹	R ²	R ^{3a}	R ^{3b}	R ⁴	R ⁵	R ⁶	X	Y
XXVI-6-1	p-Me-Ph	H	H	H	CH ₃	H	F	H	OH
XXVI-6-2	p-Me-Ph	H	H	CH ₃	CH ₃	H	F	H	OH
XXVI-6-3	p-Me-Ph	H	H	CH(CH ₃) ₂	CH ₃	H	F	H	OH
XXVI-6-4	p-Me-Ph	H	H	CH ₂ CH(CH ₃) ₂	CH ₃	H	F	H	OH
XXVI-6-5	p-Me-Ph	H	H	CH ₂ Ph	CH ₃	H	F	H	OH
XXVI-6-6	p-Me-Ph	H	H	CH ₂ -indol-3-yl	CH ₃	H	F	H	OH
XXVI-6-7	p-Me-Ph	H	H	CH ₂ CH ₂ SCH ₃	CH ₃	H	F	H	OH
XXVI-6-8	p-Me-Ph	*	H	*	CH ₃	H	F	H	OH

*R² and R^{3b} joined together by (CH₂)₃ to form five-membered ring.

Table XXVI-7.

N ^o	R ¹	R ²	R ^{3a}	R ^{3b}	R ⁴	R ⁵	R ⁶	X	Y
XXVI-7-1	p-F-Ph	H	H	H	CH ₃	H	F	H	OH
XXVI-7-2	p-F-Ph	H	H	CH ₃	CH ₃	H	F	H	OH
XXVI-7-3	p-F-Ph	H	H	CH(CH ₃) ₂	CH ₃	H	F	H	OH
XXVI-7-4	p-F-Ph	H	H	CH ₂ CH(CH ₃) ₂	CH ₃	H	F	H	OH
XXVI-7-6	p-F-Ph	H	H	CH ₂ Ph	CH ₃	H	F	H	OH
XXVI-7-7	p-F-Ph	H	H	CH ₂ -indol-3-yl	CH ₃	H	F	H	OH
XXVI-7-8	p-F-Ph	H	H	CH ₂ CH ₂ SCH ₃	CH ₃	H	F	H	OH
XXVI-7-20	p-F-Ph	*	H	*	CH ₃	H	F	H	OH

*R² and R^{3b} joined together by (CH₂)₃ to form five-membered ring.

Table XXVI-8.

N ^o	R ¹	R ²	R ^{3a}	R ^{3b}	R ⁴	R ⁵	R ⁶	X	Y
XXVI-8-1	p-Cl-Ph	H	H	H	CH ₃	H	F	H	OH
XXVI-8-2	p-Cl-Ph	H	H	CH ₃	CH ₃	H	F	H	OH
XXVI-8-3	p-Cl-Ph	H	H	CH(CH ₃) ₂	CH ₃	H	F	H	OH
XXVI-8-4	p-Cl-Ph	H	H	CH ₂ CH(CH ₃) ₂	CH ₃	H	F	H	OH
XXVI-8-5	p-Cl-Ph	H	H	CH ₂ Ph	CH ₃	H	F	H	OH
XXVI-8-6	p-Cl-Ph	H	H	CH ₂ -indol-3-yl	CH ₃	H	F	H	OH
XXVI-8-7	p-Cl-Ph	H	H	CH ₂ CH ₂ SCH ₃	CH ₃	H	F	H	OH
XXVI-8-8	p-Cl-Ph	*	H	*	CH ₃	H	F	H	OH

*R² and R^{3b} joined together by (CH₂)₃ to form five-membered ring.

Table XXVI-9.

N ^o	R ¹	R ²	R ^{3a}	R ^{3b}	R ⁴	R ⁵	R ⁶	X	Y
XXVI-9-1	p-Br-Ph	H	H	H	CH ₃	H	F	H	OH
XXVI-9-2	p-Br-Ph	H	H	CH ₃	CH ₃	H	F	H	OH
XXVI-9-3	p-Br-Ph	H	H	CH(CH ₃) ₂	CH ₃	H	F	H	OH
XXVI-9-4	p-Br-Ph	H	H	CH ₂ CH(CH ₃) ₂	CH ₃	H	F	H	OH
XXVI-9-6	p-Br-Ph	H	H	CH ₂ Ph	CH ₃	H	F	H	OH
XXVI-9-7	p-Br-Ph	H	H	CH ₂ -indol-3-yl	CH ₃	H	F	H	OH
XXVI-9-8	p-Br-Ph	H	H	CH ₂ CH ₂ SCH ₃	CH ₃	H	F	H	OH
XXVI-9-20	p-Br-Ph	*	H	*	CH ₃	H	F	H	OH

*R² and R^{3b} joined together by (CH₂)₃ to form five-membered ring.

Table XXVI-10.

N ^o	R ¹	R ²	R ^{3a}	R ^{3b}	R ⁴	R ⁵	R ⁶	X	Y
XXVI-10-1	p-I-Ph	H	H	H	CH ₃	H	F	H	OH
XXVI-10-2	p-I-Ph	H	H	CH ₃	CH ₃	H	F	H	OH
XXVI-10-3	p-I-Ph	H	H	CH(CH ₃) ₂	CH ₃	H	F	H	OH
XXVI-10-4	p-I-Ph	H	H	CH ₂ CH(CH ₃) ₂	CH ₃	H	F	H	OH
XXVI-10-5	p-I-Ph	H	H	CH ₂ Ph	CH ₃	H	F	H	OH
XXVI-10-6	p-I-Ph	H	H	CH ₂ -indol-3-yl	CH ₃	H	F	H	OH
XXVI-10-7	p-I-Ph	H	H	CH ₂ CH ₂ SCH ₃	CH ₃	H	F	H	OH
XXVI-10-8	p-I-Ph	*	H	*	CH ₃	H	F	H	OH

*R² and R^{3b} joined together by (CH₂)₃ to form five-membered ring.

Table XXVI-11.

N ^o	R ¹	R ²	R ^{3a}	R ^{3b}	R ⁴	R ⁵	R ⁶	X	Y
XXVI-11-1	CH ₃	H	H	H	Et	H	F	H	OH
XXVI-11-2	CH ₃	H	H	CH ₃	Et	H	F	H	OH
XXVI-11-3	CH ₃	H	H	CH(CH ₃) ₂	Et	H	F	H	OH
XXVI-11-4	CH ₃	H	H	CH ₂ CH(CH ₃) ₂	Et	H	F	H	OH
XXVI-11-5	CH ₃	H	H	CH ₂ Ph	Et	H	F	H	OH
XXVI-11-6	CH ₃	H	H	CH ₂ -indol-3-yl	Et	H	F	H	OH
XXVI-11-7	CH ₃	H	H	CH ₂ CH ₂ SCH ₃	Et	H	F	H	OH
XXVI-11-8	CH ₃	*	H	*	Et	H	F	H	OH

*R² and R^{3b} joined together by (CH₂)₃ to form five-membered ring.

Table XXVI-12.

N ^o	R ¹	R ²	R ^{3a}	R ^{3b}	R ⁴	R ⁵	R ⁶	X	Y
XXVI-12-1	Et	H	H	H	Et	H	F	H	OH
XXVI-12-2	Et	H	H	CH ₃	Et	H	F	H	OH
XXVI-12-3	Et	H	H	CH(CH ₃) ₂	Et	H	F	H	OH
XXVI-12-4	Et	H	H	CH ₂ CH(CH ₃) ₂	Et	H	F	H	OH
XXVI-12-5	Et	H	H	CH ₂ Ph	Et	H	F	H	OH
XXVI-12-6	Et	H	H	CH ₂ -indol-3-yl	Et	H	F	H	OH
XXVI-12-7	Et	H	H	CH ₂ CH ₂ SCH ₃	Et	H	F	H	OH
XXVI-12-8	Et	*	H	*	Et	H	F	H	OH

*R² and R^{3b} joined together by (CH₂)₃ to form five-membered ring.

Table XXVI-13.

N ^o	R ¹	R ²	R ^{3a}	R ^{3b}	R ⁴	R ⁵	R ⁶	X	Y
XXVI-13-1	ⁱ Pr	H	H	H	Et	H	F	H	OH
XXVI-13-2	ⁱ Pr	H	H	CH ₃	Et	H	F	H	OH
XXVI-13-3	ⁱ Pr	H	H	CH(CH ₃) ₂	Et	H	F	H	OH
XXVI-13-4	ⁱ Pr	H	H	CH ₂ CH(CH ₃) ₂	Et	H	F	H	OH
XXVI-13-5	ⁱ Pr	H	H	CH ₂ Ph	Et	H	F	H	OH
XXVI-13-6	ⁱ Pr	H	H	CH ₂ -indol-3-yl	Et	H	F	H	OH
XXVI-13-7	ⁱ Pr	H	H	CH ₂ CH ₂ SCH ₃	Et	H	F	H	OH
XXVI-13-8	ⁱ Pr	*	H	*	Et	H	F	H	OH

*R² and R^{3b} joined together by (CH₂)₃ to form five-membered ring.

Table XXVI-14.

N ^o	R ¹	R ²	R ^{3a}	R ^{3b}	R ⁴	R ⁵	R ⁶	X	Y
XXVI-14-1	^t Bu	H	H	H	Et	H	F	H	OH
XXVI-14-2	^t Bu	H	H	CH ₃	Et	H	F	H	OH
XXVI-14-3	^t Bu	H	H	CH(CH ₃) ₂	Et	H	F	H	OH
XXVI-14-4	^t Bu	H	H	CH ₂ CH(CH ₃) ₂	Et	H	F	H	OH
XXVI-14-5	^t Bu	H	H	CH ₂ Ph	Et	H	F	H	OH
XXVI-14-6	^t Bu	H	H	CH ₂ -indol-3-yl	Et	H	F	H	OH
XXVI-14-7	^t Bu	H	H	CH ₂ CH ₂ SCH ₃	Et	H	F	H	OH
XXVI-14-8	^t Bu	*	H	*	Et	H	F	H	OH

*R² and R^{3b} joined together by (CH₂)₃ to form five-membered ring.

Table XXVI-15.

N ^o	R ¹	R ²	R ^{3a}	R ^{3b}	R ⁴	R ⁵	R ⁶	X	Y
XXVI-15-1	Ph	H	H	H	Et	H	F	H	OH
XXVI-15-2	Ph	H	H	CH ₃	Et	H	F	H	OH
XXVI-15-3	Ph	H	H	CH(CH ₃) ₂	Et	H	F	H	OH
XXVI-15-4	Ph	H	H	CH ₂ CH(CH ₃) ₂	Et	H	F	H	OH
XXVI-15-5	Ph	H	H	CH ₂ Ph	Et	H	F	H	OH
XXVI-15-6	Ph	H	H	CH ₂ -indol-3-yl	Et	H	F	H	OH
XXVI-15-7	Ph	H	H	CH ₂ CH ₂ SCH ₃	Et	H	F	H	OH
XXVI-15-8	Ph	*	H	*	Et	H	F	H	OH

*R² and R^{3b} joined together by (CH₂)₃ to form five-membered ring.

Table XXVI-16.

N ^o	R ¹	R ²	R ^{3a}	R ^{3b}	R ⁴	R ⁵	R ⁶	X	Y
XXVI-16-1	p-Me-Ph	H	H	H	Et	H	F	H	OH
XXVI-16-2	p-Me-Ph	H	H	CH ₃	Et	H	F	H	OH
XXVI-16-3	p-Me-Ph	H	H	CH(CH ₃) ₂	Et	H	F	H	OH
XXVI-16-4	p-Me-Ph	H	H	CH ₂ CH(CH ₃) ₂	Et	H	F	H	OH
XXVI-16-5	p-Me-Ph	H	H	CH ₂ Ph	Et	H	F	H	OH
XXVI-16-6	p-Me-Ph	H	H	CH ₂ -indol-3-yl	Et	H	F	H	OH
XXVI-16-7	p-Me-Ph	H	H	CH ₂ CH ₂ SCH ₃	Et	H	F	H	OH
XXVI-16-8	p-Me-Ph	*	H	*	Et	H	F	H	OH

*R² and R^{3b} joined together by (CH₂)₃ to form five-membered ring.

Table XXVI-17.

N ^o	R ¹	R ²	R ^{3a}	R ^{3b}	R ⁴	R ⁵	R ⁶	X	Y
XXVI-17-1	p-F-Ph	H	H	H	Et	H	F	H	OH
XXVI-17-2	p-F-Ph	H	H	CH ₃	Et	H	F	H	OH
XXVI-17-3	p-F-Ph	H	H	CH(CH ₃) ₂	Et	H	F	H	OH
XXVI-17-4	p-F-Ph	H	H	CH ₂ CH(CH ₃) ₂	Et	H	F	H	OH
XXVI-17-5	p-F-Ph	H	H	CH ₂ Ph	Et	H	F	H	OH
XXVI-17-6	p-F-Ph	H	H	CH ₂ -indol-3-yl	Et	H	F	H	OH
XXVI-17-7	p-F-Ph	H	H	CH ₂ CH ₂ SCH ₃	Et	H	F	H	OH
XXVI-17-8	p-F-Ph	*	H	*	Et	H	F	H	OH

*R² and R^{3b} joined together by (CH₂)₃ to form five-membered ring.

Table XXVI-18.

N ^o	R ¹	R ²	R ^{3a}	R ^{3b}	R ⁴	R ⁵	R ⁶	X	Y
XXVI-18-1	p-Cl-Ph	H	H	H	Et	H	F	H	OH
XXVI-18-2	p-Cl-Ph	H	H	CH ₃	Et	H	F	H	OH
XXVI-18-3	p-Cl-Ph	H	H	CH(CH ₃) ₂	Et	H	F	H	OH
XXVI-18-4	p-Cl-Ph	H	H	CH ₂ CH(CH ₃) ₂	Et	H	F	H	OH
XXVI-18-5	p-Cl-Ph	H	H	CH ₂ Ph	Et	H	F	H	OH
XXVI-18-6	p-Cl-Ph	H	H	CH ₂ -indol-3-yl	Et	H	F	H	OH
XXVI-18-7	p-Cl-Ph	H	H	CH ₂ CH ₂ SCH ₃	Et	H	F	H	OH
XXVI-18-8	p-Cl-Ph	*	H	*	Et	H	F	H	OH

*R² and R^{3b} joined together by (CH₂)₃ to form five-membered ring.

Table XXVI-19.

N ^o	R ¹	R ²	R ^{3a}	R ^{3b}	R ⁴	R ⁵	R ⁶	X	Y
XXVI-19-1	p-Br-Ph	H	H	H	Et	H	F	H	OH
XXVI-19-2	p-Br-Ph	H	H	CH ₃	Et	H	F	H	OH
XXVI-19-3	p-Br-Ph	H	H	CH(CH ₃) ₂	Et	H	F	H	OH
XXVI-19-4	p-Br-Ph	H	H	CH ₂ CH(CH ₃) ₂	Et	H	F	H	OH
XXVI-19-5	p-Br-Ph	H	H	CH ₂ Ph	Et	H	F	H	OH
XXVI-19-6	p-Br-Ph	H	H	CH ₂ -indol-3-yl	Et	H	F	H	OH
XXVI-19-7	p-Br-Ph	H	H	CH ₂ CH ₂ SCH ₃	Et	H	F	H	OH
XXVI-19-8	p-Br-Ph	*	H	*	Et	H	F	H	OH

*R² and R^{3b} joined together by (CH₂)₃ to form five-membered ring.

Table XXVI-20.

N ^o	R ¹	R ²	R ^{3a}	R ^{3b}	R ⁴	R ⁵	R ⁶	X	Y
XXVI-20-1	p-I-Ph	H	H	H	Et	H	F	H	OH
XXVI-20-2	p-I-Ph	H	H	CH ₃	Et	H	F	H	OH
XXVI-20-3	p-I-Ph	H	H	CH(CH ₃) ₂	Et	H	F	H	OH
XXVI-20-4	p-I-Ph	H	H	CH ₂ CH(CH ₃) ₂	Et	H	F	H	OH
XXVI-20-5	p-I-Ph	H	H	CH ₂ Ph	Et	H	F	H	OH
XXVI-20-6	p-I-Ph	H	H	CH ₂ -indol-3-yl	Et	H	F	H	OH
XXVI-20-7	p-I-Ph	H	H	CH ₂ CH ₂ SCH ₃	Et	H	F	H	OH
XXVI-20-8	p-I-Ph	*	H	*	Et	H	F	H	OH

*R² and R^{3b} joined together by (CH₂)₃ to form five-membered ring.

Table XXVI-21.

N ^o	R ¹	R ²	R ^{3a}	R ^{3b}	R ⁴	R ⁵	R ⁶	X	Y
XXVI-21-1	CH ₃	H	H	H	ⁱ Pr	H	F	H	OH
XXVI-21-2	CH ₃	H	H	CH ₃	ⁱ Pr	H	F	H	OH
XXVI-21-3	CH ₃	H	H	CH(CH ₃) ₂	ⁱ Pr	H	F	H	OH
XXVI-21-4	CH ₃	H	H	CH ₂ CH(CH ₃) ₂	ⁱ Pr	H	F	H	OH
XXVI-21-5	CH ₃	H	H	CH ₂ Ph	ⁱ Pr	H	F	H	OH
XXVI-21-6	CH ₃	H	H	CH ₂ -indol-3-yl	ⁱ Pr	H	F	H	OH
XXVI-21-7	CH ₃	H	H	CH ₂ CH ₂ SCH ₃	ⁱ Pr	H	F	H	OH
XXVI-21-8	CH ₃	*	H	*	ⁱ Pr	H	F	H	OH

*R² and R^{3b} joined together by (CH₂)₃ to form five-membered ring.

Table XXVI-22.

N ^o	R ¹	R ²	R ^{3a}	R ^{3b}	R ⁴	R ⁵	R ⁶	X	Y
XXVI-22-1	Et	H	H	H	ⁱ Pr	H	F	H	OH
XXVI-22-2	Et	H	H	CH ₃	ⁱ Pr	H	F	H	OH
XXVI-22-3	Et	H	H	CH(CH ₃) ₂	ⁱ Pr	H	F	H	OH
XXVI-22-4	Et	H	H	CH ₂ CH(CH ₃) ₂	ⁱ Pr	H	F	H	OH
XXVI-22-5	Et	H	H	CH ₂ Ph	ⁱ Pr	H	F	H	OH
XXVI-22-6	Et	H	H	CH ₂ -indol-3-yl	ⁱ Pr	H	F	H	OH
XXVI-22-7	Et	H	H	CH ₂ CH ₂ SCH ₃	ⁱ Pr	H	F	H	OH
XXVI-22-8	Et	*	H	*	ⁱ Pr	H	F	H	OH

*R² and R^{3b} joined together by (CH₂)₃ to form five-membered ring.

Table XXVI-23.

N ^o	R ¹	R ²	R ^{3a}	R ^{3b}	R ⁴	R ⁵	R ⁶	X	Y
XXVI-23-1	ⁱ Pr	H	H	H	ⁱ Pr	H	F	H	OH
XXVI-23-2	ⁱ Pr	H	H	CH ₃	ⁱ Pr	H	F	H	OH
XXVI-23-3	ⁱ Pr	H	H	CH(CH ₃) ₂	ⁱ Pr	H	F	H	OH
XXVI-23-4	ⁱ Pr	H	H	CH ₂ CH(CH ₃) ₂	ⁱ Pr	H	F	H	OH
XXVI-23-5	ⁱ Pr	H	H	CH ₂ Ph	ⁱ Pr	H	F	H	OH
XXVI-23-6	ⁱ Pr	H	H	CH ₂ -indol-3-yl	ⁱ Pr	H	F	H	OH
XXVI-23-7	ⁱ Pr	H	H	CH ₂ CH ₂ SCH ₃	ⁱ Pr	H	F	H	OH
XXVI-23-8	ⁱ Pr	*	H	*	ⁱ Pr	H	F	H	OH

*R² and R^{3b} joined together by (CH₂)₃ to form five-membered ring.

Table XXVI-24.

N ^o	R ¹	R ²	R ^{3a}	R ^{3b}	R ⁴	R ⁵	R ⁶	X	Y
XXVI-24-1	^t Bu	H	H	H	ⁱ Pr	H	F	H	OH
XXVI-24-2	^t Bu	H	H	CH ₃	ⁱ Pr	H	F	H	OH
XXVI-24-3	^t Bu	H	H	CH(CH ₃) ₂	ⁱ Pr	H	F	H	OH
XXVI-24-4	^t Bu	H	H	CH ₂ CH(CH ₃) ₂	ⁱ Pr	H	F	H	OH
XXVI-24-5	^t Bu	H	H	CH ₂ Ph	ⁱ Pr	H	F	H	OH
XXVI-24-6	^t Bu	H	H	CH ₂ -indol-3-yl	ⁱ Pr	H	F	H	OH
XXVI-24-7	^t Bu	H	H	CH ₂ CH ₂ SCH ₃	ⁱ Pr	H	F	H	OH
XXVI-24-8	^t Bu	*	H	*	ⁱ Pr	H	F	H	OH

*R² and R^{3b} joined together by (CH₂)₃ to form five-membered ring.

Table XXVI-25.

N ^o	R ¹	R ²	R ^{3a}	R ^{3b}	R ⁴	R ⁵	R ⁶	X	Y
XXVI-25-1	Ph	H	H	H	ⁱ Pr	H	F	H	OH
XXVI-25-2	Ph	H	H	CH ₃	ⁱ Pr	H	F	H	OH
XXVI-25-3	Ph	H	H	CH(CH ₃) ₂	ⁱ Pr	H	F	H	OH
XXVI-25-4	Ph	H	H	CH ₂ CH(CH ₃) ₂	ⁱ Pr	H	F	H	OH
XXVI-25-5	Ph	H	H	CH ₂ Ph	ⁱ Pr	H	F	H	OH
XXVI-25-6	Ph	H	H	CH ₂ -indol-3-yl	ⁱ Pr	H	F	H	OH
XXVI-25-7	Ph	H	H	CH ₂ CH ₂ SCH ₃	ⁱ Pr	H	F	H	OH
XXVI-25-8	Ph	*	H	*	ⁱ Pr	H	F	H	OH

*R² and R^{3b} joined together by (CH₂)₃ to form five-membered ring.

Table XXVI-26.

N ^o	R ¹	R ²	R ^{3a}	R ^{3b}	R ⁴	R ⁵	R ⁶	X	Y
XXVI-26-1	p-Me-Ph	H	H	H	ⁱ Pr	H	F	H	OH
XXVI-26-2	p-Me-Ph	H	H	CH ₃	ⁱ Pr	H	F	H	OH
XXVI-26-3	p-Me-Ph	H	H	CH(CH ₃) ₂	ⁱ Pr	H	F	H	OH
XXVI-26-4	p-Me-Ph	H	H	CH ₂ CH(CH ₃) ₂	ⁱ Pr	H	F	H	OH
XXVI-26-5	p-Me-Ph	H	H	CH ₂ Ph	ⁱ Pr	H	F	H	OH
XXVI-26-6	p-Me-Ph	H	H	CH ₂ -indol-3-yl	ⁱ Pr	H	F	H	OH
XXVI-26-7	p-Me-Ph	H	H	CH ₂ CH ₂ SCH ₃	ⁱ Pr	H	F	H	OH
XXVI-26-8	p-Me-Ph	*	H	*	ⁱ Pr	H	F	H	OH

*R² and R^{3b} joined together by (CH₂)₃ to form five-membered ring.

Table XXVI-27.

N ^o	R ¹	R ²	R ^{3a}	R ^{3b}	R ⁴	R ⁵	R ⁶	X	Y
XXVI-27-1	p-F-Ph	H	H	H	ⁱ Pr	H	F	H	OH
XXVI-27-2	p-F-Ph	H	H	CH ₃	ⁱ Pr	H	F	H	OH
XXVI-27-3	p-F-Ph	H	H	CH(CH ₃) ₂	ⁱ Pr	H	F	H	OH
XXVI-27-4	p-F-Ph	H	H	CH ₂ CH(CH ₃) ₂	ⁱ Pr	H	F	H	OH
XXVI-27-5	p-F-Ph	H	H	CH ₂ Ph	ⁱ Pr	H	F	H	OH
XXVI-27-6	p-F-Ph	H	H	CH ₂ -indol-3-yl	ⁱ Pr	H	F	H	OH
XXVI-27-7	p-F-Ph	H	H	CH ₂ CH ₂ SCH ₃	ⁱ Pr	H	F	H	OH
XXVI-27-8	p-F-Ph	*	H	*	ⁱ Pr	H	F	H	OH

*R² and R^{3b} joined together by (CH₂)₃ to form five-membered ring.

Table XXVI-28.

N ^o	R ¹	R ²	R ^{3a}	R ^{3b}	R ⁴	R ⁵	R ⁶	X	Y
XXVI-28-1	p-Cl-Ph	H	H	H	ⁱ Pr	H	F	H	OH
XXVI-28-2	p-Cl-Ph	H	H	CH ₃	ⁱ Pr	H	F	H	OH
XXVI-28-3	p-Cl-Ph	H	H	CH(CH ₃) ₂	ⁱ Pr	H	F	H	OH
XXVI-28-4	p-Cl-Ph	H	H	CH ₂ CH(CH ₃) ₂	ⁱ Pr	H	F	H	OH
XXVI-28-5	p-Cl-Ph	H	H	CH ₂ Ph	ⁱ Pr	H	F	H	OH
XXVI-28-6	p-Cl-Ph	H	H	CH ₂ -indol-3-yl	ⁱ Pr	H	F	H	OH
XXVI-28-7	p-Cl-Ph	H	H	CH ₂ CH ₂ SCH ₃	ⁱ Pr	H	F	H	OH
XXVI-28-8	p-Cl-Ph	*	H	*	ⁱ Pr	H	F	H	OH

*R² and R^{3b} joined together by (CH₂)₃ to form five-membered ring.

Table XXVI-29.

N ^o	R ¹	R ²	R ^{3a}	R ^{3b}	R ⁴	R ⁵	R ⁶	X	Y
XXVI-29-1	p-Br-Ph	H	H	H	ⁱ Pr	H	F	H	OH
XXVI-29-2	p-Br-Ph	H	H	CH ₃	ⁱ Pr	H	F	H	OH
XXVI-29-3	p-Br-Ph	H	H	CH(CH ₃) ₂	ⁱ Pr	H	F	H	OH
XXVI-29-4	p-Br-Ph	H	H	CH ₂ CH(CH ₃) ₂	ⁱ Pr	H	F	H	OH
XXVI-29-5	p-Br-Ph	H	H	CH ₂ Ph	ⁱ Pr	H	F	H	OH
XXVI-29-6	p-Br-Ph	H	H	CH ₂ -indol-3-yl	ⁱ Pr	H	F	H	OH
XXVI-29-7	p-Br-Ph	H	H	CH ₂ CH ₂ SCH ₃	ⁱ Pr	H	F	H	OH
XXVI-29-8	p-Br-Ph	*	H	*	ⁱ Pr	H	F	H	OH

*R² and R^{3b} joined together by (CH₂)₃ to form five-membered ring.

Table XXVI-30.

N ^o	R ¹	R ²	R ^{3a}	R ^{3b}	R ⁴	R ⁵	R ⁶	X	Y
XXVI-30-1	p-I-Ph	H	H	H	ⁱ Pr	H	F	H	OH
XXVI-30-2	p-I-Ph	H	H	CH ₃	ⁱ Pr	H	F	H	OH
XXVI-30-3	p-I-Ph	H	H	CH(CH ₃) ₂	ⁱ Pr	H	F	H	OH
XXVI-30-4	p-I-Ph	H	H	CH ₂ CH(CH ₃) ₂	ⁱ Pr	H	F	H	OH
XXVI-30-5	p-I-Ph	H	H	CH ₂ Ph	ⁱ Pr	H	F	H	OH
XXVI-30-6	p-I-Ph	H	H	CH ₂ -indol-3-yl	ⁱ Pr	H	F	H	OH
XXVI-30-7	p-I-Ph	H	H	CH ₂ CH ₂ SCH ₃	ⁱ Pr	H	F	H	OH
XXVI-30-8	p-I-Ph	*	H	*	ⁱ Pr	H	F	H	OH

*R² and R^{3b} joined together by (CH₂)₃ to form five-membered ring.

Table XXVI-31.

N ^o	R ¹	R ²	R ^{3a}	R ^{3b}	R ⁴	R ⁵	R ⁶	X	Y
XXVI-31-1	CH ₃	H	H	H	ⁿ Bu	H	F	H	OH
XXVI-31-2	CH ₃	H	H	CH ₃	ⁿ Bu	H	F	H	OH
XXVI-31-3	CH ₃	H	H	CH(CH ₃) ₂	ⁿ Bu	H	F	H	OH
XXVI-31-4	CH ₃	H	H	CH ₂ CH(CH ₃) ₂	ⁿ Bu	H	F	H	OH
XXVI-31-5	CH ₃	H	H	CH ₂ Ph	ⁿ Bu	H	F	H	OH
XXVI-31-6	CH ₃	H	H	CH ₂ -indol-3-yl	ⁿ Bu	H	F	H	OH
XXVI-31-7	CH ₃	H	H	CH ₂ CH ₂ SCH ₃	ⁿ Bu	H	F	H	OH
XXVI-31-8	CH ₃	*	H	*	ⁿ Bu	H	F	H	OH

*R² and R^{3b} joined together by (CH₂)₃ to form five-membered ring.

Table XXVI-32.

N ^o	R ¹	R ²	R ^{3a}	R ^{3b}	R ⁴	R ⁵	R ⁶	X	Y
XXVI-32-1	Et	H	H	H	ⁿ Bu	H	F	H	OH
XXVI-32-2	Et	H	H	CH ₃	ⁿ Bu	H	F	H	OH
XXVI-32-3	Et	H	H	CH(CH ₃) ₂	ⁿ Bu	H	F	H	OH
XXVI-32-4	Et	H	H	CH ₂ CH(CH ₃) ₂	ⁿ Bu	H	F	H	OH
XXVI-32-5	Et	H	H	CH ₂ Ph	ⁿ Bu	H	F	H	OH
XXVI-32-6	Et	H	H	CH ₂ -indol-3-yl	ⁿ Bu	H	F	H	OH
XXVI-32-7	Et	H	H	CH ₂ CH ₂ SCH ₃	ⁿ Bu	H	F	H	OH
XXVI-32-8	Et	*	H	*	ⁿ Bu	H	F	H	OH

*R² and R^{3b} joined together by (CH₂)₃ to form five-membered ring.

Table XXVI-33.

N ^o	R ¹	R ²	R ^{3a}	R ^{3b}	R ⁴	R ⁵	R ⁶	X	Y
XXVI-33-1	ⁱ Pr	H	H	H	ⁿ Bu	H	F	H	OH
XXVI-33-2	ⁱ Pr	H	H	CH ₃	ⁿ Bu	H	F	H	OH
XXVI-33-3	ⁱ Pr	H	H	CH(CH ₃) ₂	ⁿ Bu	H	F	H	OH
XXVI-33-4	ⁱ Pr	H	H	CH ₂ CH(CH ₃) ₂	ⁿ Bu	H	F	H	OH
XXVI-33-5	ⁱ Pr	H	H	CH ₂ Ph	ⁿ Bu	H	F	H	OH
XXVI-33-6	ⁱ Pr	H	H	CH ₂ -indol-3-yl	ⁿ Bu	H	F	H	OH
XXVI-33-7	ⁱ Pr	H	H	CH ₂ CH ₂ SCH ₃	ⁿ Bu	H	F	H	OH
XXVI-33-8	ⁱ Pr	*	H	*	ⁿ Bu	H	F	H	OH

*R² and R^{3b} joined together by (CH₂)₃ to form five-membered ring.

Table XXVI-34.

N ^o	R ¹	R ²	R ^{3a}	R ^{3b}	R ⁴	R ⁵	R ⁶	X	Y
XXVI-34-1	^t Bu	H	H	H	ⁿ Bu	H	F	H	OH
XXVI-34-2	^t Bu	H	H	CH ₃	ⁿ Bu	H	F	H	OH
XXVI-34-3	^t Bu	H	H	CH(CH ₃) ₂	ⁿ Bu	H	F	H	OH
XXVI-34-4	^t Bu	H	H	CH ₂ CH(CH ₃) ₂	ⁿ Bu	H	F	H	OH
XXVI-34-5	^t Bu	H	H	CH ₂ Ph	ⁿ Bu	H	F	H	OH
XXVI-34-6	^t Bu	H	H	CH ₂ -indol-3-yl	ⁿ Bu	H	F	H	OH
XXVI-34-7	^t Bu	H	H	CH ₂ CH ₂ SCH ₃	ⁿ Bu	H	F	H	OH
XXVI-34-8	^t Bu	*	H	*	ⁿ Bu	H	F	H	OH

*R² and R^{3b} joined together by (CH₂)₃ to form five-membered ring.

Table XXVI-35.

N ^o	R ¹	R ²	R ^{3a}	R ^{3b}	R ⁴	R ⁵	R ⁶	X	Y
XXVI-35-1	Ph	H	H	H	ⁿ Bu	H	F	H	OH
XXVI-35-2	Ph	H	H	CH ₃	ⁿ Bu	H	F	H	OH
XXVI-35-3	Ph	H	H	CH(CH ₃) ₂	ⁿ Bu	H	F	H	OH
XXVI-35-4	Ph	H	H	CH ₂ CH(CH ₃) ₂	ⁿ Bu	H	F	H	OH
XXVI-35-5	Ph	H	H	CH ₂ Ph	ⁿ Bu	H	F	H	OH
XXVI-35-6	Ph	H	H	CH ₂ -indol-3-yl	ⁿ Bu	H	F	H	OH
XXVI-35-7	Ph	H	H	CH ₂ CH ₂ SCH ₃	ⁿ Bu	H	F	H	OH
XXVI-35-8	Ph	*	H	*	ⁿ Bu	H	F	H	OH

*R² and R^{3b} joined together by (CH₂)₃ to form five-membered ring.

Table XXVI-36.

N ^o	R ¹	R ²	R ^{3a}	R ^{3b}	R ⁴	R ⁵	R ⁶	X	Y
XXVI-36-1	p-Me-Ph	H	H	H	ⁿ Bu	H	F	H	OH
XXVI-36-2	p-Me-Ph	H	H	CH ₃	ⁿ Bu	H	F	H	OH
XXVI-36-3	p-Me-Ph	H	H	CH(CH ₃) ₂	ⁿ Bu	H	F	H	OH
XXVI-36-4	p-Me-Ph	H	H	CH ₂ CH(CH ₃) ₂	ⁿ Bu	H	F	H	OH
XXVI-36-5	p-Me-Ph	H	H	CH ₂ Ph	ⁿ Bu	H	F	H	OH
XXVI-36-6	p-Me-Ph	H	H	CH ₂ -indol-3-yl	ⁿ Bu	H	F	H	OH
XXVI-36-7	p-Me-Ph	H	H	CH ₂ CH ₂ SCH ₃	ⁿ Bu	H	F	H	OH
XXVI-36-8	p-Me-Ph	*	H	*	ⁿ Bu	H	F	H	OH

*R² and R^{3b} joined together by (CH₂)₃ to form five-membered ring.

Table XXVI-37.

N ^o	R ¹	R ²	R ^{3a}	R ^{3b}	R ⁴	R ⁵	R ⁶	X	Y
XXVI-37-1	p-F-Ph	H	H	H	ⁿ Bu	H	F	H	OH
XXVI-37-2	p-F-Ph	H	H	CH ₃	ⁿ Bu	H	F	H	OH
XXVI-37-3	p-F-Ph	H	H	CH(CH ₃) ₂	ⁿ Bu	H	F	H	OH
XXVI-37-4	p-F-Ph	H	H	CH ₂ CH(CH ₃) ₂	ⁿ Bu	H	F	H	OH
XXVI-37-5	p-F-Ph	H	H	CH ₂ Ph	ⁿ Bu	H	F	H	OH
XXVI-37-6	p-F-Ph	H	H	CH ₂ -indol-3-yl	ⁿ Bu	H	F	H	OH
XXVI-37-7	p-F-Ph	H	H	CH ₂ CH ₂ SCH ₃	ⁿ Bu	H	F	H	OH
XXVI-37-8	p-F-Ph	*	H	*	ⁿ Bu	H	F	H	OH

*R² and R^{3b} joined together by (CH₂)₃ to form five-membered ring.

Table XXVI-38.

N ^o	R ¹	R ²	R ^{3a}	R ^{3b}	R ⁴	R ⁵	R ⁶	X	Y
XXVI-38-1	p-Cl-Ph	H	H	H	ⁿ Bu	H	F	H	OH
XXVI-38-2	p-Cl-Ph	H	H	CH ₃	ⁿ Bu	H	F	H	OH
XXVI-38-3	p-Cl-Ph	H	H	CH(CH ₃) ₂	ⁿ Bu	H	F	H	OH
XXVI-38-4	p-Cl-Ph	H	H	CH ₂ CH(CH ₃) ₂	ⁿ Bu	H	F	H	OH
XXVI-38-5	p-Cl-Ph	H	H	CH ₂ Ph	ⁿ Bu	H	F	H	OH
XXVI-38-6	p-Cl-Ph	H	H	CH ₂ -indol-3-yl	ⁿ Bu	H	F	H	OH
XXVI-38-7	p-Cl-Ph	H	H	CH ₂ CH ₂ SCH ₃	ⁿ Bu	H	F	H	OH
XXVI-38-8	p-Cl-Ph	*	H	*	ⁿ Bu	H	F	H	OH

*R² and R^{3b} joined together by (CH₂)₃ to form five-membered ring.

Table XXVI-39.

N ^o	R ¹	R ²	R ^{3a}	R ^{3b}	R ⁴	R ⁵	R ⁶	X	Y
XXVI-39-1	p-Br-Ph	H	H	H	ⁿ Bu	H	F	H	OH
XXVI-39-2	p-Br-Ph	H	H	CH ₃	ⁿ Bu	H	F	H	OH
XXVI-39-3	p-Br-Ph	H	H	CH(CH ₃) ₂	ⁿ Bu	H	F	H	OH
XXVI-39-4	p-Br-Ph	H	H	CH ₂ CH(CH ₃) ₂	ⁿ Bu	H	F	H	OH
XXVI-39-5	p-Br-Ph	H	H	CH ₂ Ph	ⁿ Bu	H	F	H	OH
XXVI-39-6	p-Br-Ph	H	H	CH ₂ -indol-3-yl	ⁿ Bu	H	F	H	OH
XXVI-39-7	p-Br-Ph	H	H	CH ₂ CH ₂ SCH ₃	ⁿ Bu	H	F	H	OH
XXVI-39-8	p-Br-Ph	*	H	*	ⁿ Bu	H	F	H	OH

*R² and R^{3b} joined together by (CH₂)₃ to form five-membered ring.

Table XXVI-40.

N ^o	R ¹	R ²	R ^{3a}	R ^{3b}	R ⁴	R ⁵	R ⁶	X	Y
XXVI-40-1	p-I-Ph	H	H	H	ⁿ Bu	H	F	H	OH
XXVI-40-2	p-I-Ph	H	H	CH ₃	ⁿ Bu	H	F	H	OH
XXVI-40-3	p-I-Ph	H	H	CH(CH ₃) ₂	ⁿ Bu	H	F	H	OH
XXVI-40-4	p-I-Ph	H	H	CH ₂ CH(CH ₃) ₂	ⁿ Bu	H	F	H	OH
XXVI-40-5	p-I-Ph	H	H	CH ₂ Ph	ⁿ Bu	H	F	H	OH
XXVI-40-6	p-I-Ph	H	H	CH ₂ -indol-3-yl	ⁿ Bu	H	F	H	OH
XXVI-40-7	p-I-Ph	H	H	CH ₂ CH ₂ SCH ₃	ⁿ Bu	H	F	H	OH
XXVI-40-8	p-I-Ph	*	H	*	ⁿ Bu	H	F	H	OH

*R² and R^{3b} joined together by (CH₂)₃ to form five-membered ring.

Table XXVI-41.

N ^o	R ¹	R ²	R ^{3a}	R ^{3b}	R ⁴	R ⁵	R ⁶	X	Y
XXVI-41-1	CH ₃	H	H	H	Bz	H	F	H	OH
XXVI-41-2	CH ₃	H	H	CH ₃	Bz	H	F	H	OH
XXVI-41-3	CH ₃	H	H	CH(CH ₃) ₂	Bz	H	F	H	OH
XXVI-41-4	CH ₃	H	H	CH ₂ CH(CH ₃) ₂	Bz	H	F	H	OH
XXVI-41-5	CH ₃	H	H	CH ₂ Ph	Bz	H	F	H	OH
XXVI-41-6	CH ₃	H	H	CH ₂ -indol-3-yl	Bz	H	F	H	OH
XXVI-41-7	CH ₃	H	H	CH ₂ CH ₂ SCH ₃	Bz	H	F	H	OH
XXVI-41-8	CH ₃	*	H	*	Bz	H	F	H	OH

*R² and R^{3b} joined together by (CH₂)₃ to form five-membered ring.

Table XXVI-42.

N ₂	R ¹	R ²	R ^{3a}	R ^{3b}	R ⁴	R ⁵	R ⁶	X	Y
XXVI-42-1	Et	H	H	H	Bz	H	F	H	OH
XXVI-42-2	Et	H	H	CH ₃	Bz	H	F	H	OH
XXVI-42-3	Et	H	H	CH(CH ₃) ₂	Bz	H	F	H	OH
XXVI-42-4	Et	H	H	CH ₂ CH(CH ₃) ₂	Bz	H	F	H	OH
XXVI-42-5	Et	H	H	CH ₂ Ph	Bz	H	F	H	OH
XXVI-42-6	Et	H	H	CH ₂ -indol-3-yl	Bz	H	F	H	OH
XXVI-42-7	Et	H	H	CH ₂ CH ₂ SCH ₃	Bz	H	F	H	OH
XXVI-42-8	Et	*	H	*	Bz	H	F	H	OH

*R² and R^{3b} joined together by (CH₂)₃ to form five-membered ring.

Table XXVI-43.

N ₂	R ¹	R ²	R ^{3a}	R ^{3b}	R ⁴	R ⁵	R ⁶	X	Y
XXVI-43-1	ⁱ Pr	H	H	H	Bz	H	F	H	OH
XXVI-43-2	ⁱ Pr	H	H	CH ₃	Bz	H	F	H	OH
XXVI-43-3	ⁱ Pr	H	H	CH(CH ₃) ₂	Bz	H	F	H	OH
XXVI-43-4	ⁱ Pr	H	H	CH ₂ CH(CH ₃) ₂	Bz	H	F	H	OH
XXVI-43-5	ⁱ Pr	H	H	CH ₂ Ph	Bz	H	F	H	OH
XXVI-43-6	ⁱ Pr	H	H	CH ₂ -indol-3-yl	Bz	H	F	H	OH
XXVI-43-7	ⁱ Pr	H	H	CH ₂ CH ₂ SCH ₃	Bz	H	F	H	OH
XXVI-43-8	ⁱ Pr	*	H	*	Bz	H	F	H	OH

*R² and R^{3b} joined together by (CH₂)₃ to form five-membered ring.

Table XXVI-44.

N ₂	R ¹	R ²	R ^{3a}	R ^{3b}	R ⁴	R ⁵	R ⁶	X	Y
XXVI-44-1	^t Bu	H	H	H	Bz	H	F	H	OH
XXVI-44-2	^t Bu	H	H	CH ₃	Bz	H	F	H	OH
XXVI-44-3	^t Bu	H	H	CH(CH ₃) ₂	Bz	H	F	H	OH
XXVI-44-4	^t Bu	H	H	CH ₂ CH(CH ₃) ₂	Bz	H	F	H	OH
XXVI-44-5	^t Bu	H	H	CH ₂ Ph	Bz	H	F	H	OH
XXVI-44-6	^t Bu	H	H	CH ₂ -indol-3-yl	Bz	H	F	H	OH
XXVI-44-7	^t Bu	H	H	CH ₂ CH ₂ SCH ₃	Bz	H	F	H	OH
XXVI-44-8	^t Bu	*	H	*	Bz	H	F	H	OH

*R² and R^{3b} joined together by (CH₂)₃ to form five-membered ring.

Table XXVI-45.

N ^o	R ¹	R ²	R ^{3a}	R ^{3b}	R ⁴	R ⁵	R ⁶	X	Y
XXVI-45-1	Ph	H	H	H	Bz	H	F	H	OH
XXVI-45-2	Ph	H	H	CH ₃	Bz	H	F	H	OH
XXVI-45-3	Ph	H	H	CH(CH ₃) ₂	Bz	H	F	H	OH
XXVI-45-4	Ph	H	H	CH ₂ CH(CH ₃) ₂	Bz	H	F	H	OH
XXVI-45-5	Ph	H	H	CH ₂ Ph	Bz	H	F	H	OH
XXVI-45-6	Ph	H	H	CH ₂ -indol-3-yl	Bz	H	F	H	OH
XXVI-45-7	Ph	H	H	CH ₂ CH ₂ SCH ₃	Bz	H	F	H	OH
XXVI-45-8	Ph	*	H	*	Bz	H	F	H	OH

*R² and R^{3b} joined together by (CH₂)₃ to form five-membered ring.

Table XXVI-46.

N ^o	R ¹	R ²	R ^{3a}	R ^{3b}	R ⁴	R ⁵	R ⁶	X	Y
XXVI-46-1	p-Me-Ph	H	H	H	Bz	H	F	H	OH
XXVI-46-2	p-Me-Ph	H	H	CH ₃	Bz	H	F	H	OH
XXVI-46-3	p-Me-Ph	H	H	CH(CH ₃) ₂	Bz	H	F	H	OH
XXVI-46-4	p-Me-Ph	H	H	CH ₂ CH(CH ₃) ₂	Bz	H	F	H	OH
XXVI-46-5	p-Me-Ph	H	H	CH ₂ Ph	Bz	H	F	H	OH
XXVI-46-6	p-Me-Ph	H	H	CH ₂ -indol-3-yl	Bz	H	F	H	OH
XXVI-46-7	p-Me-Ph	H	H	CH ₂ CH ₂ SCH ₃	Bz	H	F	H	OH
XXVI-46-8	p-Me-Ph	*	H	*	Bz	H	F	H	OH

*R² and R^{3b} joined together by (CH₂)₃ to form five-membered ring.

Table XXVI-47.

N ^o	R ¹	R ²	R ^{3a}	R ^{3b}	R ⁴	R ⁵	R ⁶	X	Y
XXVI-47-1	p-F-Ph	H	H	H	Bz	H	F	H	OH
XXVI-47-2	p-F-Ph	H	H	CH ₃	Bz	H	F	H	OH
XXVI-47-3	p-F-Ph	H	H	CH(CH ₃) ₂	Bz	H	F	H	OH
XXVI-47-4	p-F-Ph	H	H	CH ₂ CH(CH ₃) ₂	Bz	H	F	H	OH
XXVI-47-5	p-F-Ph	H	H	CH ₂ Ph	Bz	H	F	H	OH
XXVI-47-6	p-F-Ph	H	H	CH ₂ -indol-3-yl	Bz	H	F	H	OH
XXVI-47-7	p-F-Ph	H	H	CH ₂ CH ₂ SCH ₃	Bz	H	F	H	OH
XXVI-47-8	p-F-Ph	*	H	*	Bz	H	F	H	OH

*R² and R^{3b} joined together by (CH₂)₃ to form five-membered ring.

Table XXVI-48.

N ^o	R ¹	R ²	R ^{3a}	R ^{3b}	R ⁴	R ⁵	R ⁶	X	Y
XXVI-48-1	p-Cl-Ph	H	H	H	Bz	H	F	H	OH
XXVI-48-2	p-Cl-Ph	H	H	CH ₃	Bz	H	F	H	OH
XXVI-48-3	p-Cl-Ph	H	H	CH(CH ₃) ₂	Bz	H	F	H	OH
XXVI-48-4	p-Cl-Ph	H	H	CH ₂ CH(CH ₃) ₂	Bz	H	F	H	OH
XXVI-48-5	p-Cl-Ph	H	H	CH ₂ Ph	Bz	H	F	H	OH
XXVI-48-6	p-Cl-Ph	H	H	CH ₂ -indol-3-yl	Bz	H	F	H	OH
XXVI-48-7	p-Cl-Ph	H	H	CH ₂ CH ₂ SCH ₃	Bz	H	F	H	OH
XXVI-48-8	p-Cl-Ph	*	H	*	Bz	H	F	H	OH

*R² and R^{3b} joined together by (CH₂)₃ to form five-membered ring.

Table XXVI-49.

N ^o	R ¹	R ²	R ^{3a}	R ^{3b}	R ⁴	R ⁵	R ⁶	X	Y
XXVI-49-1	p-Br-Ph	H	H	H	Bz	H	F	H	OH
XXVI-49-2	p-Br-Ph	H	H	CH ₃	Bz	H	F	H	OH
XXVI-49-3	p-Br-Ph	H	H	CH(CH ₃) ₂	Bz	H	F	H	OH
XXVI-49-4	p-Br-Ph	H	H	CH ₂ CH(CH ₃) ₂	Bz	H	F	H	OH
XXVI-49-5	p-Br-Ph	H	H	CH ₂ Ph	Bz	H	F	H	OH
XXVI-49-6	p-Br-Ph	H	H	CH ₂ -indol-3-yl	Bz	H	F	H	OH
XXVI-49-7	p-Br-Ph	H	H	CH ₂ CH ₂ SCH ₃	Bz	H	F	H	OH
XXVI-49-8	p-Br-Ph	*	H	*	Bz	H	F	H	OH

*R² and R^{3b} joined together by (CH₂)₃ to form five-membered ring.

Table XXVI-50.

N ^o	R ¹	R ²	R ^{3a}	R ^{3b}	R ⁴	R ⁵	R ⁶	X	Y
XXVI-50-1	p-I-Ph	H	H	H	Bz	H	F	H	OH
XXVI-50-2	p-I-Ph	H	H	CH ₃	Bz	H	F	H	OH
XXVI-50-3	p-I-Ph	H	H	CH(CH ₃) ₂	Bz	H	F	H	OH
XXVI-50-4	p-I-Ph	H	H	CH ₂ CH(CH ₃) ₂	Bz	H	F	H	OH
XXVI-50-5	p-I-Ph	H	H	CH ₂ Ph	Bz	H	F	H	OH
XXVI-50-6	p-I-Ph	H	H	CH ₂ -indol-3-yl	Bz	H	F	H	OH
XXVI-50-7	p-I-Ph	H	H	CH ₂ CH ₂ SCH ₃	Bz	H	F	H	OH
XXVI-50-8	p-I-Ph	*	H	*	Bz	H	F	H	OH

*R² and R^{3b} joined together by (CH₂)₃ to form five-membered ring.


**XXVII**

Table XXVII-1.

No	R ¹	R ²	R ^{3a}	R ^{3b}	R ⁴	R ⁵	R ⁶	X	Y
XXVII-1-1	CH ₃	H	H	H	CH ₃	H	F	F	OH
XXVII-1-2	CH ₃	H	H	CH ₃	CH ₃	H	F	F	OH
XXVII-1-3	CH ₃	H	H	CH(CH ₃) ₂	CH ₃	H	F	F	OH
XXVII-1-4	CH ₃	H	H	CH ₂ CH(CH ₃) ₂	CH ₃	H	F	F	OH
XXVII-1-5	CH ₃	H	H	CH ₂ Ph	CH ₃	H	F	F	OH
XXVII-1-6	CH ₃	H	H	CH ₂ -indol-3-yl	CH ₃	H	F	F	OH
XXVII-1-7	CH ₃	H	H	CH ₂ CH ₂ SCH ₃	CH ₃	H	F	F	OH
XXVII-1-8	CH ₃	*	H	*	CH ₃	H	F	F	OH

*R² and R^{3b} joined together by (CH₂)₃ to form five-membered ring.

Table XXVII-2.

No	R ¹	R ²	R ^{3a}	R ^{3b}	R ⁴	R ⁵	R ⁶	X	Y
XXVII-2-1	Et	H	H	H	CH ₃	H	F	F	OH
XXVII-2-2	Et	H	H	CH ₃	CH ₃	H	F	F	OH
XXVII-2-3	Et	H	H	CH(CH ₃) ₂	CH ₃	H	F	F	OH
XXVII-2-4	Et	H	H	CH ₂ CH(CH ₃) ₂	CH ₃	H	F	F	OH
XXVII-2-5	Et	H	H	CH ₂ Ph	CH ₃	H	F	F	OH
XXVII-2-6	Et	H	H	CH ₂ -indol-3-yl	CH ₃	H	F	F	OH
XXVII-2-7	Et	H	H	CH ₂ CH ₂ SCH ₃	CH ₃	H	F	F	OH
XXVII-2-8	Et	*	H	*	CH ₃	H	F	F	OH

*R² and R^{3b} joined together by (CH₂)₃ to form five-membered ring.

Table XXVII-3.

N ^o	R ¹	R ²	R ^{3a}	R ^{3b}	R ⁴	R ⁵	R ⁶	X	Y
XXVII-3-1	^t Pr	H	H	H	CH ₃	H	F	F	OH
XXVII-3-2	^t Pr	H	H	CH ₃	CH ₃	H	F	F	OH
XXVII-3-3	^t Pr	H	H	CH(CH ₃) ₂	CH ₃	H	F	F	OH
XXVII-3-4	^t Pr	H	H	CH ₂ CH(CH ₃) ₂	CH ₃	H	F	F	OH
XXVII-3-5	^t Pr	H	H	CH ₂ Ph	CH ₃	H	F	F	OH
XXVII-3-6	^t Pr	H	H	CH ₂ -indol-3-yl	CH ₃	H	F	F	OH
XXVII-3-7	^t Pr	H	H	CH ₂ CH ₂ SCH ₃	CH ₃	H	F	F	OH
XXVII-3-8	^t Pr	*	H	*	CH ₃	H	F	F	OH

*R² and R^{3b} joined together by (CH₂)₃ to form five-membered ring.

Table XXVII-4.

N ^o	R ¹	R ²	R ^{3a}	R ^{3b}	R ⁴	R ⁵	R ⁶	X	Y
XXVII-4-1	^t Bu	H	H	H	CH ₃	H	F	F	OH
XXVII-4-2	^t Bu	H	H	CH ₃	CH ₃	H	F	F	OH
XXVII-4-3	^t Bu	H	H	CH(CH ₃) ₂	CH ₃	H	F	F	OH
XXVII-4-4	^t Bu	H	H	CH ₂ CH(CH ₃) ₂	CH ₃	H	F	F	OH
XXVII-4-5	^t Bu	H	H	CH ₂ Ph	CH ₃	H	F	F	OH
XXVII-4-6	^t Bu	H	H	CH ₂ -indol-3-yl	CH ₃	H	F	F	OH
XXVII-4-7	^t Bu	H	H	CH ₂ CH ₂ SCH ₃	CH ₃	H	F	F	OH
XXVII-4-8	^t Bu	*	H	*	CH ₃	H	F	F	OH

*R² and R^{3b} joined together by (CH₂)₃ to form five-membered ring.

Table XXVII-5.

N ^o	R ¹	R ²	R ^{3a}	R ^{3b}	R ⁴	R ⁵	R ⁶	X	Y
XXVII-5-1	Ph	H	H	H	CH ₃	H	F	F	OH
XXVII-5-2	Ph	H	H	CH ₃	CH ₃	H	F	F	OH
XXVII-5-3	Ph	H	H	CH(CH ₃) ₂	CH ₃	H	F	F	OH
XXVII-5-4	Ph	H	H	CH ₂ CH(CH ₃) ₂	CH ₃	H	F	F	OH
XXVII-5-5	Ph	H	H	CH ₂ Ph	CH ₃	H	F	F	OH
XXVII-5-6	Ph	H	H	CH ₂ -indol-3-yl	CH ₃	H	F	F	OH
XXVII-5-7	Ph	H	H	CH ₂ CH ₂ SCH ₃	CH ₃	H	F	F	OH
XXVII-5-8	Ph	*	H	*	CH ₃	H	F	F	OH

*R² and R^{3b} joined together by (CH₂)₃ to form five-membered ring.

Table XXVII-6.

№	R ¹	R ²	R ^{3a}	R ^{3b}	R ⁴	R ⁵	R ⁶	X	Y
XXVII-6-1	p-Me-Ph	H	H	H	CH ₃	H	F	F	OH
XXVII-6-2	p-Me-Ph	H	H	CH ₃	CH ₃	H	F	F	OH
XXVII-6-3	p-Me-Ph	H	H	CH(CH ₃) ₂	CH ₃	H	F	F	OH
XXVII-6-4	p-Me-Ph	H	H	CH ₂ CH(CH ₃) ₂	CH ₃	H	F	F	OH
XXVII-6-5	p-Me-Ph	H	H	CH ₂ Ph	CH ₃	H	F	F	OH
XXVII-6-6	p-Me-Ph	H	H	CH ₂ -indol-3-yl	CH ₃	H	F	F	OH
XXVII-6-7	p-Me-Ph	H	H	CH ₂ CH ₂ SCH ₃	CH ₃	H	F	F	OH
XXVII-6-8	p-Me-Ph	*	H	*	CH ₃	H	F	F	OH

*R² and R^{3b} joined together by (CH₂)₃ to form five-membered ring.

Table XXVII-7.

№	R ¹	R ²	R ^{3a}	R ^{3b}	R ⁴	R ⁵	R ⁶	X	Y
XXVII-7-1	p-F-Ph	H	H	H	CH ₃	H	F	F	OH
XXVII-7-2	p-F-Ph	H	H	CH ₃	CH ₃	H	F	F	OH
XXVII-7-3	p-F-Ph	H	H	CH(CH ₃) ₂	CH ₃	H	F	F	OH
XXVII-7-4	p-F-Ph	H	H	CH ₂ CH(CH ₃) ₂	CH ₃	H	F	F	OH
XXVII-7-6	p-F-Ph	H	H	CH ₂ Ph	CH ₃	H	F	F	OH
XXVII-7-7	p-F-Ph	H	H	CH ₂ -indol-3-yl	CH ₃	H	F	F	OH
XXVII-7-8	p-F-Ph	H	H	CH ₂ CH ₂ SCH ₃	CH ₃	H	F	F	OH
XXVII-7-20	p-F-Ph	*	H	*	CH ₃	H	F	F	OH

*R² and R^{3b} joined together by (CH₂)₃ to form five-membered ring.

Table XXVII-8.

№	R ¹	R ²	R ^{3a}	R ^{3b}	R ⁴	R ⁵	R ⁶	X	Y
XXVII-8-1	p-Cl-Ph	H	H	H	CH ₃	H	F	F	OH
XXVII-8-2	p-Cl-Ph	H	H	CH ₃	CH ₃	H	F	F	OH
XXVII-8-3	p-Cl-Ph	H	H	CH(CH ₃) ₂	CH ₃	H	F	F	OH
XXVII-8-4	p-Cl-Ph	H	H	CH ₂ CH(CH ₃) ₂	CH ₃	H	F	F	OH
XXVII-8-5	p-Cl-Ph	H	H	CH ₂ Ph	CH ₃	H	F	F	OH
XXVII-8-6	p-Cl-Ph	H	H	CH ₂ -indol-3-yl	CH ₃	H	F	F	OH
XXVII-8-7	p-Cl-Ph	H	H	CH ₂ CH ₂ SCH ₃	CH ₃	H	F	F	OH
XXVII-8-8	p-Cl-Ph	*	H	*	CH ₃	H	F	F	OH

*R² and R^{3b} joined together by (CH₂)₃ to form five-membered ring.

Table XXVII-9.

№	R ¹	R ²	R ^{3a}	R ^{3b}	R ⁴	R ⁵	R ⁶	X	Y
XXVII-9-1	p-Br-Ph	H	H	H	CH ₃	H	F	F	OH
XXVII-9-2	p-Br-Ph	H	H	CH ₃	CH ₃	H	F	F	OH
XXVII-9-3	p-Br-Ph	H	H	CH(CH ₃) ₂	CH ₃	H	F	F	OH
XXVII-9-4	p-Br-Ph	H	H	CH ₂ CH(CH ₃) ₂	CH ₃	H	F	F	OH
XXVII-9-6	p-Br-Ph	H	H	CH ₂ Ph	CH ₃	H	F	F	OH
XXVII-9-7	p-Br-Ph	H	H	CH ₂ -indol-3-yl	CH ₃	H	F	F	OH
XXVII-9-8	p-Br-Ph	H	H	CH ₂ CH ₂ SCH ₃	CH ₃	H	F	F	OH
XXVII-9-20	p-Br-Ph	*	H	*	CH ₃	H	F	F	OH

*R² and R^{3b} joined together by (CH₂)₃ to form five-membered ring.

Table XXVII-10.

№	R ¹	R ²	R ^{3a}	R ^{3b}	R ⁴	R ⁵	R ⁶	X	Y
XXVII-10-1	p-I-Ph	H	H	H	CH ₃	H	F	F	OH
XXVII-10-2	p-I-Ph	H	H	CH ₃	CH ₃	H	F	F	OH
XXVII-10-3	p-I-Ph	H	H	CH(CH ₃) ₂	CH ₃	H	F	F	OH
XXVII-10-4	p-I-Ph	H	H	CH ₂ CH(CH ₃) ₂	CH ₃	H	F	F	OH
XXVII-10-5	p-I-Ph	H	H	CH ₂ Ph	CH ₃	H	F	F	OH
XXVII-10-6	p-I-Ph	H	H	CH ₂ -indol-3-yl	CH ₃	H	F	F	OH
XXVII-10-7	p-I-Ph	H	H	CH ₂ CH ₂ SCH ₃	CH ₃	H	F	F	OH
XXVII-10-8	p-I-Ph	*	H	*	CH ₃	H	F	F	OH

*R² and R^{3b} joined together by (CH₂)₃ to form five-membered ring.

Table XXVII-11.

№	R ¹	R ²	R ^{3a}	R ^{3b}	R ⁴	R ⁵	R ⁶	X	Y
XXVII-11-1	CH ₃	H	H	H	Et	H	F	F	OH
XXVII-11-2	CH ₃	H	H	CH ₃	Et	H	F	F	OH
XXVII-11-3	CH ₃	H	H	CH(CH ₃) ₂	Et	H	F	F	OH
XXVII-11-4	CH ₃	H	H	CH ₂ CH(CH ₃) ₂	Et	H	F	F	OH
XXVII-11-5	CH ₃	H	H	CH ₂ Ph	Et	H	F	F	OH
XXVII-11-6	CH ₃	H	H	CH ₂ -indol-3-yl	Et	H	F	F	OH
XXVII-11-7	CH ₃	H	H	CH ₂ CH ₂ SCH ₃	Et	H	F	F	OH
XXVII-11-8	CH ₃	*	H	*	Et	H	F	F	OH

*R² and R^{3b} joined together by (CH₂)₃ to form five-membered ring.

Table XXVII-12.

N ^o	R ¹	R ²	R ^{3a}	R ^{3b}	R ⁴	R ⁵	R ⁶	X	Y
XXVII-12-1	Et	H	H	H	Et	H	F	F	OH
XXVII-12-2	Et	H	H	CH ₃	Et	H	F	F	OH
XXVII-12-3	Et	H	H	CH(CH ₃) ₂	Et	H	F	F	OH
XXVII-12-4	Et	H	H	CH ₂ CH(CH ₃) ₂	Et	H	F	F	OH
XXVII-12-5	Et	H	H	CH ₂ Ph	Et	H	F	F	OH
XXVII-12-6	Et	H	H	CH ₂ -indol-3-yl	Et	H	F	F	OH
XXVII-12-7	Et	H	H	CH ₂ CH ₂ SCH ₃	Et	H	F	F	OH
XXVII-12-8	Et	*	H	*	Et	H	F	F	OH

*R² and R^{3b} joined together by (CH₂)₃ to form five-membered ring.

Table XXVII-13.

N ^o	R ¹	R ²	R ^{3a}	R ^{3b}	R ⁴	R ⁵	R ⁶	X	Y
XXVII-13-1	ⁱ Pr	H	H	H	Et	H	F	F	OH
XXVII-13-2	ⁱ Pr	H	H	CH ₃	Et	H	F	F	OH
XXVII-13-3	ⁱ Pr	H	H	CH(CH ₃) ₂	Et	H	F	F	OH
XXVII-13-4	ⁱ Pr	H	H	CH ₂ CH(CH ₃) ₂	Et	H	F	F	OH
XXVII-13-5	ⁱ Pr	H	H	CH ₂ Ph	Et	H	F	F	OH
XXVII-13-6	ⁱ Pr	H	H	CH ₂ -indol-3-yl	Et	H	F	F	OH
XXVII-13-7	ⁱ Pr	H	H	CH ₂ CH ₂ SCH ₃	Et	H	F	F	OH
XXVII-13-8	ⁱ Pr	*	H	*	Et	H	F	F	OH

*R² and R^{3b} joined together by (CH₂)₃ to form five-membered ring.

Table XXVII-14.

N ^o	R ¹	R ²	R ^{3a}	R ^{3b}	R ⁴	R ⁵	R ⁶	X	Y
XXVII-14-1	^t Bu	H	H	H	Et	H	F	F	OH
XXVII-14-2	^t Bu	H	H	CH ₃	Et	H	F	F	OH
XXVII-14-3	^t Bu	H	H	CH(CH ₃) ₂	Et	H	F	F	OH
XXVII-14-4	^t Bu	H	H	CH ₂ CH(CH ₃) ₂	Et	H	F	F	OH
XXVII-14-5	^t Bu	H	H	CH ₂ Ph	Et	H	F	F	OH
XXVII-14-6	^t Bu	H	H	CH ₂ -indol-3-yl	Et	H	F	F	OH
XXVII-14-7	^t Bu	H	H	CH ₂ CH ₂ SCH ₃	Et	H	F	F	OH
XXVII-14-8	^t Bu	*	H	*	Et	H	F	F	OH

*R² and R^{3b} joined together by (CH₂)₃ to form five-membered ring.

Table XXVII-15.

N ^o	R ¹	R ²	R ^{3a}	R ^{3b}	R ⁴	R ⁵	R ⁶	X	Y
XXVII-15-1	Ph	H	H	H	Et	H	F	F	OH
XXVII-15-2	Ph	H	H	CH ₃	Et	H	F	F	OH
XXVII-15-3	Ph	H	H	CH(CH ₃) ₂	Et	H	F	F	OH
XXVII-15-4	Ph	H	H	CH ₂ CH(CH ₃) ₂	Et	H	F	F	OH
XXVII-15-5	Ph	H	H	CH ₂ Ph	Et	H	F	F	OH
XXVII-15-6	Ph	H	H	CH ₂ -indol-3-yl	Et	H	F	F	OH
XXVII-15-7	Ph	H	H	CH ₂ CH ₂ SCH ₃	Et	H	F	F	OH
XXVII-15-8	Ph	*	H	*	Et	H	F	F	OH

*R² and R^{3b} joined together by (CH₂)₃ to form five-membered ring.

Table XXVII-16.

N ^o	R ¹	R ²	R ^{3a}	R ^{3b}	R ⁴	R ⁵	R ⁶	X	Y
XXVII-16-1	p-Me-Ph	H	H	H	Et	H	F	F	OH
XXVII-16-2	p-Me-Ph	H	H	CH ₃	Et	H	F	F	OH
XXVII-16-3	p-Me-Ph	H	H	CH(CH ₃) ₂	Et	H	F	F	OH
XXVII-16-4	p-Me-Ph	H	H	CH ₂ CH(CH ₃) ₂	Et	H	F	F	OH
XXVII-16-5	p-Me-Ph	H	H	CH ₂ Ph	Et	H	F	F	OH
XXVII-16-6	p-Me-Ph	H	H	CH ₂ -indol-3-yl	Et	H	F	F	OH
XXVII-16-7	p-Me-Ph	H	H	CH ₂ CH ₂ SCH ₃	Et	H	F	F	OH
XXVII-16-8	p-Me-Ph	*	H	*	Et	H	F	F	OH

*R² and R^{3b} joined together by (CH₂)₃ to form five-membered ring.

Table XXVII-17.

N ^o	R ¹	R ²	R ^{3a}	R ^{3b}	R ⁴	R ⁵	R ⁶	X	Y
XXVII-17-1	p-F-Ph	H	H	H	Et	H	F	F	OH
XXVII-17-2	p-F-Ph	H	H	CH ₃	Et	H	F	F	OH
XXVII-17-3	p-F-Ph	H	H	CH(CH ₃) ₂	Et	H	F	F	OH
XXVII-17-4	p-F-Ph	H	H	CH ₂ CH(CH ₃) ₂	Et	H	F	F	OH
XXVII-17-5	p-F-Ph	H	H	CH ₂ Ph	Et	H	F	F	OH
XXVII-17-6	p-F-Ph	H	H	CH ₂ -indol-3-yl	Et	H	F	F	OH
XXVII-17-7	p-F-Ph	H	H	CH ₂ CH ₂ SCH ₃	Et	H	F	F	OH
XXVII-17-8	p-F-Ph	*	H	*	Et	H	F	F	OH

*R² and R^{3b} joined together by (CH₂)₃ to form five-membered ring.

Table XXVII-18.

N ^o	R ¹	R ²	R ^{3a}	R ^{3b}	R ⁴	R ⁵	R ⁶	X	Y
XXVII-18-1	p-Cl-Ph	H	H	H	Et	H	F	F	OH
XXVII-18-2	p-Cl-Ph	H	H	CH ₃	Et	H	F	F	OH
XXVII-18-3	p-Cl-Ph	H	H	CH(CH ₃) ₂	Et	H	F	F	OH
XXVII-18-4	p-Cl-Ph	H	H	CH ₂ CH(CH ₃) ₂	Et	H	F	F	OH
XXVII-18-5	p-Cl-Ph	H	H	CH ₂ Ph	Et	H	F	F	OH
XXVII-18-6	p-Cl-Ph	H	H	CH ₂ -indol-3-yl	Et	H	F	F	OH
XXVII-18-7	p-Cl-Ph	H	H	CH ₂ CH ₂ SCH ₃	Et	H	F	F	OH
XXVII-18-8	p-Cl-Ph	*	H	*	Et	H	F	F	OH

*R² and R^{3b} joined together by (CH₂)₃ to form five-membered ring.

Table XXVII-19.

N ^o	R ¹	R ²	R ^{3a}	R ^{3b}	R ⁴	R ⁵	R ⁶	X	Y
XXVII-19-1	p-Br-Ph	H	H	H	Et	H	F	F	OH
XXVII-19-2	p-Br-Ph	H	H	CH ₃	Et	H	F	F	OH
XXVII-19-3	p-Br-Ph	H	H	CH(CH ₃) ₂	Et	H	F	F	OH
XXVII-19-4	p-Br-Ph	H	H	CH ₂ CH(CH ₃) ₂	Et	H	F	F	OH
XXVII-19-5	p-Br-Ph	H	H	CH ₂ Ph	Et	H	F	F	OH
XXVII-19-6	p-Br-Ph	H	H	CH ₂ -indol-3-yl	Et	H	F	F	OH
XXVII-19-7	p-Br-Ph	H	H	CH ₂ CH ₂ SCH ₃	Et	H	F	F	OH
XXVII-19-8	p-Br-Ph	*	H	*	Et	H	F	F	OH

*R² and R^{3b} joined together by (CH₂)₃ to form five-membered ring.

Table XXVII-20.

N ^o	R ¹	R ²	R ^{3a}	R ^{3b}	R ⁴	R ⁵	R ⁶	X	Y
XXVII-20-1	p-I-Ph	H	H	H	Et	H	F	F	OH
XXVII-20-2	p-I-Ph	H	H	CH ₃	Et	H	F	F	OH
XXVII-20-3	p-I-Ph	H	H	CH(CH ₃) ₂	Et	H	F	F	OH
XXVII-20-4	p-I-Ph	H	H	CH ₂ CH(CH ₃) ₂	Et	H	F	F	OH
XXVII-20-5	p-I-Ph	H	H	CH ₂ Ph	Et	H	F	F	OH
XXVII-20-6	p-I-Ph	H	H	CH ₂ -indol-3-yl	Et	H	F	F	OH
XXVII-20-7	p-I-Ph	H	H	CH ₂ CH ₂ SCH ₃	Et	H	F	F	OH
XXVII-20-8	p-I-Ph	*	H	*	Et	H	F	F	OH

*R² and R^{3b} joined together by (CH₂)₃ to form five-membered ring.

Table XXVII-21.

N ^o	R ¹	R ²	R ^{3a}	R ^{3b}	R ⁴	R ⁵	R ⁶	X	Y
XXVII-21-1	CH ₃	H	H	H	ⁱ Pr	H	F	F	OH
XXVII-21-2	CH ₃	H	H	CH ₃	ⁱ Pr	H	F	F	OH
XXVII-21-3	CH ₃	H	H	CH(CH ₃) ₂	ⁱ Pr	H	F	F	OH
XXVII-21-4	CH ₃	H	H	CH ₂ CH(CH ₃) ₂	ⁱ Pr	H	F	F	OH
XXVII-21-5	CH ₃	H	H	CH ₂ Ph	ⁱ Pr	H	F	F	OH
XXVII-21-6	CH ₃	H	H	CH ₂ -indol-3-yl	ⁱ Pr	H	F	F	OH
XXVII-21-7	CH ₃	H	H	CH ₂ CH ₂ SCH ₃	ⁱ Pr	H	F	F	OH
XXVII-21-8	CH ₃	*	H	*	ⁱ Pr	H	F	F	OH

*R² and R^{3b} joined together by (CH₂)₃ to form five-membered ring.

Table XXVII-22.

N ^o	R ¹	R ²	R ^{3a}	R ^{3b}	R ⁴	R ⁵	R ⁶	X	Y
XXVII-22-1	Et	H	H	H	ⁱ Pr	H	F	F	OH
XXVII-22-2	Et	H	H	CH ₃	ⁱ Pr	H	F	F	OH
XXVII-22-3	Et	H	H	CH(CH ₃) ₂	ⁱ Pr	H	F	F	OH
XXVII-22-4	Et	H	H	CH ₂ CH(CH ₃) ₂	ⁱ Pr	H	F	F	OH
XXVII-22-5	Et	H	H	CH ₂ Ph	ⁱ Pr	H	F	F	OH
XXVII-22-6	Et	H	H	CH ₂ -indol-3-yl	ⁱ Pr	H	F	F	OH
XXVII-22-7	Et	H	H	CH ₂ CH ₂ SCH ₃	ⁱ Pr	H	F	F	OH
XXVII-22-8	Et	*	H	*	ⁱ Pr	H	F	F	OH

*R² and R^{3b} joined together by (CH₂)₃ to form five-membered ring.

Table XXVII-23.

N ^o	R ¹	R ²	R ^{3a}	R ^{3b}	R ⁴	R ⁵	R ⁶	X	Y
XXVII-23-1	ⁱ Pr	H	H	H	ⁱ Pr	H	F	F	OH
XXVII-23-2	ⁱ Pr	H	H	CH ₃	ⁱ Pr	H	F	F	OH
XXVII-23-3	ⁱ Pr	H	H	CH(CH ₃) ₂	ⁱ Pr	H	F	F	OH
XXVII-23-4	ⁱ Pr	H	H	CH ₂ CH(CH ₃) ₂	ⁱ Pr	H	F	F	OH
XXVII-23-5	ⁱ Pr	H	H	CH ₂ Ph	ⁱ Pr	H	F	F	OH
XXVII-23-6	ⁱ Pr	H	H	CH ₂ -indol-3-yl	ⁱ Pr	H	F	F	OH
XXVII-23-7	ⁱ Pr	H	H	CH ₂ CH ₂ SCH ₃	ⁱ Pr	H	F	F	OH
XXVII-23-8	ⁱ Pr	*	H	*	ⁱ Pr	H	F	F	OH

*R² and R^{3b} joined together by (CH₂)₃ to form five-membered ring.

Table XXVII-24.

N ^o	R ¹	R ²	R ^{3a}	R ^{3b}	R ⁴	R ⁵	R ⁶	X	Y
XXVII-24-1	^t Bu	H	H	H	ⁱ Pr	H	F	F	OH
XXVII-24-2	^t Bu	H	H	CH ₃	ⁱ Pr	H	F	F	OH
XXVII-24-3	^t Bu	H	H	CH(CH ₃) ₂	ⁱ Pr	H	F	F	OH
XXVII-24-4	^t Bu	H	H	CH ₂ CH(CH ₃) ₂	ⁱ Pr	H	F	F	OH
XXVII-24-5	^t Bu	H	H	CH ₂ Ph	ⁱ Pr	H	F	F	OH
XXVII-24-6	^t Bu	H	H	CH ₂ -indol-3-yl	ⁱ Pr	H	F	F	OH
XXVII-24-7	^t Bu	H	H	CH ₂ CH ₂ SCH ₃	ⁱ Pr	H	F	F	OH
XXVII-24-8	^t Bu	*	H	*	ⁱ Pr	H	F	F	OH

*R² and R^{3b} joined together by (CH₂)₃ to form five-membered ring.

Table XXVII-25.

N ^o	R ¹	R ²	R ^{3a}	R ^{3b}	R ⁴	R ⁵	R ⁶	X	Y
XXVII-25-1	Ph	H	H	H	ⁱ Pr	H	F	F	OH
XXVII-25-2	Ph	H	H	CH ₃	ⁱ Pr	H	F	F	OH
XXVII-25-3	Ph	H	H	CH(CH ₃) ₂	ⁱ Pr	H	F	F	OH
XXVII-25-4	Ph	H	H	CH ₂ CH(CH ₃) ₂	ⁱ Pr	H	F	F	OH
XXVII-25-5	Ph	H	H	CH ₂ Ph	ⁱ Pr	H	F	F	OH
XXVII-25-6	Ph	H	H	CH ₂ -indol-3-yl	ⁱ Pr	H	F	F	OH
XXVII-25-7	Ph	H	H	CH ₂ CH ₂ SCH ₃	ⁱ Pr	H	F	F	OH
XXVII-25-8	Ph	*	H	*	ⁱ Pr	H	F	F	OH

*R² and R^{3b} joined together by (CH₂)₃ to form five-membered ring.

Table XXVII-26.

N ^o	R ¹	R ²	R ^{3a}	R ^{3b}	R ⁴	R ⁵	R ⁶	X	Y
XXVII-26-1	p-Me-Ph	H	H	H	ⁱ Pr	H	F	F	OH
XXVII-26-2	p-Me-Ph	H	H	CH ₃	ⁱ Pr	H	F	F	OH
XXVII-26-3	p-Me-Ph	H	H	CH(CH ₃) ₂	ⁱ Pr	H	F	F	OH
XXVII-26-4	p-Me-Ph	H	H	CH ₂ CH(CH ₃) ₂	ⁱ Pr	H	F	F	OH
XXVII-26-5	p-Me-Ph	H	H	CH ₂ Ph	ⁱ Pr	H	F	F	OH
XXVII-26-6	p-Me-Ph	H	H	CH ₂ -indol-3-yl	ⁱ Pr	H	F	F	OH
XXVII-26-7	p-Me-Ph	H	H	CH ₂ CH ₂ SCH ₃	ⁱ Pr	H	F	F	OH
XXVII-26-8	p-Me-Ph	*	H	*	ⁱ Pr	H	F	F	OH

*R² and R^{3b} joined together by (CH₂)₃ to form five-membered ring.

Table XXVII-27.

N ^o	R ¹	R ²	R ^{3a}	R ^{3b}	R ⁴	R ⁵	R ⁶	X	Y
XXVII-27-1	p-F-Ph	H	H	H	ⁱ Pr	H	F	F	OH
XXVII-27-2	p-F-Ph	H	H	CH ₃	ⁱ Pr	H	F	F	OH
XXVII-27-3	p-F-Ph	H	H	CH(CH ₃) ₂	ⁱ Pr	H	F	F	OH
XXVII-27-4	p-F-Ph	H	H	CH ₂ CH(CH ₃) ₂	ⁱ Pr	H	F	F	OH
XXVII-27-5	p-F-Ph	H	H	CH ₂ Ph	ⁱ Pr	H	F	F	OH
XXVII-27-6	p-F-Ph	H	H	CH ₂ -indol-3-yl	ⁱ Pr	H	F	F	OH
XXVII-27-7	p-F-Ph	H	H	CH ₂ CH ₂ SCH ₃	ⁱ Pr	H	F	F	OH
XXVII-27-8	p-F-Ph	*	H	*	ⁱ Pr	H	F	F	OH

*R² and R^{3b} joined together by (CH₂)₃ to form five-membered ring.

Table XXVII-28.

N ^o	R ¹	R ²	R ^{3a}	R ^{3b}	R ⁴	R ⁵	R ⁶	X	Y
XXVII-28-1	p-Cl-Ph	H	H	H	ⁱ Pr	H	F	F	OH
XXVII-28-2	p-Cl-Ph	H	H	CH ₃	ⁱ Pr	H	F	F	OH
XXVII-28-3	p-Cl-Ph	H	H	CH(CH ₃) ₂	ⁱ Pr	H	F	F	OH
XXVII-28-4	p-Cl-Ph	H	H	CH ₂ CH(CH ₃) ₂	ⁱ Pr	H	F	F	OH
XXVII-28-5	p-Cl-Ph	H	H	CH ₂ Ph	ⁱ Pr	H	F	F	OH
XXVII-28-6	p-Cl-Ph	H	H	CH ₂ -indol-3-yl	ⁱ Pr	H	F	F	OH
XXVII-28-7	p-Cl-Ph	H	H	CH ₂ CH ₂ SCH ₃	ⁱ Pr	H	F	F	OH
XXVII-28-8	p-Cl-Ph	*	H	*	ⁱ Pr	H	F	F	OH

*R² and R^{3b} joined together by (CH₂)₃ to form five-membered ring.

Table XXVII-29.

N ^o	R ¹	R ²	R ^{3a}	R ^{3b}	R ⁴	R ⁵	R ⁶	X	Y
XXVII-29-1	p-Br-Ph	H	H	H	ⁱ Pr	H	F	F	OH
XXVII-29-2	p-Br-Ph	H	H	CH ₃	ⁱ Pr	H	F	F	OH
XXVII-29-3	p-Br-Ph	H	H	CH(CH ₃) ₂	ⁱ Pr	H	F	F	OH
XXVII-29-4	p-Br-Ph	H	H	CH ₂ CH(CH ₃) ₂	ⁱ Pr	H	F	F	OH
XXVII-29-5	p-Br-Ph	H	H	CH ₂ Ph	ⁱ Pr	H	F	F	OH
XXVII-29-6	p-Br-Ph	H	H	CH ₂ -indol-3-yl	ⁱ Pr	H	F	F	OH
XXVII-29-7	p-Br-Ph	H	H	CH ₂ CH ₂ SCH ₃	ⁱ Pr	H	F	F	OH
XXVII-29-8	p-Br-Ph	*	H	*	ⁱ Pr	H	F	F	OH

*R² and R^{3b} joined together by (CH₂)₃ to form five-membered ring.

Table XXVII-30.

N ^o	R ¹	R ²	R ^{3a}	R ^{3b}	R ⁴	R ⁵	R ⁶	X	Y
XXVII-30-1	p-I-Ph	H	H	H	ⁱ Pr	H	F	F	OH
XXVII-30-2	p-I-Ph	H	H	CH ₃	ⁱ Pr	H	F	F	OH
XXVII-30-3	p-I-Ph	H	H	CH(CH ₃) ₂	ⁱ Pr	H	F	F	OH
XXVII-30-4	p-I-Ph	H	H	CH ₂ CH(CH ₃) ₂	ⁱ Pr	H	F	F	OH
XXVII-30-5	p-I-Ph	H	H	CH ₂ Ph	ⁱ Pr	H	F	F	OH
XXVII-30-6	p-I-Ph	H	H	CH ₂ -indol-3-yl	ⁱ Pr	H	F	F	OH
XXVII-30-7	p-I-Ph	H	H	CH ₂ CH ₂ SCH ₃	ⁱ Pr	H	F	F	OH
XXVII-30-8	p-I-Ph	*	H	*	ⁱ Pr	H	F	F	OH

*R² and R^{3b} joined together by (CH₂)₃ to form five-membered ring.

Table XXVII-31.

N ^o	R ¹	R ²	R ^{3a}	R ^{3b}	R ⁴	R ⁵	R ⁶	X	Y
XXVII-31-1	CH ₃	H	H	H	ⁿ Bu	H	F	F	OH
XXVII-31-2	CH ₃	H	H	CH ₃	ⁿ Bu	H	F	F	OH
XXVII-31-3	CH ₃	H	H	CH(CH ₃) ₂	ⁿ Bu	H	F	F	OH
XXVII-31-4	CH ₃	H	H	CH ₂ CH(CH ₃) ₂	ⁿ Bu	H	F	F	OH
XXVII-31-5	CH ₃	H	H	CH ₂ Ph	ⁿ Bu	H	F	F	OH
XXVII-31-6	CH ₃	H	H	CH ₂ -indol-3-yl	ⁿ Bu	H	F	F	OH
XXVII-31-7	CH ₃	H	H	CH ₂ CH ₂ SCH ₃	ⁿ Bu	H	F	F	OH
XXVII-31-8	CH ₃	*	H	*	ⁿ Bu	H	F	F	OH

*R² and R^{3b} joined together by (CH₂)₃ to form five-membered ring.

Table XXVII-32.

N ^o	R ¹	R ²	R ^{3a}	R ^{3b}	R ⁴	R ⁵	R ⁶	X	Y
XXVII-32-1	Et	H	H	H	ⁿ Bu	H	F	F	OH
XXVII-32-2	Et	H	H	CH ₃	ⁿ Bu	H	F	F	OH
XXVII-32-3	Et	H	H	CH(CH ₃) ₂	ⁿ Bu	H	F	F	OH
XXVII-32-4	Et	H	H	CH ₂ CH(CH ₃) ₂	ⁿ Bu	H	F	F	OH
XXVII-32-5	Et	H	H	CH ₂ Ph	ⁿ Bu	H	F	F	OH
XXVII-32-6	Et	H	H	CH ₂ -indol-3-yl	ⁿ Bu	H	F	F	OH
XXVII-32-7	Et	H	H	CH ₂ CH ₂ SCH ₃	ⁿ Bu	H	F	F	OH
XXVII-32-8	Et	*	H	*	ⁿ Bu	H	F	F	OH

*R² and R^{3b} joined together by (CH₂)₃ to form five-membered ring.

Table XXVII-33.

N ₂	R ¹	R ²	R ^{3a}	R ^{3b}	R ⁴	R ⁵	R ⁶	X	Y
XXVII-33-1	^t Pr	H	H	H	ⁿ Bu	H	F	F	OH
XXVII-33-2	^t Pr	H	H	CH ₃	ⁿ Bu	H	F	F	OH
XXVII-33-3	^t Pr	H	H	CH(CH ₃) ₂	ⁿ Bu	H	F	F	OH
XXVII-33-4	^t Pr	H	H	CH ₂ CH(CH ₃) ₂	ⁿ Bu	H	F	F	OH
XXVII-33-5	^t Pr	H	H	CH ₂ Ph	ⁿ Bu	H	F	F	OH
XXVII-33-6	^t Pr	H	H	CH ₂ -indol-3-yl	ⁿ Bu	H	F	F	OH
XXVII-33-7	^t Pr	H	H	CH ₂ CH ₂ SCH ₃	ⁿ Bu	H	F	F	OH
XXVII-33-8	^t Pr	*	H	*	ⁿ Bu	H	F	F	OH

*R² and R^{3b} joined together by (CH₂)₃ to form five-membered ring.

Table XXVII-34.

N ₂	R ¹	R ²	R ^{3a}	R ^{3b}	R ⁴	R ⁵	R ⁶	X	Y
XXVII-34-1	^t Bu	H	H	H	ⁿ Bu	H	F	F	OH
XXVII-34-2	^t Bu	H	H	CH ₃	ⁿ Bu	H	F	F	OH
XXVII-34-3	^t Bu	H	H	CH(CH ₃) ₂	ⁿ Bu	H	F	F	OH
XXVII-34-4	^t Bu	H	H	CH ₂ CH(CH ₃) ₂	ⁿ Bu	H	F	F	OH
XXVII-34-5	^t Bu	H	H	CH ₂ Ph	ⁿ Bu	H	F	F	OH
XXVII-34-6	^t Bu	H	H	CH ₂ -indol-3-yl	ⁿ Bu	H	F	F	OH
XXVII-34-7	^t Bu	H	H	CH ₂ CH ₂ SCH ₃	ⁿ Bu	H	F	F	OH
XXVII-34-8	^t Bu	*	H	*	ⁿ Bu	H	F	F	OH

*R² and R^{3b} joined together by (CH₂)₃ to form five-membered ring.

Table XXVII-35.

N ₂	R ¹	R ²	R ^{3a}	R ^{3b}	R ⁴	R ⁵	R ⁶	X	Y
XXVII-35-1	Ph	H	H	H	ⁿ Bu	H	F	F	OH
XXVII-35-2	Ph	H	H	CH ₃	ⁿ Bu	H	F	F	OH
XXVII-35-3	Ph	H	H	CH(CH ₃) ₂	ⁿ Bu	H	F	F	OH
XXVII-35-4	Ph	H	H	CH ₂ CH(CH ₃) ₂	ⁿ Bu	H	F	F	OH
XXVII-35-5	Ph	H	H	CH ₂ Ph	ⁿ Bu	H	F	F	OH
XXVII-35-6	Ph	H	H	CH ₂ -indol-3-yl	ⁿ Bu	H	F	F	OH
XXVII-35-7	Ph	H	H	CH ₂ CH ₂ SCH ₃	ⁿ Bu	H	F	F	OH
XXVII-35-8	Ph	*	H	*	ⁿ Bu	H	F	F	OH

*R² and R^{3b} joined together by (CH₂)₃ to form five-membered ring.

Table XXVII-36.

№	R ¹	R ²	R ^{3a}	R ^{3b}	R ⁴	R ⁵	R ⁶	X	Y
XXVII-36-1	p-Me-Ph	H	H	H	ⁿ Bu	H	F	F	OH
XXVII-36-2	p-Me-Ph	H	H	CH ₃	ⁿ Bu	H	F	F	OH
XXVII-36-3	p-Me-Ph	H	H	CH(CH ₃) ₂	ⁿ Bu	H	F	F	OH
XXVII-36-4	p-Me-Ph	H	H	CH ₂ CH(CH ₃) ₂	ⁿ Bu	H	F	F	OH
XXVII-36-5	p-Me-Ph	H	H	CH ₂ Ph	ⁿ Bu	H	F	F	OH
XXVII-36-6	p-Me-Ph	H	H	CH ₂ -indol-3-yl	ⁿ Bu	H	F	F	OH
XXVII-36-7	p-Me-Ph	H	H	CH ₂ CH ₂ SCH ₃	ⁿ Bu	H	F	F	OH
XXVII-36-8	p-Me-Ph	*	H	*	ⁿ Bu	H	F	F	OH

*R² and R^{3b} joined together by (CH₂)₃ to form five-membered ring.

Table XXVII-37.

№	R ¹	R ²	R ^{3a}	R ^{3b}	R ⁴	R ⁵	R ⁶	X	Y
XXVII-37-1	p-F-Ph	H	H	H	ⁿ Bu	H	F	F	OH
XXVII-37-2	p-F-Ph	H	H	CH ₃	ⁿ Bu	H	F	F	OH
XXVII-37-3	p-F-Ph	H	H	CH(CH ₃) ₂	ⁿ Bu	H	F	F	OH
XXVII-37-4	p-F-Ph	H	H	CH ₂ CH(CH ₃) ₂	ⁿ Bu	H	F	F	OH
XXVII-37-5	p-F-Ph	H	H	CH ₂ Ph	ⁿ Bu	H	F	F	OH
XXVII-37-6	p-F-Ph	H	H	CH ₂ -indol-3-yl	ⁿ Bu	H	F	F	OH
XXVII-37-7	p-F-Ph	H	H	CH ₂ CH ₂ SCH ₃	ⁿ Bu	H	F	F	OH
XXVII-37-8	p-F-Ph	*	H	*	ⁿ Bu	H	F	F	OH

*R² and R^{3b} joined together by (CH₂)₃ to form five-membered ring.

Table XXVII-38.

№	R ¹	R ²	R ^{3a}	R ^{3b}	R ⁴	R ⁵	R ⁶	X	Y
XXVII-38-1	p-Cl-Ph	H	H	H	ⁿ Bu	H	F	F	OH
XXVII-38-2	p-Cl-Ph	H	H	CH ₃	ⁿ Bu	H	F	F	OH
XXVII-38-3	p-Cl-Ph	H	H	CH(CH ₃) ₂	ⁿ Bu	H	F	F	OH
XXVII-38-4	p-Cl-Ph	H	H	CH ₂ CH(CH ₃) ₂	ⁿ Bu	H	F	F	OH
XXVII-38-5	p-Cl-Ph	H	H	CH ₂ Ph	ⁿ Bu	H	F	F	OH
XXVII-38-6	p-Cl-Ph	H	H	CH ₂ -indol-3-yl	ⁿ Bu	H	F	F	OH
XXVII-38-7	p-Cl-Ph	H	H	CH ₂ CH ₂ SCH ₃	ⁿ Bu	H	F	F	OH
XXVII-38-8	p-Cl-Ph	*	H	*	ⁿ Bu	H	F	F	OH

*R² and R^{3b} joined together by (CH₂)₃ to form five-membered ring.

Table XXVII-39.

N ^o	R ¹	R ²	R ^{3a}	R ^{3b}	R ⁴	R ⁵	R ⁶	X	Y
XXVII-39-1	p-Br-Ph	H	H	H	ⁿ Bu	H	F	F	OH
XXVII-39-2	p-Br-Ph	H	H	CH ₃	ⁿ Bu	H	F	F	OH
XXVII-39-3	p-Br-Ph	H	H	CH(CH ₃) ₂	ⁿ Bu	H	F	F	OH
XXVII-39-4	p-Br-Ph	H	H	CH ₂ CH(CH ₃) ₂	ⁿ Bu	H	F	F	OH
XXVII-39-5	p-Br-Ph	H	H	CH ₂ Ph	ⁿ Bu	H	F	F	OH
XXVII-39-6	p-Br-Ph	H	H	CH ₂ -indol-3-yl	ⁿ Bu	H	F	F	OH
XXVII-39-7	p-Br-Ph	H	H	CH ₂ CH ₂ SCH ₃	ⁿ Bu	H	F	F	OH
XXVII-39-8	p-Br-Ph	*	H	*	ⁿ Bu	H	F	F	OH

*R² and R^{3b} joined together by (CH₂)₃ to form five-membered ring.

Table XXVII-40.

N ^o	R ¹	R ²	R ^{3a}	R ^{3b}	R ⁴	R ⁵	R ⁶	X	Y
XXVII-40-1	p-I-Ph	H	H	H	ⁿ Bu	H	F	F	OH
XXVII-40-2	p-I-Ph	H	H	CH ₃	ⁿ Bu	H	F	F	OH
XXVII-40-3	p-I-Ph	H	H	CH(CH ₃) ₂	ⁿ Bu	H	F	F	OH
XXVII-40-4	p-I-Ph	H	H	CH ₂ CH(CH ₃) ₂	ⁿ Bu	H	F	F	OH
XXVII-40-5	p-I-Ph	H	H	CH ₂ Ph	ⁿ Bu	H	F	F	OH
XXVII-40-6	p-I-Ph	H	H	CH ₂ -indol-3-yl	ⁿ Bu	H	F	F	OH
XXVII-40-7	p-I-Ph	H	H	CH ₂ CH ₂ SCH ₃	ⁿ Bu	H	F	F	OH
XXVII-40-8	p-I-Ph	*	H	*	ⁿ Bu	H	F	F	OH

*R² and R^{3b} joined together by (CH₂)₃ to form five-membered ring.

Table XXVII-41.

N ^o	R ¹	R ²	R ^{3a}	R ^{3b}	R ⁴	R ⁵	R ⁶	X	Y
XXVII-41-1	CH ₃	H	H	H	Bz	H	F	F	OH
XXVII-41-2	CH ₃	H	H	CH ₃	Bz	H	F	F	OH
XXVII-41-3	CH ₃	H	H	CH(CH ₃) ₂	Bz	H	F	F	OH
XXVII-41-4	CH ₃	H	H	CH ₂ CH(CH ₃) ₂	Bz	H	F	F	OH
XXVII-41-5	CH ₃	H	H	CH ₂ Ph	Bz	H	F	F	OH
XXVII-41-6	CH ₃	H	H	CH ₂ -indol-3-yl	Bz	H	F	F	OH
XXVII-41-7	CH ₃	H	H	CH ₂ CH ₂ SCH ₃	Bz	H	F	F	OH
XXVII-41-8	CH ₃	*	H	*	Bz	H	F	F	OH

*R² and R^{3b} joined together by (CH₂)₃ to form five-membered ring.

Table XXVII-42.

N ^o	R ¹	R ²	R ^{3a}	R ^{3b}	R ⁴	R ⁵	R ⁶	X	Y
XXVII-42-1	Et	H	H	H	Bz	H	F	F	OH
XXVII-42-2	Et	H	H	CH ₃	Bz	H	F	F	OH
XXVII-42-3	Et	H	H	CH(CH ₃) ₂	Bz	H	F	F	OH
XXVII-42-4	Et	H	H	CH ₂ CH(CH ₃) ₂	Bz	H	F	F	OH
XXVII-42-5	Et	H	H	CH ₂ Ph	Bz	H	F	F	OH
XXVII-42-6	Et	H	H	CH ₂ -indol-3-yl	Bz	H	F	F	OH
XXVII-42-7	Et	H	H	CH ₂ CH ₂ SCH ₃	Bz	H	F	F	OH
XXVII-42-8	Et	*	H	*	Bz	H	F	F	OH

*R² and R^{3b} joined together by (CH₂)₃ to form five-membered ring.

Table XXVII-43.

N ^o	R ¹	R ²	R ^{3a}	R ^{3b}	R ⁴	R ⁵	R ⁶	X	Y
XXVII-43-1	ⁱ Pr	H	H	H	Bz	H	F	F	OH
XXVII-43-2	ⁱ Pr	H	H	CH ₃	Bz	H	F	F	OH
XXVII-43-3	ⁱ Pr	H	H	CH(CH ₃) ₂	Bz	H	F	F	OH
XXVII-43-4	ⁱ Pr	H	H	CH ₂ CH(CH ₃) ₂	Bz	H	F	F	OH
XXVII-43-5	ⁱ Pr	H	H	CH ₂ Ph	Bz	H	F	F	OH
XXVII-43-6	ⁱ Pr	H	H	CH ₂ -indol-3-yl	Bz	H	F	F	OH
XXVII-43-7	ⁱ Pr	H	H	CH ₂ CH ₂ SCH ₃	Bz	H	F	F	OH
XXVII-43-8	ⁱ Pr	*	H	*	Bz	H	F	F	OH

*R² and R^{3b} joined together by (CH₂)₃ to form five-membered ring.

Table XXVII-44.

N ^o	R ¹	R ²	R ^{3a}	R ^{3b}	R ⁴	R ⁵	R ⁶	X	Y
XXVII-44-1	^t Bu	H	H	H	Bz	H	F	F	OH
XXVII-44-2	^t Bu	H	H	CH ₃	Bz	H	F	F	OH
XXVII-44-3	^t Bu	H	H	CH(CH ₃) ₂	Bz	H	F	F	OH
XXVII-44-4	^t Bu	H	H	CH ₂ CH(CH ₃) ₂	Bz	H	F	F	OH
XXVII-44-5	^t Bu	H	H	CH ₂ Ph	Bz	H	F	F	OH
XXVII-44-6	^t Bu	H	H	CH ₂ -indol-3-yl	Bz	H	F	F	OH
XXVII-44-7	^t Bu	H	H	CH ₂ CH ₂ SCH ₃	Bz	H	F	F	OH
XXVII-44-8	^t Bu	*	H	*	Bz	H	F	F	OH

*R² and R^{3b} joined together by (CH₂)₃ to form five-membered ring.

Table XXVII-45.

N ^o	R ¹	R ²	R ^{3a}	R ^{3b}	R ⁴	R ⁵	R ⁶	X	Y
XXVII-45-1	Ph	H	H	H	Bz	H	F	F	OH
XXVII-45-2	Ph	H	H	CH ₃	Bz	H	F	F	OH
XXVII-45-3	Ph	H	H	CH(CH ₃) ₂	Bz	H	F	F	OH
XXVII-45-4	Ph	H	H	CH ₂ CH(CH ₃) ₂	Bz	H	F	F	OH
XXVII-45-5	Ph	H	H	CH ₂ Ph	Bz	H	F	F	OH
XXVII-45-6	Ph	H	H	CH ₂ -indol-3-yl	Bz	H	F	F	OH
XXVII-45-7	Ph	H	H	CH ₂ CH ₂ SCH ₃	Bz	H	F	F	OH
XXVII-45-8	Ph	*	H	*	Bz	H	F	F	OH

*R² and R^{3b} joined together by (CH₂)₃ to form five-membered ring.

Table XXVII-46.

N ^o	R ¹	R ²	R ^{3a}	R ^{3b}	R ⁴	R ⁵	R ⁶	X	Y
XXVII-46-1	p-Me-Ph	H	H	H	Bz	H	F	F	OH
XXVII-46-2	p-Me-Ph	H	H	CH ₃	Bz	H	F	F	OH
XXVII-46-3	p-Me-Ph	H	H	CH(CH ₃) ₂	Bz	H	F	F	OH
XXVII-46-4	p-Me-Ph	H	H	CH ₂ CH(CH ₃) ₂	Bz	H	F	F	OH
XXVII-46-5	p-Me-Ph	H	H	CH ₂ Ph	Bz	H	F	F	OH
XXVII-46-6	p-Me-Ph	H	H	CH ₂ -indol-3-yl	Bz	H	F	F	OH
XXVII-46-7	p-Me-Ph	H	H	CH ₂ CH ₂ SCH ₃	Bz	H	F	F	OH
XXVII-46-8	p-Me-Ph	*	H	*	Bz	H	F	F	OH

*R² and R^{3b} joined together by (CH₂)₃ to form five-membered ring.

Table XXVII-47.

N ^o	R ¹	R ²	R ^{3a}	R ^{3b}	R ⁴	R ⁵	R ⁶	X	Y
XXVII-47-1	p-F-Ph	H	H	H	Bz	H	F	F	OH
XXVII-47-2	p-F-Ph	H	H	CH ₃	Bz	H	F	F	OH
XXVII-47-3	p-F-Ph	H	H	CH(CH ₃) ₂	Bz	H	F	F	OH
XXVII-47-4	p-F-Ph	H	H	CH ₂ CH(CH ₃) ₂	Bz	H	F	F	OH
XXVII-47-5	p-F-Ph	H	H	CH ₂ Ph	Bz	H	F	F	OH
XXVII-47-6	p-F-Ph	H	H	CH ₂ -indol-3-yl	Bz	H	F	F	OH
XXVII-47-7	p-F-Ph	H	H	CH ₂ CH ₂ SCH ₃	Bz	H	F	F	OH
XXVII-47-8	p-F-Ph	*	H	*	Bz	H	F	F	OH

*R² and R^{3b} joined together by (CH₂)₃ to form five-membered ring.

Table XXVII-48.

N ^o	R ¹	R ²	R ^{3a}	R ^{3b}	R ⁴	R ⁵	R ⁶	X	Y
XXVII-48-1	p-Cl-Ph	H	H	H	Bz	H	F	F	OH
XXVII-48-2	p-Cl-Ph	H	H	CH ₃	Bz	H	F	F	OH
XXVII-48-3	p-Cl-Ph	H	H	CH(CH ₃) ₂	Bz	H	F	F	OH
XXVII-48-4	p-Cl-Ph	H	H	CH ₂ CH(CH ₃) ₂	Bz	H	F	F	OH
XXVII-48-5	p-Cl-Ph	H	H	CH ₂ Ph	Bz	H	F	F	OH
XXVII-48-6	p-Cl-Ph	H	H	CH ₂ -indol-3-yl	Bz	H	F	F	OH
XXVII-48-7	p-Cl-Ph	H	H	CH ₂ CH ₂ SCH ₃	Bz	H	F	F	OH
XXVII-48-8	p-Cl-Ph	*	H	*	Bz	H	F	F	OH

*R² and R^{3b} joined together by (CH₂)₃ to form five-membered ring.

Table XXVII-49.

N ^o	R ¹	R ²	R ^{3a}	R ^{3b}	R ⁴	R ⁵	R ⁶	X	Y
XXVII-49-1	p-Br-Ph	H	H	H	Bz	H	F	F	OH
XXVII-49-2	p-Br-Ph	H	H	CH ₃	Bz	H	F	F	OH
XXVII-49-3	p-Br-Ph	H	H	CH(CH ₃) ₂	Bz	H	F	F	OH
XXVII-49-4	p-Br-Ph	H	H	CH ₂ CH(CH ₃) ₂	Bz	H	F	F	OH
XXVII-49-5	p-Br-Ph	H	H	CH ₂ Ph	Bz	H	F	F	OH
XXVII-49-6	p-Br-Ph	H	H	CH ₂ -indol-3-yl	Bz	H	F	F	OH
XXVII-49-7	p-Br-Ph	H	H	CH ₂ CH ₂ SCH ₃	Bz	H	F	F	OH
XXVII-49-8	p-Br-Ph	*	H	*	Bz	H	F	F	OH

*R² and R^{3b} joined together by (CH₂)₃ to form five-membered ring.

Table XXVII-50.

N ^o	R ¹	R ²	R ^{3a}	R ^{3b}	R ⁴	R ⁵	R ⁶	X	Y
XXVII-50-1	p-I-Ph	H	H	H	Bz	H	F	F	OH
XXVII-50-2	p-I-Ph	H	H	CH ₃	Bz	H	F	F	OH
XXVII-50-3	p-I-Ph	H	H	CH(CH ₃) ₂	Bz	H	F	F	OH
XXVII-50-4	p-I-Ph	H	H	CH ₂ CH(CH ₃) ₂	Bz	H	F	F	OH
XXVII-50-5	p-I-Ph	H	H	CH ₂ Ph	Bz	H	F	F	OH
XXVII-50-6	p-I-Ph	H	H	CH ₂ -indol-3-yl	Bz	H	F	F	OH
XXVII-50-7	p-I-Ph	H	H	CH ₂ CH ₂ SCH ₃	Bz	H	F	F	OH
XXVII-50-8	p-I-Ph	*	H	*	Bz	H	F	F	OH

*R² and R^{3b} joined together by (CH₂)₃ to form five-membered ring.


**XXVIII**

Table XXVIII-1.

No	R ¹	R ²	R ^{3a}	R ^{3b}	R ⁴	R ⁵	R ⁶	X	Y
XXVIII-1-1	CH ₃	H	H	H	CH ₃	H	H	F	OH
XXVIII-1-2	CH ₃	H	H	CH ₃	CH ₃	H	H	F	OH
XXVIII-1-3	CH ₃	H	H	CH(CH ₃) ₂	CH ₃	H	H	F	OH
XXVIII-1-4	CH ₃	H	H	CH ₂ CH(CH ₃) ₂	CH ₃	H	H	F	OH
XXVIII-1-5	CH ₃	H	H	CH ₂ Ph	CH ₃	H	H	F	OH
XXVIII-1-6	CH ₃	H	H	CH ₂ -indol-3-yl	CH ₃	H	H	F	OH
XXVIII-1-7	CH ₃	H	H	CH ₂ CH ₂ SCH ₃	CH ₃	H	H	F	OH
XXVIII-1-8	CH ₃	*	H	*	CH ₃	H	H	F	OH

*R² and R^{3b} joined together by (CH₂)₃ to form five-membered ring.

Table XXVIII-2.

No	R ¹	R ²	R ^{3a}	R ^{3b}	R ⁴	R ⁵	R ⁶	X	Y
XXVIII-2-1	Et	H	H	H	CH ₃	H	H	F	OH
XXVIII-2-2	Et	H	H	CH ₃	CH ₃	H	H	F	OH
XXVIII-2-3	Et	H	H	CH(CH ₃) ₂	CH ₃	H	H	F	OH
XXVIII-2-4	Et	H	H	CH ₂ CH(CH ₃) ₂	CH ₃	H	H	F	OH
XXVIII-2-5	Et	H	H	CH ₂ Ph	CH ₃	H	H	F	OH
XXVIII-2-6	Et	H	H	CH ₂ -indol-3-yl	CH ₃	H	H	F	OH
XXVIII-2-7	Et	H	H	CH ₂ CH ₂ SCH ₃	CH ₃	H	H	F	OH
XXVIII-2-8	Et	*	H	*	CH ₃	H	H	F	OH

*R² and R^{3b} joined together by (CH₂)₃ to form five-membered ring.

Table XXVIII-3.

N ^o	R ¹	R ²	R ^{3a}	R ^{3b}	R ⁴	R ⁵	R ⁶	X	Y
XXVIII-3-1	ⁱ Pr	H	H	H	CH ₃	H	H	F	OH
XXVIII-3-2	ⁱ Pr	H	H	CH ₃	CH ₃	H	H	F	OH
XXVIII-3-3	ⁱ Pr	H	H	CH(CH ₃) ₂	CH ₃	H	H	F	OH
XXVIII-3-4	ⁱ Pr	H	H	CH ₂ CH(CH ₃) ₂	CH ₃	H	H	F	OH
XXVIII-3-5	ⁱ Pr	H	H	CH ₂ Ph	CH ₃	H	H	F	OH
XXVIII-3-6	ⁱ Pr	H	H	CH ₂ -indol-3-yl	CH ₃	H	H	F	OH
XXVIII-3-7	ⁱ Pr	H	H	CH ₂ CH ₂ SCH ₃	CH ₃	H	H	F	OH
XXVIII-3-8	ⁱ Pr	*	H	*	CH ₃	H	H	F	OH

*R² and R^{3b} joined together by (CH₂)₃ to form five-membered ring.

Table XXVIII-4.

N ^o	R ¹	R ²	R ^{3a}	R ^{3b}	R ⁴	R ⁵	R ⁶	X	Y
XXVIII-4-1	^t Bu	H	H	H	CH ₃	H	H	F	OH
XXVIII-4-2	^t Bu	H	H	CH ₃	CH ₃	H	H	F	OH
XXVIII-4-3	^t Bu	H	H	CH(CH ₃) ₂	CH ₃	H	H	F	OH
XXVIII-4-4	^t Bu	H	H	CH ₂ CH(CH ₃) ₂	CH ₃	H	H	F	OH
XXVIII-4-5	^t Bu	H	H	CH ₂ Ph	CH ₃	H	H	F	OH
XXVIII-4-6	^t Bu	H	H	CH ₂ -indol-3-yl	CH ₃	H	H	F	OH
XXVIII-4-7	^t Bu	H	H	CH ₂ CH ₂ SCH ₃	CH ₃	H	H	F	OH
XXVIII-4-8	^t Bu	*	H	*	CH ₃	H	H	F	OH

*R² and R^{3b} joined together by (CH₂)₃ to form five-membered ring.

Table XXVIII-5.

N ^o	R ¹	R ²	R ^{3a}	R ^{3b}	R ⁴	R ⁵	R ⁶	X	Y
XXVIII-5-1	Ph	H	H	H	CH ₃	H	H	F	OH
XXVIII-5-2	Ph	H	H	CH ₃	CH ₃	H	H	F	OH
XXVIII-5-3	Ph	H	H	CH(CH ₃) ₂	CH ₃	H	H	F	OH
XXVIII-5-4	Ph	H	H	CH ₂ CH(CH ₃) ₂	CH ₃	H	H	F	OH
XXVIII-5-5	Ph	H	H	CH ₂ Ph	CH ₃	H	H	F	OH
XXVIII-5-6	Ph	H	H	CH ₂ -indol-3-yl	CH ₃	H	H	F	OH
XXVIII-5-7	Ph	H	H	CH ₂ CH ₂ SCH ₃	CH ₃	H	H	F	OH
XXVIII-5-8	Ph	*	H	*	CH ₃	H	H	F	OH

*R² and R^{3b} joined together by (CH₂)₃ to form five-membered ring.

Table XXVIII-6.

№	R ¹	R ²	R ^{3a}	R ^{3b}	R ⁴	R ⁵	R ⁶	X	Y
XXVIII-6-1	p-Me-Ph	H	H	H	CH ₃	H	H	F	OH
XXVIII-6-2	p-Me-Ph	H	H	CH ₃	CH ₃	H	H	F	OH
XXVIII-6-3	p-Me-Ph	H	H	CH(CH ₃) ₂	CH ₃	H	H	F	OH
XXVIII-6-4	p-Me-Ph	H	H	CH ₂ CH(CH ₃) ₂	CH ₃	H	H	F	OH
XXVIII-6-5	p-Me-Ph	H	H	CH ₂ Ph	CH ₃	H	H	F	OH
XXVIII-6-6	p-Me-Ph	H	H	CH ₂ -indol-3-yl	CH ₃	H	H	F	OH
XXVIII-6-7	p-Me-Ph	H	H	CH ₂ CH ₂ SCH ₃	CH ₃	H	H	F	OH
XXVIII-6-8	p-Me-Ph	*	H	*	CH ₃	H	H	F	OH

*R² and R^{3b} joined together by (CH₂)₃ to form five-membered ring.

Table XXVIII-7.

№	R ¹	R ²	R ^{3a}	R ^{3b}	R ⁴	R ⁵	R ⁶	X	Y
XXVIII-7-1	p-F-Ph	H	H	H	CH ₃	H	H	F	OH
XXVIII-7-2	p-F-Ph	H	H	CH ₃	CH ₃	H	H	F	OH
XXVIII-7-3	p-F-Ph	H	H	CH(CH ₃) ₂	CH ₃	H	H	F	OH
XXVIII-7-4	p-F-Ph	H	H	CH ₂ CH(CH ₃) ₂	CH ₃	H	H	F	OH
XXVIII-7-6	p-F-Ph	H	H	CH ₂ Ph	CH ₃	H	H	F	OH
XXVIII-7-7	p-F-Ph	H	H	CH ₂ -indol-3-yl	CH ₃	H	H	F	OH
XXVIII-7-8	p-F-Ph	H	H	CH ₂ CH ₂ SCH ₃	CH ₃	H	H	F	OH
XXVIII-7-20	p-F-Ph	*	H	*	CH ₃	H	H	F	OH

*R² and R^{3b} joined together by (CH₂)₃ to form five-membered ring.

Table XXVIII-8.

№	R ¹	R ²	R ^{3a}	R ^{3b}	R ⁴	R ⁵	R ⁶	X	Y
XXVIII-8-1	p-Cl-Ph	H	H	H	CH ₃	H	H	F	OH
XXVIII-8-2	p-Cl-Ph	H	H	CH ₃	CH ₃	H	H	F	OH
XXVIII-8-3	p-Cl-Ph	H	H	CH(CH ₃) ₂	CH ₃	H	H	F	OH
XXVIII-8-4	p-Cl-Ph	H	H	CH ₂ CH(CH ₃) ₂	CH ₃	H	H	F	OH
XXVIII-8-5	p-Cl-Ph	H	H	CH ₂ Ph	CH ₃	H	H	F	OH
XXVIII-8-6	p-Cl-Ph	H	H	CH ₂ -indol-3-yl	CH ₃	H	H	F	OH
XXVIII-8-7	p-Cl-Ph	H	H	CH ₂ CH ₂ SCH ₃	CH ₃	H	H	F	OH
XXVIII-8-8	p-Cl-Ph	*	H	*	CH ₃	H	H	F	OH

*R² and R^{3b} joined together by (CH₂)₃ to form five-membered ring.

Table XXVIII-9.

№	R ¹	R ²	R ^{3a}	R ^{3b}	R ⁴	R ⁵	R ⁶	X	Y
XXVIII-9-1	p-Br-Ph	H	H	H	CH ₃	H	H	F	OH
XXVIII-9-2	p-Br-Ph	H	H	CH ₃	CH ₃	H	H	F	OH
XXVIII-9-3	p-Br-Ph	H	H	CH(CH ₃) ₂	CH ₃	H	H	F	OH
XXVIII-9-4	p-Br-Ph	H	H	CH ₂ CH(CH ₃) ₂	CH ₃	H	H	F	OH
XXVIII-9-6	p-Br-Ph	H	H	CH ₂ Ph	CH ₃	H	H	F	OH
XXVIII-9-7	p-Br-Ph	H	H	CH ₂ -indol-3-yl	CH ₃	H	H	F	OH
XXVIII-9-8	p-Br-Ph	H	H	CH ₂ CH ₂ SCH ₃	CH ₃	H	H	F	OH
XXVIII-9-20	p-Br-Ph	*	H	*	CH ₃	H	H	F	OH

*R² and R^{3b} joined together by (CH₂)₃ to form five-membered ring.

Table XXVIII-10.

№	R ¹	R ²	R ^{3a}	R ^{3b}	R ⁴	R ⁵	R ⁶	X	Y
XXVIII-10-1	p-I-Ph	H	H	H	CH ₃	H	H	F	OH
XXVIII-10-2	p-I-Ph	H	H	CH ₃	CH ₃	H	H	F	OH
XXVIII-10-3	p-I-Ph	H	H	CH(CH ₃) ₂	CH ₃	H	H	F	OH
XXVIII-10-4	p-I-Ph	H	H	CH ₂ CH(CH ₃) ₂	CH ₃	H	H	F	OH
XXVIII-10-5	p-I-Ph	H	H	CH ₂ Ph	CH ₃	H	H	F	OH
XXVIII-10-6	p-I-Ph	H	H	CH ₂ -indol-3-yl	CH ₃	H	H	F	OH
XXVIII-10-7	p-I-Ph	H	H	CH ₂ CH ₂ SCH ₃	CH ₃	H	H	F	OH
XXVIII-10-8	p-I-Ph	*	H	*	CH ₃	H	H	F	OH

*R² and R^{3b} joined together by (CH₂)₃ to form five-membered ring.

Table XXVIII-11.

№	R ¹	R ²	R ^{3a}	R ^{3b}	R ⁴	R ⁵	R ⁶	X	Y
XXVIII-11-1	CH ₃	H	H	H	Et	H	H	F	OH
XXVIII-11-2	CH ₃	H	H	CH ₃	Et	H	H	F	OH
XXVIII-11-3	CH ₃	H	H	CH(CH ₃) ₂	Et	H	H	F	OH
XXVIII-11-4	CH ₃	H	H	CH ₂ CH(CH ₃) ₂	Et	H	H	F	OH
XXVIII-11-5	CH ₃	H	H	CH ₂ Ph	Et	H	H	F	OH
XXVIII-11-6	CH ₃	H	H	CH ₂ -indol-3-yl	Et	H	H	F	OH
XXVIII-11-7	CH ₃	H	H	CH ₂ CH ₂ SCH ₃	Et	H	H	F	OH
XXVIII-11-8	CH ₃	*	H	*	Et	H	H	F	OH

*R² and R^{3b} joined together by (CH₂)₃ to form five-membered ring.

Table XXVIII-12.

N ^o	R ¹	R ²	R ^{3a}	R ^{3b}	R ⁴	R ⁵	R ⁶	X	Y
XXVIII-12-1	Et	H	H	H	Et	H	H	F	OH
XXVIII-12-2	Et	H	H	CH ₃	Et	H	H	F	OH
XXVIII-12-3	Et	H	H	CH(CH ₃) ₂	Et	H	H	F	OH
XXVIII-12-4	Et	H	H	CH ₂ CH(CH ₃) ₂	Et	H	H	F	OH
XXVIII-12-5	Et	H	H	CH ₂ Ph	Et	H	H	F	OH
XXVIII-12-6	Et	H	H	CH ₂ -indol-3-yl	Et	H	H	F	OH
XXVIII-12-7	Et	H	H	CH ₂ CH ₂ SCH ₃	Et	H	H	F	OH
XXVIII-12-8	Et	*	H	*	Et	H	H	F	OH

*R² and R^{3b} joined together by (CH₂)₃ to form five-membered ring.

Table XXVIII-13.

N ^o	R ¹	R ²	R ^{3a}	R ^{3b}	R ⁴	R ⁵	R ⁶	X	Y
XXVIII-13-1	ⁱ Pr	H	H	H	Et	H	H	F	OH
XXVIII-13-2	ⁱ Pr	H	H	CH ₃	Et	H	H	F	OH
XXVIII-13-3	ⁱ Pr	H	H	CH(CH ₃) ₂	Et	H	H	F	OH
XXVIII-13-4	ⁱ Pr	H	H	CH ₂ CH(CH ₃) ₂	Et	H	H	F	OH
XXVIII-13-5	ⁱ Pr	H	H	CH ₂ Ph	Et	H	H	F	OH
XXVIII-13-6	ⁱ Pr	H	H	CH ₂ -indol-3-yl	Et	H	H	F	OH
XXVIII-13-7	ⁱ Pr	H	H	CH ₂ CH ₂ SCH ₃	Et	H	H	F	OH
XXVIII-13-8	ⁱ Pr	*	H	*	Et	H	H	F	OH

*R² and R^{3b} joined together by (CH₂)₃ to form five-membered ring.

Table XXVIII-14.

N ^o	R ¹	R ²	R ^{3a}	R ^{3b}	R ⁴	R ⁵	R ⁶	X	Y
XXVIII-14-1	^t Bu	H	H	H	Et	H	H	F	OH
XXVIII-14-2	^t Bu	H	H	CH ₃	Et	H	H	F	OH
XXVIII-14-3	^t Bu	H	H	CH(CH ₃) ₂	Et	H	H	F	OH
XXVIII-14-4	^t Bu	H	H	CH ₂ CH(CH ₃) ₂	Et	H	H	F	OH
XXVIII-14-5	^t Bu	H	H	CH ₂ Ph	Et	H	H	F	OH
XXVIII-14-6	^t Bu	H	H	CH ₂ -indol-3-yl	Et	H	H	F	OH
XXVIII-14-7	^t Bu	H	H	CH ₂ CH ₂ SCH ₃	Et	H	H	F	OH
XXVIII-14-8	^t Bu	*	H	*	Et	H	H	F	OH

*R² and R^{3b} joined together by (CH₂)₃ to form five-membered ring.

Table XXVIII-15.

N ^o	R ¹	R ²	R ^{3a}	R ^{3b}	R ⁴	R ⁵	R ⁶	X	Y
XXVIII-15-1	Ph	H	H	H	Et	H	H	F	OH
XXVIII-15-2	Ph	H	H	CH ₃	Et	H	H	F	OH
XXVIII-15-3	Ph	H	H	CH(CH ₃) ₂	Et	H	H	F	OH
XXVIII-15-4	Ph	H	H	CH ₂ CH(CH ₃) ₂	Et	H	H	F	OH
XXVIII-15-5	Ph	H	H	CH ₂ Ph	Et	H	H	F	OH
XXVIII-15-6	Ph	H	H	CH ₂ -indol-3-yl	Et	H	H	F	OH
XXVIII-15-7	Ph	H	H	CH ₂ CH ₂ SCH ₃	Et	H	H	F	OH
XXVIII-15-8	Ph	*	H	*	Et	H	H	F	OH

*R² and R^{3b} joined together by (CH₂)₃ to form five-membered ring.

Table XXVIII-16.

N ^o	R ¹	R ²	R ^{3a}	R ^{3b}	R ⁴	R ⁵	R ⁶	X	Y
XXVIII-16-1	p-Me-Ph	H	H	H	Et	H	H	F	OH
XXVIII-16-2	p-Me-Ph	H	H	CH ₃	Et	H	H	F	OH
XXVIII-16-3	p-Me-Ph	H	H	CH(CH ₃) ₂	Et	H	H	F	OH
XXVIII-16-4	p-Me-Ph	H	H	CH ₂ CH(CH ₃) ₂	Et	H	H	F	OH
XXVIII-16-5	p-Me-Ph	H	H	CH ₂ Ph	Et	H	H	F	OH
XXVIII-16-6	p-Me-Ph	H	H	CH ₂ -indol-3-yl	Et	H	H	F	OH
XXVIII-16-7	p-Me-Ph	H	H	CH ₂ CH ₂ SCH ₃	Et	H	H	F	OH
XXVIII-16-8	p-Me-Ph	*	H	*	Et	H	H	F	OH

*R² and R^{3b} joined together by (CH₂)₃ to form five-membered ring.

Table XXVIII-17.

N ^o	R ¹	R ²	R ^{3a}	R ^{3b}	R ⁴	R ⁵	R ⁶	X	Y
XXVIII-17-1	p-F-Ph	H	H	H	Et	H	H	F	OH
XXVIII-17-2	p-F-Ph	H	H	CH ₃	Et	H	H	F	OH
XXVIII-17-3	p-F-Ph	H	H	CH(CH ₃) ₂	Et	H	H	F	OH
XXVIII-17-4	p-F-Ph	H	H	CH ₂ CH(CH ₃) ₂	Et	H	H	F	OH
XXVIII-17-5	p-F-Ph	H	H	CH ₂ Ph	Et	H	H	F	OH
XXVIII-17-6	p-F-Ph	H	H	CH ₂ -indol-3-yl	Et	H	H	F	OH
XXVIII-17-7	p-F-Ph	H	H	CH ₂ CH ₂ SCH ₃	Et	H	H	F	OH
XXVIII-17-8	p-F-Ph	*	H	*	Et	H	H	F	OH

*R² and R^{3b} joined together by (CH₂)₃ to form five-membered ring.

Table XXVIII-18.

№	R ¹	R ²	R ^{3a}	R ^{3b}	R ⁴	R ⁵	R ⁶	X	Y
XXVIII-18-1	p-Cl-Ph	H	H	H	Et	H	H	F	OH
XXVIII-18-2	p-Cl-Ph	H	H	CH ₃	Et	H	H	F	OH
XXVIII-18-3	p-Cl-Ph	H	H	CH(CH ₃) ₂	Et	H	H	F	OH
XXVIII-18-4	p-Cl-Ph	H	H	CH ₂ CH(CH ₃) ₂	Et	H	H	F	OH
XXVIII-18-5	p-Cl-Ph	H	H	CH ₂ Ph	Et	H	H	F	OH
XXVIII-18-6	p-Cl-Ph	H	H	CH ₂ -indol-3-yl	Et	H	H	F	OH
XXVIII-18-7	p-Cl-Ph	H	H	CH ₂ CH ₂ SCH ₃	Et	H	H	F	OH
XXVIII-18-8	p-Cl-Ph	*	H	*	Et	H	H	F	OH

*R² and R^{3b} joined together by (CH₂)₃ to form five-membered ring.

Table XXVIII-19.

№	R ¹	R ²	R ^{3a}	R ^{3b}	R ⁴	R ⁵	R ⁶	X	Y
XXVIII-19-1	p-Br-Ph	H	H	H	Et	H	H	F	OH
XXVIII-19-2	p-Br-Ph	H	H	CH ₃	Et	H	H	F	OH
XXVIII-19-3	p-Br-Ph	H	H	CH(CH ₃) ₂	Et	H	H	F	OH
XXVIII-19-4	p-Br-Ph	H	H	CH ₂ CH(CH ₃) ₂	Et	H	H	F	OH
XXVIII-19-5	p-Br-Ph	H	H	CH ₂ Ph	Et	H	H	F	OH
XXVIII-19-6	p-Br-Ph	H	H	CH ₂ -indol-3-yl	Et	H	H	F	OH
XXVIII-19-7	p-Br-Ph	H	H	CH ₂ CH ₂ SCH ₃	Et	H	H	F	OH
XXVIII-19-8	p-Br-Ph	*	H	*	Et	H	H	F	OH

*R² and R^{3b} joined together by (CH₂)₃ to form five-membered ring.

Table XXVIII-20.

№	R ¹	R ²	R ^{3a}	R ^{3b}	R ⁴	R ⁵	R ⁶	X	Y
XXVIII-20-1	p-I-Ph	H	H	H	Et	H	H	F	OH
XXVIII-20-2	p-I-Ph	H	H	CH ₃	Et	H	H	F	OH
XXVIII-20-3	p-I-Ph	H	H	CH(CH ₃) ₂	Et	H	H	F	OH
XXVIII-20-4	p-I-Ph	H	H	CH ₂ CH(CH ₃) ₂	Et	H	H	F	OH
XXVIII-20-5	p-I-Ph	H	H	CH ₂ Ph	Et	H	H	F	OH
XXVIII-20-6	p-I-Ph	H	H	CH ₂ -indol-3-yl	Et	H	H	F	OH
XXVIII-20-7	p-I-Ph	H	H	CH ₂ CH ₂ SCH ₃	Et	H	H	F	OH
XXVIII-20-8	p-I-Ph	*	H	*	Et	H	H	F	OH

*R² and R^{3b} joined together by (CH₂)₃ to form five-membered ring.

Table XXVIII-21.

N ^o	R ¹	R ²	R ^{3a}	R ^{3b}	R ⁴	R ⁵	R ⁶	X	Y
XXVIII-21-1	CH ₃	H	H	H	ⁱ Pr	H	H	F	OH
XXVIII-21-2	CH ₃	H	H	CH ₃	ⁱ Pr	H	H	F	OH
XXVIII-21-3	CH ₃	H	H	CH(CH ₃) ₂	ⁱ Pr	H	H	F	OH
XXVIII-21-4	CH ₃	H	H	CH ₂ CH(CH ₃) ₂	ⁱ Pr	H	H	F	OH
XXVIII-21-5	CH ₃	H	H	CH ₂ Ph	ⁱ Pr	H	H	F	OH
XXVIII-21-6	CH ₃	H	H	CH ₂ -indol-3-yl	ⁱ Pr	H	H	F	OH
XXVIII-21-7	CH ₃	H	H	CH ₂ CH ₂ SCH ₃	ⁱ Pr	H	H	F	OH
XXVIII-21-8	CH ₃	*	H	*	ⁱ Pr	H	H	F	OH

*R² and R^{3b} joined together by (CH₂)₃ to form five-membered ring.

Table XXVIII-22.

N ^o	R ¹	R ²	R ^{3a}	R ^{3b}	R ⁴	R ⁵	R ⁶	X	Y
XXVIII-22-1	Et	H	H	H	ⁱ Pr	H	H	F	OH
XXVIII-22-2	Et	H	H	CH ₃	ⁱ Pr	H	H	F	OH
XXVIII-22-3	Et	H	H	CH(CH ₃) ₂	ⁱ Pr	H	H	F	OH
XXVIII-22-4	Et	H	H	CH ₂ CH(CH ₃) ₂	ⁱ Pr	H	H	F	OH
XXVIII-22-5	Et	H	H	CH ₂ Ph	ⁱ Pr	H	H	F	OH
XXVIII-22-6	Et	H	H	CH ₂ -indol-3-yl	ⁱ Pr	H	H	F	OH
XXVIII-22-7	Et	H	H	CH ₂ CH ₂ SCH ₃	ⁱ Pr	H	H	F	OH
XXVIII-22-8	Et	*	H	*	ⁱ Pr	H	H	F	OH

*R² and R^{3b} joined together by (CH₂)₃ to form five-membered ring.

Table XXVIII-23.

N ^o	R ¹	R ²	R ^{3a}	R ^{3b}	R ⁴	R ⁵	R ⁶	X	Y
XXVIII-23-1	ⁱ Pr	H	H	H	ⁱ Pr	H	H	F	OH
XXVIII-23-2	ⁱ Pr	H	H	CH ₃	ⁱ Pr	H	H	F	OH
XXVIII-23-3	ⁱ Pr	H	H	CH(CH ₃) ₂	ⁱ Pr	H	H	F	OH
XXVIII-23-4	ⁱ Pr	H	H	CH ₂ CH(CH ₃) ₂	ⁱ Pr	H	H	F	OH
XXVIII-23-5	ⁱ Pr	H	H	CH ₂ Ph	ⁱ Pr	H	H	F	OH
XXVIII-23-6	ⁱ Pr	H	H	CH ₂ -indol-3-yl	ⁱ Pr	H	H	F	OH
XXVIII-23-7	ⁱ Pr	H	H	CH ₂ CH ₂ SCH ₃	ⁱ Pr	H	H	F	OH
XXVIII-23-8	ⁱ Pr	*	H	*	ⁱ Pr	H	H	F	OH

*R² and R^{3b} joined together by (CH₂)₃ to form five-membered ring.

Table XXVIII-24.

N ^o	R ¹	R ²	R ^{3a}	R ^{3b}	R ⁴	R ⁵	R ⁶	X	Y
XXVIII-24-1	^t Bu	H	H	H	ⁱ Pr	H	H	F	OH
XXVIII-24-2	^t Bu	H	H	CH ₃	ⁱ Pr	H	H	F	OH
XXVIII-24-3	^t Bu	H	H	CH(CH ₃) ₂	ⁱ Pr	H	H	F	OH
XXVIII-24-4	^t Bu	H	H	CH ₂ CH(CH ₃) ₂	ⁱ Pr	H	H	F	OH
XXVIII-24-5	^t Bu	H	H	CH ₂ Ph	ⁱ Pr	H	H	F	OH
XXVIII-24-6	^t Bu	H	H	CH ₂ -indol-3-yl	ⁱ Pr	H	H	F	OH
XXVIII-24-7	^t Bu	H	H	CH ₂ CH ₂ SCH ₃	ⁱ Pr	H	H	F	OH
XXVIII-24-8	^t Bu	*	H	*	ⁱ Pr	H	H	F	OH

*R² and R^{3b} joined together by (CH₂)₃ to form five-membered ring.

Table XXVIII-25.

N ^o	R ¹	R ²	R ^{3a}	R ^{3b}	R ⁴	R ⁵	R ⁶	X	Y
XXVIII-25-1	Ph	H	H	H	ⁱ Pr	H	H	F	OH
XXVIII-25-2	Ph	H	H	CH ₃	ⁱ Pr	H	H	F	OH
XXVIII-25-3	Ph	H	H	CH(CH ₃) ₂	ⁱ Pr	H	H	F	OH
XXVIII-25-4	Ph	H	H	CH ₂ CH(CH ₃) ₂	ⁱ Pr	H	H	F	OH
XXVIII-25-5	Ph	H	H	CH ₂ Ph	ⁱ Pr	H	H	F	OH
XXVIII-25-6	Ph	H	H	CH ₂ -indol-3-yl	ⁱ Pr	H	H	F	OH
XXVIII-25-7	Ph	H	H	CH ₂ CH ₂ SCH ₃	ⁱ Pr	H	H	F	OH
XXVIII-25-8	Ph	*	H	*	ⁱ Pr	H	H	F	OH

*R² and R^{3b} joined together by (CH₂)₃ to form five-membered ring.

Table XXVIII-26.

N ^o	R ¹	R ²	R ^{3a}	R ^{3b}	R ⁴	R ⁵	R ⁶	X	Y
XXVIII-26-1	p-Me-Ph	H	H	H	ⁱ Pr	H	H	F	OH
XXVIII-26-2	p-Me-Ph	H	H	CH ₃	ⁱ Pr	H	H	F	OH
XXVIII-26-3	p-Me-Ph	H	H	CH(CH ₃) ₂	ⁱ Pr	H	H	F	OH
XXVIII-26-4	p-Me-Ph	H	H	CH ₂ CH(CH ₃) ₂	ⁱ Pr	H	H	F	OH
XXVIII-26-5	p-Me-Ph	H	H	CH ₂ Ph	ⁱ Pr	H	H	F	OH
XXVIII-26-6	p-Me-Ph	H	H	CH ₂ -indol-3-yl	ⁱ Pr	H	H	F	OH
XXVIII-26-7	p-Me-Ph	H	H	CH ₂ CH ₂ SCH ₃	ⁱ Pr	H	H	F	OH
XXVIII-26-8	p-Me-Ph	*	H	*	ⁱ Pr	H	H	F	OH

*R² and R^{3b} joined together by (CH₂)₃ to form five-membered ring.

Table XXVIII-27.

N ^o	R ¹	R ²	R ^{3a}	R ^{3b}	R ⁴	R ⁵	R ⁶	X	Y
XXVIII-27-1	p-F-Ph	H	H	H	ⁱ Pr	H	H	F	OH
XXVIII-27-2	p-F-Ph	H	H	CH ₃	ⁱ Pr	H	H	F	OH
XXVIII-27-3	p-F-Ph	H	H	CH(CH ₃) ₂	ⁱ Pr	H	H	F	OH
XXVIII-27-4	p-F-Ph	H	H	CH ₂ CH(CH ₃) ₂	ⁱ Pr	H	H	F	OH
XXVIII-27-5	p-F-Ph	H	H	CH ₂ Ph	ⁱ Pr	H	H	F	OH
XXVIII-27-6	p-F-Ph	H	H	CH ₂ -indol-3-yl	ⁱ Pr	H	H	F	OH
XXVIII-27-7	p-F-Ph	H	H	CH ₂ CH ₂ SCH ₃	ⁱ Pr	H	H	F	OH
XXVIII-27-8	p-F-Ph	*	H	*	ⁱ Pr	H	H	F	OH

*R² and R^{3b} joined together by (CH₂)₃ to form five-membered ring.

Table XXVIII-28.

N ^o	R ¹	R ²	R ^{3a}	R ^{3b}	R ⁴	R ⁵	R ⁶	X	Y
XXVIII-28-1	p-Cl-Ph	H	H	H	ⁱ Pr	H	H	F	OH
XXVIII-28-2	p-Cl-Ph	H	H	CH ₃	ⁱ Pr	H	H	F	OH
XXVIII-28-3	p-Cl-Ph	H	H	CH(CH ₃) ₂	ⁱ Pr	H	H	F	OH
XXVIII-28-4	p-Cl-Ph	H	H	CH ₂ CH(CH ₃) ₂	ⁱ Pr	H	H	F	OH
XXVIII-28-5	p-Cl-Ph	H	H	CH ₂ Ph	ⁱ Pr	H	H	F	OH
XXVIII-28-6	p-Cl-Ph	H	H	CH ₂ -indol-3-yl	ⁱ Pr	H	H	F	OH
XXVIII-28-7	p-Cl-Ph	H	H	CH ₂ CH ₂ SCH ₃	ⁱ Pr	H	H	F	OH
XXVIII-28-8	p-Cl-Ph	*	H	*	ⁱ Pr	H	H	F	OH

*R² and R^{3b} joined together by (CH₂)₃ to form five-membered ring.

Table XXVIII-29.

N ^o	R ¹	R ²	R ^{3a}	R ^{3b}	R ⁴	R ⁵	R ⁶	X	Y
XXVIII-29-1	p-Br-Ph	H	H	H	ⁱ Pr	H	H	F	OH
XXVIII-29-2	p-Br-Ph	H	H	CH ₃	ⁱ Pr	H	H	F	OH
XXVIII-29-3	p-Br-Ph	H	H	CH(CH ₃) ₂	ⁱ Pr	H	H	F	OH
XXVIII-29-4	p-Br-Ph	H	H	CH ₂ CH(CH ₃) ₂	ⁱ Pr	H	H	F	OH
XXVIII-29-5	p-Br-Ph	H	H	CH ₂ Ph	ⁱ Pr	H	H	F	OH
XXVIII-29-6	p-Br-Ph	H	H	CH ₂ -indol-3-yl	ⁱ Pr	H	H	F	OH
XXVIII-29-7	p-Br-Ph	H	H	CH ₂ CH ₂ SCH ₃	ⁱ Pr	H	H	F	OH
XXVIII-29-8	p-Br-Ph	*	H	*	ⁱ Pr	H	H	F	OH

*R² and R^{3b} joined together by (CH₂)₃ to form five-membered ring.

Table XXVIII-30.

N ^o	R ¹	R ²	R ^{3a}	R ^{3b}	R ⁴	R ⁵	R ⁶	X	Y
XXVIII-30-1	p-I-Ph	H	H	H	ⁱ Pr	H	H	F	OH
XXVIII-30-2	p-I-Ph	H	H	CH ₃	ⁱ Pr	H	H	F	OH
XXVIII-30-3	p-I-Ph	H	H	CH(CH ₃) ₂	ⁱ Pr	H	H	F	OH
XXVIII-30-4	p-I-Ph	H	H	CH ₂ CH(CH ₃) ₂	ⁱ Pr	H	H	F	OH
XXVIII-30-5	p-I-Ph	H	H	CH ₂ Ph	ⁱ Pr	H	H	F	OH
XXVIII-30-6	p-I-Ph	H	H	CH ₂ -indol-3-yl	ⁱ Pr	H	H	F	OH
XXVIII-30-7	p-I-Ph	H	H	CH ₂ CH ₂ SCH ₃	ⁱ Pr	H	H	F	OH
XXVIII-30-8	p-I-Ph	*	H	*	ⁱ Pr	H	H	F	OH

*R² and R^{3b} joined together by (CH₂)₃ to form five-membered ring.

Table XXVIII-31.

N ^o	R ¹	R ²	R ^{3a}	R ^{3b}	R ⁴	R ⁵	R ⁶	X	Y
XXVIII-31-1	CH ₃	H	H	H	ⁿ Bu	H	H	F	OH
XXVIII-31-2	CH ₃	H	H	CH ₃	ⁿ Bu	H	H	F	OH
XXVIII-31-3	CH ₃	H	H	CH(CH ₃) ₂	ⁿ Bu	H	H	F	OH
XXVIII-31-4	CH ₃	H	H	CH ₂ CH(CH ₃) ₂	ⁿ Bu	H	H	F	OH
XXVIII-31-5	CH ₃	H	H	CH ₂ Ph	ⁿ Bu	H	H	F	OH
XXVIII-31-6	CH ₃	H	H	CH ₂ -indol-3-yl	ⁿ Bu	H	H	F	OH
XXVIII-31-7	CH ₃	H	H	CH ₂ CH ₂ SCH ₃	ⁿ Bu	H	H	F	OH
XXVIII-31-8	CH ₃	*	H	*	ⁿ Bu	H	H	F	OH

*R² and R^{3b} joined together by (CH₂)₃ to form five-membered ring.

Table XXVIII-32.

N ^o	R ¹	R ²	R ^{3a}	R ^{3b}	R ⁴	R ⁵	R ⁶	X	Y
XXVIII-32-1	Et	H	H	H	ⁿ Bu	H	H	F	OH
XXVIII-32-2	Et	H	H	CH ₃	ⁿ Bu	H	H	F	OH
XXVIII-32-3	Et	H	H	CH(CH ₃) ₂	ⁿ Bu	H	H	F	OH
XXVIII-32-4	Et	H	H	CH ₂ CH(CH ₃) ₂	ⁿ Bu	H	H	F	OH
XXVIII-32-5	Et	H	H	CH ₂ Ph	ⁿ Bu	H	H	F	OH
XXVIII-32-6	Et	H	H	CH ₂ -indol-3-yl	ⁿ Bu	H	H	F	OH
XXVIII-32-7	Et	H	H	CH ₂ CH ₂ SCH ₃	ⁿ Bu	H	H	F	OH
XXVIII-32-8	Et	*	H	*	ⁿ Bu	H	H	F	OH

*R² and R^{3b} joined together by (CH₂)₃ to form five-membered ring.

Table XXVIII-33.

N ^o	R ¹	R ²	R ^{3a}	R ^{3b}	R ⁴	R ⁵	R ⁶	X	Y
XXVIII-33-1	ⁱ Pr	H	H	H	ⁿ Bu	H	H	F	OH
XXVIII-33-2	ⁱ Pr	H	H	CH ₃	ⁿ Bu	H	H	F	OH
XXVIII-33-3	ⁱ Pr	H	H	CH(CH ₃) ₂	ⁿ Bu	H	H	F	OH
XXVIII-33-4	ⁱ Pr	H	H	CH ₂ CH(CH ₃) ₂	ⁿ Bu	H	H	F	OH
XXVIII-33-5	ⁱ Pr	H	H	CH ₂ Ph	ⁿ Bu	H	H	F	OH
XXVIII-33-6	ⁱ Pr	H	H	CH ₂ -indol-3-yl	ⁿ Bu	H	H	F	OH
XXVIII-33-7	ⁱ Pr	H	H	CH ₂ CH ₂ SCH ₃	ⁿ Bu	H	H	F	OH
XXVIII-33-8	ⁱ Pr	*	H	*	ⁿ Bu	H	H	F	OH

*R² and R^{3b} joined together by (CH₂)₃ to form five-membered ring.

Table XXVIII-34.

N ^o	R ¹	R ²	R ^{3a}	R ^{3b}	R ⁴	R ⁵	R ⁶	X	Y
XXVIII-34-1	^t Bu	H	H	H	ⁿ Bu	H	H	F	OH
XXVIII-34-2	^t Bu	H	H	CH ₃	ⁿ Bu	H	H	F	OH
XXVIII-34-3	^t Bu	H	H	CH(CH ₃) ₂	ⁿ Bu	H	H	F	OH
XXVIII-34-4	^t Bu	H	H	CH ₂ CH(CH ₃) ₂	ⁿ Bu	H	H	F	OH
XXVIII-34-5	^t Bu	H	H	CH ₂ Ph	ⁿ Bu	H	H	F	OH
XXVIII-34-6	^t Bu	H	H	CH ₂ -indol-3-yl	ⁿ Bu	H	H	F	OH
XXVIII-34-7	^t Bu	H	H	CH ₂ CH ₂ SCH ₃	ⁿ Bu	H	H	F	OH
XXVIII-34-8	^t Bu	*	H	*	ⁿ Bu	H	H	F	OH

*R² and R^{3b} joined together by (CH₂)₃ to form five-membered ring.

Table XXVIII-35.

N ^o	R ¹	R ²	R ^{3a}	R ^{3b}	R ⁴	R ⁵	R ⁶	X	Y
XXVIII-35-1	Ph	H	H	H	ⁿ Bu	H	H	F	OH
XXVIII-35-2	Ph	H	H	CH ₃	ⁿ Bu	H	H	F	OH
XXVIII-35-3	Ph	H	H	CH(CH ₃) ₂	ⁿ Bu	H	H	F	OH
XXVIII-35-4	Ph	H	H	CH ₂ CH(CH ₃) ₂	ⁿ Bu	H	H	F	OH
XXVIII-35-5	Ph	H	H	CH ₂ Ph	ⁿ Bu	H	H	F	OH
XXVIII-35-6	Ph	H	H	CH ₂ -indol-3-yl	ⁿ Bu	H	H	F	OH
XXVIII-35-7	Ph	H	H	CH ₂ CH ₂ SCH ₃	ⁿ Bu	H	H	F	OH
XXVIII-35-8	Ph	*	H	*	ⁿ Bu	H	H	F	OH

*R² and R^{3b} joined together by (CH₂)₃ to form five-membered ring.

Table XXVIII-36.

N ^o	R ¹	R ²	R ^{3a}	R ^{3b}	R ⁴	R ⁵	R ⁶	X	Y
XXVIII-36-1	p-Me-Ph	H	H	H	ⁿ Bu	H	H	F	OH
XXVIII-36-2	p-Me-Ph	H	H	CH ₃	ⁿ Bu	H	H	F	OH
XXVIII-36-3	p-Me-Ph	H	H	CH(CH ₃) ₂	ⁿ Bu	H	H	F	OH
XXVIII-36-4	p-Me-Ph	H	H	CH ₂ CH(CH ₃) ₂	ⁿ Bu	H	H	F	OH
XXVIII-36-5	p-Me-Ph	H	H	CH ₂ Ph	ⁿ Bu	H	H	F	OH
XXVIII-36-6	p-Me-Ph	H	H	CH ₂ -indol-3-yl	ⁿ Bu	H	H	F	OH
XXVIII-36-7	p-Me-Ph	H	H	CH ₂ CH ₂ SCH ₃	ⁿ Bu	H	H	F	OH
XXVIII-36-8	p-Me-Ph	*	H	*	ⁿ Bu	H	H	F	OH

*R² and R^{3b} joined together by (CH₂)₃ to form five-membered ring.

Table XXVIII-37.

N ^o	R ¹	R ²	R ^{3a}	R ^{3b}	R ⁴	R ⁵	R ⁶	X	Y
XXVIII-37-1	p-F-Ph	H	H	H	ⁿ Bu	H	H	F	OH
XXVIII-37-2	p-F-Ph	H	H	CH ₃	ⁿ Bu	H	H	F	OH
XXVIII-37-3	p-F-Ph	H	H	CH(CH ₃) ₂	ⁿ Bu	H	H	F	OH
XXVIII-37-4	p-F-Ph	H	H	CH ₂ CH(CH ₃) ₂	ⁿ Bu	H	H	F	OH
XXVIII-37-5	p-F-Ph	H	H	CH ₂ Ph	ⁿ Bu	H	H	F	OH
XXVIII-37-6	p-F-Ph	H	H	CH ₂ -indol-3-yl	ⁿ Bu	H	H	F	OH
XXVIII-37-7	p-F-Ph	H	H	CH ₂ CH ₂ SCH ₃	ⁿ Bu	H	H	F	OH
XXVIII-37-8	p-F-Ph	*	H	*	ⁿ Bu	H	H	F	OH

*R² and R^{3b} joined together by (CH₂)₃ to form five-membered ring.

Table XXVIII-38.

N ^o	R ¹	R ²	R ^{3a}	R ^{3b}	R ⁴	R ⁵	R ⁶	X	Y
XXVIII-38-1	p-Cl-Ph	H	H	H	ⁿ Bu	H	H	F	OH
XXVIII-38-2	p-Cl-Ph	H	H	CH ₃	ⁿ Bu	H	H	F	OH
XXVIII-38-3	p-Cl-Ph	H	H	CH(CH ₃) ₂	ⁿ Bu	H	H	F	OH
XXVIII-38-4	p-Cl-Ph	H	H	CH ₂ CH(CH ₃) ₂	ⁿ Bu	H	H	F	OH
XXVIII-38-5	p-Cl-Ph	H	H	CH ₂ Ph	ⁿ Bu	H	H	F	OH
XXVIII-38-6	p-Cl-Ph	H	H	CH ₂ -indol-3-yl	ⁿ Bu	H	H	F	OH
XXVIII-38-7	p-Cl-Ph	H	H	CH ₂ CH ₂ SCH ₃	ⁿ Bu	H	H	F	OH
XXVIII-38-8	p-Cl-Ph	*	H	*	ⁿ Bu	H	H	F	OH

*R² and R^{3b} joined together by (CH₂)₃ to form five-membered ring.

Table XXVIII-39.

№	R ¹	R ²	R ^{3a}	R ^{3b}	R ⁴	R ⁵	R ⁶	X	Y
XXVIII-39-1	p-Br-Ph	H	H	H	ⁿ Bu	H	H	F	OH
XXVIII-39-2	p-Br-Ph	H	H	CH ₃	ⁿ Bu	H	H	F	OH
XXVIII-39-3	p-Br-Ph	H	H	CH(CH ₃) ₂	ⁿ Bu	H	H	F	OH
XXVIII-39-4	p-Br-Ph	H	H	CH ₂ CH(CH ₃) ₂	ⁿ Bu	H	H	F	OH
XXVIII-39-5	p-Br-Ph	H	H	CH ₂ Ph	ⁿ Bu	H	H	F	OH
XXVIII-39-6	p-Br-Ph	H	H	CH ₂ -indol-3-yl	ⁿ Bu	H	H	F	OH
XXVIII-39-7	p-Br-Ph	H	H	CH ₂ CH ₂ SCH ₃	ⁿ Bu	H	H	F	OH
XXVIII-39-8	p-Br-Ph	*	H	*	ⁿ Bu	H	H	F	OH

*R² and R^{3b} joined together by (CH₂)₃ to form five-membered ring.

Table XXVIII-40.

№	R ¹	R ²	R ^{3a}	R ^{3b}	R ⁴	R ⁵	R ⁶	X	Y
XXVIII-40-1	p-I-Ph	H	H	H	ⁿ Bu	H	H	F	OH
XXVIII-40-2	p-I-Ph	H	H	CH ₃	ⁿ Bu	H	H	F	OH
XXVIII-40-3	p-I-Ph	H	H	CH(CH ₃) ₂	ⁿ Bu	H	H	F	OH
XXVIII-40-4	p-I-Ph	H	H	CH ₂ CH(CH ₃) ₂	ⁿ Bu	H	H	F	OH
XXVIII-40-5	p-I-Ph	H	H	CH ₂ Ph	ⁿ Bu	H	H	F	OH
XXVIII-40-6	p-I-Ph	H	H	CH ₂ -indol-3-yl	ⁿ Bu	H	H	F	OH
XXVIII-40-7	p-I-Ph	H	H	CH ₂ CH ₂ SCH ₃	ⁿ Bu	H	H	F	OH
XXVIII-40-8	p-I-Ph	*	H	*	ⁿ Bu	H	H	F	OH

*R² and R^{3b} joined together by (CH₂)₃ to form five-membered ring.

Table XXVIII-41.

№	R ¹	R ²	R ^{3a}	R ^{3b}	R ⁴	R ⁵	R ⁶	X	Y
XXVIII-41-1	CH ₃	H	H	H	Bz	H	H	F	OH
XXVIII-41-2	CH ₃	H	H	CH ₃	Bz	H	H	F	OH
XXVIII-41-3	CH ₃	H	H	CH(CH ₃) ₂	Bz	H	H	F	OH
XXVIII-41-4	CH ₃	H	H	CH ₂ CH(CH ₃) ₂	Bz	H	H	F	OH
XXVIII-41-5	CH ₃	H	H	CH ₂ Ph	Bz	H	H	F	OH
XXVIII-41-6	CH ₃	H	H	CH ₂ -indol-3-yl	Bz	H	H	F	OH
XXVIII-41-7	CH ₃	H	H	CH ₂ CH ₂ SCH ₃	Bz	H	H	F	OH
XXVIII-41-8	CH ₃	*	H	*	Bz	H	H	F	OH

*R² and R^{3b} joined together by (CH₂)₃ to form five-membered ring.

Table XXVIII-42.

N ^o	R ¹	R ²	R ^{3a}	R ^{3b}	R ⁴	R ⁵	R ⁶	X	Y
XXVIII-42-1	Et	H	H	H	Bz	H	H	F	OH
XXVIII-42-2	Et	H	H	CH ₃	Bz	H	H	F	OH
XXVIII-42-3	Et	H	H	CH(CH ₃) ₂	Bz	H	H	F	OH
XXVIII-42-4	Et	H	H	CH ₂ CH(CH ₃) ₂	Bz	H	H	F	OH
XXVIII-42-5	Et	H	H	CH ₂ Ph	Bz	H	H	F	OH
XXVIII-42-6	Et	H	H	CH ₂ -indol-3-yl	Bz	H	H	F	OH
XXVIII-42-7	Et	H	H	CH ₂ CH ₂ SCH ₃	Bz	H	H	F	OH
XXVIII-42-8	Et	*	H	*	Bz	H	H	F	OH

*R² and R^{3b} joined together by (CH₂)₃ to form five-membered ring.

Table XXVIII-43.

N ^o	R ¹	R ²	R ^{3a}	R ^{3b}	R ⁴	R ⁵	R ⁶	X	Y
XXVIII-43-1	^t Pr	H	H	H	Bz	H	H	F	OH
XXVIII-43-2	^t Pr	H	H	CH ₃	Bz	H	H	F	OH
XXVIII-43-3	^t Pr	H	H	CH(CH ₃) ₂	Bz	H	H	F	OH
XXVIII-43-4	^t Pr	H	H	CH ₂ CH(CH ₃) ₂	Bz	H	H	F	OH
XXVIII-43-5	^t Pr	H	H	CH ₂ Ph	Bz	H	H	F	OH
XXVIII-43-6	^t Pr	H	H	CH ₂ -indol-3-yl	Bz	H	H	F	OH
XXVIII-43-7	^t Pr	H	H	CH ₂ CH ₂ SCH ₃	Bz	H	H	F	OH
XXVIII-43-8	^t Pr	*	H	*	Bz	H	H	F	OH

*R² and R^{3b} joined together by (CH₂)₃ to form five-membered ring.

Table XXVIII-44.

N ^o	R ¹	R ²	R ^{3a}	R ^{3b}	R ⁴	R ⁵	R ⁶	X	Y
XXVIII-44-1	^t Bu	H	H	H	Bz	H	H	F	OH
XXVIII-44-2	^t Bu	H	H	CH ₃	Bz	H	H	F	OH
XXVIII-44-3	^t Bu	H	H	CH(CH ₃) ₂	Bz	H	H	F	OH
XXVIII-44-4	^t Bu	H	H	CH ₂ CH(CH ₃) ₂	Bz	H	H	F	OH
XXVIII-44-5	^t Bu	H	H	CH ₂ Ph	Bz	H	H	F	OH
XXVIII-44-6	^t Bu	H	H	CH ₂ -indol-3-yl	Bz	H	H	F	OH
XXVIII-44-7	^t Bu	H	H	CH ₂ CH ₂ SCH ₃	Bz	H	H	F	OH
XXVIII-44-8	^t Bu	*	H	*	Bz	H	H	F	OH

*R² and R^{3b} joined together by (CH₂)₃ to form five-membered ring.

Table XXVIII-45.

N ^o	R ¹	R ²	R ^{3a}	R ^{3b}	R ⁴	R ⁵	R ⁶	X	Y
XXVIII-45-1	Ph	H	H	H	Bz	H	H	F	OH
XXVIII-45-2	Ph	H	H	CH ₃	Bz	H	H	F	OH
XXVIII-45-3	Ph	H	H	CH(CH ₃) ₂	Bz	H	H	F	OH
XXVIII-45-4	Ph	H	H	CH ₂ CH(CH ₃) ₂	Bz	H	H	F	OH
XXVIII-45-5	Ph	H	H	CH ₂ Ph	Bz	H	H	F	OH
XXVIII-45-6	Ph	H	H	CH ₂ -indol-3-yl	Bz	H	H	F	OH
XXVIII-45-7	Ph	H	H	CH ₂ CH ₂ SCH ₃	Bz	H	H	F	OH
XXVIII-45-8	Ph	*	H	*	Bz	H	H	F	OH

*R² and R^{3b} joined together by (CH₂)₃ to form five-membered ring.

Table XXVIII-46.

N ^o	R ¹	R ²	R ^{3a}	R ^{3b}	R ⁴	R ⁵	R ⁶	X	Y
XXVIII-46-1	p-Me-Ph	H	H	H	Bz	H	H	F	OH
XXVIII-46-2	p-Me-Ph	H	H	CH ₃	Bz	H	H	F	OH
XXVIII-46-3	p-Me-Ph	H	H	CH(CH ₃) ₂	Bz	H	H	F	OH
XXVIII-46-4	p-Me-Ph	H	H	CH ₂ CH(CH ₃) ₂	Bz	H	H	F	OH
XXVIII-46-5	p-Me-Ph	H	H	CH ₂ Ph	Bz	H	H	F	OH
XXVIII-46-6	p-Me-Ph	H	H	CH ₂ -indol-3-yl	Bz	H	H	F	OH
XXVIII-46-7	p-Me-Ph	H	H	CH ₂ CH ₂ SCH ₃	Bz	H	H	F	OH
XXVIII-46-8	p-Me-Ph	*	H	*	Bz	H	H	F	OH

*R² and R^{3b} joined together by (CH₂)₃ to form five-membered ring.

Table XXVIII-47.

N ^o	R ¹	R ²	R ^{3a}	R ^{3b}	R ⁴	R ⁵	R ⁶	X	Y
XXVIII-47-1	p-F-Ph	H	H	H	Bz	H	H	F	OH
XXVIII-47-2	p-F-Ph	H	H	CH ₃	Bz	H	H	F	OH
XXVIII-47-3	p-F-Ph	H	H	CH(CH ₃) ₂	Bz	H	H	F	OH
XXVIII-47-4	p-F-Ph	H	H	CH ₂ CH(CH ₃) ₂	Bz	H	H	F	OH
XXVIII-47-5	p-F-Ph	H	H	CH ₂ Ph	Bz	H	H	F	OH
XXVIII-47-6	p-F-Ph	H	H	CH ₂ -indol-3-yl	Bz	H	H	F	OH
XXVIII-47-7	p-F-Ph	H	H	CH ₂ CH ₂ SCH ₃	Bz	H	H	F	OH
XXVIII-47-8	p-F-Ph	*	H	*	Bz	H	H	F	OH

*R² and R^{3b} joined together by (CH₂)₃ to form five-membered ring.

Table XXVIII-48.

№	R ¹	R ²	R ^{3a}	R ^{3b}	R ⁴	R ⁵	R ⁶	X	Y
XXVIII-48-1	p-Cl-Ph	H	H	H	Bz	H	H	F	OH
XXVIII-48-2	p-Cl-Ph	H	H	CH ₃	Bz	H	H	F	OH
XXVIII-48-3	p-Cl-Ph	H	H	CH(CH ₃) ₂	Bz	H	H	F	OH
XXVIII-48-4	p-Cl-Ph	H	H	CH ₂ CH(CH ₃) ₂	Bz	H	H	F	OH
XXVIII-48-5	p-Cl-Ph	H	H	CH ₂ Ph	Bz	H	H	F	OH
XXVIII-48-6	p-Cl-Ph	H	H	CH ₂ -indol-3-yl	Bz	H	H	F	OH
XXVIII-48-7	p-Cl-Ph	H	H	CH ₂ CH ₂ SCH ₃	Bz	H	H	F	OH
XXVIII-48-8	p-Cl-Ph	*	H	*	Bz	H	H	F	OH

*R² and R^{3b} joined together by (CH₂)₃ to form five-membered ring.

Table XXVIII-49.

№	R ¹	R ²	R ^{3a}	R ^{3b}	R ⁴	R ⁵	R ⁶	X	Y
XXVIII-49-1	p-Br-Ph	H	H	H	Bz	H	H	F	OH
XXVIII-49-2	p-Br-Ph	H	H	CH ₃	Bz	H	H	F	OH
XXVIII-49-3	p-Br-Ph	H	H	CH(CH ₃) ₂	Bz	H	H	F	OH
XXVIII-49-4	p-Br-Ph	H	H	CH ₂ CH(CH ₃) ₂	Bz	H	H	F	OH
XXVIII-49-5	p-Br-Ph	H	H	CH ₂ Ph	Bz	H	H	F	OH
XXVIII-49-6	p-Br-Ph	H	H	CH ₂ -indol-3-yl	Bz	H	H	F	OH
XXVIII-49-7	p-Br-Ph	H	H	CH ₂ CH ₂ SCH ₃	Bz	H	H	F	OH
XXVIII-49-8	p-Br-Ph	*	H	*	Bz	H	H	F	OH

*R² and R^{3b} joined together by (CH₂)₃ to form five-membered ring.

Table XXVIII-50.

№	R ¹	R ²	R ^{3a}	R ^{3b}	R ⁴	R ⁵	R ⁶	X	Y
XXVIII-50-1	p-I-Ph	H	H	H	Bz	H	H	F	OH
XXVIII-50-2	p-I-Ph	H	H	CH ₃	Bz	H	H	F	OH
XXVIII-50-3	p-I-Ph	H	H	CH(CH ₃) ₂	Bz	H	H	F	OH
XXVIII-50-4	p-I-Ph	H	H	CH ₂ CH(CH ₃) ₂	Bz	H	H	F	OH
XXVIII-50-5	p-I-Ph	H	H	CH ₂ Ph	Bz	H	H	F	OH
XXVIII-50-6	p-I-Ph	H	H	CH ₂ -indol-3-yl	Bz	H	H	F	OH
XXVIII-50-7	p-I-Ph	H	H	CH ₂ CH ₂ SCH ₃	Bz	H	H	F	OH
XXVIII-50-8	p-I-Ph	*	H	*	Bz	H	H	F	OH

*R² and R^{3b} joined together by (CH₂)₃ to form five-membered ring.


**XXIX**

Table XXIX-1.

No	R ¹	R ²	R ^{3a}	R ^{3b}	R ⁴	R ⁵	R ⁶	X	Y
XXIX-1-1	CH ₃	H	H	H	CH ₃	H	CH ₃	F	OH
XXIX-1-2	CH ₃	H	H	CH ₃	CH ₃	H	CH ₃	F	OH
XXIX-1-3	CH ₃	H	H	CH(CH ₃) ₂	CH ₃	H	CH ₃	F	OH
XXIX-1-4	CH ₃	H	H	CH ₂ CH(CH ₃) ₂	CH ₃	H	CH ₃	F	OH
XXIX-1-5	CH ₃	H	H	CH ₂ Ph	CH ₃	H	CH ₃	F	OH
XXIX-1-6	CH ₃	H	H	CH ₂ -indol-3-yl	CH ₃	H	CH ₃	F	OH
XXIX-1-7	CH ₃	H	H	CH ₂ CH ₂ SCH ₃	CH ₃	H	CH ₃	F	OH
XXIX-1-8	CH ₃	*	H	*	CH ₃	H	CH ₃	F	OH

*R² and R^{3b} joined together by (CH₂)₃ to form five-membered ring.

Table XXIX-2.

No	R ¹	R ²	R ^{3a}	R ^{3b}	R ⁴	R ⁵	R ⁶	X	Y
XXIX-2-1	Et	H	H	H	CH ₃	H	CH ₃	F	OH
XXIX-2-2	Et	H	H	CH ₃	CH ₃	H	CH ₃	F	OH
XXIX-2-3	Et	H	H	CH(CH ₃) ₂	CH ₃	H	CH ₃	F	OH
XXIX-2-4	Et	H	H	CH ₂ CH(CH ₃) ₂	CH ₃	H	CH ₃	F	OH
XXIX-2-5	Et	H	H	CH ₂ Ph	CH ₃	H	CH ₃	F	OH
XXIX-2-6	Et	H	H	CH ₂ -indol-3-yl	CH ₃	H	CH ₃	F	OH
XXIX-2-7	Et	H	H	CH ₂ CH ₂ SCH ₃	CH ₃	H	CH ₃	F	OH
XXIX-2-8	Et	*	H	*	CH ₃	H	CH ₃	F	OH

*R² and R^{3b} joined together by (CH₂)₃ to form five-membered ring.

Table XXIX-3.

№	R ¹	R ²	R ^{3a}	R ^{3b}	R ⁴	R ⁵	R ⁶	X	Y
XXIX-3-1	^t Pr	H	H	H	CH ₃	H	CH ₃	F	OH
XXIX-3-2	^t Pr	H	H	CH ₃	CH ₃	H	CH ₃	F	OH
XXIX-3-3	^t Pr	H	H	CH(CH ₃) ₂	CH ₃	H	CH ₃	F	OH
XXIX-3-4	^t Pr	H	H	CH ₂ CH(CH ₃) ₂	CH ₃	H	CH ₃	F	OH
XXIX-3-5	^t Pr	H	H	CH ₂ Ph	CH ₃	H	CH ₃	F	OH
XXIX-3-6	^t Pr	H	H	CH ₂ -indol-3-yl	CH ₃	H	CH ₃	F	OH
XXIX-3-7	^t Pr	H	H	CH ₂ CH ₂ SCH ₃	CH ₃	H	CH ₃	F	OH
XXIX-3-8	^t Pr	*	H	*	CH ₃	H	CH ₃	F	OH

*R² and R^{3b} joined together by (CH₂)₃ to form five-membered ring.

Table XXIX-4.

№	R ¹	R ²	R ^{3a}	R ^{3b}	R ⁴	R ⁵	R ⁶	X	Y
XXIX-4-1	^t Bu	H	H	H	CH ₃	H	CH ₃	F	OH
XXIX-4-2	^t Bu	H	H	CH ₃	CH ₃	H	CH ₃	F	OH
XXIX-4-3	^t Bu	H	H	CH(CH ₃) ₂	CH ₃	H	CH ₃	F	OH
XXIX-4-4	^t Bu	H	H	CH ₂ CH(CH ₃) ₂	CH ₃	H	CH ₃	F	OH
XXIX-4-5	^t Bu	H	H	CH ₂ Ph	CH ₃	H	CH ₃	F	OH
XXIX-4-6	^t Bu	H	H	CH ₂ -indol-3-yl	CH ₃	H	CH ₃	F	OH
XXIX-4-7	^t Bu	H	H	CH ₂ CH ₂ SCH ₃	CH ₃	H	CH ₃	F	OH
XXIX-4-8	^t Bu	*	H	*	CH ₃	H	CH ₃	F	OH

*R² and R^{3b} joined together by (CH₂)₃ to form five-membered ring.

Table XXIX-5.

№	R ¹	R ²	R ^{3a}	R ^{3b}	R ⁴	R ⁵	R ⁶	X	Y
XXIX-5-1	Ph	H	H	H	CH ₃	H	CH ₃	F	OH
XXIX-5-2	Ph	H	H	CH ₃	CH ₃	H	CH ₃	F	OH
XXIX-5-3	Ph	H	H	CH(CH ₃) ₂	CH ₃	H	CH ₃	F	OH
XXIX-5-4	Ph	H	H	CH ₂ CH(CH ₃) ₂	CH ₃	H	CH ₃	F	OH
XXIX-5-5	Ph	H	H	CH ₂ Ph	CH ₃	H	CH ₃	F	OH
XXIX-5-6	Ph	H	H	CH ₂ -indol-3-yl	CH ₃	H	CH ₃	F	OH
XXIX-5-7	Ph	H	H	CH ₂ CH ₂ SCH ₃	CH ₃	H	CH ₃	F	OH

N ^o	R ¹	R ²	R ^{3a}	R ^{3b}	R ⁴	R ⁵	R ⁶	X	Y
XXIX-5-8	Ph	*	H	*	CH ₃	H	CH ₃	F	OH

*R² and R^{3b} joined together by (CH₂)₃ to form five-membered ring.

Table XXIX-6.

N ^o	R ¹	R ²	R ^{3a}	R ^{3b}	R ⁴	R ⁵	R ⁶	X	Y
XXIX-6-1	p-Me-Ph	H	H	H	CH ₃	H	CH ₃	F	OH
XXIX-6-2	p-Me-Ph	H	H	CH ₃	CH ₃	H	CH ₃	F	OH
XXIX-6-3	p-Me-Ph	H	H	CH(CH ₃) ₂	CH ₃	H	CH ₃	F	OH
XXIX-6-4	p-Me-Ph	H	H	CH ₂ CH(CH ₃) ₂	CH ₃	H	CH ₃	F	OH
XXIX-6-5	p-Me-Ph	H	H	CH ₂ Ph	CH ₃	H	CH ₃	F	OH
XXIX-6-6	p-Me-Ph	H	H	CH ₂ -indol-3-yl	CH ₃	H	CH ₃	F	OH
XXIX-6-7	p-Me-Ph	H	H	CH ₂ CH ₂ SCH ₃	CH ₃	H	CH ₃	F	OH
XXIX-6-8	p-Me-Ph	*	H	*	CH ₃	H	CH ₃	F	OH

*R² and R^{3b} joined together by (CH₂)₃ to form five-membered ring.

Table XXIX-7.

N ^o	R ¹	R ²	R ^{3a}	R ^{3b}	R ⁴	R ⁵	R ⁶	X	Y
XXIX-7-1	p-F-Ph	H	H	H	CH ₃	H	CH ₃	F	OH
XXIX-7-2	p-F-Ph	H	H	CH ₃	CH ₃	H	CH ₃	F	OH
XXIX-7-3	p-F-Ph	H	H	CH(CH ₃) ₂	CH ₃	H	CH ₃	F	OH
XXIX-7-4	p-F-Ph	H	H	CH ₂ CH(CH ₃) ₂	CH ₃	H	CH ₃	F	OH
XXIX-7-6	p-F-Ph	H	H	CH ₂ Ph	CH ₃	H	CH ₃	F	OH
XXIX-7-7	p-F-Ph	H	H	CH ₂ -indol-3-yl	CH ₃	H	CH ₃	F	OH
XXIX-7-8	p-F-Ph	H	H	CH ₂ CH ₂ SCH ₃	CH ₃	H	CH ₃	F	OH
XXIX-7-20	p-F-Ph	*	H	*	CH ₃	H	CH ₃	F	OH

*R² and R^{3b} joined together by (CH₂)₃ to form five-membered ring.

Table XXIX-8.

N ^o	R ¹	R ²	R ^{3a}	R ^{3b}	R ⁴	R ⁵	R ⁶	X	Y
XXIX-8-1	p-Cl-Ph	H	H	H	CH ₃	H	CH ₃	F	OH
XXIX-8-2	p-Cl-Ph	H	H	CH ₃	CH ₃	H	CH ₃	F	OH
XXIX-8-3	p-Cl-Ph	H	H	CH(CH ₃) ₂	CH ₃	H	CH ₃	F	OH
XXIX-8-4	p-Cl-Ph	H	H	CH ₂ CH(CH ₃) ₂	CH ₃	H	CH ₃	F	OH
XXIX-8-5	p-Cl-Ph	H	H	CH ₂ Ph	CH ₃	H	CH ₃	F	OH

№	R ¹	R ²	R ^{3a}	R ^{3b}	R ⁴	R ⁵	R ⁶	X	Y
XXIX-8-6	p-Cl-Ph	H	H	CH ₂ -indol-3-yl	CH ₃	H	CH ₃	F	OH
XXIX-8-7	p-Cl-Ph	H	H	CH ₂ CH ₂ SCH ₃	CH ₃	H	CH ₃	F	OH
XXIX-8-8	p-Cl-Ph	*	H	*	CH ₃	H	CH ₃	F	OH

*R² and R^{3b} joined together by (CH₂)₃ to form five-membered ring.

Table XXIX-9.

№	R ¹	R ²	R ^{3a}	R ^{3b}	R ⁴	R ⁵	R ⁶	X	Y
XXIX-9-1	p-Br-Ph	H	H	H	CH ₃	H	CH ₃	F	OH
XXIX-9-2	p-Br-Ph	H	H	CH ₃	CH ₃	H	CH ₃	F	OH
XXIX-9-3	p-Br-Ph	H	H	CH(CH ₃) ₂	CH ₃	H	CH ₃	F	OH
XXIX-9-4	p-Br-Ph	H	H	CH ₂ CH(CH ₃) ₂	CH ₃	H	CH ₃	F	OH
XXIX-9-6	p-Br-Ph	H	H	CH ₂ Ph	CH ₃	H	CH ₃	F	OH
XXIX-9-7	p-Br-Ph	H	H	CH ₂ -indol-3-yl	CH ₃	H	CH ₃	F	OH
XXIX-9-8	p-Br-Ph	H	H	CH ₂ CH ₂ SCH ₃	CH ₃	H	CH ₃	F	OH
XXIX-9-20	p-Br-Ph	*	H	*	CH ₃	H	CH ₃	F	OH

*R² and R^{3b} joined together by (CH₂)₃ to form five-membered ring.

Table XXIX-10.

№	R ¹	R ²	R ^{3a}	R ^{3b}	R ⁴	R ⁵	R ⁶	X	Y
XXIX-10-1	p-I-Ph	H	H	H	CH ₃	H	CH ₃	F	OH
XXIX-10-2	p-I-Ph	H	H	CH ₃	CH ₃	H	CH ₃	F	OH
XXIX-10-3	p-I-Ph	H	H	CH(CH ₃) ₂	CH ₃	H	CH ₃	F	OH
XXIX-10-4	p-I-Ph	H	H	CH ₂ CH(CH ₃) ₂	CH ₃	H	CH ₃	F	OH
XXIX-10-5	p-I-Ph	H	H	CH ₂ Ph	CH ₃	H	CH ₃	F	OH
XXIX-10-6	p-I-Ph	H	H	CH ₂ -indol-3-yl	CH ₃	H	CH ₃	F	OH
XXIX-10-7	p-I-Ph	H	H	CH ₂ CH ₂ SCH ₃	CH ₃	H	CH ₃	F	OH
XXIX-10-8	p-I-Ph	*	H	*	CH ₃	H	CH ₃	F	OH

*R² and R^{3b} joined together by (CH₂)₃ to form five-membered ring.

Table XXIX-11.

№	R ¹	R ²	R ^{3a}	R ^{3b}	R ⁴	R ⁵	R ⁶	X	Y
XXIX-11-1	CH ₃	H	H	H	Et	H	CH ₃	F	OH
XXIX-11-2	CH ₃	H	H	CH ₃	Et	H	CH ₃	F	OH
XXIX-11-3	CH ₃	H	H	CH(CH ₃) ₂	Et	H	CH ₃	F	OH

N ₂	R ¹	R ²	R ^{3a}	R ^{3b}	R ⁴	R ⁵	R ⁶	X	Y
XXIX-11-4	CH ₃	H	H	CH ₂ CH(CH ₃) ₂	Et	H	CH ₃	F	OH
XXIX-11-5	CH ₃	H	H	CH ₂ Ph	Et	H	CH ₃	F	OH
XXIX-11-6	CH ₃	H	H	CH ₂ -indol-3-yl	Et	H	CH ₃	F	OH
XXIX-11-7	CH ₃	H	H	CH ₂ CH ₂ SCH ₃	Et	H	CH ₃	F	OH
XXIX-11-8	CH ₃	*	H	*	Et	H	CH ₃	F	OH

*R² and R^{3b} joined together by (CH₂)₃ to form five-membered ring.

Table XXIX-12.

N ₂	R ¹	R ²	R ^{3a}	R ^{3b}	R ⁴	R ⁵	R ⁶	X	Y
XXIX-12-1	Et	H	H	H	Et	H	CH ₃	F	OH
XXIX-12-2	Et	H	H	CH ₃	Et	H	CH ₃	F	OH
XXIX-12-3	Et	H	H	CH(CH ₃) ₂	Et	H	CH ₃	F	OH
XXIX-12-4	Et	H	H	CH ₂ CH(CH ₃) ₂	Et	H	CH ₃	F	OH
XXIX-12-5	Et	H	H	CH ₂ Ph	Et	H	CH ₃	F	OH
XXIX-12-6	Et	H	H	CH ₂ -indol-3-yl	Et	H	CH ₃	F	OH
XXIX-12-7	Et	H	H	CH ₂ CH ₂ SCH ₃	Et	H	CH ₃	F	OH
XXIX-12-8	Et	*	H	*	Et	H	CH ₃	F	OH

*R² and R^{3b} joined together by (CH₂)₃ to form five-membered ring.

Table XXIX-13.

N ₂	R ¹	R ²	R ^{3a}	R ^{3b}	R ⁴	R ⁵	R ⁶	X	Y
XXIX-13-1	ⁱ Pr	H	H	H	Et	H	CH ₃	F	OH
XXIX-13-2	ⁱ Pr	H	H	CH ₃	Et	H	CH ₃	F	OH
XXIX-13-3	ⁱ Pr	H	H	CH(CH ₃) ₂	Et	H	CH ₃	F	OH
XXIX-13-4	ⁱ Pr	H	H	CH ₂ CH(CH ₃) ₂	Et	H	CH ₃	F	OH
XXIX-13-5	ⁱ Pr	H	H	CH ₂ Ph	Et	H	CH ₃	F	OH
XXIX-13-6	ⁱ Pr	H	H	CH ₂ -indol-3-yl	Et	H	CH ₃	F	OH
XXIX-13-7	ⁱ Pr	H	H	CH ₂ CH ₂ SCH ₃	Et	H	CH ₃	F	OH
XXIX-13-8	ⁱ Pr	*	H	*	Et	H	CH ₃	F	OH

*R² and R^{3b} joined together by (CH₂)₃ to form five-membered ring.

Table XXIX-14.

№	R ¹	R ²	R ^{3a}	R ^{3b}	R ⁴	R ⁵	R ⁶	X	Y
XXIX-14-1	^t Bu	H	H	H	Et	H	CH ₃	F	OH
XXIX-14-2	^t Bu	H	H	CH ₃	Et	H	CH ₃	F	OH
XXIX-14-3	^t Bu	H	H	CH(CH ₃) ₂	Et	H	CH ₃	F	OH
XXIX-14-4	^t Bu	H	H	CH ₂ CH(CH ₃) ₂	Et	H	CH ₃	F	OH
XXIX-14-5	^t Bu	H	H	CH ₂ Ph	Et	H	CH ₃	F	OH
XXIX-14-6	^t Bu	H	H	CH ₂ -indol-3-yl	Et	H	CH ₃	F	OH
XXIX-14-7	^t Bu	H	H	CH ₂ CH ₂ SCH ₃	Et	H	CH ₃	F	OH
XXIX-14-8	^t Bu	*	H	*	Et	H	CH ₃	F	OH

*R² and R^{3b} joined together by (CH₂)₃ to form five-membered ring.

Table XXIX-15.

№	R ¹	R ²	R ^{3a}	R ^{3b}	R ⁴	R ⁵	R ⁶	X	Y
XXIX-15-1	Ph	H	H	H	Et	H	CH ₃	F	OH
XXIX-15-2	Ph	H	H	CH ₃	Et	H	CH ₃	F	OH
XXIX-15-3	Ph	H	H	CH(CH ₃) ₂	Et	H	CH ₃	F	OH
XXIX-15-4	Ph	H	H	CH ₂ CH(CH ₃) ₂	Et	H	CH ₃	F	OH
XXIX-15-5	Ph	H	H	CH ₂ Ph	Et	H	CH ₃	F	OH
XXIX-15-6	Ph	H	H	CH ₂ -indol-3-yl	Et	H	CH ₃	F	OH
XXIX-15-7	Ph	H	H	CH ₂ CH ₂ SCH ₃	Et	H	CH ₃	F	OH
XXIX-15-8	Ph	*	H	*	Et	H	CH ₃	F	OH

*R² and R^{3b} joined together by (CH₂)₃ to form five-membered ring.

Table XXIX-16.

№	R ¹	R ²	R ^{3a}	R ^{3b}	R ⁴	R ⁵	R ⁶	X	Y
XXIX-16-1	p-Me-Ph	H	H	H	Et	H	CH ₃	F	OH
XXIX-16-2	p-Me-Ph	H	H	CH ₃	Et	H	CH ₃	F	OH
XXIX-16-3	p-Me-Ph	H	H	CH(CH ₃) ₂	Et	H	CH ₃	F	OH
XXIX-16-4	p-Me-Ph	H	H	CH ₂ CH(CH ₃) ₂	Et	H	CH ₃	F	OH
XXIX-16-5	p-Me-Ph	H	H	CH ₂ Ph	Et	H	CH ₃	F	OH
XXIX-16-6	p-Me-Ph	H	H	CH ₂ -indol-3-yl	Et	H	CH ₃	F	OH
XXIX-16-7	p-Me-Ph	H	H	CH ₂ CH ₂ SCH ₃	Et	H	CH ₃	F	OH
XXIX-16-8	p-Me-Ph	*	H	*	Et	H	CH ₃	F	OH

*R² and R^{3b} joined together by (CH₂)₃ to form five-membered ring.

Table XXIX-17.

№	R ¹	R ²	R ^{3a}	R ^{3b}	R ⁴	R ⁵	R ⁶	X	Y
XXIX-17-1	p-F-Ph	H	H	H	Et	H	CH ₃	F	OH
XXIX-17-2	p-F-Ph	H	H	CH ₃	Et	H	CH ₃	F	OH
XXIX-17-3	p-F-Ph	H	H	CH(CH ₃) ₂	Et	H	CH ₃	F	OH
XXIX-17-4	p-F-Ph	H	H	CH ₂ CH(CH ₃) ₂	Et	H	CH ₃	F	OH
XXIX-17-5	p-F-Ph	H	H	CH ₂ Ph	Et	H	CH ₃	F	OH
XXIX-17-6	p-F-Ph	H	H	CH ₂ -indol-3-yl	Et	H	CH ₃	F	OH
XXIX-17-7	p-F-Ph	H	H	CH ₂ CH ₂ SCH ₃	Et	H	CH ₃	F	OH
XXIX-17-8	p-F-Ph	*	H	*	Et	H	CH ₃	F	OH

*R² and R^{3b} joined together by (CH₂)₃ to form five-membered ring.

Table XXIX-18.

№	R ¹	R ²	R ^{3a}	R ^{3b}	R ⁴	R ⁵	R ⁶	X	Y
XXIX-18-1	p-Cl-Ph	H	H	H	Et	H	CH ₃	F	OH
XXIX-18-2	p-Cl-Ph	H	H	CH ₃	Et	H	CH ₃	F	OH
XXIX-18-3	p-Cl-Ph	H	H	CH(CH ₃) ₂	Et	H	CH ₃	F	OH
XXIX-18-4	p-Cl-Ph	H	H	CH ₂ CH(CH ₃) ₂	Et	H	CH ₃	F	OH
XXIX-18-5	p-Cl-Ph	H	H	CH ₂ Ph	Et	H	CH ₃	F	OH
XXIX-18-6	p-Cl-Ph	H	H	CH ₂ -indol-3-yl	Et	H	CH ₃	F	OH
XXIX-18-7	p-Cl-Ph	H	H	CH ₂ CH ₂ SCH ₃	Et	H	CH ₃	F	OH
XXIX-18-8	p-Cl-Ph	*	H	*	Et	H	CH ₃	F	OH

*R² and R^{3b} joined together by (CH₂)₃ to form five-membered ring.

Table XXIX-19.

№	R ¹	R ²	R ^{3a}	R ^{3b}	R ⁴	R ⁵	R ⁶	X	Y
XXIX-19-1	p-Br-Ph	H	H	H	Et	H	CH ₃	F	OH
XXIX-19-2	p-Br-Ph	H	H	CH ₃	Et	H	CH ₃	F	OH
XXIX-19-3	p-Br-Ph	H	H	CH(CH ₃) ₂	Et	H	CH ₃	F	OH
XXIX-19-4	p-Br-Ph	H	H	CH ₂ CH(CH ₃) ₂	Et	H	CH ₃	F	OH
XXIX-19-5	p-Br-Ph	H	H	CH ₂ Ph	Et	H	CH ₃	F	OH
XXIX-19-6	p-Br-Ph	H	H	CH ₂ -indol-3-yl	Et	H	CH ₃	F	OH
XXIX-19-7	p-Br-Ph	H	H	CH ₂ CH ₂ SCH ₃	Et	H	CH ₃	F	OH
XXIX-19-8	p-Br-Ph	*	H	*	Et	H	CH ₃	F	OH

*R² and R^{3b} joined together by (CH₂)₃ to form five-membered ring.

Table XXIX-20.

N ^o	R ¹	R ²	R ^{3a}	R ^{3b}	R ⁴	R ⁵	R ⁶	X	Y
XXIX-20-1	p-I-Ph	H	H	H	Et	H	CH ₃	F	OH
XXIX-20-2	p-I-Ph	H	H	CH ₃	Et	H	CH ₃	F	OH
XXIX-20-3	p-I-Ph	H	H	CH(CH ₃) ₂	Et	H	CH ₃	F	OH
XXIX-20-4	p-I-Ph	H	H	CH ₂ CH(CH ₃) ₂	Et	H	CH ₃	F	OH
XXIX-20-5	p-I-Ph	H	H	CH ₂ Ph	Et	H	CH ₃	F	OH
XXIX-20-6	p-I-Ph	H	H	CH ₂ -indol-3-yl	Et	H	CH ₃	F	OH
XXIX-20-7	p-I-Ph	H	H	CH ₂ CH ₂ SCH ₃	Et	H	CH ₃	F	OH
XXIX-20-8	p-I-Ph	*	H	*	Et	H	CH ₃	F	OH

*R² and R^{3b} joined together by (CH₂)₃ to form five-membered ring.

Table XXIX-21.

N ^o	R ¹	R ²	R ^{3a}	R ^{3b}	R ⁴	R ⁵	R ⁶	X	Y
XXIX-21-1	CH ₃	H	H	H	ⁱ Pr	H	CH ₃	F	OH
XXIX-21-2	CH ₃	H	H	CH ₃	ⁱ Pr	H	CH ₃	F	OH
XXIX-21-3	CH ₃	H	H	CH(CH ₃) ₂	ⁱ Pr	H	CH ₃	F	OH
XXIX-21-4	CH ₃	H	H	CH ₂ CH(CH ₃) ₂	ⁱ Pr	H	CH ₃	F	OH
XXIX-21-5	CH ₃	H	H	CH ₂ Ph	ⁱ Pr	H	CH ₃	F	OH
XXIX-21-6	CH ₃	H	H	CH ₂ -indol-3-yl	ⁱ Pr	H	CH ₃	F	OH
XXIX-21-7	CH ₃	H	H	CH ₂ CH ₂ SCH ₃	ⁱ Pr	H	CH ₃	F	OH
XXIX-21-8	CH ₃	*	H	*	ⁱ Pr	H	CH ₃	F	OH

*R² and R^{3b} joined together by (CH₂)₃ to form five-membered ring.

Table XXIX-22.

N ^o	R ¹	R ²	R ^{3a}	R ^{3b}	R ⁴	R ⁵	R ⁶	X	Y
XXIX-22-1	Et	H	H	H	ⁱ Pr	H	CH ₃	F	OH
XXIX-22-2	Et	H	H	CH ₃	ⁱ Pr	H	CH ₃	F	OH
XXIX-22-3	Et	H	H	CH(CH ₃) ₂	ⁱ Pr	H	CH ₃	F	OH
XXIX-22-4	Et	H	H	CH ₂ CH(CH ₃) ₂	ⁱ Pr	H	CH ₃	F	OH
XXIX-22-5	Et	H	H	CH ₂ Ph	ⁱ Pr	H	CH ₃	F	OH
XXIX-22-6	Et	H	H	CH ₂ -indol-3-yl	ⁱ Pr	H	CH ₃	F	OH
XXIX-22-7	Et	H	H	CH ₂ CH ₂ SCH ₃	ⁱ Pr	H	CH ₃	F	OH
XXIX-22-8	Et	*	H	*	ⁱ Pr	H	CH ₃	F	OH

*R² and R^{3b} joined together by (CH₂)₃ to form five-membered ring.

Table XXIX-23.

N ^o	R ¹	R ²	R ^{3a}	R ^{3b}	R ⁴	R ⁵	R ⁶	X	Y
XXIX-23-1	ⁱ Pr	H	H	H	ⁱ Pr	H	CH ₃	F	OH
XXIX-23-2	ⁱ Pr	H	H	CH ₃	ⁱ Pr	H	CH ₃	F	OH
XXIX-23-3	ⁱ Pr	H	H	CH(CH ₃) ₂	ⁱ Pr	H	CH ₃	F	OH
XXIX-23-4	ⁱ Pr	H	H	CH ₂ CH(CH ₃) ₂	ⁱ Pr	H	CH ₃	F	OH
XXIX-23-5	ⁱ Pr	H	H	CH ₂ Ph	ⁱ Pr	H	CH ₃	F	OH
XXIX-23-6	ⁱ Pr	H	H	CH ₂ -indol-3-yl	ⁱ Pr	H	CH ₃	F	OH
XXIX-23-7	ⁱ Pr	H	H	CH ₂ CH ₂ SCH ₃	ⁱ Pr	H	CH ₃	F	OH
XXIX-23-8	ⁱ Pr	*	H	*	ⁱ Pr	H	CH ₃	F	OH

*R² and R^{3b} joined together by (CH₂)₃ to form five-membered ring.

Table XXIX-24.

N ^o	R ¹	R ²	R ^{3a}	R ^{3b}	R ⁴	R ⁵	R ⁶	X	Y
XXIX-24-1	^t Bu	H	H	H	ⁱ Pr	H	CH ₃	F	OH
XXIX-24-2	^t Bu	H	H	CH ₃	ⁱ Pr	H	CH ₃	F	OH
XXIX-24-3	^t Bu	H	H	CH(CH ₃) ₂	ⁱ Pr	H	CH ₃	F	OH
XXIX-24-4	^t Bu	H	H	CH ₂ CH(CH ₃) ₂	ⁱ Pr	H	CH ₃	F	OH
XXIX-24-5	^t Bu	H	H	CH ₂ Ph	ⁱ Pr	H	CH ₃	F	OH
XXIX-24-6	^t Bu	H	H	CH ₂ -indol-3-yl	ⁱ Pr	H	CH ₃	F	OH
XXIX-24-7	^t Bu	H	H	CH ₂ CH ₂ SCH ₃	ⁱ Pr	H	CH ₃	F	OH
XXIX-24-8	^t Bu	*	H	*	ⁱ Pr	H	CH ₃	F	OH

*R² and R^{3b} joined together by (CH₂)₃ to form five-membered ring.

Table XXIX-25.

N ^o	R ¹	R ²	R ^{3a}	R ^{3b}	R ⁴	R ⁵	R ⁶	X	Y
XXIX-25-1	Ph	H	H	H	ⁱ Pr	H	CH ₃	F	OH
XXIX-25-2	Ph	H	H	CH ₃	ⁱ Pr	H	CH ₃	F	OH
XXIX-25-3	Ph	H	H	CH(CH ₃) ₂	ⁱ Pr	H	CH ₃	F	OH
XXIX-25-4	Ph	H	H	CH ₂ CH(CH ₃) ₂	ⁱ Pr	H	CH ₃	F	OH
XXIX-25-5	Ph	H	H	CH ₂ Ph	ⁱ Pr	H	CH ₃	F	OH
XXIX-25-6	Ph	H	H	CH ₂ -indol-3-yl	ⁱ Pr	H	CH ₃	F	OH
XXIX-25-7	Ph	H	H	CH ₂ CH ₂ SCH ₃	ⁱ Pr	H	CH ₃	F	OH
XXIX-25-8	Ph	*	H	*	ⁱ Pr	H	CH ₃	F	OH

*R² and R^{3b} joined together by (CH₂)₃ to form five-membered ring.

Table XXIX-26.

№	R ¹	R ²	R ^{3a}	R ^{3b}	R ⁴	R ⁵	R ⁶	X	Y
XXIX-26-1	p-Me-Ph	H	H	H	ⁱ Pr	H	CH ₃	F	OH
XXIX-26-2	p-Me-Ph	H	H	CH ₃	ⁱ Pr	H	CH ₃	F	OH
XXIX-26-3	p-Me-Ph	H	H	CH(CH ₃) ₂	ⁱ Pr	H	CH ₃	F	OH
XXIX-26-4	p-Me-Ph	H	H	CH ₂ CH(CH ₃) ₂	ⁱ Pr	H	CH ₃	F	OH
XXIX-26-5	p-Me-Ph	H	H	CH ₂ Ph	ⁱ Pr	H	CH ₃	F	OH
XXIX-26-6	p-Me-Ph	H	H	CH ₂ -indol-3-yl	ⁱ Pr	H	CH ₃	F	OH
XXIX-26-7	p-Me-Ph	H	H	CH ₂ CH ₂ SCH ₃	ⁱ Pr	H	CH ₃	F	OH
XXIX-26-8	p-Me-Ph	*	H	*	ⁱ Pr	H	CH ₃	F	OH

*R² and R^{3b} joined together by (CH₂)₃ to form five-membered ring.

Table XXIX-27.

№	R ¹	R ²	R ^{3a}	R ^{3b}	R ⁴	R ⁵	R ⁶	X	Y
XXIX-27-1	p-F-Ph	H	H	H	ⁱ Pr	H	CH ₃	F	OH
XXIX-27-2	p-F-Ph	H	H	CH ₃	ⁱ Pr	H	CH ₃	F	OH
XXIX-27-3	p-F-Ph	H	H	CH(CH ₃) ₂	ⁱ Pr	H	CH ₃	F	OH
XXIX-27-4	p-F-Ph	H	H	CH ₂ CH(CH ₃) ₂	ⁱ Pr	H	CH ₃	F	OH
XXIX-27-5	p-F-Ph	H	H	CH ₂ Ph	ⁱ Pr	H	CH ₃	F	OH
XXIX-27-6	p-F-Ph	H	H	CH ₂ -indol-3-yl	ⁱ Pr	H	CH ₃	F	OH
XXIX-27-7	p-F-Ph	H	H	CH ₂ CH ₂ SCH ₃	ⁱ Pr	H	CH ₃	F	OH
XXIX-27-8	p-F-Ph	*	H	*	ⁱ Pr	H	CH ₃	F	OH

*R² and R^{3b} joined together by (CH₂)₃ to form five-membered ring.

Table XXIX-28.

№	R ¹	R ²	R ^{3a}	R ^{3b}	R ⁴	R ⁵	R ⁶	X	Y
XXIX-28-1	p-Cl-Ph	H	H	H	ⁱ Pr	H	CH ₃	F	OH
XXIX-28-2	p-Cl-Ph	H	H	CH ₃	ⁱ Pr	H	CH ₃	F	OH
XXIX-28-3	p-Cl-Ph	H	H	CH(CH ₃) ₂	ⁱ Pr	H	CH ₃	F	OH
XXIX-28-4	p-Cl-Ph	H	H	CH ₂ CH(CH ₃) ₂	ⁱ Pr	H	CH ₃	F	OH
XXIX-28-5	p-Cl-Ph	H	H	CH ₂ Ph	ⁱ Pr	H	CH ₃	F	OH
XXIX-28-6	p-Cl-Ph	H	H	CH ₂ -indol-3-yl	ⁱ Pr	H	CH ₃	F	OH
XXIX-28-7	p-Cl-Ph	H	H	CH ₂ CH ₂ SCH ₃	ⁱ Pr	H	CH ₃	F	OH
XXIX-28-8	p-Cl-Ph	*	H	*	ⁱ Pr	H	CH ₃	F	OH

*R² and R^{3b} joined together by (CH₂)₃ to form five-membered ring.

Table XXIX-29.

N ^o	R ¹	R ²	R ^{3a}	R ^{3b}	R ⁴	R ⁵	R ⁶	X	Y
XXIX-29-1	p-Br-Ph	H	H	H	ⁱ Pr	H	CH ₃	F	OH
XXIX-29-2	p-Br-Ph	H	H	CH ₃	ⁱ Pr	H	CH ₃	F	OH
XXIX-29-3	p-Br-Ph	H	H	CH(CH ₃) ₂	ⁱ Pr	H	CH ₃	F	OH
XXIX-29-4	p-Br-Ph	H	H	CH ₂ CH(CH ₃) ₂	ⁱ Pr	H	CH ₃	F	OH
XXIX-29-5	p-Br-Ph	H	H	CH ₂ Ph	ⁱ Pr	H	CH ₃	F	OH
XXIX-29-6	p-Br-Ph	H	H	CH ₂ -indol-3-yl	ⁱ Pr	H	CH ₃	F	OH
XXIX-29-7	p-Br-Ph	H	H	CH ₂ CH ₂ SCH ₃	ⁱ Pr	H	CH ₃	F	OH
XXIX-29-8	p-Br-Ph	*	H	*	ⁱ Pr	H	CH ₃	F	OH

*R² and R^{3b} joined together by (CH₂)₃ to form five-membered ring.

Table XXIX-30.

N ^o	R ¹	R ²	R ^{3a}	R ^{3b}	R ⁴	R ⁵	R ⁶	X	Y
XXIX-30-1	p-I-Ph	H	H	H	ⁱ Pr	H	CH ₃	F	OH
XXIX-30-2	p-I-Ph	H	H	CH ₃	ⁱ Pr	H	CH ₃	F	OH
XXIX-30-3	p-I-Ph	H	H	CH(CH ₃) ₂	ⁱ Pr	H	CH ₃	F	OH
XXIX-30-4	p-I-Ph	H	H	CH ₂ CH(CH ₃) ₂	ⁱ Pr	H	CH ₃	F	OH
XXIX-30-5	p-I-Ph	H	H	CH ₂ Ph	ⁱ Pr	H	CH ₃	F	OH
XXIX-30-6	p-I-Ph	H	H	CH ₂ -indol-3-yl	ⁱ Pr	H	CH ₃	F	OH
XXIX-30-7	p-I-Ph	H	H	CH ₂ CH ₂ SCH ₃	ⁱ Pr	H	CH ₃	F	OH
XXIX-30-8	p-I-Ph	*	H	*	ⁱ Pr	H	CH ₃	F	OH

*R² and R^{3b} joined together by (CH₂)₃ to form five-membered ring.

Table XXIX-31.

N ^o	R ¹	R ²	R ^{3a}	R ^{3b}	R ⁴	R ⁵	R ⁶	X	Y
XXIX-31-1	CH ₃	H	H	H	ⁿ Bu	H	CH ₃	F	OH
XXIX-31-2	CH ₃	H	H	CH ₃	ⁿ Bu	H	CH ₃	F	OH
XXIX-31-3	CH ₃	H	H	CH(CH ₃) ₂	ⁿ Bu	H	CH ₃	F	OH
XXIX-31-4	CH ₃	H	H	CH ₂ CH(CH ₃) ₂	ⁿ Bu	H	CH ₃	F	OH
XXIX-31-5	CH ₃	H	H	CH ₂ Ph	ⁿ Bu	H	CH ₃	F	OH
XXIX-31-6	CH ₃	H	H	CH ₂ -indol-3-yl	ⁿ Bu	H	CH ₃	F	OH
XXIX-31-7	CH ₃	H	H	CH ₂ CH ₂ SCH ₃	ⁿ Bu	H	CH ₃	F	OH
XXIX-31-8	CH ₃	*	H	*	ⁿ Bu	H	CH ₃	F	OH

*R² and R^{3b} joined together by (CH₂)₃ to form five-membered ring.

Table XXIX-32.

N ^o	R ¹	R ²	R ^{3a}	R ^{3b}	R ⁴	R ⁵	R ⁶	X	Y
XXIX-32-1	Et	H	H	H	ⁿ Bu	H	CH ₃	F	OH
XXIX-32-2	Et	H	H	CH ₃	ⁿ Bu	H	CH ₃	F	OH
XXIX-32-3	Et	H	H	CH(CH ₃) ₂	ⁿ Bu	H	CH ₃	F	OH
XXIX-32-4	Et	H	H	CH ₂ CH(CH ₃) ₂	ⁿ Bu	H	CH ₃	F	OH
XXIX-32-5	Et	H	H	CH ₂ Ph	ⁿ Bu	H	CH ₃	F	OH
XXIX-32-6	Et	H	H	CH ₂ -indol-3-yl	ⁿ Bu	H	CH ₃	F	OH
XXIX-32-7	Et	H	H	CH ₂ CH ₂ SCH ₃	ⁿ Bu	H	CH ₃	F	OH
XXIX-32-8	Et	*	H	*	ⁿ Bu	H	CH ₃	F	OH

*R² and R^{3b} joined together by (CH₂)₃ to form five-membered ring.

Table XXIX-33.

N ^o	R ¹	R ²	R ^{3a}	R ^{3b}	R ⁴	R ⁵	R ⁶	X	Y
XXIX-33-1	ⁱ Pr	H	H	H	ⁿ Bu	H	CH ₃	F	OH
XXIX-33-2	ⁱ Pr	H	H	CH ₃	ⁿ Bu	H	CH ₃	F	OH
XXIX-33-3	ⁱ Pr	H	H	CH(CH ₃) ₂	ⁿ Bu	H	CH ₃	F	OH
XXIX-33-4	ⁱ Pr	H	H	CH ₂ CH(CH ₃) ₂	ⁿ Bu	H	CH ₃	F	OH
XXIX-33-5	ⁱ Pr	H	H	CH ₂ Ph	ⁿ Bu	H	CH ₃	F	OH
XXIX-33-6	ⁱ Pr	H	H	CH ₂ -indol-3-yl	ⁿ Bu	H	CH ₃	F	OH
XXIX-33-7	ⁱ Pr	H	H	CH ₂ CH ₂ SCH ₃	ⁿ Bu	H	CH ₃	F	OH
XXIX-33-8	ⁱ Pr	*	H	*	ⁿ Bu	H	CH ₃	F	OH

*R² and R^{3b} joined together by (CH₂)₃ to form five-membered ring.

Table XXIX-34.

N ^o	R ¹	R ²	R ^{3a}	R ^{3b}	R ⁴	R ⁵	R ⁶	X	Y
XXIX-34-1	^t Bu	H	H	H	ⁿ Bu	H	CH ₃	F	OH
XXIX-34-2	^t Bu	H	H	CH ₃	ⁿ Bu	H	CH ₃	F	OH
XXIX-34-3	^t Bu	H	H	CH(CH ₃) ₂	ⁿ Bu	H	CH ₃	F	OH
XXIX-34-4	^t Bu	H	H	CH ₂ CH(CH ₃) ₂	ⁿ Bu	H	CH ₃	F	OH
XXIX-34-5	^t Bu	H	H	CH ₂ Ph	ⁿ Bu	H	CH ₃	F	OH
XXIX-34-6	^t Bu	H	H	CH ₂ -indol-3-yl	ⁿ Bu	H	CH ₃	F	OH
XXIX-34-7	^t Bu	H	H	CH ₂ CH ₂ SCH ₃	ⁿ Bu	H	CH ₃	F	OH
XXIX-34-8	^t Bu	*	H	*	ⁿ Bu	H	CH ₃	F	OH

*R² and R^{3b} joined together by (CH₂)₃ to form five-membered ring.

Table XXIX-35.

N ^o	R ¹	R ²	R ^{3a}	R ^{3b}	R ⁴	R ⁵	R ⁶	X	Y
XXIX-35-1	Ph	H	H	H	ⁿ Bu	H	CH ₃	F	OH
XXIX-35-2	Ph	H	H	CH ₃	ⁿ Bu	H	CH ₃	F	OH
XXIX-35-3	Ph	H	H	CH(CH ₃) ₂	ⁿ Bu	H	CH ₃	F	OH
XXIX-35-4	Ph	H	H	CH ₂ CH(CH ₃) ₂	ⁿ Bu	H	CH ₃	F	OH
XXIX-35-5	Ph	H	H	CH ₂ Ph	ⁿ Bu	H	CH ₃	F	OH
XXIX-35-6	Ph	H	H	CH ₂ -indol-3-yl	ⁿ Bu	H	CH ₃	F	OH
XXIX-35-7	Ph	H	H	CH ₂ CH ₂ SCH ₃	ⁿ Bu	H	CH ₃	F	OH
XXIX-35-8	Ph	*	H	*	ⁿ Bu	H	CH ₃	F	OH

*R² and R^{3b} joined together by (CH₂)₃ to form five-membered ring.

Table XXIX-36.

N ^o	R ¹	R ²	R ^{3a}	R ^{3b}	R ⁴	R ⁵	R ⁶	X	Y
XXIX-36-1	p-Me-Ph	H	H	H	ⁿ Bu	H	CH ₃	F	OH
XXIX-36-2	p-Me-Ph	H	H	CH ₃	ⁿ Bu	H	CH ₃	F	OH
XXIX-36-3	p-Me-Ph	H	H	CH(CH ₃) ₂	ⁿ Bu	H	CH ₃	F	OH
XXIX-36-4	p-Me-Ph	H	H	CH ₂ CH(CH ₃) ₂	ⁿ Bu	H	CH ₃	F	OH
XXIX-36-5	p-Me-Ph	H	H	CH ₂ Ph	ⁿ Bu	H	CH ₃	F	OH
XXIX-36-6	p-Me-Ph	H	H	CH ₂ -indol-3-yl	ⁿ Bu	H	CH ₃	F	OH
XXIX-36-7	p-Me-Ph	H	H	CH ₂ CH ₂ SCH ₃	ⁿ Bu	H	CH ₃	F	OH
XXIX-36-8	p-Me-Ph	*	H	*	ⁿ Bu	H	CH ₃	F	OH

*R² and R^{3b} joined together by (CH₂)₃ to form five-membered ring.

Table XXIX-37.

N ^o	R ¹	R ²	R ^{3a}	R ^{3b}	R ⁴	R ⁵	R ⁶	X	Y
XXIX-37-1	p-F-Ph	H	H	H	ⁿ Bu	H	CH ₃	F	OH
XXIX-37-2	p-F-Ph	H	H	CH ₃	ⁿ Bu	H	CH ₃	F	OH
XXIX-37-3	p-F-Ph	H	H	CH(CH ₃) ₂	ⁿ Bu	H	CH ₃	F	OH
XXIX-37-4	p-F-Ph	H	H	CH ₂ CH(CH ₃) ₂	ⁿ Bu	H	CH ₃	F	OH
XXIX-37-5	p-F-Ph	H	H	CH ₂ Ph	ⁿ Bu	H	CH ₃	F	OH
XXIX-37-6	p-F-Ph	H	H	CH ₂ -indol-3-yl	ⁿ Bu	H	CH ₃	F	OH
XXIX-37-7	p-F-Ph	H	H	CH ₂ CH ₂ SCH ₃	ⁿ Bu	H	CH ₃	F	OH
XXIX-37-8	p-F-Ph	*	H	*	ⁿ Bu	H	CH ₃	F	OH

*R² and R^{3b} joined together by (CH₂)₃ to form five-membered ring.

Table XXIX-38.

№	R ¹	R ²	R ^{3a}	R ^{3b}	R ⁴	R ⁵	R ⁶	X	Y
XXIX-38-1	p-Cl-Ph	H	H	H	ⁿ Bu	H	CH ₃	F	OH
XXIX-38-2	p-Cl-Ph	H	H	CH ₃	ⁿ Bu	H	CH ₃	F	OH
XXIX-38-3	p-Cl-Ph	H	H	CH(CH ₃) ₂	ⁿ Bu	H	CH ₃	F	OH
XXIX-38-4	p-Cl-Ph	H	H	CH ₂ CH(CH ₃) ₂	ⁿ Bu	H	CH ₃	F	OH
XXIX-38-5	p-Cl-Ph	H	H	CH ₂ Ph	ⁿ Bu	H	CH ₃	F	OH
XXIX-38-6	p-Cl-Ph	H	H	CH ₂ -indol-3-yl	ⁿ Bu	H	CH ₃	F	OH
XXIX-38-7	p-Cl-Ph	H	H	CH ₂ CH ₂ SCH ₃	ⁿ Bu	H	CH ₃	F	OH
XXIX-38-8	p-Cl-Ph	*	H	*	ⁿ Bu	H	CH ₃	F	OH

*R² and R^{3b} joined together by (CH₂)₃ to form five-membered ring.

Table XXIX-39.

№	R ¹	R ²	R ^{3a}	R ^{3b}	R ⁴	R ⁵	R ⁶	X	Y
XXIX-39-1	p-Br-Ph	H	H	H	ⁿ Bu	H	CH ₃	F	OH
XXIX-39-2	p-Br-Ph	H	H	CH ₃	ⁿ Bu	H	CH ₃	F	OH
XXIX-39-3	p-Br-Ph	H	H	CH(CH ₃) ₂	ⁿ Bu	H	CH ₃	F	OH
XXIX-39-4	p-Br-Ph	H	H	CH ₂ CH(CH ₃) ₂	ⁿ Bu	H	CH ₃	F	OH
XXIX-39-5	p-Br-Ph	H	H	CH ₂ Ph	ⁿ Bu	H	CH ₃	F	OH
XXIX-39-6	p-Br-Ph	H	H	CH ₂ -indol-3-yl	ⁿ Bu	H	CH ₃	F	OH
XXIX-39-7	p-Br-Ph	H	H	CH ₂ CH ₂ SCH ₃	ⁿ Bu	H	CH ₃	F	OH
XXIX-39-8	p-Br-Ph	*	H	*	ⁿ Bu	H	CH ₃	F	OH

*R² and R^{3b} joined together by (CH₂)₃ to form five-membered ring.

Table XXIX-40.

№	R ¹	R ²	R ^{3a}	R ^{3b}	R ⁴	R ⁵	R ⁶	X	Y
XXIX-40-1	p-I-Ph	H	H	H	ⁿ Bu	H	CH ₃	F	OH
XXIX-40-2	p-I-Ph	H	H	CH ₃	ⁿ Bu	H	CH ₃	F	OH
XXIX-40-3	p-I-Ph	H	H	CH(CH ₃) ₂	ⁿ Bu	H	CH ₃	F	OH
XXIX-40-4	p-I-Ph	H	H	CH ₂ CH(CH ₃) ₂	ⁿ Bu	H	CH ₃	F	OH
XXIX-40-5	p-I-Ph	H	H	CH ₂ Ph	ⁿ Bu	H	CH ₃	F	OH
XXIX-40-6	p-I-Ph	H	H	CH ₂ -indol-3-yl	ⁿ Bu	H	CH ₃	F	OH
XXIX-40-7	p-I-Ph	H	H	CH ₂ CH ₂ SCH ₃	ⁿ Bu	H	CH ₃	F	OH
XXIX-40-8	p-I-Ph	*	H	*	ⁿ Bu	H	CH ₃	F	OH

*R² and R^{3b} joined together by (CH₂)₃ to form five-membered ring.

Table XXIX-41.

N ^o	R ¹	R ²	R ^{3a}	R ^{3b}	R ⁴	R ⁵	R ⁶	X	Y
XXIX-41-1	CH ₃	H	H	H	Bz	H	CH ₃	F	OH
XXIX-41-2	CH ₃	H	H	CH ₃	Bz	H	CH ₃	F	OH
XXIX-41-3	CH ₃	H	H	CH(CH ₃) ₂	Bz	H	CH ₃	F	OH
XXIX-41-4	CH ₃	H	H	CH ₂ CH(CH ₃) ₂	Bz	H	CH ₃	F	OH
XXIX-41-5	CH ₃	H	H	CH ₂ Ph	Bz	H	CH ₃	F	OH
XXIX-41-6	CH ₃	H	H	CH ₂ -indol-3-yl	Bz	H	CH ₃	F	OH
XXIX-41-7	CH ₃	H	H	CH ₂ CH ₂ SCH ₃	Bz	H	CH ₃	F	OH
XXIX-41-8	CH ₃	*	H	*	Bz	H	CH ₃	F	OH

*R² and R^{3b} joined together by (CH₂)₃ to form five-membered ring.

Table XXIX-42.

N ^o	R ¹	R ²	R ^{3a}	R ^{3b}	R ⁴	R ⁵	R ⁶	X	Y
XXIX-42-1	Et	H	H	H	Bz	H	CH ₃	F	OH
XXIX-42-2	Et	H	H	CH ₃	Bz	H	CH ₃	F	OH
XXIX-42-3	Et	H	H	CH(CH ₃) ₂	Bz	H	CH ₃	F	OH
XXIX-42-4	Et	H	H	CH ₂ CH(CH ₃) ₂	Bz	H	CH ₃	F	OH
XXIX-42-5	Et	H	H	CH ₂ Ph	Bz	H	CH ₃	F	OH
XXIX-42-6	Et	H	H	CH ₂ -indol-3-yl	Bz	H	CH ₃	F	OH
XXIX-42-7	Et	H	H	CH ₂ CH ₂ SCH ₃	Bz	H	CH ₃	F	OH
XXIX-42-8	Et	*	H	*	Bz	H	CH ₃	F	OH

*R² and R^{3b} joined together by (CH₂)₃ to form five-membered ring.

Table XXIX-43.

N ^o	R ¹	R ²	R ^{3a}	R ^{3b}	R ⁴	R ⁵	R ⁶	X	Y
XXIX-43-1	ⁱ Pr	H	H	H	Bz	H	CH ₃	F	OH
XXIX-43-2	ⁱ Pr	H	H	CH ₃	Bz	H	CH ₃	F	OH
XXIX-43-3	ⁱ Pr	H	H	CH(CH ₃) ₂	Bz	H	CH ₃	F	OH
XXIX-43-4	ⁱ Pr	H	H	CH ₂ CH(CH ₃) ₂	Bz	H	CH ₃	F	OH
XXIX-43-5	ⁱ Pr	H	H	CH ₂ Ph	Bz	H	CH ₃	F	OH
XXIX-43-6	ⁱ Pr	H	H	CH ₂ -indol-3-yl	Bz	H	CH ₃	F	OH
XXIX-43-7	ⁱ Pr	H	H	CH ₂ CH ₂ SCH ₃	Bz	H	CH ₃	F	OH
XXIX-43-8	ⁱ Pr	*	H	*	Bz	H	CH ₃	F	OH

*R² and R^{3b} joined together by (CH₂)₃ to form five-membered ring.

Table XXIX-44.

№	R ¹	R ²	R ^{3a}	R ^{3b}	R ⁴	R ⁵	R ⁶	X	Y
XXIX-44-1	^t Bu	H	H	H	Bz	H	CH ₃	F	OH
XXIX-44-2	^t Bu	H	H	CH ₃	Bz	H	CH ₃	F	OH
XXIX-44-3	^t Bu	H	H	CH(CH ₃) ₂	Bz	H	CH ₃	F	OH
XXIX-44-4	^t Bu	H	H	CH ₂ CH(CH ₃) ₂	Bz	H	CH ₃	F	OH
XXIX-44-5	^t Bu	H	H	CH ₂ Ph	Bz	H	CH ₃	F	OH
XXIX-44-6	^t Bu	H	H	CH ₂ -indol-3-yl	Bz	H	CH ₃	F	OH
XXIX-44-7	^t Bu	H	H	CH ₂ CH ₂ SCH ₃	Bz	H	CH ₃	F	OH
XXIX-44-8	^t Bu	*	H	*	Bz	H	CH ₃	F	OH

*R² and R^{3b} joined together by (CH₂)₃ to form five-membered ring.

Table XXIX-45.

№	R ¹	R ²	R ^{3a}	R ^{3b}	R ⁴	R ⁵	R ⁶	X	Y
XXIX-45-1	Ph	H	H	H	Bz	H	CH ₃	F	OH
XXIX-45-2	Ph	H	H	CH ₃	Bz	H	CH ₃	F	OH
XXIX-45-3	Ph	H	H	CH(CH ₃) ₂	Bz	H	CH ₃	F	OH
XXIX-45-4	Ph	H	H	CH ₂ CH(CH ₃) ₂	Bz	H	CH ₃	F	OH
XXIX-45-5	Ph	H	H	CH ₂ Ph	Bz	H	CH ₃	F	OH
XXIX-45-6	Ph	H	H	CH ₂ -indol-3-yl	Bz	H	CH ₃	F	OH
XXIX-45-7	Ph	H	H	CH ₂ CH ₂ SCH ₃	Bz	H	CH ₃	F	OH
XXIX-45-8	Ph	*	H	*	Bz	H	CH ₃	F	OH

*R² and R^{3b} joined together by (CH₂)₃ to form five-membered ring.

Table XXIX-46.

№	R ¹	R ²	R ^{3a}	R ^{3b}	R ⁴	R ⁵	R ⁶	X	Y
XXIX-46-1	p-Me-Ph	H	H	H	Bz	H	CH ₃	F	OH
XXIX-46-2	p-Me-Ph	H	H	CH ₃	Bz	H	CH ₃	F	OH
XXIX-46-3	p-Me-Ph	H	H	CH(CH ₃) ₂	Bz	H	CH ₃	F	OH
XXIX-46-4	p-Me-Ph	H	H	CH ₂ CH(CH ₃) ₂	Bz	H	CH ₃	F	OH
XXIX-46-5	p-Me-Ph	H	H	CH ₂ Ph	Bz	H	CH ₃	F	OH
XXIX-46-6	p-Me-Ph	H	H	CH ₂ -indol-3-yl	Bz	H	CH ₃	F	OH
XXIX-46-7	p-Me-Ph	H	H	CH ₂ CH ₂ SCH ₃	Bz	H	CH ₃	F	OH

N ₂	R ¹	R ²	R ^{3a}	R ^{3b}	R ⁴	R ⁵	R ⁶	X	Y
XXIX-46-8	p-Me-Ph	*	H	*	Bz	H	CH ₃	F	OH

*R² and R^{3b} joined together by (CH₂)₃ to form five-membered ring.

Table XXIX-47.

N ₂	R ¹	R ²	R ^{3a}	R ^{3b}	R ⁴	R ⁵	R ⁶	X	Y
XXIX-47-1	p-F-Ph	H	H	H	Bz	H	CH ₃	F	OH
XXIX-47-2	p-F-Ph	H	H	CH ₃	Bz	H	CH ₃	F	OH
XXIX-47-3	p-F-Ph	H	H	CH(CH ₃) ₂	Bz	H	CH ₃	F	OH
XXIX-47-4	p-F-Ph	H	H	CH ₂ CH(CH ₃) ₂	Bz	H	CH ₃	F	OH
XXIX-47-5	p-F-Ph	H	H	CH ₂ Ph	Bz	H	CH ₃	F	OH
XXIX-47-6	p-F-Ph	H	H	CH ₂ -indol-3-yl	Bz	H	CH ₃	F	OH
XXIX-47-7	p-F-Ph	H	H	CH ₂ CH ₂ SCH ₃	Bz	H	CH ₃	F	OH
XXIX-47-8	p-F-Ph	*	H	*	Bz	H	CH ₃	F	OH

*R² and R^{3b} joined together by (CH₂)₃ to form five-membered ring.

Table XXIX-48.

N ₂	R ¹	R ²	R ^{3a}	R ^{3b}	R ⁴	R ⁵	R ⁶	X	Y
XXIX-48-1	p-Cl-Ph	H	H	H	Bz	H	CH ₃	F	OH
XXIX-48-2	p-Cl-Ph	H	H	CH ₃	Bz	H	CH ₃	F	OH
XXIX-48-3	p-Cl-Ph	H	H	CH(CH ₃) ₂	Bz	H	CH ₃	F	OH
XXIX-48-4	p-Cl-Ph	H	H	CH ₂ CH(CH ₃) ₂	Bz	H	CH ₃	F	OH
XXIX-48-5	p-Cl-Ph	H	H	CH ₂ Ph	Bz	H	CH ₃	F	OH
XXIX-48-6	p-Cl-Ph	H	H	CH ₂ -indol-3-yl	Bz	H	CH ₃	F	OH
XXIX-48-7	p-Cl-Ph	H	H	CH ₂ CH ₂ SCH ₃	Bz	H	CH ₃	F	OH
XXIX-48-8	p-Cl-Ph	*	H	*	Bz	H	CH ₃	F	OH

*R² and R^{3b} joined together by (CH₂)₃ to form five-membered ring.

Table XXIX-49.

N ₂	R ¹	R ²	R ^{3a}	R ^{3b}	R ⁴	R ⁵	R ⁶	X	Y
XXIX-49-1	p-Br-Ph	H	H	H	Bz	H	CH ₃	F	OH
XXIX-49-2	p-Br-Ph	H	H	CH ₃	Bz	H	CH ₃	F	OH
XXIX-49-3	p-Br-Ph	H	H	CH(CH ₃) ₂	Bz	H	CH ₃	F	OH
XXIX-49-4	p-Br-Ph	H	H	CH ₂ CH(CH ₃) ₂	Bz	H	CH ₃	F	OH
XXIX-49-5	p-Br-Ph	H	H	CH ₂ Ph	Bz	H	CH ₃	F	OH


No	R ¹	R ²	R ^{3a}	R ^{3b}	R ⁴	R ⁵	R ⁶	X	Y
XXIX-49-6	p-Br-Ph	H	H	CH ₂ -indol-3-yl	Bz	H	CH ₃	F	OH
XXIX-49-7	p-Br-Ph	H	H	CH ₂ CH ₂ SCH ₃	Bz	H	CH ₃	F	OH
XXIX-49-8	p-Br-Ph	*	H	*	Bz	H	CH ₃	F	OH

*R² and R^{3b} joined together by (CH₂)₃ to form five-membered ring.

Table XXIX-50.

No	R ¹	R ²	R ^{3a}	R ^{3b}	R ⁴	R ⁵	R ⁶	X	Y
XXIX-50-1	p-I-Ph	H	H	H	Bz	H	CH ₃	F	OH
XXIX-50-2	p-I-Ph	H	H	CH ₃	Bz	H	CH ₃	F	OH
XXIX-50-3	p-I-Ph	H	H	CH(CH ₃) ₂	Bz	H	CH ₃	F	OH
XXIX-50-4	p-I-Ph	H	H	CH ₂ CH(CH ₃) ₂	Bz	H	CH ₃	F	OH
XXIX-50-5	p-I-Ph	H	H	CH ₂ Ph	Bz	H	CH ₃	F	OH
XXIX-50-6	p-I-Ph	H	H	CH ₂ -indol-3-yl	Bz	H	CH ₃	F	OH
XXIX-50-7	p-I-Ph	H	H	CH ₂ CH ₂ SCH ₃	Bz	H	CH ₃	F	OH
XXIX-50-8	p-I-Ph	*	H	*	Bz	H	CH ₃	F	OH

*R² and R^{3b} joined together by (CH₂)₃ to form five-membered ring.



XXX

Table XXX-1.

N ₂	R ¹	R ²	R ^{3a}	R ^{3b}	R ⁴	R ⁵	R ⁶	X	Y
XXX-1-1	CH ₃	H	H	H	CH ₃	H	F	H	OH
XXX-1-2	CH ₃	H	H	CH ₃	CH ₃	H	F	H	OH
XXX-1-3	CH ₃	H	H	CH(CH ₃) ₂	CH ₃	H	F	H	OH
XXX-1-4	CH ₃	H	H	CH ₂ CH(CH ₃) ₂	CH ₃	H	F	H	OH
XXX-1-5	CH ₃	H	H	CH ₂ Ph	CH ₃	H	F	H	OH
XXX-1-6	CH ₃	H	H	CH ₂ -indol-3-yl	CH ₃	H	F	H	OH
XXX-1-7	CH ₃	H	H	CH ₂ CH ₂ SCH ₃	CH ₃	H	F	H	OH
XXX-1-8	CH ₃	*	H	*	CH ₃	H	F	H	OH

*R² and R^{3b} joined together by (CH₂)₃ to form five-membered ring.

Table XXX-2.

N ₂	R ¹	R ²	R ^{3a}	R ^{3b}	R ⁴	R ⁵	R ⁶	X	Y
XXX-2-1	Et	H	H	H	CH ₃	H	F	H	OH
XXX-2-2	Et	H	H	CH ₃	CH ₃	H	F	H	OH
XXX-2-3	Et	H	H	CH(CH ₃) ₂	CH ₃	H	F	H	OH
XXX-2-4	Et	H	H	CH ₂ CH(CH ₃) ₂	CH ₃	H	F	H	OH
XXX-2-5	Et	H	H	CH ₂ Ph	CH ₃	H	F	H	OH
XXX-2-6	Et	H	H	CH ₂ -indol-3-yl	CH ₃	H	F	H	OH
XXX-2-7	Et	H	H	CH ₂ CH ₂ SCH ₃	CH ₃	H	F	H	OH
XXX-2-8	Et	*	H	*	CH ₃	H	F	H	OH

*R² and R^{3b} joined together by (CH₂)₃ to form five-membered ring.

Table XXX-3.

N ₂	R ¹	R ²	R ^{3a}	R ^{3b}	R ⁴	R ⁵	R ⁶	X	Y
XXX-3-1	ⁱ P _r	H	H	H	CH ₃	H	F	H	OH
XXX-3-2	ⁱ P _r	H	H	CH ₃	CH ₃	H	F	H	OH
XXX-3-3	ⁱ P _r	H	H	CH(CH ₃) ₂	CH ₃	H	F	H	OH
XXX-3-4	ⁱ P _r	H	H	CH ₂ CH(CH ₃) ₂	CH ₃	H	F	H	OH
XXX-3-5	ⁱ P _r	H	H	CH ₂ Ph	CH ₃	H	F	H	OH
XXX-3-6	ⁱ P _r	H	H	CH ₂ -indol-3-yl	CH ₃	H	F	H	OH
XXX-3-7	ⁱ P _r	H	H	CH ₂ CH ₂ SCH ₃	CH ₃	H	F	H	OH
XXX-3-8	ⁱ P _r	*	H	*	CH ₃	H	F	H	OH

*R² and R^{3b} joined together by (CH₂)₃ to form five-membered ring.

Table XXX-4.

N ^o	R ¹	R ²	R ^{3a}	R ^{3b}	R ⁴	R ⁵	R ⁶	X	Y
XXX-4-1	^t Bu	H	H	H	CH ₃	H	F	H	OH
XXX-4-2	^t Bu	H	H	CH ₃	CH ₃	H	F	H	OH
XXX-4-3	^t Bu	H	H	CH(CH ₃) ₂	CH ₃	H	F	H	OH
XXX-4-4	^t Bu	H	H	CH ₂ CH(CH ₃) ₂	CH ₃	H	F	H	OH
XXX-4-5	^t Bu	H	H	CH ₂ Ph	CH ₃	H	F	H	OH
XXX-4-6	^t Bu	H	H	CH ₂ -indol-3-yl	CH ₃	H	F	H	OH
XXX-4-7	^t Bu	H	H	CH ₂ CH ₂ SCH ₃	CH ₃	H	F	H	OH
XXX-4-8	^t Bu	*	H	*	CH ₃	H	F	H	OH

*R² and R^{3b} joined together by (CH₂)₃ to form five-membered ring.

Table XXX-5.

N ^o	R ¹	R ²	R ^{3a}	R ^{3b}	R ⁴	R ⁵	R ⁶	X	Y
XXX-5-1	Ph	H	H	H	CH ₃	H	F	H	OH
XXX-5-2	Ph	H	H	CH ₃	CH ₃	H	F	H	OH
XXX-5-3	Ph	H	H	CH(CH ₃) ₂	CH ₃	H	F	H	OH
XXX-5-4	Ph	H	H	CH ₂ CH(CH ₃) ₂	CH ₃	H	F	H	OH
XXX-5-5	Ph	H	H	CH ₂ Ph	CH ₃	H	F	H	OH
XXX-5-6	Ph	H	H	CH ₂ -indol-3-yl	CH ₃	H	F	H	OH
XXX-5-7	Ph	H	H	CH ₂ CH ₂ SCH ₃	CH ₃	H	F	H	OH
XXX-5-8	Ph	*	H	*	CH ₃	H	F	H	OH

*R² and R^{3b} joined together by (CH₂)₃ to form five-membered ring.

Table XXX-6.

N ^o	R ¹	R ²	R ^{3a}	R ^{3b}	R ⁴	R ⁵	R ⁶	X	Y
XXX-6-1	p-Me-Ph	H	H	H	CH ₃	H	F	H	OH
XXX-6-2	p-Me-Ph	H	H	CH ₃	CH ₃	H	F	H	OH
XXX-6-3	p-Me-Ph	H	H	CH(CH ₃) ₂	CH ₃	H	F	H	OH
XXX-6-4	p-Me-Ph	H	H	CH ₂ CH(CH ₃) ₂	CH ₃	H	F	H	OH
XXX-6-5	p-Me-Ph	H	H	CH ₂ Ph	CH ₃	H	F	H	OH
XXX-6-6	p-Me-Ph	H	H	CH ₂ -indol-3-yl	CH ₃	H	F	H	OH
XXX-6-7	p-Me-Ph	H	H	CH ₂ CH ₂ SCH ₃	CH ₃	H	F	H	OH
XXX-6-8	p-Me-Ph	*	H	*	CH ₃	H	F	H	OH

*R² and R^{3b} joined together by (CH₂)₃ to form five-membered ring.

Table XXX-7.

N ^o	R ¹	R ²	R ^{3a}	R ^{3b}	R ⁴	R ⁵	R ⁶	X	Y
XXX-7-1	p-F-Ph	H	H	H	CH ₃	H	F	H	OH
XXX-7-2	p-F-Ph	H	H	CH ₃	CH ₃	H	F	H	OH
XXX-7-3	p-F-Ph	H	H	CH(CH ₃) ₂	CH ₃	H	F	H	OH
XXX-7-4	p-F-Ph	H	H	CH ₂ CH(CH ₃) ₂	CH ₃	H	F	H	OH
XXX-7-6	p-F-Ph	H	H	CH ₂ Ph	CH ₃	H	F	H	OH
XXX-7-7	p-F-Ph	H	H	CH ₂ -indol-3-yl	CH ₃	H	F	H	OH
XXX-7-8	p-F-Ph	H	H	CH ₂ CH ₂ SCH ₃	CH ₃	H	F	H	OH
XXX-7-20	p-F-Ph	*	H	*	CH ₃	H	F	H	OH

*R² and R^{3b} joined together by (CH₂)₃ to form five-membered ring.

Table XXX-8.

N ^o	R ¹	R ²	R ^{3a}	R ^{3b}	R ⁴	R ⁵	R ⁶	X	Y
XXX-8-1	p-Cl-Ph	H	H	H	CH ₃	H	F	H	OH
XXX-8-2	p-Cl-Ph	H	H	CH ₃	CH ₃	H	F	H	OH
XXX-8-3	p-Cl-Ph	H	H	CH(CH ₃) ₂	CH ₃	H	F	H	OH
XXX-8-4	p-Cl-Ph	H	H	CH ₂ CH(CH ₃) ₂	CH ₃	H	F	H	OH
XXX-8-5	p-Cl-Ph	H	H	CH ₂ Ph	CH ₃	H	F	H	OH
XXX-8-6	p-Cl-Ph	H	H	CH ₂ -indol-3-yl	CH ₃	H	F	H	OH
XXX-8-7	p-Cl-Ph	H	H	CH ₂ CH ₂ SCH ₃	CH ₃	H	F	H	OH
XXX-8-8	p-Cl-Ph	*	H	*	CH ₃	H	F	H	OH

*R² and R^{3b} joined together by (CH₂)₃ to form five-membered ring.

Table XXX-9.

N ^o	R ¹	R ²	R ^{3a}	R ^{3b}	R ⁴	R ⁵	R ⁶	X	Y
XXX-9-1	p-Br-Ph	H	H	H	CH ₃	H	F	H	OH
XXX-9-2	p-Br-Ph	H	H	CH ₃	CH ₃	H	F	H	OH
XXX-9-3	p-Br-Ph	H	H	CH(CH ₃) ₂	CH ₃	H	F	H	OH
XXX-9-4	p-Br-Ph	H	H	CH ₂ CH(CH ₃) ₂	CH ₃	H	F	H	OH
XXX-9-6	p-Br-Ph	H	H	CH ₂ Ph	CH ₃	H	F	H	OH
XXX-9-7	p-Br-Ph	H	H	CH ₂ -indol-3-yl	CH ₃	H	F	H	OH
XXX-9-8	p-Br-Ph	H	H	CH ₂ CH ₂ SCH ₃	CH ₃	H	F	H	OH
XXX-9-20	p-Br-Ph	*	H	*	CH ₃	H	F	H	OH

*R² and R^{3b} joined together by (CH₂)₃ to form five-membered ring.

Table XXX-10.

N ₂	R ¹	R ²	R ^{3a}	R ^{3b}	R ⁴	R ⁵	R ⁶	X	Y
XXX-10-1	p-I-Ph	H	H	H	CH ₃	H	F	H	OH
XXX-10-2	p-I-Ph	H	H	CH ₃	CH ₃	H	F	H	OH
XXX-10-3	p-I-Ph	H	H	CH(CH ₃) ₂	CH ₃	H	F	H	OH
XXX-10-4	p-I-Ph	H	H	CH ₂ CH(CH ₃) ₂	CH ₃	H	F	H	OH
XXX-10-5	p-I-Ph	H	H	CH ₂ Ph	CH ₃	H	F	H	OH
XXX-10-6	p-I-Ph	H	H	CH ₂ -indol-3-yl	CH ₃	H	F	H	OH
XXX-10-7	p-I-Ph	H	H	CH ₂ CH ₂ SCH ₃	CH ₃	H	F	H	OH
XXX-10-8	p-I-Ph	*	H	*	CH ₃	H	F	H	OH

*R² and R^{3b} joined together by (CH₂)₃ to form five-membered ring.

Table XXX-11.

N ₂	R ¹	R ²	R ^{3a}	R ^{3b}	R ⁴	R ⁵	R ⁶	X	Y
XXX-11-1	CH ₃	H	H	H	Et	H	F	H	OH
XXX-11-2	CH ₃	H	H	CH ₃	Et	H	F	H	OH
XXX-11-3	CH ₃	H	H	CH(CH ₃) ₂	Et	H	F	H	OH
XXX-11-4	CH ₃	H	H	CH ₂ CH(CH ₃) ₂	Et	H	F	H	OH
XXX-11-5	CH ₃	H	H	CH ₂ Ph	Et	H	F	H	OH
XXX-11-6	CH ₃	H	H	CH ₂ -indol-3-yl	Et	H	F	H	OH
XXX-11-7	CH ₃	H	H	CH ₂ CH ₂ SCH ₃	Et	H	F	H	OH
XXX-11-8	CH ₃	*	H	*	Et	H	F	H	OH

*R² and R^{3b} joined together by (CH₂)₃ to form five-membered ring.

Table XXX-12.

N ₂	R ¹	R ²	R ^{3a}	R ^{3b}	R ⁴	R ⁵	R ⁶	X	Y
XXX-12-1	Et	H	H	H	Et	H	F	H	OH
XXX-12-2	Et	H	H	CH ₃	Et	H	F	H	OH
XXX-12-3	Et	H	H	CH(CH ₃) ₂	Et	H	F	H	OH
XXX-12-4	Et	H	H	CH ₂ CH(CH ₃) ₂	Et	H	F	H	OH
XXX-12-5	Et	H	H	CH ₂ Ph	Et	H	F	H	OH
XXX-12-6	Et	H	H	CH ₂ -indol-3-yl	Et	H	F	H	OH
XXX-12-7	Et	H	H	CH ₂ CH ₂ SCH ₃	Et	H	F	H	OH
XXX-12-8	Et	*	H	*	Et	H	F	H	OH

*R² and R^{3b} joined together by (CH₂)₃ to form five-membered ring.

Table XXX-13.

N ^o	R ¹	R ²	R ^{3a}	R ^{3b}	R ⁴	R ⁵	R ⁶	X	Y
XXX-13-1	ⁱ Pr	H	H	H	Et	H	F	H	OH
XXX-13-2	ⁱ Pr	H	H	CH ₃	Et	H	F	H	OH
XXX-13-3	ⁱ Pr	H	H	CH(CH ₃) ₂	Et	H	F	H	OH
XXX-13-4	ⁱ Pr	H	H	CH ₂ CH(CH ₃) ₂	Et	H	F	H	OH
XXX-13-5	ⁱ Pr	H	H	CH ₂ Ph	Et	H	F	H	OH
XXX-13-6	ⁱ Pr	H	H	CH ₂ -indol-3-yl	Et	H	F	H	OH
XXX-13-7	ⁱ Pr	H	H	CH ₂ CH ₂ SCH ₃	Et	H	F	H	OH
XXX-13-8	ⁱ Pr	*	H	*	Et	H	F	H	OH

*R² and R^{3b} joined together by (CH₂)₃ to form five-membered ring.

Table XXX-14.

N ^o	R ¹	R ²	R ^{3a}	R ^{3b}	R ⁴	R ⁵	R ⁶	X	Y
XXX-14-1	^t Bu	H	H	H	Et	H	F	H	OH
XXX-14-2	^t Bu	H	H	CH ₃	Et	H	F	H	OH
XXX-14-3	^t Bu	H	H	CH(CH ₃) ₂	Et	H	F	H	OH
XXX-14-4	^t Bu	H	H	CH ₂ CH(CH ₃) ₂	Et	H	F	H	OH
XXX-14-5	^t Bu	H	H	CH ₂ Ph	Et	H	F	H	OH
XXX-14-6	^t Bu	H	H	CH ₂ -indol-3-yl	Et	H	F	H	OH
XXX-14-7	^t Bu	H	H	CH ₂ CH ₂ SCH ₃	Et	H	F	H	OH
XXX-14-8	^t Bu	*	H	*	Et	H	F	H	OH

*R² and R^{3b} joined together by (CH₂)₃ to form five-membered ring.

Table XXX-15.

N ^o	R ¹	R ²	R ^{3a}	R ^{3b}	R ⁴	R ⁵	R ⁶	X	Y
XXX-15-1	Ph	H	H	H	Et	H	F	H	OH
XXX-15-2	Ph	H	H	CH ₃	Et	H	F	H	OH
XXX-15-3	Ph	H	H	CH(CH ₃) ₂	Et	H	F	H	OH
XXX-15-4	Ph	H	H	CH ₂ CH(CH ₃) ₂	Et	H	F	H	OH
XXX-15-5	Ph	H	H	CH ₂ Ph	Et	H	F	H	OH
XXX-15-6	Ph	H	H	CH ₂ -indol-3-yl	Et	H	F	H	OH
XXX-15-7	Ph	H	H	CH ₂ CH ₂ SCH ₃	Et	H	F	H	OH
XXX-15-8	Ph	*	H	*	Et	H	F	H	OH

*R² and R^{3b} joined together by (CH₂)₃ to form five-membered ring.

Table XXX-16.

N ^o	R ¹	R ²	R ^{3a}	R ^{3b}	R ⁴	R ⁵	R ⁶	X	Y
XXX-16-1	p-Me-Ph	H	H	H	Et	H	F	H	OH
XXX-16-2	p-Me-Ph	H	H	CH ₃	Et	H	F	H	OH
XXX-16-3	p-Me-Ph	H	H	CH(CH ₃) ₂	Et	H	F	H	OH
XXX-16-4	p-Me-Ph	H	H	CH ₂ CH(CH ₃) ₂	Et	H	F	H	OH
XXX-16-5	p-Me-Ph	H	H	CH ₂ Ph	Et	H	F	H	OH
XXX-16-6	p-Me-Ph	H	H	CH ₂ -indol-3-yl	Et	H	F	H	OH
XXX-16-7	p-Me-Ph	H	H	CH ₂ CH ₂ SCH ₃	Et	H	F	H	OH
XXX-16-8	p-Me-Ph	*	H	*	Et	H	F	H	OH

*R² and R^{3b} joined together by (CH₂)₃ to form five-membered ring.

Table XXX-17.

N ^o	R ¹	R ²	R ^{3a}	R ^{3b}	R ⁴	R ⁵	R ⁶	X	Y
XXX-17-1	p-F-Ph	H	H	H	Et	H	F	H	OH
XXX-17-2	p-F-Ph	H	H	CH ₃	Et	H	F	H	OH
XXX-17-3	p-F-Ph	H	H	CH(CH ₃) ₂	Et	H	F	H	OH
XXX-17-4	p-F-Ph	H	H	CH ₂ CH(CH ₃) ₂	Et	H	F	H	OH
XXX-17-5	p-F-Ph	H	H	CH ₂ Ph	Et	H	F	H	OH
XXX-17-6	p-F-Ph	H	H	CH ₂ -indol-3-yl	Et	H	F	H	OH
XXX-17-7	p-F-Ph	H	H	CH ₂ CH ₂ SCH ₃	Et	H	F	H	OH
XXX-17-8	p-F-Ph	*	H	*	Et	H	F	H	OH

*R² and R^{3b} joined together by (CH₂)₃ to form five-membered ring.

Table XXX-18.

N ^o	R ¹	R ²	R ^{3a}	R ^{3b}	R ⁴	R ⁵	R ⁶	X	Y
XXX-18-1	p-Cl-Ph	H	H	H	Et	H	F	H	OH
XXX-18-2	p-Cl-Ph	H	H	CH ₃	Et	H	F	H	OH
XXX-18-3	p-Cl-Ph	H	H	CH(CH ₃) ₂	Et	H	F	H	OH
XXX-18-4	p-Cl-Ph	H	H	CH ₂ CH(CH ₃) ₂	Et	H	F	H	OH
XXX-18-5	p-Cl-Ph	H	H	CH ₂ Ph	Et	H	F	H	OH
XXX-18-6	p-Cl-Ph	H	H	CH ₂ -indol-3-yl	Et	H	F	H	OH
XXX-18-7	p-Cl-Ph	H	H	CH ₂ CH ₂ SCH ₃	Et	H	F	H	OH
XXX-18-8	p-Cl-Ph	*	H	*	Et	H	F	H	OH

*R² and R^{3b} joined together by (CH₂)₃ to form five-membered ring.

Table XXX-19.

N ^o	R ¹	R ²	R ^{3a}	R ^{3b}	R ⁴	R ⁵	R ⁶	X	Y
XXX-19-1	p-Br-Ph	H	H	H	Et	H	F	H	OH
XXX-19-2	p-Br-Ph	H	H	CH ₃	Et	H	F	H	OH
XXX-19-3	p-Br-Ph	H	H	CH(CH ₃) ₂	Et	H	F	H	OH
XXX-19-4	p-Br-Ph	H	H	CH ₂ CH(CH ₃) ₂	Et	H	F	H	OH
XXX-19-5	p-Br-Ph	H	H	CH ₂ Ph	Et	H	F	H	OH
XXX-19-6	p-Br-Ph	H	H	CH ₂ -indol-3-yl	Et	H	F	H	OH
XXX-19-7	p-Br-Ph	H	H	CH ₂ CH ₂ SCH ₃	Et	H	F	H	OH
XXX-19-8	p-Br-Ph	*	H	*	Et	H	F	H	OH

*R² and R^{3b} joined together by (CH₂)₃ to form five-membered ring.

Table XXX-20.

N ^o	R ¹	R ²	R ^{3a}	R ^{3b}	R ⁴	R ⁵	R ⁶	X	Y
XXX-20-1	p-I-Ph	H	H	H	Et	H	F	H	OH
XXX-20-2	p-I-Ph	H	H	CH ₃	Et	H	F	H	OH
XXX-20-3	p-I-Ph	H	H	CH(CH ₃) ₂	Et	H	F	H	OH
XXX-20-4	p-I-Ph	H	H	CH ₂ CH(CH ₃) ₂	Et	H	F	H	OH
XXX-20-5	p-I-Ph	H	H	CH ₂ Ph	Et	H	F	H	OH
XXX-20-6	p-I-Ph	H	H	CH ₂ -indol-3-yl	Et	H	F	H	OH
XXX-20-7	p-I-Ph	H	H	CH ₂ CH ₂ SCH ₃	Et	H	F	H	OH
XXX-20-8	p-I-Ph	*	H	*	Et	H	F	H	OH

*R² and R^{3b} joined together by (CH₂)₃ to form five-membered ring.

Table XXX-21.

N ^o	R ¹	R ²	R ^{3a}	R ^{3b}	R ⁴	R ⁵	R ⁶	X	Y
XXX-21-1	CH ₃	H	H	H	ⁱ Pr	H	F	H	OH
XXX-21-2	CH ₃	H	H	CH ₃	ⁱ Pr	H	F	H	OH
XXX-21-3	CH ₃	H	H	CH(CH ₃) ₂	ⁱ Pr	H	F	H	OH
XXX-21-4	CH ₃	H	H	CH ₂ CH(CH ₃) ₂	ⁱ Pr	H	F	H	OH
XXX-21-5	CH ₃	H	H	CH ₂ Ph	ⁱ Pr	H	F	H	OH
XXX-21-6	CH ₃	H	H	CH ₂ -indol-3-yl	ⁱ Pr	H	F	H	OH
XXX-21-7	CH ₃	H	H	CH ₂ CH ₂ SCH ₃	ⁱ Pr	H	F	H	OH
XXX-21-8	CH ₃	*	H	*	ⁱ Pr	H	F	H	OH

*R² and R^{3b} joined together by (CH₂)₃ to form five-membered ring.

Table XXX-22.

N ^o	R ¹	R ²	R ^{3a}	R ^{3b}	R ⁴	R ⁵	R ⁶	X	Y
XXX-22-1	Et	H	H	H	ⁱ Pr	H	F	H	OH
XXX-22-2	Et	H	H	CH ₃	ⁱ Pr	H	F	H	OH
XXX-22-3	Et	H	H	CH(CH ₃) ₂	ⁱ Pr	H	F	H	OH
XXX-22-4	Et	H	H	CH ₂ CH(CH ₃) ₂	ⁱ Pr	H	F	H	OH
XXX-22-5	Et	H	H	CH ₂ Ph	ⁱ Pr	H	F	H	OH
XXX-22-6	Et	H	H	CH ₂ -indol-3-yl	ⁱ Pr	H	F	H	OH
XXX-22-7	Et	H	H	CH ₂ CH ₂ SCH ₃	ⁱ Pr	H	F	H	OH
XXX-22-8	Et	*	H	*	ⁱ Pr	H	F	H	OH

*R² and R^{3b} joined together by (CH₂)₃ to form five-membered ring.

Table XXX-23.

N ^o	R ¹	R ²	R ^{3a}	R ^{3b}	R ⁴	R ⁵	R ⁶	X	Y
XXX-23-1	ⁱ Pr	H	H	H	ⁱ Pr	H	F	H	OH
XXX-23-2	ⁱ Pr	H	H	CH ₃	ⁱ Pr	H	F	H	OH
XXX-23-3	ⁱ Pr	H	H	CH(CH ₃) ₂	ⁱ Pr	H	F	H	OH
XXX-23-4	ⁱ Pr	H	H	CH ₂ CH(CH ₃) ₂	ⁱ Pr	H	F	H	OH
XXX-23-5	ⁱ Pr	H	H	CH ₂ Ph	ⁱ Pr	H	F	H	OH
XXX-23-6	ⁱ Pr	H	H	CH ₂ -indol-3-yl	ⁱ Pr	H	F	H	OH
XXX-23-7	ⁱ Pr	H	H	CH ₂ CH ₂ SCH ₃	ⁱ Pr	H	F	H	OH
XXX-23-8	ⁱ Pr	*	H	*	ⁱ Pr	H	F	H	OH

*R² and R^{3b} joined together by (CH₂)₃ to form five-membered ring.

Table XXX-24.

N ^o	R ¹	R ²	R ^{3a}	R ^{3b}	R ⁴	R ⁵	R ⁶	X	Y
XXX-24-1	^t Bu	H	H	H	ⁱ Pr	H	F	H	OH
XXX-24-2	^t Bu	H	H	CH ₃	ⁱ Pr	H	F	H	OH
XXX-24-3	^t Bu	H	H	CH(CH ₃) ₂	ⁱ Pr	H	F	H	OH
XXX-24-4	^t Bu	H	H	CH ₂ CH(CH ₃) ₂	ⁱ Pr	H	F	H	OH
XXX-24-5	^t Bu	H	H	CH ₂ Ph	ⁱ Pr	H	F	H	OH
XXX-24-6	^t Bu	H	H	CH ₂ -indol-3-yl	ⁱ Pr	H	F	H	OH
XXX-24-7	^t Bu	H	H	CH ₂ CH ₂ SCH ₃	ⁱ Pr	H	F	H	OH
XXX-24-8	^t Bu	*	H	*	ⁱ Pr	H	F	H	OH

*R² and R^{3b} joined together by (CH₂)₃ to form five-membered ring.

Table XXX-25.

N ^o	R ¹	R ²	R ^{3a}	R ^{3b}	R ⁴	R ⁵	R ⁶	X	Y
XXX-25-1	Ph	H	H	H	ⁱ Pr	H	F	H	OH
XXX-25-2	Ph	H	H	CH ₃	ⁱ Pr	H	F	H	OH
XXX-25-3	Ph	H	H	CH(CH ₃) ₂	ⁱ Pr	H	F	H	OH
XXX-25-4	Ph	H	H	CH ₂ CH(CH ₃) ₂	ⁱ Pr	H	F	H	OH
XXX-25-5	Ph	H	H	CH ₂ Ph	ⁱ Pr	H	F	H	OH
XXX-25-6	Ph	H	H	CH ₂ -indol-3-yl	ⁱ Pr	H	F	H	OH
XXX-25-7	Ph	H	H	CH ₂ CH ₂ SCH ₃	ⁱ Pr	H	F	H	OH
XXX-25-8	Ph	*	H	*	ⁱ Pr	H	F	H	OH

*R² and R^{3b} joined together by (CH₂)₃ to form five-membered ring.

Table XXX-26.

N ^o	R ¹	R ²	R ^{3a}	R ^{3b}	R ⁴	R ⁵	R ⁶	X	Y
XXX-26-1	p-Me-Ph	H	H	H	ⁱ Pr	H	F	H	OH
XXX-26-2	p-Me-Ph	H	H	CH ₃	ⁱ Pr	H	F	H	OH
XXX-26-3	p-Me-Ph	H	H	CH(CH ₃) ₂	ⁱ Pr	H	F	H	OH
XXX-26-4	p-Me-Ph	H	H	CH ₂ CH(CH ₃) ₂	ⁱ Pr	H	F	H	OH
XXX-26-5	p-Me-Ph	H	H	CH ₂ Ph	ⁱ Pr	H	F	H	OH
XXX-26-6	p-Me-Ph	H	H	CH ₂ -indol-3-yl	ⁱ Pr	H	F	H	OH
XXX-26-7	p-Me-Ph	H	H	CH ₂ CH ₂ SCH ₃	ⁱ Pr	H	F	H	OH
XXX-26-8	p-Me-Ph	*	H	*	ⁱ Pr	H	F	H	OH

*R² and R^{3b} joined together by (CH₂)₃ to form five-membered ring.

Table XXX-27.

N ^o	R ¹	R ²	R ^{3a}	R ^{3b}	R ⁴	R ⁵	R ⁶	X	Y
XXX-27-1	p-F-Ph	H	H	H	ⁱ Pr	H	F	H	OH
XXX-27-2	p-F-Ph	H	H	CH ₃	ⁱ Pr	H	F	H	OH
XXX-27-3	p-F-Ph	H	H	CH(CH ₃) ₂	ⁱ Pr	H	F	H	OH
XXX-27-4	p-F-Ph	H	H	CH ₂ CH(CH ₃) ₂	ⁱ Pr	H	F	H	OH
XXX-27-5	p-F-Ph	H	H	CH ₂ Ph	ⁱ Pr	H	F	H	OH
XXX-27-6	p-F-Ph	H	H	CH ₂ -indol-3-yl	ⁱ Pr	H	F	H	OH
XXX-27-7	p-F-Ph	H	H	CH ₂ CH ₂ SCH ₃	ⁱ Pr	H	F	H	OH
XXX-27-8	p-F-Ph	*	H	*	ⁱ Pr	H	F	H	OH

*R² and R^{3b} joined together by (CH₂)₃ to form five-membered ring.

Table XXX-28.

N ^o	R ¹	R ²	R ^{3a}	R ^{3b}	R ⁴	R ⁵	R ⁶	X	Y
XXX-28-1	p-Cl-Ph	H	H	H	ⁱ Pr	H	F	H	OH
XXX-28-2	p-Cl-Ph	H	H	CH ₃	ⁱ Pr	H	F	H	OH
XXX-28-3	p-Cl-Ph	H	H	CH(CH ₃) ₂	ⁱ Pr	H	F	H	OH
XXX-28-4	p-Cl-Ph	H	H	CH ₂ CH(CH ₃) ₂	ⁱ Pr	H	F	H	OH
XXX-28-5	p-Cl-Ph	H	H	CH ₂ Ph	ⁱ Pr	H	F	H	OH
XXX-28-6	p-Cl-Ph	H	H	CH ₂ -indol-3-yl	ⁱ Pr	H	F	H	OH
XXX-28-7	p-Cl-Ph	H	H	CH ₂ CH ₂ SCH ₃	ⁱ Pr	H	F	H	OH
XXX-28-8	p-Cl-Ph	*	H	*	ⁱ Pr	H	F	H	OH

*R² and R^{3b} joined together by (CH₂)₃ to form five-membered ring.

Table XXX-29.

N ^o	R ¹	R ²	R ^{3a}	R ^{3b}	R ⁴	R ⁵	R ⁶	X	Y
XXX-29-1	p-Br-Ph	H	H	H	ⁱ Pr	H	F	H	OH
XXX-29-2	p-Br-Ph	H	H	CH ₃	ⁱ Pr	H	F	H	OH
XXX-29-3	p-Br-Ph	H	H	CH(CH ₃) ₂	ⁱ Pr	H	F	H	OH
XXX-29-4	p-Br-Ph	H	H	CH ₂ CH(CH ₃) ₂	ⁱ Pr	H	F	H	OH
XXX-29-5	p-Br-Ph	H	H	CH ₂ Ph	ⁱ Pr	H	F	H	OH
XXX-29-6	p-Br-Ph	H	H	CH ₂ -indol-3-yl	ⁱ Pr	H	F	H	OH
XXX-29-7	p-Br-Ph	H	H	CH ₂ CH ₂ SCH ₃	ⁱ Pr	H	F	H	OH
XXX-29-8	p-Br-Ph	*	H	*	ⁱ Pr	H	F	H	OH

*R² and R^{3b} joined together by (CH₂)₃ to form five-membered ring.

Table XXX-30.

N ^o	R ¹	R ²	R ^{3a}	R ^{3b}	R ⁴	R ⁵	R ⁶	X	Y
XXX-30-1	p-I-Ph	H	H	H	ⁱ Pr	H	F	H	OH
XXX-30-2	p-I-Ph	H	H	CH ₃	ⁱ Pr	H	F	H	OH
XXX-30-3	p-I-Ph	H	H	CH(CH ₃) ₂	ⁱ Pr	H	F	H	OH
XXX-30-4	p-I-Ph	H	H	CH ₂ CH(CH ₃) ₂	ⁱ Pr	H	F	H	OH
XXX-30-5	p-I-Ph	H	H	CH ₂ Ph	ⁱ Pr	H	F	H	OH
XXX-30-6	p-I-Ph	H	H	CH ₂ -indol-3-yl	ⁱ Pr	H	F	H	OH
XXX-30-7	p-I-Ph	H	H	CH ₂ CH ₂ SCH ₃	ⁱ Pr	H	F	H	OH
XXX-30-8	p-I-Ph	*	H	*	ⁱ Pr	H	F	H	OH

*R² and R^{3b} joined together by (CH₂)₃ to form five-membered ring.

Table XXX-31.

N ^o	R ¹	R ²	R ^{3a}	R ^{3b}	R ⁴	R ⁵	R ⁶	X	Y
XXX-31-1	CH ₃	H	H	H	ⁿ Bu	H	F	H	OH
XXX-31-2	CH ₃	H	H	CH ₃	ⁿ Bu	H	F	H	OH
XXX-31-3	CH ₃	H	H	CH(CH ₃) ₂	ⁿ Bu	H	F	H	OH
XXX-31-4	CH ₃	H	H	CH ₂ CH(CH ₃) ₂	ⁿ Bu	H	F	H	OH
XXX-31-5	CH ₃	H	H	CH ₂ Ph	ⁿ Bu	H	F	H	OH
XXX-31-6	CH ₃	H	H	CH ₂ -indol-3-yl	ⁿ Bu	H	F	H	OH
XXX-31-7	CH ₃	H	H	CH ₂ CH ₂ SCH ₃	ⁿ Bu	H	F	H	OH
XXX-31-8	CH ₃	*	H	*	ⁿ Bu	H	F	H	OH

*R² and R^{3b} joined together by (CH₂)₃ to form five-membered ring.

Table XXX-32.

N ^o	R ¹	R ²	R ^{3a}	R ^{3b}	R ⁴	R ⁵	R ⁶	X	Y
XXX-32-1	Et	H	H	H	ⁿ Bu	H	F	H	OH
XXX-32-2	Et	H	H	CH ₃	ⁿ Bu	H	F	H	OH
XXX-32-3	Et	H	H	CH(CH ₃) ₂	ⁿ Bu	H	F	H	OH
XXX-32-4	Et	H	H	CH ₂ CH(CH ₃) ₂	ⁿ Bu	H	F	H	OH
XXX-32-5	Et	H	H	CH ₂ Ph	ⁿ Bu	H	F	H	OH
XXX-32-6	Et	H	H	CH ₂ -indol-3-yl	ⁿ Bu	H	F	H	OH
XXX-32-7	Et	H	H	CH ₂ CH ₂ SCH ₃	ⁿ Bu	H	F	H	OH
XXX-32-8	Et	*	H	*	ⁿ Bu	H	F	H	OH

*R² and R^{3b} joined together by (CH₂)₃ to form five-membered ring.

Table XXX-33.

N ^o	R ¹	R ²	R ^{3a}	R ^{3b}	R ⁴	R ⁵	R ⁶	X	Y
XXX-33-1	ⁱ Pr	H	H	H	ⁿ Bu	H	F	H	OH
XXX-33-2	ⁱ Pr	H	H	CH ₃	ⁿ Bu	H	F	H	OH
XXX-33-3	ⁱ Pr	H	H	CH(CH ₃) ₂	ⁿ Bu	H	F	H	OH
XXX-33-4	ⁱ Pr	H	H	CH ₂ CH(CH ₃) ₂	ⁿ Bu	H	F	H	OH
XXX-33-5	ⁱ Pr	H	H	CH ₂ Ph	ⁿ Bu	H	F	H	OH
XXX-33-6	ⁱ Pr	H	H	CH ₂ -indol-3-yl	ⁿ Bu	H	F	H	OH
XXX-33-7	ⁱ Pr	H	H	CH ₂ CH ₂ SCH ₃	ⁿ Bu	H	F	H	OH
XXX-33-8	ⁱ Pr	*	H	*	ⁿ Bu	H	F	H	OH

*R² and R^{3b} joined together by (CH₂)₃ to form five-membered ring.

Table XXX-34.

N ^o	R ¹	R ²	R ^{3a}	R ^{3b}	R ⁴	R ⁵	R ⁶	X	Y
XXX-34-1	^t Bu	H	H	H	ⁿ Bu	H	F	H	OH
XXX-34-2	^t Bu	H	H	CH ₃	ⁿ Bu	H	F	H	OH
XXX-34-3	^t Bu	H	H	CH(CH ₃) ₂	ⁿ Bu	H	F	H	OH
XXX-34-4	^t Bu	H	H	CH ₂ CH(CH ₃) ₂	ⁿ Bu	H	F	H	OH
XXX-34-5	^t Bu	H	H	CH ₂ Ph	ⁿ Bu	H	F	H	OH
XXX-34-6	^t Bu	H	H	CH ₂ -indol-3-yl	ⁿ Bu	H	F	H	OH
XXX-34-7	^t Bu	H	H	CH ₂ CH ₂ SCH ₃	ⁿ Bu	H	F	H	OH
XXX-34-8	^t Bu	*	H	*	ⁿ Bu	H	F	H	OH

*R² and R^{3b} joined together by (CH₂)₃ to form five-membered ring.

Table XXX-35.

N ^o	R ¹	R ²	R ^{3a}	R ^{3b}	R ⁴	R ⁵	R ⁶	X	Y
XXX-35-1	Ph	H	H	H	ⁿ Bu	H	F	H	OH
XXX-35-2	Ph	H	H	CH ₃	ⁿ Bu	H	F	H	OH
XXX-35-3	Ph	H	H	CH(CH ₃) ₂	ⁿ Bu	H	F	H	OH
XXX-35-4	Ph	H	H	CH ₂ CH(CH ₃) ₂	ⁿ Bu	H	F	H	OH
XXX-35-5	Ph	H	H	CH ₂ Ph	ⁿ Bu	H	F	H	OH
XXX-35-6	Ph	H	H	CH ₂ -indol-3-yl	ⁿ Bu	H	F	H	OH
XXX-35-7	Ph	H	H	CH ₂ CH ₂ SCH ₃	ⁿ Bu	H	F	H	OH
XXX-35-8	Ph	*	H	*	ⁿ Bu	H	F	H	OH

*R² and R^{3b} joined together by (CH₂)₃ to form five-membered ring.

Table XXX-36.

N ^o	R ¹	R ²	R ^{3a}	R ^{3b}	R ⁴	R ⁵	R ⁶	X	Y
XXX-36-1	p-Me-Ph	H	H	H	ⁿ Bu	H	F	H	OH
XXX-36-2	p-Me-Ph	H	H	CH ₃	ⁿ Bu	H	F	H	OH
XXX-36-3	p-Me-Ph	H	H	CH(CH ₃) ₂	ⁿ Bu	H	F	H	OH
XXX-36-4	p-Me-Ph	H	H	CH ₂ CH(CH ₃) ₂	ⁿ Bu	H	F	H	OH
XXX-36-5	p-Me-Ph	H	H	CH ₂ Ph	ⁿ Bu	H	F	H	OH
XXX-36-6	p-Me-Ph	H	H	CH ₂ -indol-3-yl	ⁿ Bu	H	F	H	OH
XXX-36-7	p-Me-Ph	H	H	CH ₂ CH ₂ SCH ₃	ⁿ Bu	H	F	H	OH
XXX-36-8	p-Me-Ph	*	H	*	ⁿ Bu	H	F	H	OH

*R² and R^{3b} joined together by (CH₂)₃ to form five-membered ring.

Table XXX-37.

N ^o	R ¹	R ²	R ^{3a}	R ^{3b}	R ⁴	R ⁵	R ⁶	X	Y
XXX-37-1	p-F-Ph	H	H	H	ⁿ Bu	H	F	H	OH
XXX-37-2	p-F-Ph	H	H	CH ₃	ⁿ Bu	H	F	H	OH
XXX-37-3	p-F-Ph	H	H	CH(CH ₃) ₂	ⁿ Bu	H	F	H	OH
XXX-37-4	p-F-Ph	H	H	CH ₂ CH(CH ₃) ₂	ⁿ Bu	H	F	H	OH
XXX-37-5	p-F-Ph	H	H	CH ₂ Ph	ⁿ Bu	H	F	H	OH
XXX-37-6	p-F-Ph	H	H	CH ₂ -indol-3-yl	ⁿ Bu	H	F	H	OH
XXX-37-7	p-F-Ph	H	H	CH ₂ CH ₂ SCH ₃	ⁿ Bu	H	F	H	OH
XXX-37-8	p-F-Ph	*	H	*	ⁿ Bu	H	F	H	OH

*R² and R^{3b} joined together by (CH₂)₃ to form five-membered ring.

Table XXX-38.

N ^o	R ¹	R ²	R ^{3a}	R ^{3b}	R ⁴	R ⁵	R ⁶	X	Y
XXX-38-1	p-Cl-Ph	H	H	H	ⁿ Bu	H	F	H	OH
XXX-38-2	p-Cl-Ph	H	H	CH ₃	ⁿ Bu	H	F	H	OH
XXX-38-3	p-Cl-Ph	H	H	CH(CH ₃) ₂	ⁿ Bu	H	F	H	OH
XXX-38-4	p-Cl-Ph	H	H	CH ₂ CH(CH ₃) ₂	ⁿ Bu	H	F	H	OH
XXX-38-5	p-Cl-Ph	H	H	CH ₂ Ph	ⁿ Bu	H	F	H	OH
XXX-38-6	p-Cl-Ph	H	H	CH ₂ -indol-3-yl	ⁿ Bu	H	F	H	OH
XXX-38-7	p-Cl-Ph	H	H	CH ₂ CH ₂ SCH ₃	ⁿ Bu	H	F	H	OH
XXX-38-8	p-Cl-Ph	*	H	*	ⁿ Bu	H	F	H	OH

*R² and R^{3b} joined together by (CH₂)₃ to form five-membered ring.

Table XXX-39.

N ^o	R ¹	R ²	R ^{3a}	R ^{3b}	R ⁴	R ⁵	R ⁶	X	Y
XXX-39-1	p-Br-Ph	H	H	H	ⁿ Bu	H	F	H	OH
XXX-39-2	p-Br-Ph	H	H	CH ₃	ⁿ Bu	H	F	H	OH
XXX-39-3	p-Br-Ph	H	H	CH(CH ₃) ₂	ⁿ Bu	H	F	H	OH
XXX-39-4	p-Br-Ph	H	H	CH ₂ CH(CH ₃) ₂	ⁿ Bu	H	F	H	OH
XXX-39-5	p-Br-Ph	H	H	CH ₂ Ph	ⁿ Bu	H	F	H	OH
XXX-39-6	p-Br-Ph	H	H	CH ₂ -indol-3-yl	ⁿ Bu	H	F	H	OH
XXX-39-7	p-Br-Ph	H	H	CH ₂ CH ₂ SCH ₃	ⁿ Bu	H	F	H	OH
XXX-39-8	p-Br-Ph	*	H	*	ⁿ Bu	H	F	H	OH

*R² and R^{3b} joined together by (CH₂)₃ to form five-membered ring.

Table XXX-40.

N ^o	R ¹	R ²	R ^{3a}	R ^{3b}	R ⁴	R ⁵	R ⁶	X	Y
XXX-40-1	p-I-Ph	H	H	H	ⁿ Bu	H	F	H	OH
XXX-40-2	p-I-Ph	H	H	CH ₃	ⁿ Bu	H	F	H	OH
XXX-40-3	p-I-Ph	H	H	CH(CH ₃) ₂	ⁿ Bu	H	F	H	OH
XXX-40-4	p-I-Ph	H	H	CH ₂ CH(CH ₃) ₂	ⁿ Bu	H	F	H	OH
XXX-40-5	p-I-Ph	H	H	CH ₂ Ph	ⁿ Bu	H	F	H	OH
XXX-40-6	p-I-Ph	H	H	CH ₂ -indol-3-yl	ⁿ Bu	H	F	H	OH
XXX-40-7	p-I-Ph	H	H	CH ₂ CH ₂ SCH ₃	ⁿ Bu	H	F	H	OH
XXX-40-8	p-I-Ph	*	H	*	ⁿ Bu	H	F	H	OH

*R² and R^{3b} joined together by (CH₂)₃ to form five-membered ring.

Table XXX-41.

N ^o	R ¹	R ²	R ^{3a}	R ^{3b}	R ⁴	R ⁵	R ⁶	X	Y
XXX-41-1	CH ₃	H	H	H	Bz	H	F	H	OH
XXX-41-2	CH ₃	H	H	CH ₃	Bz	H	F	H	OH
XXX-41-3	CH ₃	H	H	CH(CH ₃) ₂	Bz	H	F	H	OH
XXX-41-4	CH ₃	H	H	CH ₂ CH(CH ₃) ₂	Bz	H	F	H	OH
XXX-41-5	CH ₃	H	H	CH ₂ Ph	Bz	H	F	H	OH
XXX-41-6	CH ₃	H	H	CH ₂ -indol-3-yl	Bz	H	F	H	OH
XXX-41-7	CH ₃	H	H	CH ₂ CH ₂ SCH ₃	Bz	H	F	H	OH
XXX-41-8	CH ₃	*	H	*	Bz	H	F	H	OH

*R² and R^{3b} joined together by (CH₂)₃ to form five-membered ring.

Table XXX-42.

N ^o	R ¹	R ²	R ^{3a}	R ^{3b}	R ⁴	R ⁵	R ⁶	X	Y
XXX-42-1	Et	H	H	H	Bz	H	F	H	OH
XXX-42-2	Et	H	H	CH ₃	Bz	H	F	H	OH
XXX-42-3	Et	H	H	CH(CH ₃) ₂	Bz	H	F	H	OH
XXX-42-4	Et	H	H	CH ₂ CH(CH ₃) ₂	Bz	H	F	H	OH
XXX-42-5	Et	H	H	CH ₂ Ph	Bz	H	F	H	OH
XXX-42-6	Et	H	H	CH ₂ -indol-3-yl	Bz	H	F	H	OH
XXX-42-7	Et	H	H	CH ₂ CH ₂ SCH ₃	Bz	H	F	H	OH
XXX-42-8	Et	*	H	*	Bz	H	F	H	OH

*R² and R^{3b} joined together by (CH₂)₃ to form five-membered ring.

Table XXX-43.

N ^o	R ¹	R ²	R ^{3a}	R ^{3b}	R ⁴	R ⁵	R ⁶	X	Y
XXX-43-1	ⁱ Pr	H	H	H	Bz	H	F	H	OH
XXX-43-2	ⁱ Pr	H	H	CH ₃	Bz	H	F	H	OH
XXX-43-3	ⁱ Pr	H	H	CH(CH ₃) ₂	Bz	H	F	H	OH
XXX-43-4	ⁱ Pr	H	H	CH ₂ CH(CH ₃) ₂	Bz	H	F	H	OH
XXX-43-5	ⁱ Pr	H	H	CH ₂ Ph	Bz	H	F	H	OH
XXX-43-6	ⁱ Pr	H	H	CH ₂ -indol-3-yl	Bz	H	F	H	OH
XXX-43-7	ⁱ Pr	H	H	CH ₂ CH ₂ SCH ₃	Bz	H	F	H	OH
XXX-43-8	ⁱ Pr	*	H	*	Bz	H	F	H	OH

*R² and R^{3b} joined together by (CH₂)₃ to form five-membered ring.

Table XXX-44.

N ^o	R ¹	R ²	R ^{3a}	R ^{3b}	R ⁴	R ⁵	R ⁶	X	Y
XXX-44-1	^t Bu	H	H	H	Bz	H	F	H	OH
XXX-44-2	^t Bu	H	H	CH ₃	Bz	H	F	H	OH
XXX-44-3	^t Bu	H	H	CH(CH ₃) ₂	Bz	H	F	H	OH
XXX-44-4	^t Bu	H	H	CH ₂ CH(CH ₃) ₂	Bz	H	F	H	OH
XXX-44-5	^t Bu	H	H	CH ₂ Ph	Bz	H	F	H	OH
XXX-44-6	^t Bu	H	H	CH ₂ -indol-3-yl	Bz	H	F	H	OH
XXX-44-7	^t Bu	H	H	CH ₂ CH ₂ SCH ₃	Bz	H	F	H	OH
XXX-44-8	^t Bu	*	H	*	Bz	H	F	H	OH

*R² and R^{3b} joined together by (CH₂)₃ to form five-membered ring.

Table XXX-45.

N ^o	R ¹	R ²	R ^{3a}	R ^{3b}	R ⁴	R ⁵	R ⁶	X	Y
XXX-45-1	Ph	H	H	H	Bz	H	F	H	OH
XXX-45-2	Ph	H	H	CH ₃	Bz	H	F	H	OH
XXX-45-3	Ph	H	H	CH(CH ₃) ₂	Bz	H	F	H	OH
XXX-45-4	Ph	H	H	CH ₂ CH(CH ₃) ₂	Bz	H	F	H	OH
XXX-45-5	Ph	H	H	CH ₂ Ph	Bz	H	F	H	OH
XXX-45-6	Ph	H	H	CH ₂ -indol-3-yl	Bz	H	F	H	OH
XXX-45-7	Ph	H	H	CH ₂ CH ₂ SCH ₃	Bz	H	F	H	OH
XXX-45-8	Ph	*	H	*	Bz	H	F	H	OH

*R² and R^{3b} joined together by (CH₂)₃ to form five-membered ring.

Table XXX-46.

N ^o	R ¹	R ²	R ^{3a}	R ^{3b}	R ⁴	R ⁵	R ⁶	X	Y
XXX-46-1	p-Me-Ph	H	H	H	Bz	H	F	H	OH
XXX-46-2	p-Me-Ph	H	H	CH ₃	Bz	H	F	H	OH
XXX-46-3	p-Me-Ph	H	H	CH(CH ₃) ₂	Bz	H	F	H	OH
XXX-46-4	p-Me-Ph	H	H	CH ₂ CH(CH ₃) ₂	Bz	H	F	H	OH
XXX-46-5	p-Me-Ph	H	H	CH ₂ Ph	Bz	H	F	H	OH
XXX-46-6	p-Me-Ph	H	H	CH ₂ -indol-3-yl	Bz	H	F	H	OH
XXX-46-7	p-Me-Ph	H	H	CH ₂ CH ₂ SCH ₃	Bz	H	F	H	OH
XXX-46-8	p-Me-Ph	*	H	*	Bz	H	F	H	OH

*R² and R^{3b} joined together by (CH₂)₃ to form five-membered ring.

Table XXX-47.

N ^o	R ¹	R ²	R ^{3a}	R ^{3b}	R ⁴	R ⁵	R ⁶	X	Y
XXX-47-1	p-F-Ph	H	H	H	Bz	H	F	H	OH
XXX-47-2	p-F-Ph	H	H	CH ₃	Bz	H	F	H	OH
XXX-47-3	p-F-Ph	H	H	CH(CH ₃) ₂	Bz	H	F	H	OH
XXX-47-4	p-F-Ph	H	H	CH ₂ CH(CH ₃) ₂	Bz	H	F	H	OH
XXX-47-5	p-F-Ph	H	H	CH ₂ Ph	Bz	H	F	H	OH
XXX-47-6	p-F-Ph	H	H	CH ₂ -indol-3-yl	Bz	H	F	H	OH
XXX-47-7	p-F-Ph	H	H	CH ₂ CH ₂ SCH ₃	Bz	H	F	H	OH
XXX-47-8	p-F-Ph	*	H	*	Bz	H	F	H	OH

*R² and R^{3b} joined together by (CH₂)₃ to form five-membered ring.

Table XXX-48.

N ^o	R ¹	R ²	R ^{3a}	R ^{3b}	R ⁴	R ⁵	R ⁶	X	Y
XXX-48-1	p-Cl-Ph	H	H	H	Bz	H	F	H	OH
XXX-48-2	p-Cl-Ph	H	H	CH ₃	Bz	H	F	H	OH
XXX-48-3	p-Cl-Ph	H	H	CH(CH ₃) ₂	Bz	H	F	H	OH
XXX-48-4	p-Cl-Ph	H	H	CH ₂ CH(CH ₃) ₂	Bz	H	F	H	OH
XXX-48-5	p-Cl-Ph	H	H	CH ₂ Ph	Bz	H	F	H	OH
XXX-48-6	p-Cl-Ph	H	H	CH ₂ -indol-3-yl	Bz	H	F	H	OH
XXX-48-7	p-Cl-Ph	H	H	CH ₂ CH ₂ SCH ₃	Bz	H	F	H	OH

N ₂	R ¹	R ²	R ^{3a}	R ^{3b}	R ⁴	R ⁵	R ⁶	X	Y
XXX-48-8	p-Cl-Ph	*	H	*	Bz	H	F	H	OH

*R² and R^{3b} joined together by (CH₂)₃ to form five-membered ring.

Table XXX-49.

N ₂	R ¹	R ²	R ^{3a}	R ^{3b}	R ⁴	R ⁵	R ⁶	X	Y
XXX-49-1	p-Br-Ph	H	H	H	Bz	H	F	H	OH
XXX-49-2	p-Br-Ph	H	H	CH ₃	Bz	H	F	H	OH
XXX-49-3	p-Br-Ph	H	H	CH(CH ₃) ₂	Bz	H	F	H	OH
XXX-49-4	p-Br-Ph	H	H	CH ₂ CH(CH ₃) ₂	Bz	H	F	H	OH
XXX-49-5	p-Br-Ph	H	H	CH ₂ Ph	Bz	H	F	H	OH
XXX-49-6	p-Br-Ph	H	H	CH ₂ -indol-3-yl	Bz	H	F	H	OH
XXX-49-7	p-Br-Ph	H	H	CH ₂ CH ₂ SCH ₃	Bz	H	F	H	OH
XXX-49-8	p-Br-Ph	*	H	*	Bz	H	F	H	OH

*R² and R^{3b} joined together by (CH₂)₃ to form five-membered ring.

Table XXX-50.

N ₂	R ¹	R ²	R ^{3a}	R ^{3b}	R ⁴	R ⁵	R ⁶	X	Y
XXX-50-1	p-I-Ph	H	H	H	Bz	H	F	H	OH
XXX-50-2	p-I-Ph	H	H	CH ₃	Bz	H	F	H	OH
XXX-50-3	p-I-Ph	H	H	CH(CH ₃) ₂	Bz	H	F	H	OH
XXX-50-4	p-I-Ph	H	H	CH ₂ CH(CH ₃) ₂	Bz	H	F	H	OH
XXX-50-5	p-I-Ph	H	H	CH ₂ Ph	Bz	H	F	H	OH
XXX-50-6	p-I-Ph	H	H	CH ₂ -indol-3-yl	Bz	H	F	H	OH
XXX-50-7	p-I-Ph	H	H	CH ₂ CH ₂ SCH ₃	Bz	H	F	H	OH
XXX-50-8	p-I-Ph	*	H	*	Bz	H	F	H	OH

*R² and R^{3b} joined together by (CH₂)₃ to form five-membered ring.


**XXXI**

Table XXXI-1.

No	R ¹	R ²	R ^{3a}	R ^{3b}	R ⁴	R ⁵	R ⁶	X	Y
XXXI-1-1	CH ₃	H	H	H	CH ₃	H	F	F	OH
XXXI-1-2	CH ₃	H	H	CH ₃	CH ₃	H	F	F	OH
XXXI-1-3	CH ₃	H	H	CH(CH ₃) ₂	CH ₃	H	F	F	OH
XXXI-1-4	CH ₃	H	H	CH ₂ CH(CH ₃) ₂	CH ₃	H	F	F	OH
XXXI-1-5	CH ₃	H	H	CH ₂ Ph	CH ₃	H	F	F	OH
XXXI-1-6	CH ₃	H	H	CH ₂ -indol-3-yl	CH ₃	H	F	F	OH
XXXI-1-7	CH ₃	H	H	CH ₂ CH ₂ SCH ₃	CH ₃	H	F	F	OH
XXXI-1-8	CH ₃	*	H	*	CH ₃	H	F	F	OH

*R² and R^{3b} joined together by (CH₂)₃ to form five-membered ring.

Table XXXI-2.

No	R ¹	R ²	R ^{3a}	R ^{3b}	R ⁴	R ⁵	R ⁶	X	Y
XXXI-2-1	Et	H	H	H	CH ₃	H	F	F	OH
XXXI-2-2	Et	H	H	CH ₃	CH ₃	H	F	F	OH
XXXI-2-3	Et	H	H	CH(CH ₃) ₂	CH ₃	H	F	F	OH
XXXI-2-4	Et	H	H	CH ₂ CH(CH ₃) ₂	CH ₃	H	F	F	OH
XXXI-2-5	Et	H	H	CH ₂ Ph	CH ₃	H	F	F	OH
XXXI-2-6	Et	H	H	CH ₂ -indol-3-yl	CH ₃	H	F	F	OH
XXXI-2-7	Et	H	H	CH ₂ CH ₂ SCH ₃	CH ₃	H	F	F	OH
XXXI-2-8	Et	*	H	*	CH ₃	H	F	F	OH

*R² and R^{3b} joined together by (CH₂)₃ to form five-membered ring.

Table XXXI-3.

N ^o	R ¹	R ²	R ^{3a}	R ^{3b}	R ⁴	R ⁵	R ⁶	X	Y
XXXI-3-1	ⁱ Pr	H	H	H	CH ₃	H	F	F	OH
XXXI-3-2	ⁱ Pr	H	H	CH ₃	CH ₃	H	F	F	OH
XXXI-3-3	ⁱ Pr	H	H	CH(CH ₃) ₂	CH ₃	H	F	F	OH
XXXI-3-4	ⁱ Pr	H	H	CH ₂ CH(CH ₃) ₂	CH ₃	H	F	F	OH
XXXI-3-5	ⁱ Pr	H	H	CH ₂ Ph	CH ₃	H	F	F	OH
XXXI-3-6	ⁱ Pr	H	H	CH ₂ -indol-3-yl	CH ₃	H	F	F	OH
XXXI-3-7	ⁱ Pr	H	H	CH ₂ CH ₂ SCH ₃	CH ₃	H	F	F	OH
XXXI-3-8	ⁱ Pr	*	H	*	CH ₃	H	F	F	OH

*R² and R^{3b} joined together by (CH₂)₃ to form five-membered ring.

Table XXXI-4.

N ^o	R ¹	R ²	R ^{3a}	R ^{3b}	R ⁴	R ⁵	R ⁶	X	Y
XXXI-4-1	^t Bu	H	H	H	CH ₃	H	F	F	OH
XXXI-4-2	^t Bu	H	H	CH ₃	CH ₃	H	F	F	OH
XXXI-4-3	^t Bu	H	H	CH(CH ₃) ₂	CH ₃	H	F	F	OH
XXXI-4-4	^t Bu	H	H	CH ₂ CH(CH ₃) ₂	CH ₃	H	F	F	OH
XXXI-4-5	^t Bu	H	H	CH ₂ Ph	CH ₃	H	F	F	OH
XXXI-4-6	^t Bu	H	H	CH ₂ -indol-3-yl	CH ₃	H	F	F	OH
XXXI-4-7	^t Bu	H	H	CH ₂ CH ₂ SCH ₃	CH ₃	H	F	F	OH
XXXI-4-8	^t Bu	*	H	*	CH ₃	H	F	F	OH

*R² and R^{3b} joined together by (CH₂)₃ to form five-membered ring.

Table XXXI-5.

N ^o	R ¹	R ²	R ^{3a}	R ^{3b}	R ⁴	R ⁵	R ⁶	X	Y
XXXI-5-1	Ph	H	H	H	CH ₃	H	F	F	OH
XXXI-5-2	Ph	H	H	CH ₃	CH ₃	H	F	F	OH
XXXI-5-3	Ph	H	H	CH(CH ₃) ₂	CH ₃	H	F	F	OH
XXXI-5-4	Ph	H	H	CH ₂ CH(CH ₃) ₂	CH ₃	H	F	F	OH
XXXI-5-5	Ph	H	H	CH ₂ Ph	CH ₃	H	F	F	OH
XXXI-5-6	Ph	H	H	CH ₂ -indol-3-yl	CH ₃	H	F	F	OH
XXXI-5-7	Ph	H	H	CH ₂ CH ₂ SCH ₃	CH ₃	H	F	F	OH
XXXI-5-8	Ph	*	H	*	CH ₃	H	F	F	OH

*R² and R^{3b} joined together by (CH₂)₃ to form five-membered ring.

Table XXXI-6.

N ^o	R ¹	R ²	R ^{3a}	R ^{3b}	R ⁴	R ⁵	R ⁶	X	Y
XXXI-6-1	p-Me-Ph	H	H	H	CH ₃	H	F	F	OH
XXXI-6-2	p-Me-Ph	H	H	CH ₃	CH ₃	H	F	F	OH
XXXI-6-3	p-Me-Ph	H	H	CH(CH ₃) ₂	CH ₃	H	F	F	OH
XXXI-6-4	p-Me-Ph	H	H	CH ₂ CH(CH ₃) ₂	CH ₃	H	F	F	OH
XXXI-6-5	p-Me-Ph	H	H	CH ₂ Ph	CH ₃	H	F	F	OH
XXXI-6-6	p-Me-Ph	H	H	CH ₂ -indol-3-yl	CH ₃	H	F	F	OH
XXXI-6-7	p-Me-Ph	H	H	CH ₂ CH ₂ SCH ₃	CH ₃	H	F	F	OH
XXXI-6-8	p-Me-Ph	*	H	*	CH ₃	H	F	F	OH

*R² and R^{3b} joined together by (CH₂)₃ to form five-membered ring.

Table XXXI-7.

N ^o	R ¹	R ²	R ^{3a}	R ^{3b}	R ⁴	R ⁵	R ⁶	X	Y
XXXI-7-1	p-F-Ph	H	H	H	CH ₃	H	F	F	OH
XXXI-7-2	p-F-Ph	H	H	CH ₃	CH ₃	H	F	F	OH
XXXI-7-3	p-F-Ph	H	H	CH(CH ₃) ₂	CH ₃	H	F	F	OH
XXXI-7-4	p-F-Ph	H	H	CH ₂ CH(CH ₃) ₂	CH ₃	H	F	F	OH
XXXI-7-6	p-F-Ph	H	H	CH ₂ Ph	CH ₃	H	F	F	OH
XXXI-7-7	p-F-Ph	H	H	CH ₂ -indol-3-yl	CH ₃	H	F	F	OH
XXXI-7-8	p-F-Ph	H	H	CH ₂ CH ₂ SCH ₃	CH ₃	H	F	F	OH
XXXI-7-20	p-F-Ph	*	H	*	CH ₃	H	F	F	OH

*R² and R^{3b} joined together by (CH₂)₃ to form five-membered ring.

Table XXXI-8.

N ^o	R ¹	R ²	R ^{3a}	R ^{3b}	R ⁴	R ⁵	R ⁶	X	Y
XXXI-8-1	p-Cl-Ph	H	H	H	CH ₃	H	F	F	OH
XXXI-8-2	p-Cl-Ph	H	H	CH ₃	CH ₃	H	F	F	OH
XXXI-8-3	p-Cl-Ph	H	H	CH(CH ₃) ₂	CH ₃	H	F	F	OH
XXXI-8-4	p-Cl-Ph	H	H	CH ₂ CH(CH ₃) ₂	CH ₃	H	F	F	OH
XXXI-8-5	p-Cl-Ph	H	H	CH ₂ Ph	CH ₃	H	F	F	OH
XXXI-8-6	p-Cl-Ph	H	H	CH ₂ -indol-3-yl	CH ₃	H	F	F	OH
XXXI-8-7	p-Cl-Ph	H	H	CH ₂ CH ₂ SCH ₃	CH ₃	H	F	F	OH
XXXI-8-8	p-Cl-Ph	*	H	*	CH ₃	H	F	F	OH

*R² and R^{3b} joined together by (CH₂)₃ to form five-membered ring.

Table XXXI-9.

N ^o	R ¹	R ²	R ^{3a}	R ^{3b}	R ⁴	R ⁵	R ⁶	X	Y
XXXI-9-1	p-Br-Ph	H	H	H	CH ₃	H	F	F	OH
XXXI-9-2	p-Br-Ph	H	H	CH ₃	CH ₃	H	F	F	OH
XXXI-9-3	p-Br-Ph	H	H	CH(CH ₃) ₂	CH ₃	H	F	F	OH
XXXI-9-4	p-Br-Ph	H	H	CH ₂ CH(CH ₃) ₂	CH ₃	H	F	F	OH
XXXI-9-6	p-Br-Ph	H	H	CH ₂ Ph	CH ₃	H	F	F	OH
XXXI-9-7	p-Br-Ph	H	H	CH ₂ -indol-3-yl	CH ₃	H	F	F	OH
XXXI-9-8	p-Br-Ph	H	H	CH ₂ CH ₂ SCH ₃	CH ₃	H	F	F	OH
XXXI-9-20	p-Br-Ph	*	H	*	CH ₃	H	F	F	OH

*R² and R^{3b} joined together by (CH₂)₃ to form five-membered ring.

Table XXXI-10.

N ^o	R ¹	R ²	R ^{3a}	R ^{3b}	R ⁴	R ⁵	R ⁶	X	Y
XXXI-10-1	p-I-Ph	H	H	H	CH ₃	H	F	F	OH
XXXI-10-2	p-I-Ph	H	H	CH ₃	CH ₃	H	F	F	OH
XXXI-10-3	p-I-Ph	H	H	CH(CH ₃) ₂	CH ₃	H	F	F	OH
XXXI-10-4	p-I-Ph	H	H	CH ₂ CH(CH ₃) ₂	CH ₃	H	F	F	OH
XXXI-10-5	p-I-Ph	H	H	CH ₂ Ph	CH ₃	H	F	F	OH
XXXI-10-6	p-I-Ph	H	H	CH ₂ -indol-3-yl	CH ₃	H	F	F	OH
XXXI-10-7	p-I-Ph	H	H	CH ₂ CH ₂ SCH ₃	CH ₃	H	F	F	OH
XXXI-10-8	p-I-Ph	*	H	*	CH ₃	H	F	F	OH

*R² and R^{3b} joined together by (CH₂)₃ to form five-membered ring.

Table XXXI-11.

N ^o	R ¹	R ²	R ^{3a}	R ^{3b}	R ⁴	R ⁵	R ⁶	X	Y
XXXI-11-1	CH ₃	H	H	H	Et	H	F	F	OH
XXXI-11-2	CH ₃	H	H	CH ₃	Et	H	F	F	OH
XXXI-11-3	CH ₃	H	H	CH(CH ₃) ₂	Et	H	F	F	OH
XXXI-11-4	CH ₃	H	H	CH ₂ CH(CH ₃) ₂	Et	H	F	F	OH
XXXI-11-5	CH ₃	H	H	CH ₂ Ph	Et	H	F	F	OH
XXXI-11-6	CH ₃	H	H	CH ₂ -indol-3-yl	Et	H	F	F	OH
XXXI-11-7	CH ₃	H	H	CH ₂ CH ₂ SCH ₃	Et	H	F	F	OH
XXXI-11-8	CH ₃	*	H	*	Et	H	F	F	OH

*R² and R^{3b} joined together by (CH₂)₃ to form five-membered ring.

Table XXXI-12.

N ^o	R ¹	R ²	R ^{3a}	R ^{3b}	R ⁴	R ⁵	R ⁶	X	Y
XXXI-12-1	Et	H	H	H	Et	H	F	F	OH
XXXI-12-2	Et	H	H	CH ₃	Et	H	F	F	OH
XXXI-12-3	Et	H	H	CH(CH ₃) ₂	Et	H	F	F	OH
XXXI-12-4	Et	H	H	CH ₂ CH(CH ₃) ₂	Et	H	F	F	OH
XXXI-12-5	Et	H	H	CH ₂ Ph	Et	H	F	F	OH
XXXI-12-6	Et	H	H	CH ₂ -indol-3-yl	Et	H	F	F	OH
XXXI-12-7	Et	H	H	CH ₂ CH ₂ SCH ₃	Et	H	F	F	OH
XXXI-12-8	Et	*	H	*	Et	H	F	F	OH

*R² and R^{3b} joined together by (CH₂)₃ to form five-membered ring.

Table XXXI-13.

N ^o	R ¹	R ²	R ^{3a}	R ^{3b}	R ⁴	R ⁵	R ⁶	X	Y
XXXI-13-1	ⁱ Pr	H	H	H	Et	H	F	F	OH
XXXI-13-2	ⁱ Pr	H	H	CH ₃	Et	H	F	F	OH
XXXI-13-3	ⁱ Pr	H	H	CH(CH ₃) ₂	Et	H	F	F	OH
XXXI-13-4	ⁱ Pr	H	H	CH ₂ CH(CH ₃) ₂	Et	H	F	F	OH
XXXI-13-5	ⁱ Pr	H	H	CH ₂ Ph	Et	H	F	F	OH
XXXI-13-6	ⁱ Pr	H	H	CH ₂ -indol-3-yl	Et	H	F	F	OH
XXXI-13-7	ⁱ Pr	H	H	CH ₂ CH ₂ SCH ₃	Et	H	F	F	OH
XXXI-13-8	ⁱ Pr	*	H	*	Et	H	F	F	OH

*R² and R^{3b} joined together by (CH₂)₃ to form five-membered ring.

Table XXXI-14.

N ^o	R ¹	R ²	R ^{3a}	R ^{3b}	R ⁴	R ⁵	R ⁶	X	Y
XXXI-14-1	^t Bu	H	H	H	Et	H	F	F	OH
XXXI-14-2	^t Bu	H	H	CH ₃	Et	H	F	F	OH
XXXI-14-3	^t Bu	H	H	CH(CH ₃) ₂	Et	H	F	F	OH
XXXI-14-4	^t Bu	H	H	CH ₂ CH(CH ₃) ₂	Et	H	F	F	OH
XXXI-14-5	^t Bu	H	H	CH ₂ Ph	Et	H	F	F	OH
XXXI-14-6	^t Bu	H	H	CH ₂ -indol-3-yl	Et	H	F	F	OH
XXXI-14-7	^t Bu	H	H	CH ₂ CH ₂ SCH ₃	Et	H	F	F	OH
XXXI-14-8	^t Bu	*	H	*	Et	H	F	F	OH

*R² and R^{3b} joined together by (CH₂)₃ to form five-membered ring.

Table XXXI-15.

N ^o	R ¹	R ²	R ^{3a}	R ^{3b}	R ⁴	R ⁵	R ⁶	X	Y
XXXI-15-1	Ph	H	H	H	Et	H	F	F	OH
XXXI-15-2	Ph	H	H	CH ₃	Et	H	F	F	OH
XXXI-15-3	Ph	H	H	CH(CH ₃) ₂	Et	H	F	F	OH
XXXI-15-4	Ph	H	H	CH ₂ CH(CH ₃) ₂	Et	H	F	F	OH
XXXI-15-5	Ph	H	H	CH ₂ Ph	Et	H	F	F	OH
XXXI-15-6	Ph	H	H	CH ₂ -indol-3-yl	Et	H	F	F	OH
XXXI-15-7	Ph	H	H	CH ₂ CH ₂ SCH ₃	Et	H	F	F	OH
XXXI-15-8	Ph	*	H	*	Et	H	F	F	OH

*R² and R^{3b} joined together by (CH₂)₃ to form five-membered ring.

Table XXXI-16.

N ^o	R ¹	R ²	R ^{3a}	R ^{3b}	R ⁴	R ⁵	R ⁶	X	Y
XXXI-16-1	p-Me-Ph	H	H	H	Et	H	F	F	OH
XXXI-16-2	p-Me-Ph	H	H	CH ₃	Et	H	F	F	OH
XXXI-16-3	p-Me-Ph	H	H	CH(CH ₃) ₂	Et	H	F	F	OH
XXXI-16-4	p-Me-Ph	H	H	CH ₂ CH(CH ₃) ₂	Et	H	F	F	OH
XXXI-16-5	p-Me-Ph	H	H	CH ₂ Ph	Et	H	F	F	OH
XXXI-16-6	p-Me-Ph	H	H	CH ₂ -indol-3-yl	Et	H	F	F	OH
XXXI-16-7	p-Me-Ph	H	H	CH ₂ CH ₂ SCH ₃	Et	H	F	F	OH
XXXI-16-8	p-Me-Ph	*	H	*	Et	H	F	F	OH

*R² and R^{3b} joined together by (CH₂)₃ to form five-membered ring.

Table XXXI-17.

N ^o	R ¹	R ²	R ^{3a}	R ^{3b}	R ⁴	R ⁵	R ⁶	X	Y
XXXI-17-1	p-F-Ph	H	H	H	Et	H	F	F	OH
XXXI-17-2	p-F-Ph	H	H	CH ₃	Et	H	F	F	OH
XXXI-17-3	p-F-Ph	H	H	CH(CH ₃) ₂	Et	H	F	F	OH
XXXI-17-4	p-F-Ph	H	H	CH ₂ CH(CH ₃) ₂	Et	H	F	F	OH
XXXI-17-5	p-F-Ph	H	H	CH ₂ Ph	Et	H	F	F	OH
XXXI-17-6	p-F-Ph	H	H	CH ₂ -indol-3-yl	Et	H	F	F	OH
XXXI-17-7	p-F-Ph	H	H	CH ₂ CH ₂ SCH ₃	Et	H	F	F	OH
XXXI-17-8	p-F-Ph	*	H	*	Et	H	F	F	OH

*R² and R^{3b} joined together by (CH₂)₃ to form five-membered ring.

Table XXXI-18.

N ^o	R ¹	R ²	R ^{3a}	R ^{3b}	R ⁴	R ⁵	R ⁶	X	Y
XXXI-18-1	p-Cl-Ph	H	H	H	Et	H	F	F	OH
XXXI-18-2	p-Cl-Ph	H	H	CH ₃	Et	H	F	F	OH
XXXI-18-3	p-Cl-Ph	H	H	CH(CH ₃) ₂	Et	H	F	F	OH
XXXI-18-4	p-Cl-Ph	H	H	CH ₂ CH(CH ₃) ₂	Et	H	F	F	OH
XXXI-18-5	p-Cl-Ph	H	H	CH ₂ Ph	Et	H	F	F	OH
XXXI-18-6	p-Cl-Ph	H	H	CH ₂ -indol-3-yl	Et	H	F	F	OH
XXXI-18-7	p-Cl-Ph	H	H	CH ₂ CH ₂ SCH ₃	Et	H	F	F	OH
XXXI-18-8	p-Cl-Ph	*	H	*	Et	H	F	F	OH

*R² and R^{3b} joined together by (CH₂)₃ to form five-membered ring.

Table XXXI-19.

N ^o	R ¹	R ²	R ^{3a}	R ^{3b}	R ⁴	R ⁵	R ⁶	X	Y
XXXI-19-1	p-Br-Ph	H	H	H	Et	H	F	F	OH
XXXI-19-2	p-Br-Ph	H	H	CH ₃	Et	H	F	F	OH
XXXI-19-3	p-Br-Ph	H	H	CH(CH ₃) ₂	Et	H	F	F	OH
XXXI-19-4	p-Br-Ph	H	H	CH ₂ CH(CH ₃) ₂	Et	H	F	F	OH
XXXI-19-5	p-Br-Ph	H	H	CH ₂ Ph	Et	H	F	F	OH
XXXI-19-6	p-Br-Ph	H	H	CH ₂ -indol-3-yl	Et	H	F	F	OH
XXXI-19-7	p-Br-Ph	H	H	CH ₂ CH ₂ SCH ₃	Et	H	F	F	OH
XXXI-19-8	p-Br-Ph	*	H	*	Et	H	F	F	OH

*R² and R^{3b} joined together by (CH₂)₃ to form five-membered ring.

Table XXXI-20.

N ^o	R ¹	R ²	R ^{3a}	R ^{3b}	R ⁴	R ⁵	R ⁶	X	Y
XXXI-20-1	p-I-Ph	H	H	H	Et	H	F	F	OH
XXXI-20-2	p-I-Ph	H	H	CH ₃	Et	H	F	F	OH
XXXI-20-3	p-I-Ph	H	H	CH(CH ₃) ₂	Et	H	F	F	OH
XXXI-20-4	p-I-Ph	H	H	CH ₂ CH(CH ₃) ₂	Et	H	F	F	OH
XXXI-20-5	p-I-Ph	H	H	CH ₂ Ph	Et	H	F	F	OH
XXXI-20-6	p-I-Ph	H	H	CH ₂ -indol-3-yl	Et	H	F	F	OH
XXXI-20-7	p-I-Ph	H	H	CH ₂ CH ₂ SCH ₃	Et	H	F	F	OH
XXXI-20-8	p-I-Ph	*	H	*	Et	H	F	F	OH

*R² and R^{3b} joined together by (CH₂)₃ to form five-membered ring.

Table XXXI-21.

N ^o	R ¹	R ²	R ^{3a}	R ^{3b}	R ⁴	R ⁵	R ⁶	X	Y
XXXI-21-1	CH ₃	H	H	H	ⁱ Pr	H	F	F	OH
XXXI-21-2	CH ₃	H	H	CH ₃	ⁱ Pr	H	F	F	OH
XXXI-21-3	CH ₃	H	H	CH(CH ₃) ₂	ⁱ Pr	H	F	F	OH
XXXI-21-4	CH ₃	H	H	CH ₂ CH(CH ₃) ₂	ⁱ Pr	H	F	F	OH
XXXI-21-5	CH ₃	H	H	CH ₂ Ph	ⁱ Pr	H	F	F	OH
XXXI-21-6	CH ₃	H	H	CH ₂ -indol-3-yl	ⁱ Pr	H	F	F	OH
XXXI-21-7	CH ₃	H	H	CH ₂ CH ₂ SCH ₃	ⁱ Pr	H	F	F	OH
XXXI-21-8	CH ₃	*	H	*	ⁱ Pr	H	F	F	OH

*R² and R^{3b} joined together by (CH₂)₃ to form five-membered ring.

Table XXXI-22.

N ^o	R ¹	R ²	R ^{3a}	R ^{3b}	R ⁴	R ⁵	R ⁶	X	Y
XXXI-22-1	Et	H	H	H	ⁱ Pr	H	F	F	OH
XXXI-22-2	Et	H	H	CH ₃	ⁱ Pr	H	F	F	OH
XXXI-22-3	Et	H	H	CH(CH ₃) ₂	ⁱ Pr	H	F	F	OH
XXXI-22-4	Et	H	H	CH ₂ CH(CH ₃) ₂	ⁱ Pr	H	F	F	OH
XXXI-22-5	Et	H	H	CH ₂ Ph	ⁱ Pr	H	F	F	OH
XXXI-22-6	Et	H	H	CH ₂ -indol-3-yl	ⁱ Pr	H	F	F	OH
XXXI-22-7	Et	H	H	CH ₂ CH ₂ SCH ₃	ⁱ Pr	H	F	F	OH
XXXI-22-8	Et	*	H	*	ⁱ Pr	H	F	F	OH

*R² and R^{3b} joined together by (CH₂)₃ to form five-membered ring.

Table XXXI-23.

N ^o	R ¹	R ²	R ^{3a}	R ^{3b}	R ⁴	R ⁵	R ⁶	X	Y
XXXI-23-1	ⁱ Pr	H	H	H	ⁱ Pr	H	F	F	OH
XXXI-23-2	ⁱ Pr	H	H	CH ₃	ⁱ Pr	H	F	F	OH
XXXI-23-3	ⁱ Pr	H	H	CH(CH ₃) ₂	ⁱ Pr	H	F	F	OH
XXXI-23-4	ⁱ Pr	H	H	CH ₂ CH(CH ₃) ₂	ⁱ Pr	H	F	F	OH
XXXI-23-5	ⁱ Pr	H	H	CH ₂ Ph	ⁱ Pr	H	F	F	OH
XXXI-23-6	ⁱ Pr	H	H	CH ₂ -indol-3-yl	ⁱ Pr	H	F	F	OH
XXXI-23-7	ⁱ Pr	H	H	CH ₂ CH ₂ SCH ₃	ⁱ Pr	H	F	F	OH
XXXI-23-8	ⁱ Pr	*	H	*	ⁱ Pr	H	F	F	OH

*R² and R^{3b} joined together by (CH₂)₃ to form five-membered ring.

Table XXXI-24.

N ^o	R ¹	R ²	R ^{3a}	R ^{3b}	R ⁴	R ⁵	R ⁶	X	Y
XXXI-24-1	^t Bu	H	H	H	ⁱ Pr	H	F	F	OH
XXXI-24-2	^t Bu	H	H	CH ₃	ⁱ Pr	H	F	F	OH
XXXI-24-3	^t Bu	H	H	CH(CH ₃) ₂	ⁱ Pr	H	F	F	OH
XXXI-24-4	^t Bu	H	H	CH ₂ CH(CH ₃) ₂	ⁱ Pr	H	F	F	OH
XXXI-24-5	^t Bu	H	H	CH ₂ Ph	ⁱ Pr	H	F	F	OH
XXXI-24-6	^t Bu	H	H	CH ₂ -indol-3-yl	ⁱ Pr	H	F	F	OH
XXXI-24-7	^t Bu	H	H	CH ₂ CH ₂ SCH ₃	ⁱ Pr	H	F	F	OH
XXXI-24-8	^t Bu	*	H	*	ⁱ Pr	H	F	F	OH

*R² and R^{3b} joined together by (CH₂)₃ to form five-membered ring.

Table XXXI-25.

N ^o	R ¹	R ²	R ^{3a}	R ^{3b}	R ⁴	R ⁵	R ⁶	X	Y
XXXI-25-1	Ph	H	H	H	ⁱ Pr	H	F	F	OH
XXXI-25-2	Ph	H	H	CH ₃	ⁱ Pr	H	F	F	OH
XXXI-25-3	Ph	H	H	CH(CH ₃) ₂	ⁱ Pr	H	F	F	OH
XXXI-25-4	Ph	H	H	CH ₂ CH(CH ₃) ₂	ⁱ Pr	H	F	F	OH
XXXI-25-5	Ph	H	H	CH ₂ Ph	ⁱ Pr	H	F	F	OH
XXXI-25-6	Ph	H	H	CH ₂ -indol-3-yl	ⁱ Pr	H	F	F	OH
XXXI-25-7	Ph	H	H	CH ₂ CH ₂ SCH ₃	ⁱ Pr	H	F	F	OH
XXXI-25-8	Ph	*	H	*	ⁱ Pr	H	F	F	OH

*R² and R^{3b} joined together by (CH₂)₃ to form five-membered ring.

Table XXXI-26.

N ^o	R ¹	R ²	R ^{3a}	R ^{3b}	R ⁴	R ⁵	R ⁶	X	Y
XXXI-26-1	p-Me-Ph	H	H	H	ⁱ Pr	H	F	F	OH
XXXI-26-2	p-Me-Ph	H	H	CH ₃	ⁱ Pr	H	F	F	OH
XXXI-26-3	p-Me-Ph	H	H	CH(CH ₃) ₂	ⁱ Pr	H	F	F	OH
XXXI-26-4	p-Me-Ph	H	H	CH ₂ CH(CH ₃) ₂	ⁱ Pr	H	F	F	OH
XXXI-26-5	p-Me-Ph	H	H	CH ₂ Ph	ⁱ Pr	H	F	F	OH
XXXI-26-6	p-Me-Ph	H	H	CH ₂ -indol-3-yl	ⁱ Pr	H	F	F	OH
XXXI-26-7	p-Me-Ph	H	H	CH ₂ CH ₂ SCH ₃	ⁱ Pr	H	F	F	OH
XXXI-26-8	p-Me-Ph	*	H	*	ⁱ Pr	H	F	F	OH

*R² and R^{3b} joined together by (CH₂)₃ to form five-membered ring.

Table XXXI-27.

N ^o	R ¹	R ²	R ^{3a}	R ^{3b}	R ⁴	R ⁵	R ⁶	X	Y
XXXI-27-1	p-F-Ph	H	H	H	ⁱ Pr	H	F	F	OH
XXXI-27-2	p-F-Ph	H	H	CH ₃	ⁱ Pr	H	F	F	OH
XXXI-27-3	p-F-Ph	H	H	CH(CH ₃) ₂	ⁱ Pr	H	F	F	OH
XXXI-27-4	p-F-Ph	H	H	CH ₂ CH(CH ₃) ₂	ⁱ Pr	H	F	F	OH
XXXI-27-5	p-F-Ph	H	H	CH ₂ Ph	ⁱ Pr	H	F	F	OH
XXXI-27-6	p-F-Ph	H	H	CH ₂ -indol-3-yl	ⁱ Pr	H	F	F	OH
XXXI-27-7	p-F-Ph	H	H	CH ₂ CH ₂ SCH ₃	ⁱ Pr	H	F	F	OH
XXXI-27-8	p-F-Ph	*	H	*	ⁱ Pr	H	F	F	OH

*R² and R^{3b} joined together by (CH₂)₃ to form five-membered ring.

Table XXXI-28.

N ^o	R ¹	R ²	R ^{3a}	R ^{3b}	R ⁴	R ⁵	R ⁶	X	Y
XXXI-28-1	p-Cl-Ph	H	H	H	ⁱ Pr	H	F	F	OH
XXXI-28-2	p-Cl-Ph	H	H	CH ₃	ⁱ Pr	H	F	F	OH
XXXI-28-3	p-Cl-Ph	H	H	CH(CH ₃) ₂	ⁱ Pr	H	F	F	OH
XXXI-28-4	p-Cl-Ph	H	H	CH ₂ CH(CH ₃) ₂	ⁱ Pr	H	F	F	OH
XXXI-28-5	p-Cl-Ph	H	H	CH ₂ Ph	ⁱ Pr	H	F	F	OH
XXXI-28-6	p-Cl-Ph	H	H	CH ₂ -indol-3-yl	ⁱ Pr	H	F	F	OH
XXXI-28-7	p-Cl-Ph	H	H	CH ₂ CH ₂ SCH ₃	ⁱ Pr	H	F	F	OH
XXXI-28-8	p-Cl-Ph	*	H	*	ⁱ Pr	H	F	F	OH

*R² and R^{3b} joined together by (CH₂)₃ to form five-membered ring.

Table XXXI-29.

N ^o	R ¹	R ²	R ^{3a}	R ^{3b}	R ⁴	R ⁵	R ⁶	X	Y
XXXI-29-1	p-Br-Ph	H	H	H	ⁱ Pr	H	F	F	OH
XXXI-29-2	p-Br-Ph	H	H	CH ₃	ⁱ Pr	H	F	F	OH
XXXI-29-3	p-Br-Ph	H	H	CH(CH ₃) ₂	ⁱ Pr	H	F	F	OH
XXXI-29-4	p-Br-Ph	H	H	CH ₂ CH(CH ₃) ₂	ⁱ Pr	H	F	F	OH
XXXI-29-5	p-Br-Ph	H	H	CH ₂ Ph	ⁱ Pr	H	F	F	OH
XXXI-29-6	p-Br-Ph	H	H	CH ₂ -indol-3-yl	ⁱ Pr	H	F	F	OH
XXXI-29-7	p-Br-Ph	H	H	CH ₂ CH ₂ SCH ₃	ⁱ Pr	H	F	F	OH
XXXI-29-8	p-Br-Ph	*	H	*	ⁱ Pr	H	F	F	OH

*R² and R^{3b} joined together by (CH₂)₃ to form five-membered ring.

Table XXXI-30.

N ^o	R ¹	R ²	R ^{3a}	R ^{3b}	R ⁴	R ⁵	R ⁶	X	Y
XXXI-30-1	p-I-Ph	H	H	H	ⁱ Pr	H	F	F	OH
XXXI-30-2	p-I-Ph	H	H	CH ₃	ⁱ Pr	H	F	F	OH
XXXI-30-3	p-I-Ph	H	H	CH(CH ₃) ₂	ⁱ Pr	H	F	F	OH
XXXI-30-4	p-I-Ph	H	H	CH ₂ CH(CH ₃) ₂	ⁱ Pr	H	F	F	OH
XXXI-30-5	p-I-Ph	H	H	CH ₂ Ph	ⁱ Pr	H	F	F	OH
XXXI-30-6	p-I-Ph	H	H	CH ₂ -indol-3-yl	ⁱ Pr	H	F	F	OH
XXXI-30-7	p-I-Ph	H	H	CH ₂ CH ₂ SCH ₃	ⁱ Pr	H	F	F	OH
XXXI-30-8	p-I-Ph	*	H	*	ⁱ Pr	H	F	F	OH

*R² and R^{3b} joined together by (CH₂)₃ to form five-membered ring.

Table XXXI-31.

N ^o	R ¹	R ²	R ^{3a}	R ^{3b}	R ⁴	R ⁵	R ⁶	X	Y
XXXI-31-1	CH ₃	H	H	H	ⁿ Bu	H	F	F	OH
XXXI-31-2	CH ₃	H	H	CH ₃	ⁿ Bu	H	F	F	OH
XXXI-31-3	CH ₃	H	H	CH(CH ₃) ₂	ⁿ Bu	H	F	F	OH
XXXI-31-4	CH ₃	H	H	CH ₂ CH(CH ₃) ₂	ⁿ Bu	H	F	F	OH
XXXI-31-5	CH ₃	H	H	CH ₂ Ph	ⁿ Bu	H	F	F	OH
XXXI-31-6	CH ₃	H	H	CH ₂ -indol-3-yl	ⁿ Bu	H	F	F	OH
XXXI-31-7	CH ₃	H	H	CH ₂ CH ₂ SCH ₃	ⁿ Bu	H	F	F	OH
XXXI-31-8	CH ₃	*	H	*	ⁿ Bu	H	F	F	OH

*R² and R^{3b} joined together by (CH₂)₃ to form five-membered ring.

Table XXXI-32.

N ^o	R ¹	R ²	R ^{3a}	R ^{3b}	R ⁴	R ⁵	R ⁶	X	Y
XXXI-32-1	Et	H	H	H	ⁿ Bu	H	F	F	OH
XXXI-32-2	Et	H	H	CH ₃	ⁿ Bu	H	F	F	OH
XXXI-32-3	Et	H	H	CH(CH ₃) ₂	ⁿ Bu	H	F	F	OH
XXXI-32-4	Et	H	H	CH ₂ CH(CH ₃) ₂	ⁿ Bu	H	F	F	OH
XXXI-32-5	Et	H	H	CH ₂ Ph	ⁿ Bu	H	F	F	OH
XXXI-32-6	Et	H	H	CH ₂ -indol-3-yl	ⁿ Bu	H	F	F	OH
XXXI-32-7	Et	H	H	CH ₂ CH ₂ SCH ₃	ⁿ Bu	H	F	F	OH
XXXI-32-8	Et	*	H	*	ⁿ Bu	H	F	F	OH

*R² and R^{3b} joined together by (CH₂)₃ to form five-membered ring.

Table XXXI-33.

N ^o	R ¹	R ²	R ^{3a}	R ^{3b}	R ⁴	R ⁵	R ⁶	X	Y
XXXI-33-1	ⁱ Pr	H	H	H	ⁿ Bu	H	F	F	OH
XXXI-33-2	ⁱ Pr	H	H	CH ₃	ⁿ Bu	H	F	F	OH
XXXI-33-3	ⁱ Pr	H	H	CH(CH ₃) ₂	ⁿ Bu	H	F	F	OH
XXXI-33-4	ⁱ Pr	H	H	CH ₂ CH(CH ₃) ₂	ⁿ Bu	H	F	F	OH
XXXI-33-5	ⁱ Pr	H	H	CH ₂ Ph	ⁿ Bu	H	F	F	OH
XXXI-33-6	ⁱ Pr	H	H	CH ₂ -indol-3-yl	ⁿ Bu	H	F	F	OH
XXXI-33-7	ⁱ Pr	H	H	CH ₂ CH ₂ SCH ₃	ⁿ Bu	H	F	F	OH
XXXI-33-8	ⁱ Pr	*	H	*	ⁿ Bu	H	F	F	OH

*R² and R^{3b} joined together by (CH₂)₃ to form five-membered ring.

Table XXXI-34.

N ^o	R ¹	R ²	R ^{3a}	R ^{3b}	R ⁴	R ⁵	R ⁶	X	Y
XXXI-34-1	^t Bu	H	H	H	ⁿ Bu	H	F	F	OH
XXXI-34-2	^t Bu	H	H	CH ₃	ⁿ Bu	H	F	F	OH
XXXI-34-3	^t Bu	H	H	CH(CH ₃) ₂	ⁿ Bu	H	F	F	OH
XXXI-34-4	^t Bu	H	H	CH ₂ CH(CH ₃) ₂	ⁿ Bu	H	F	F	OH
XXXI-34-5	^t Bu	H	H	CH ₂ Ph	ⁿ Bu	H	F	F	OH
XXXI-34-6	^t Bu	H	H	CH ₂ -indol-3-yl	ⁿ Bu	H	F	F	OH
XXXI-34-7	^t Bu	H	H	CH ₂ CH ₂ SCH ₃	ⁿ Bu	H	F	F	OH
XXXI-34-8	^t Bu	*	H	*	ⁿ Bu	H	F	F	OH

*R² and R^{3b} joined together by (CH₂)₃ to form five-membered ring.

Table XXXI-35.

N ^o	R ¹	R ²	R ^{3a}	R ^{3b}	R ⁴	R ⁵	R ⁶	X	Y
XXXI-35-1	Ph	H	H	H	ⁿ Bu	H	F	F	OH
XXXI-35-2	Ph	H	H	CH ₃	ⁿ Bu	H	F	F	OH
XXXI-35-3	Ph	H	H	CH(CH ₃) ₂	ⁿ Bu	H	F	F	OH
XXXI-35-4	Ph	H	H	CH ₂ CH(CH ₃) ₂	ⁿ Bu	H	F	F	OH
XXXI-35-5	Ph	H	H	CH ₂ Ph	ⁿ Bu	H	F	F	OH
XXXI-35-6	Ph	H	H	CH ₂ -indol-3-yl	ⁿ Bu	H	F	F	OH
XXXI-35-7	Ph	H	H	CH ₂ CH ₂ SCH ₃	ⁿ Bu	H	F	F	OH
XXXI-35-8	Ph	*	H	*	ⁿ Bu	H	F	F	OH

*R² and R^{3b} joined together by (CH₂)₃ to form five-membered ring.

Table XXXI-36.

N ^o	R ¹	R ²	R ^{3a}	R ^{3b}	R ⁴	R ⁵	R ⁶	X	Y
XXXI-36-1	p-Me-Ph	H	H	H	ⁿ Bu	H	F	F	OH
XXXI-36-2	p-Me-Ph	H	H	CH ₃	ⁿ Bu	H	F	F	OH
XXXI-36-3	p-Me-Ph	H	H	CH(CH ₃) ₂	ⁿ Bu	H	F	F	OH
XXXI-36-4	p-Me-Ph	H	H	CH ₂ CH(CH ₃) ₂	ⁿ Bu	H	F	F	OH
XXXI-36-5	p-Me-Ph	H	H	CH ₂ Ph	ⁿ Bu	H	F	F	OH
XXXI-36-6	p-Me-Ph	H	H	CH ₂ -indol-3-yl	ⁿ Bu	H	F	F	OH
XXXI-36-7	p-Me-Ph	H	H	CH ₂ CH ₂ SCH ₃	ⁿ Bu	H	F	F	OH
XXXI-36-8	p-Me-Ph	*	H	*	ⁿ Bu	H	F	F	OH

*R² and R^{3b} joined together by (CH₂)₃ to form five-membered ring.

Table XXXI-37.

N ^o	R ¹	R ²	R ^{3a}	R ^{3b}	R ⁴	R ⁵	R ⁶	X	Y
XXXI-37-1	p-F-Ph	H	H	H	ⁿ Bu	H	F	F	OH
XXXI-37-2	p-F-Ph	H	H	CH ₃	ⁿ Bu	H	F	F	OH
XXXI-37-3	p-F-Ph	H	H	CH(CH ₃) ₂	ⁿ Bu	H	F	F	OH
XXXI-37-4	p-F-Ph	H	H	CH ₂ CH(CH ₃) ₂	ⁿ Bu	H	F	F	OH
XXXI-37-5	p-F-Ph	H	H	CH ₂ Ph	ⁿ Bu	H	F	F	OH
XXXI-37-6	p-F-Ph	H	H	CH ₂ -indol-3-yl	ⁿ Bu	H	F	F	OH
XXXI-37-7	p-F-Ph	H	H	CH ₂ CH ₂ SCH ₃	ⁿ Bu	H	F	F	OH
XXXI-37-8	p-F-Ph	*	H	*	ⁿ Bu	H	F	F	OH

*R² and R^{3b} joined together by (CH₂)₃ to form five-membered ring.

Table XXXI-38.

N ^o	R ¹	R ²	R ^{3a}	R ^{3b}	R ⁴	R ⁵	R ⁶	X	Y
XXXI-38-1	p-Cl-Ph	H	H	H	ⁿ Bu	H	F	F	OH
XXXI-38-2	p-Cl-Ph	H	H	CH ₃	ⁿ Bu	H	F	F	OH
XXXI-38-3	p-Cl-Ph	H	H	CH(CH ₃) ₂	ⁿ Bu	H	F	F	OH
XXXI-38-4	p-Cl-Ph	H	H	CH ₂ CH(CH ₃) ₂	ⁿ Bu	H	F	F	OH
XXXI-38-5	p-Cl-Ph	H	H	CH ₂ Ph	ⁿ Bu	H	F	F	OH
XXXI-38-6	p-Cl-Ph	H	H	CH ₂ -indol-3-yl	ⁿ Bu	H	F	F	OH
XXXI-38-7	p-Cl-Ph	H	H	CH ₂ CH ₂ SCH ₃	ⁿ Bu	H	F	F	OH
XXXI-38-8	p-Cl-Ph	*	H	*	ⁿ Bu	H	F	F	OH

*R² and R^{3b} joined together by (CH₂)₃ to form five-membered ring.

Table XXXI-39.

N ^o	R ¹	R ²	R ^{3a}	R ^{3b}	R ⁴	R ⁵	R ⁶	X	Y
XXXI-39-1	p-Br-Ph	H	H	H	ⁿ Bu	H	F	F	OH
XXXI-39-2	p-Br-Ph	H	H	CH ₃	ⁿ Bu	H	F	F	OH
XXXI-39-3	p-Br-Ph	H	H	CH(CH ₃) ₂	ⁿ Bu	H	F	F	OH
XXXI-39-4	p-Br-Ph	H	H	CH ₂ CH(CH ₃) ₂	ⁿ Bu	H	F	F	OH
XXXI-39-5	p-Br-Ph	H	H	CH ₂ Ph	ⁿ Bu	H	F	F	OH
XXXI-39-6	p-Br-Ph	H	H	CH ₂ -indol-3-yl	ⁿ Bu	H	F	F	OH
XXXI-39-7	p-Br-Ph	H	H	CH ₂ CH ₂ SCH ₃	ⁿ Bu	H	F	F	OH
XXXI-39-8	p-Br-Ph	*	H	*	ⁿ Bu	H	F	F	OH

*R² and R^{3b} joined together by (CH₂)₃ to form five-membered ring.

Table XXXI-40.

N ^o	R ¹	R ²	R ^{3a}	R ^{3b}	R ⁴	R ⁵	R ⁶	X	Y
XXXI-40-1	p-I-Ph	H	H	H	ⁿ Bu	H	F	F	OH
XXXI-40-2	p-I-Ph	H	H	CH ₃	ⁿ Bu	H	F	F	OH
XXXI-40-3	p-I-Ph	H	H	CH(CH ₃) ₂	ⁿ Bu	H	F	F	OH
XXXI-40-4	p-I-Ph	H	H	CH ₂ CH(CH ₃) ₂	ⁿ Bu	H	F	F	OH
XXXI-40-5	p-I-Ph	H	H	CH ₂ Ph	ⁿ Bu	H	F	F	OH
XXXI-40-6	p-I-Ph	H	H	CH ₂ -indol-3-yl	ⁿ Bu	H	F	F	OH
XXXI-40-7	p-I-Ph	H	H	CH ₂ CH ₂ SCH ₃	ⁿ Bu	H	F	F	OH
XXXI-40-8	p-I-Ph	*	H	*	ⁿ Bu	H	F	F	OH

*R² and R^{3b} joined together by (CH₂)₃ to form five-membered ring.

Table XXXI-41.

N ^o	R ¹	R ²	R ^{3a}	R ^{3b}	R ⁴	R ⁵	R ⁶	X	Y
XXXI-41-1	CH ₃	H	H	H	Bz	H	F	F	OH
XXXI-41-2	CH ₃	H	H	CH ₃	Bz	H	F	F	OH
XXXI-41-3	CH ₃	H	H	CH(CH ₃) ₂	Bz	H	F	F	OH
XXXI-41-4	CH ₃	H	H	CH ₂ CH(CH ₃) ₂	Bz	H	F	F	OH
XXXI-41-5	CH ₃	H	H	CH ₂ Ph	Bz	H	F	F	OH
XXXI-41-6	CH ₃	H	H	CH ₂ -indol-3-yl	Bz	H	F	F	OH
XXXI-41-7	CH ₃	H	H	CH ₂ CH ₂ SCH ₃	Bz	H	F	F	OH
XXXI-41-8	CH ₃	*	H	*	Bz	H	F	F	OH

*R² and R^{3b} joined together by (CH₂)₃ to form five-membered ring.

Table XXXI-42.

N ^o	R ¹	R ²	R ^{3a}	R ^{3b}	R ⁴	R ⁵	R ⁶	X	Y
XXXI-42-1	Et	H	H	H	Bz	H	F	F	OH
XXXI-42-2	Et	H	H	CH ₃	Bz	H	F	F	OH
XXXI-42-3	Et	H	H	CH(CH ₃) ₂	Bz	H	F	F	OH
XXXI-42-4	Et	H	H	CH ₂ CH(CH ₃) ₂	Bz	H	F	F	OH
XXXI-42-5	Et	H	H	CH ₂ Ph	Bz	H	F	F	OH
XXXI-42-6	Et	H	H	CH ₂ -indol-3-yl	Bz	H	F	F	OH
XXXI-42-7	Et	H	H	CH ₂ CH ₂ SCH ₃	Bz	H	F	F	OH
XXXI-42-8	Et	*	H	*	Bz	H	F	F	OH

*R² and R^{3b} joined together by (CH₂)₃ to form five-membered ring.

Table XXXI-43.

N ^o	R ¹	R ²	R ^{3a}	R ^{3b}	R ⁴	R ⁵	R ⁶	X	Y
XXXI-43-1	ⁱ Pr	H	H	H	Bz	H	F	F	OH
XXXI-43-2	ⁱ Pr	H	H	CH ₃	Bz	H	F	F	OH
XXXI-43-3	ⁱ Pr	H	H	CH(CH ₃) ₂	Bz	H	F	F	OH
XXXI-43-4	ⁱ Pr	H	H	CH ₂ CH(CH ₃) ₂	Bz	H	F	F	OH
XXXI-43-5	ⁱ Pr	H	H	CH ₂ Ph	Bz	H	F	F	OH
XXXI-43-6	ⁱ Pr	H	H	CH ₂ -indol-3-yl	Bz	H	F	F	OH
XXXI-43-7	ⁱ Pr	H	H	CH ₂ CH ₂ SCH ₃	Bz	H	F	F	OH
XXXI-43-8	ⁱ Pr	*	H	*	Bz	H	F	F	OH

*R² and R^{3b} joined together by (CH₂)₃ to form five-membered ring.

Table XXXI-44.

N ^o	R ¹	R ²	R ^{3a}	R ^{3b}	R ⁴	R ⁵	R ⁶	X	Y
XXXI-44-1	^t Bu	H	H	H	Bz	H	F	F	OH
XXXI-44-2	^t Bu	H	H	CH ₃	Bz	H	F	F	OH
XXXI-44-3	^t Bu	H	H	CH(CH ₃) ₂	Bz	H	F	F	OH
XXXI-44-4	^t Bu	H	H	CH ₂ CH(CH ₃) ₂	Bz	H	F	F	OH
XXXI-44-5	^t Bu	H	H	CH ₂ Ph	Bz	H	F	F	OH
XXXI-44-6	^t Bu	H	H	CH ₂ -indol-3-yl	Bz	H	F	F	OH
XXXI-44-7	^t Bu	H	H	CH ₂ CH ₂ SCH ₃	Bz	H	F	F	OH
XXXI-44-8	^t Bu	*	H	*	Bz	H	F	F	OH

*R² and R^{3b} joined together by (CH₂)₃ to form five-membered ring.

Table XXXI-45.

N ^o	R ¹	R ²	R ^{3a}	R ^{3b}	R ⁴	R ⁵	R ⁶	X	Y
XXXI-45-1	Ph	H	H	H	Bz	H	F	F	OH
XXXI-45-2	Ph	H	H	CH ₃	Bz	H	F	F	OH
XXXI-45-3	Ph	H	H	CH(CH ₃) ₂	Bz	H	F	F	OH
XXXI-45-4	Ph	H	H	CH ₂ CH(CH ₃) ₂	Bz	H	F	F	OH
XXXI-45-5	Ph	H	H	CH ₂ Ph	Bz	H	F	F	OH
XXXI-45-6	Ph	H	H	CH ₂ -indol-3-yl	Bz	H	F	F	OH
XXXI-45-7	Ph	H	H	CH ₂ CH ₂ SCH ₃	Bz	H	F	F	OH
XXXI-45-8	Ph	*	H	*	Bz	H	F	F	OH

*R² and R^{3b} joined together by (CH₂)₃ to form five-membered ring.

Table XXXI-46.

N ^o	R ¹	R ²	R ^{3a}	R ^{3b}	R ⁴	R ⁵	R ⁶	X	Y
XXXI-46-1	p-Me-Ph	H	H	H	Bz	H	F	F	OH
XXXI-46-2	p-Me-Ph	H	H	CH ₃	Bz	H	F	F	OH
XXXI-46-3	p-Me-Ph	H	H	CH(CH ₃) ₂	Bz	H	F	F	OH
XXXI-46-4	p-Me-Ph	H	H	CH ₂ CH(CH ₃) ₂	Bz	H	F	F	OH
XXXI-46-5	p-Me-Ph	H	H	CH ₂ Ph	Bz	H	F	F	OH
XXXI-46-6	p-Me-Ph	H	H	CH ₂ -indol-3-yl	Bz	H	F	F	OH
XXXI-46-7	p-Me-Ph	H	H	CH ₂ CH ₂ SCH ₃	Bz	H	F	F	OH
XXXI-46-8	p-Me-Ph	*	H	*	Bz	H	F	F	OH

*R² and R^{3b} joined together by (CH₂)₃ to form five-membered ring.

Table XXXI-47.

N ^o	R ¹	R ²	R ^{3a}	R ^{3b}	R ⁴	R ⁵	R ⁶	X	Y
XXXI-47-1	p-F-Ph	H	H	H	Bz	H	F	F	OH
XXXI-47-2	p-F-Ph	H	H	CH ₃	Bz	H	F	F	OH
XXXI-47-3	p-F-Ph	H	H	CH(CH ₃) ₂	Bz	H	F	F	OH
XXXI-47-4	p-F-Ph	H	H	CH ₂ CH(CH ₃) ₂	Bz	H	F	F	OH
XXXI-47-5	p-F-Ph	H	H	CH ₂ Ph	Bz	H	F	F	OH
XXXI-47-6	p-F-Ph	H	H	CH ₂ -indol-3-yl	Bz	H	F	F	OH
XXXI-47-7	p-F-Ph	H	H	CH ₂ CH ₂ SCH ₃	Bz	H	F	F	OH

N ₂	R ¹	R ²	R ^{3a}	R ^{3b}	R ⁴	R ⁵	R ⁶	X	Y
XXXI-47-8	p-F-Ph	*	H	*	Bz	H	F	F	OH

*R² and R^{3b} joined together by (CH₂)₃ to form five-membered ring.

Table XXXI-48.

N ₂	R ¹	R ²	R ^{3a}	R ^{3b}	R ⁴	R ⁵	R ⁶	X	Y
XXXI-48-1	p-Cl-Ph	H	H	H	Bz	H	F	F	OH
XXXI-48-2	p-Cl-Ph	H	H	CH ₃	Bz	H	F	F	OH
XXXI-48-3	p-Cl-Ph	H	H	CH(CH ₃) ₂	Bz	H	F	F	OH
XXXI-48-4	p-Cl-Ph	H	H	CH ₂ CH(CH ₃) ₂	Bz	H	F	F	OH
XXXI-48-5	p-Cl-Ph	H	H	CH ₂ Ph	Bz	H	F	F	OH
XXXI-48-6	p-Cl-Ph	H	H	CH ₂ -indol-3-yl	Bz	H	F	F	OH
XXXI-48-7	p-Cl-Ph	H	H	CH ₂ CH ₂ SCH ₃	Bz	H	F	F	OH
XXXI-48-8	p-Cl-Ph	*	H	*	Bz	H	F	F	OH

*R² and R^{3b} joined together by (CH₂)₃ to form five-membered ring.

Table XXXI-49.

N ₂	R ¹	R ²	R ^{3a}	R ^{3b}	R ⁴	R ⁵	R ⁶	X	Y
XXXI-49-1	p-Br-Ph	H	H	H	Bz	H	F	F	OH
XXXI-49-2	p-Br-Ph	H	H	CH ₃	Bz	H	F	F	OH
XXXI-49-3	p-Br-Ph	H	H	CH(CH ₃) ₂	Bz	H	F	F	OH
XXXI-49-4	p-Br-Ph	H	H	CH ₂ CH(CH ₃) ₂	Bz	H	F	F	OH
XXXI-49-5	p-Br-Ph	H	H	CH ₂ Ph	Bz	H	F	F	OH
XXXI-49-6	p-Br-Ph	H	H	CH ₂ -indol-3-yl	Bz	H	F	F	OH
XXXI-49-7	p-Br-Ph	H	H	CH ₂ CH ₂ SCH ₃	Bz	H	F	F	OH
XXXI-49-8	p-Br-Ph	*	H	*	Bz	H	F	F	OH


*R² and R^{3b} joined together by (CH₂)₃ to form five-membered ring.

Table XXXI-50.

N ₂	R ¹	R ²	R ^{3a}	R ^{3b}	R ⁴	R ⁵	R ⁶	X	Y
XXXI-50-1	p-I-Ph	H	H	H	Bz	H	F	F	OH
XXXI-50-2	p-I-Ph	H	H	CH ₃	Bz	H	F	F	OH
XXXI-50-3	p-I-Ph	H	H	CH(CH ₃) ₂	Bz	H	F	F	OH
XXXI-50-4	p-I-Ph	H	H	CH ₂ CH(CH ₃) ₂	Bz	H	F	F	OH
XXXI-50-5	p-I-Ph	H	H	CH ₂ Ph	Bz	H	F	F	OH

N ₂	R ¹	R ²	R ^{3a}	R ^{3b}	R ⁴	R ⁵	R ⁶	X	Y
XXXI-50-6	p-I-Ph	H	H	CH ₂ -indol-3-yl	Bz	H	F	F	OH
XXXI-50-7	p-I-Ph	H	H	CH ₂ CH ₂ SCH ₃	Bz	H	F	F	OH
XXXI-50-8	p-I-Ph	*	H	*	Bz	H	F	F	OH

*R² and R^{3b} joined together by (CH₂)₃ to form five-membered ring.



XXXII

Table XXXII-1.

N ₂	R ¹	R ²	R ^{3a}	R ^{3b}	R ⁴	R ⁵	R ⁶	X	Y
XXXII-1-1	CH ₃	H	H	H	CH ₃	H	H	F	OH
XXXII-1-2	CH ₃	H	H	CH ₃	CH ₃	H	H	F	OH
XXXII-1-3	CH ₃	H	H	CH(CH ₃) ₂	CH ₃	H	H	F	OH
XXXII-1-4	CH ₃	H	H	CH ₂ CH(CH ₃) ₂	CH ₃	H	H	F	OH
XXXII-1-5	CH ₃	H	H	CH ₂ Ph	CH ₃	H	H	F	OH
XXXII-1-6	CH ₃	H	H	CH ₂ -indol-3-yl	CH ₃	H	H	F	OH
XXXII-1-7	CH ₃	H	H	CH ₂ CH ₂ SCH ₃	CH ₃	H	H	F	OH
XXXII-1-8	CH ₃	*	H	*	CH ₃	H	H	F	OH

*R² and R^{3b} joined together by (CH₂)₃ to form five-membered ring.

Table XXXII-2.

N ₂	R ¹	R ²	R ^{3a}	R ^{3b}	R ⁴	R ⁵	R ⁶	X	Y
XXXII-2-1	Et	H	H	H	CH ₃	H	H	F	OH
XXXII-2-2	Et	H	H	CH ₃	CH ₃	H	H	F	OH
XXXII-2-3	Et	H	H	CH(CH ₃) ₂	CH ₃	H	H	F	OH

N ₂	R ¹	R ²	R ^{3a}	R ^{3b}	R ⁴	R ⁵	R ⁶	X	Y
XXXII-2-4	Et	H	H	CH ₂ CH(CH ₃) ₂	CH ₃	H	H	F	OH
XXXII-2-5	Et	H	H	CH ₂ Ph	CH ₃	H	H	F	OH
XXXII-2-6	Et	H	H	CH ₂ -indol-3-yl	CH ₃	H	H	F	OH
XXXII-2-7	Et	H	H	CH ₂ CH ₂ SCH ₃	CH ₃	H	H	F	OH
XXXII-2-8	Et	*	H	*	CH ₃	H	H	F	OH

*R² and R^{3b} joined together by (CH₂)₃ to form five-membered ring.

Table XXXII-3.

N ₂	R ¹	R ²	R ^{3a}	R ^{3b}	R ⁴	R ⁵	R ⁶	X	Y
XXXII-3-1	^t Pr	H	H	H	CH ₃	H	H	F	OH
XXXII-3-2	^t Pr	H	H	CH ₃	CH ₃	H	H	F	OH
XXXII-3-3	^t Pr	H	H	CH(CH ₃) ₂	CH ₃	H	H	F	OH
XXXII-3-4	^t Pr	H	H	CH ₂ CH(CH ₃) ₂	CH ₃	H	H	F	OH
XXXII-3-5	^t Pr	H	H	CH ₂ Ph	CH ₃	H	H	F	OH
XXXII-3-6	^t Pr	H	H	CH ₂ -indol-3-yl	CH ₃	H	H	F	OH
XXXII-3-7	^t Pr	H	H	CH ₂ CH ₂ SCH ₃	CH ₃	H	H	F	OH
XXXII-3-8	^t Pr	*	H	*	CH ₃	H	H	F	OH

*R² and R^{3b} joined together by (CH₂)₃ to form five-membered ring.

Table XXXII-4.

N ₂	R ¹	R ²	R ^{3a}	R ^{3b}	R ⁴	R ⁵	R ⁶	X	Y
XXXII-4-1	^t Bu	H	H	H	CH ₃	H	H	F	OH
XXXII-4-2	^t Bu	H	H	CH ₃	CH ₃	H	H	F	OH
XXXII-4-3	^t Bu	H	H	CH(CH ₃) ₂	CH ₃	H	H	F	OH
XXXII-4-4	^t Bu	H	H	CH ₂ CH(CH ₃) ₂	CH ₃	H	H	F	OH
XXXII-4-5	^t Bu	H	H	CH ₂ Ph	CH ₃	H	H	F	OH
XXXII-4-6	^t Bu	H	H	CH ₂ -indol-3-yl	CH ₃	H	H	F	OH
XXXII-4-7	^t Bu	H	H	CH ₂ CH ₂ SCH ₃	CH ₃	H	H	F	OH
XXXII-4-8	^t Bu	*	H	*	CH ₃	H	H	F	OH

*R² and R^{3b} joined together by (CH₂)₃ to form five-membered ring.

Table XXXII-5.

N ^o	R ¹	R ²	R ^{3a}	R ^{3b}	R ⁴	R ⁵	R ⁶	X	Y
XXXII-5-1	Ph	H	H	H	CH ₃	H	H	F	OH
XXXII-5-2	Ph	H	H	CH ₃	CH ₃	H	H	F	OH
XXXII-5-3	Ph	H	H	CH(CH ₃) ₂	CH ₃	H	H	F	OH
XXXII-5-4	Ph	H	H	CH ₂ CH(CH ₃) ₂	CH ₃	H	H	F	OH
XXXII-5-5	Ph	H	H	CH ₂ Ph	CH ₃	H	H	F	OH
XXXII-5-6	Ph	H	H	CH ₂ -indol-3-yl	CH ₃	H	H	F	OH
XXXII-5-7	Ph	H	H	CH ₂ CH ₂ SCH ₃	CH ₃	H	H	F	OH
XXXII-5-8	Ph	*	H	*	CH ₃	H	H	F	OH

*R² and R^{3b} joined together by (CH₂)₃ to form five-membered ring.

Table XXXII-6.

N ^o	R ¹	R ²	R ^{3a}	R ^{3b}	R ⁴	R ⁵	R ⁶	X	Y
XXXII-6-1	p-Me-Ph	H	H	H	CH ₃	H	H	F	OH
XXXII-6-2	p-Me-Ph	H	H	CH ₃	CH ₃	H	H	F	OH
XXXII-6-3	p-Me-Ph	H	H	CH(CH ₃) ₂	CH ₃	H	H	F	OH
XXXII-6-4	p-Me-Ph	H	H	CH ₂ CH(CH ₃) ₂	CH ₃	H	H	F	OH
XXXII-6-5	p-Me-Ph	H	H	CH ₂ Ph	CH ₃	H	H	F	OH
XXXII-6-6	p-Me-Ph	H	H	CH ₂ -indol-3-yl	CH ₃	H	H	F	OH
XXXII-6-7	p-Me-Ph	H	H	CH ₂ CH ₂ SCH ₃	CH ₃	H	H	F	OH
XXXII-6-8	p-Me-Ph	*	H	*	CH ₃	H	H	F	OH

*R² and R^{3b} joined together by (CH₂)₃ to form five-membered ring.

Table XXXII-7.

N ^o	R ¹	R ²	R ^{3a}	R ^{3b}	R ⁴	R ⁵	R ⁶	X	Y
XXXII-7-1	p-F-Ph	H	H	H	CH ₃	H	H	F	OH
XXXII-7-2	p-F-Ph	H	H	CH ₃	CH ₃	H	H	F	OH
XXXII-7-3	p-F-Ph	H	H	CH(CH ₃) ₂	CH ₃	H	H	F	OH
XXXII-7-4	p-F-Ph	H	H	CH ₂ CH(CH ₃) ₂	CH ₃	H	H	F	OH
XXXII-7-6	p-F-Ph	H	H	CH ₂ Ph	CH ₃	H	H	F	OH
XXXII-7-7	p-F-Ph	H	H	CH ₂ -indol-3-yl	CH ₃	H	H	F	OH
XXXII-7-8	p-F-Ph	H	H	CH ₂ CH ₂ SCH ₃	CH ₃	H	H	F	OH
XXXII-7-20	p-F-Ph	*	H	*	CH ₃	H	H	F	OH

*R² and R^{3b} joined together by (CH₂)₃ to form five-membered ring.

Table XXXII-8.

N ^o	R ¹	R ²	R ^{3a}	R ^{3b}	R ⁴	R ⁵	R ⁶	X	Y
XXXII-8-1	p-Cl-Ph	H	H	H	CH ₃	H	H	F	OH
XXXII-8-2	p-Cl-Ph	H	H	CH ₃	CH ₃	H	H	F	OH
XXXII-8-3	p-Cl-Ph	H	H	CH(CH ₃) ₂	CH ₃	H	H	F	OH
XXXII-8-4	p-Cl-Ph	H	H	CH ₂ CH(CH ₃) ₂	CH ₃	H	H	F	OH
XXXII-8-5	p-Cl-Ph	H	H	CH ₂ Ph	CH ₃	H	H	F	OH
XXXII-8-6	p-Cl-Ph	H	H	CH ₂ -indol-3-yl	CH ₃	H	H	F	OH
XXXII-8-7	p-Cl-Ph	H	H	CH ₂ CH ₂ SCH ₃	CH ₃	H	H	F	OH
XXXII-8-8	p-Cl-Ph	*	H	*	CH ₃	H	H	F	OH

*R² and R^{3b} joined together by (CH₂)₃ to form five-membered ring.

Table XXXII-9.

N ^o	R ¹	R ²	R ^{3a}	R ^{3b}	R ⁴	R ⁵	R ⁶	X	Y
XXXII-9-1	p-Br-Ph	H	H	H	CH ₃	H	H	F	OH
XXXII-9-2	p-Br-Ph	H	H	CH ₃	CH ₃	H	H	F	OH
XXXII-9-3	p-Br-Ph	H	H	CH(CH ₃) ₂	CH ₃	H	H	F	OH
XXXII-9-4	p-Br-Ph	H	H	CH ₂ CH(CH ₃) ₂	CH ₃	H	H	F	OH
XXXII-9-6	p-Br-Ph	H	H	CH ₂ Ph	CH ₃	H	H	F	OH
XXXII-9-7	p-Br-Ph	H	H	CH ₂ -indol-3-yl	CH ₃	H	H	F	OH
XXXII-9-8	p-Br-Ph	H	H	CH ₂ CH ₂ SCH ₃	CH ₃	H	H	F	OH
XXXII-9-20	p-Br-Ph	*	H	*	CH ₃	H	H	F	OH

*R² and R^{3b} joined together by (CH₂)₃ to form five-membered ring.

Table XXXII-10.

N ^o	R ¹	R ²	R ^{3a}	R ^{3b}	R ⁴	R ⁵	R ⁶	X	Y
XXXII-10-1	p-I-Ph	H	H	H	CH ₃	H	H	F	OH
XXXII-10-2	p-I-Ph	H	H	CH ₃	CH ₃	H	H	F	OH
XXXII-10-3	p-I-Ph	H	H	CH(CH ₃) ₂	CH ₃	H	H	F	OH
XXXII-10-4	p-I-Ph	H	H	CH ₂ CH(CH ₃) ₂	CH ₃	H	H	F	OH
XXXII-10-5	p-I-Ph	H	H	CH ₂ Ph	CH ₃	H	H	F	OH
XXXII-10-6	p-I-Ph	H	H	CH ₂ -indol-3-yl	CH ₃	H	H	F	OH
XXXII-10-7	p-I-Ph	H	H	CH ₂ CH ₂ SCH ₃	CH ₃	H	H	F	OH
XXXII-10-8	p-I-Ph	*	H	*	CH ₃	H	H	F	OH

*R² and R^{3b} joined together by (CH₂)₃ to form five-membered ring.

Table XXXII-11.

N ^o	R ¹	R ²	R ^{3a}	R ^{3b}	R ⁴	R ⁵	R ⁶	X	Y
XXXII-11-1	CH ₃	H	H	H	Et	H	H	F	OH
XXXII-11-2	CH ₃	H	H	CH ₃	Et	H	H	F	OH
XXXII-11-3	CH ₃	H	H	CH(CH ₃) ₂	Et	H	H	F	OH
XXXII-11-4	CH ₃	H	H	CH ₂ CH(CH ₃) ₂	Et	H	H	F	OH
XXXII-11-5	CH ₃	H	H	CH ₂ Ph	Et	H	H	F	OH
XXXII-11-6	CH ₃	H	H	CH ₂ -indol-3-yl	Et	H	H	F	OH
XXXII-11-7	CH ₃	H	H	CH ₂ CH ₂ SCH ₃	Et	H	H	F	OH
XXXII-11-8	CH ₃	*	H	*	Et	H	H	F	OH

*R² and R^{3b} joined together by (CH₂)₃ to form five-membered ring.

Table XXXII-12.

N ^o	R ¹	R ²	R ^{3a}	R ^{3b}	R ⁴	R ⁵	R ⁶	X	Y
XXXII-12-1	Et	H	H	H	Et	H	H	F	OH
XXXII-12-2	Et	H	H	CH ₃	Et	H	H	F	OH
XXXII-12-3	Et	H	H	CH(CH ₃) ₂	Et	H	H	F	OH
XXXII-12-4	Et	H	H	CH ₂ CH(CH ₃) ₂	Et	H	H	F	OH
XXXII-12-5	Et	H	H	CH ₂ Ph	Et	H	H	F	OH
XXXII-12-6	Et	H	H	CH ₂ -indol-3-yl	Et	H	H	F	OH
XXXII-12-7	Et	H	H	CH ₂ CH ₂ SCH ₃	Et	H	H	F	OH
XXXII-12-8	Et	*	H	*	Et	H	H	F	OH

*R² and R^{3b} joined together by (CH₂)₃ to form five-membered ring.

Table XXXII-13.

N ^o	R ¹	R ²	R ^{3a}	R ^{3b}	R ⁴	R ⁵	R ⁶	X	Y
XXXII-13-1	ⁱ Pr	H	H	H	Et	H	H	F	OH
XXXII-13-2	ⁱ Pr	H	H	CH ₃	Et	H	H	F	OH
XXXII-13-3	ⁱ Pr	H	H	CH(CH ₃) ₂	Et	H	H	F	OH
XXXII-13-4	ⁱ Pr	H	H	CH ₂ CH(CH ₃) ₂	Et	H	H	F	OH
XXXII-13-5	ⁱ Pr	H	H	CH ₂ Ph	Et	H	H	F	OH
XXXII-13-6	ⁱ Pr	H	H	CH ₂ -indol-3-yl	Et	H	H	F	OH
XXXII-13-7	ⁱ Pr	H	H	CH ₂ CH ₂ SCH ₃	Et	H	H	F	OH
XXXII-13-8	ⁱ Pr	*	H	*	Et	H	H	F	OH

*R² and R^{3b} joined together by (CH₂)₃ to form five-membered ring.

Table XXXII-14.

N ^o	R ¹	R ²	R ^{3a}	R ^{3b}	R ⁴	R ⁵	R ⁶	X	Y
XXXII-14-1	^t Bu	H	H	H	Et	H	H	F	OH
XXXII-14-2	^t Bu	H	H	CH ₃	Et	H	H	F	OH
XXXII-14-3	^t Bu	H	H	CH(CH ₃) ₂	Et	H	H	F	OH
XXXII-14-4	^t Bu	H	H	CH ₂ CH(CH ₃) ₂	Et	H	H	F	OH
XXXII-14-5	^t Bu	H	H	CH ₂ Ph	Et	H	H	F	OH
XXXII-14-6	^t Bu	H	H	CH ₂ -indol-3-yl	Et	H	H	F	OH
XXXII-14-7	^t Bu	H	H	CH ₂ CH ₂ SCH ₃	Et	H	H	F	OH
XXXII-14-8	^t Bu	*	H	*	Et	H	H	F	OH

*R² and R^{3b} joined together by (CH₂)₃ to form five-membered ring.

Table XXXII-15.

N ^o	R ¹	R ²	R ^{3a}	R ^{3b}	R ⁴	R ⁵	R ⁶	X	Y
XXXII-15-1	Ph	H	H	H	Et	H	H	F	OH
XXXII-15-2	Ph	H	H	CH ₃	Et	H	H	F	OH
XXXII-15-3	Ph	H	H	CH(CH ₃) ₂	Et	H	H	F	OH
XXXII-15-4	Ph	H	H	CH ₂ CH(CH ₃) ₂	Et	H	H	F	OH
XXXII-15-5	Ph	H	H	CH ₂ Ph	Et	H	H	F	OH
XXXII-15-6	Ph	H	H	CH ₂ -indol-3-yl	Et	H	H	F	OH
XXXII-15-7	Ph	H	H	CH ₂ CH ₂ SCH ₃	Et	H	H	F	OH
XXXII-15-8	Ph	*	H	*	Et	H	H	F	OH

*R² and R^{3b} joined together by (CH₂)₃ to form five-membered ring.

Table XXXII-16.

N ^o	R ¹	R ²	R ^{3a}	R ^{3b}	R ⁴	R ⁵	R ⁶	X	Y
XXXII-16-1	p-Me-Ph	H	H	H	Et	H	H	F	OH
XXXII-16-2	p-Me-Ph	H	H	CH ₃	Et	H	H	F	OH
XXXII-16-3	p-Me-Ph	H	H	CH(CH ₃) ₂	Et	H	H	F	OH
XXXII-16-4	p-Me-Ph	H	H	CH ₂ CH(CH ₃) ₂	Et	H	H	F	OH
XXXII-16-5	p-Me-Ph	H	H	CH ₂ Ph	Et	H	H	F	OH
XXXII-16-6	p-Me-Ph	H	H	CH ₂ -indol-3-yl	Et	H	H	F	OH
XXXII-16-7	p-Me-Ph	H	H	CH ₂ CH ₂ SCH ₃	Et	H	H	F	OH
XXXII-16-8	p-Me-Ph	*	H	*	Et	H	H	F	OH

*R² and R^{3b} joined together by (CH₂)₃ to form five-membered ring.

Table XXXII-17.

N ^o	R ¹	R ²	R ^{3a}	R ^{3b}	R ⁴	R ⁵	R ⁶	X	Y
XXXII-17-1	p-F-Ph	H	H	H	Et	H	H	F	OH
XXXII-17-2	p-F-Ph	H	H	CH ₃	Et	H	H	F	OH
XXXII-17-3	p-F-Ph	H	H	CH(CH ₃) ₂	Et	H	H	F	OH
XXXII-17-4	p-F-Ph	H	H	CH ₂ CH(CH ₃) ₂	Et	H	H	F	OH
XXXII-17-5	p-F-Ph	H	H	CH ₂ Ph	Et	H	H	F	OH
XXXII-17-6	p-F-Ph	H	H	CH ₂ -indol-3-yl	Et	H	H	F	OH
XXXII-17-7	p-F-Ph	H	H	CH ₂ CH ₂ SCH ₃	Et	H	H	F	OH
XXXII-17-8	p-F-Ph	*	H	*	Et	H	H	F	OH

*R² and R^{3b} joined together by (CH₂)₃ to form five-membered ring.

Table XXXII-18.

N ^o	R ¹	R ²	R ^{3a}	R ^{3b}	R ⁴	R ⁵	R ⁶	X	Y
XXXII-18-1	p-Cl-Ph	H	H	H	Et	H	H	F	OH
XXXII-18-2	p-Cl-Ph	H	H	CH ₃	Et	H	H	F	OH
XXXII-18-3	p-Cl-Ph	H	H	CH(CH ₃) ₂	Et	H	H	F	OH
XXXII-18-4	p-Cl-Ph	H	H	CH ₂ CH(CH ₃) ₂	Et	H	H	F	OH
XXXII-18-5	p-Cl-Ph	H	H	CH ₂ Ph	Et	H	H	F	OH
XXXII-18-6	p-Cl-Ph	H	H	CH ₂ -indol-3-yl	Et	H	H	F	OH
XXXII-18-7	p-Cl-Ph	H	H	CH ₂ CH ₂ SCH ₃	Et	H	H	F	OH
XXXII-18-8	p-Cl-Ph	*	H	*	Et	H	H	F	OH

*R² and R^{3b} joined together by (CH₂)₃ to form five-membered ring.

Table XXXII-19.

N ^o	R ¹	R ²	R ^{3a}	R ^{3b}	R ⁴	R ⁵	R ⁶	X	Y
XXXII-19-1	p-Br-Ph	H	H	H	Et	H	H	F	OH
XXXII-19-2	p-Br-Ph	H	H	CH ₃	Et	H	H	F	OH
XXXII-19-3	p-Br-Ph	H	H	CH(CH ₃) ₂	Et	H	H	F	OH
XXXII-19-4	p-Br-Ph	H	H	CH ₂ CH(CH ₃) ₂	Et	H	H	F	OH
XXXII-19-5	p-Br-Ph	H	H	CH ₂ Ph	Et	H	H	F	OH
XXXII-19-6	p-Br-Ph	H	H	CH ₂ -indol-3-yl	Et	H	H	F	OH
XXXII-19-7	p-Br-Ph	H	H	CH ₂ CH ₂ SCH ₃	Et	H	H	F	OH
XXXII-19-8	p-Br-Ph	*	H	*	Et	H	H	F	OH

*R² and R^{3b} joined together by (CH₂)₃ to form five-membered ring.

Table XXXII-20.

N ^o	R ¹	R ²	R ^{3a}	R ^{3b}	R ⁴	R ⁵	R ⁶	X	Y
XXXII-20-1	p-I-Ph	H	H	H	Et	H	H	F	OH
XXXII-20-2	p-I-Ph	H	H	CH ₃	Et	H	H	F	OH
XXXII-20-3	p-I-Ph	H	H	CH(CH ₃) ₂	Et	H	H	F	OH
XXXII-20-4	p-I-Ph	H	H	CH ₂ CH(CH ₃) ₂	Et	H	H	F	OH
XXXII-20-5	p-I-Ph	H	H	CH ₂ Ph	Et	H	H	F	OH
XXXII-20-6	p-I-Ph	H	H	CH ₂ -indol-3-yl	Et	H	H	F	OH
XXXII-20-7	p-I-Ph	H	H	CH ₂ CH ₂ SCH ₃	Et	H	H	F	OH
XXXII-20-8	p-I-Ph	*	H	*	Et	H	H	F	OH

*R² and R^{3b} joined together by (CH₂)₃ to form five-membered ring.

Table XXXII-21.

N ^o	R ¹	R ²	R ^{3a}	R ^{3b}	R ⁴	R ⁵	R ⁶	X	Y
XXXII-21-1	CH ₃	H	H	H	^t Pr	H	H	F	OH
XXXII-21-2	CH ₃	H	H	CH ₃	^t Pr	H	H	F	OH
XXXII-21-3	CH ₃	H	H	CH(CH ₃) ₂	^t Pr	H	H	F	OH
XXXII-21-4	CH ₃	H	H	CH ₂ CH(CH ₃) ₂	^t Pr	H	H	F	OH
XXXII-21-5	CH ₃	H	H	CH ₂ Ph	^t Pr	H	H	F	OH
XXXII-21-6	CH ₃	H	H	CH ₂ -indol-3-yl	^t Pr	H	H	F	OH
XXXII-21-7	CH ₃	H	H	CH ₂ CH ₂ SCH ₃	^t Pr	H	H	F	OH
XXXII-21-8	CH ₃	*	H	*	^t Pr	H	H	F	OH

*R² and R^{3b} joined together by (CH₂)₃ to form five-membered ring.

Table XXXII-22.

N ^o	R ¹	R ²	R ^{3a}	R ^{3b}	R ⁴	R ⁵	R ⁶	X	Y
XXXII-22-1	Et	H	H	H	^t Pr	H	H	F	OH
XXXII-22-2	Et	H	H	CH ₃	^t Pr	H	H	F	OH
XXXII-22-3	Et	H	H	CH(CH ₃) ₂	^t Pr	H	H	F	OH
XXXII-22-4	Et	H	H	CH ₂ CH(CH ₃) ₂	^t Pr	H	H	F	OH
XXXII-22-5	Et	H	H	CH ₂ Ph	^t Pr	H	H	F	OH
XXXII-22-6	Et	H	H	CH ₂ -indol-3-yl	^t Pr	H	H	F	OH
XXXII-22-7	Et	H	H	CH ₂ CH ₂ SCH ₃	^t Pr	H	H	F	OH
XXXII-22-8	Et	*	H	*	^t Pr	H	H	F	OH

*R² and R^{3b} joined together by (CH₂)₃ to form five-membered ring.

Table XXXII-23.

N ^o	R ¹	R ²	R ^{3a}	R ^{3b}	R ⁴	R ⁵	R ⁶	X	Y
XXXII-23-1	ⁱ Pr	H	H	H	ⁱ Pr	H	H	F	OH
XXXII-23-2	ⁱ Pr	H	H	CH ₃	ⁱ Pr	H	H	F	OH
XXXII-23-3	ⁱ Pr	H	H	CH(CH ₃) ₂	ⁱ Pr	H	H	F	OH
XXXII-23-4	ⁱ Pr	H	H	CH ₂ CH(CH ₃) ₂	ⁱ Pr	H	H	F	OH
XXXII-23-5	ⁱ Pr	H	H	CH ₂ Ph	ⁱ Pr	H	H	F	OH
XXXII-23-6	ⁱ Pr	H	H	CH ₂ -indol-3-yl	ⁱ Pr	H	H	F	OH
XXXII-23-7	ⁱ Pr	H	H	CH ₂ CH ₂ SCH ₃	ⁱ Pr	H	H	F	OH
XXXII-23-8	ⁱ Pr	*	H	*	ⁱ Pr	H	H	F	OH

*R² and R^{3b} joined together by (CH₂)₃ to form five-membered ring.

Table XXXII-24.

N ^o	R ¹	R ²	R ^{3a}	R ^{3b}	R ⁴	R ⁵	R ⁶	X	Y
XXXII-24-1	ⁱ Bu	H	H	H	ⁱ Pr	H	H	F	OH
XXXII-24-2	ⁱ Bu	H	H	CH ₃	ⁱ Pr	H	H	F	OH
XXXII-24-3	ⁱ Bu	H	H	CH(CH ₃) ₂	ⁱ Pr	H	H	F	OH
XXXII-24-4	ⁱ Bu	H	H	CH ₂ CH(CH ₃) ₂	ⁱ Pr	H	H	F	OH
XXXII-24-5	ⁱ Bu	H	H	CH ₂ Ph	ⁱ Pr	H	H	F	OH
XXXII-24-6	ⁱ Bu	H	H	CH ₂ -indol-3-yl	ⁱ Pr	H	H	F	OH
XXXII-24-7	ⁱ Bu	H	H	CH ₂ CH ₂ SCH ₃	ⁱ Pr	H	H	F	OH
XXXII-24-8	ⁱ Bu	*	H	*	ⁱ Pr	H	H	F	OH

*R² and R^{3b} joined together by (CH₂)₃ to form five-membered ring.

Table XXXII-25.

N ^o	R ¹	R ²	R ^{3a}	R ^{3b}	R ⁴	R ⁵	R ⁶	X	Y
XXXII-25-1	Ph	H	H	H	ⁱ Pr	H	H	F	OH
XXXII-25-2	Ph	H	H	CH ₃	ⁱ Pr	H	H	F	OH
XXXII-25-3	Ph	H	H	CH(CH ₃) ₂	ⁱ Pr	H	H	F	OH
XXXII-25-4	Ph	H	H	CH ₂ CH(CH ₃) ₂	ⁱ Pr	H	H	F	OH
XXXII-25-5	Ph	H	H	CH ₂ Ph	ⁱ Pr	H	H	F	OH
XXXII-25-6	Ph	H	H	CH ₂ -indol-3-yl	ⁱ Pr	H	H	F	OH
XXXII-25-7	Ph	H	H	CH ₂ CH ₂ SCH ₃	ⁱ Pr	H	H	F	OH
XXXII-25-8	Ph	*	H	*	ⁱ Pr	H	H	F	OH

*R² and R^{3b} joined together by (CH₂)₃ to form five-membered ring.

Table XXXII-26.

№	R ¹	R ²	R ^{3a}	R ^{3b}	R ⁴	R ⁵	R ⁶	X	Y
XXXII-26-1	p-Me-Ph	H	H	H	^t Pr	H	H	F	OH
XXXII-26-2	p-Me-Ph	H	H	CH ₃	^t Pr	H	H	F	OH
XXXII-26-3	p-Me-Ph	H	H	CH(CH ₃) ₂	^t Pr	H	H	F	OH
XXXII-26-4	p-Me-Ph	H	H	CH ₂ CH(CH ₃) ₂	^t Pr	H	H	F	OH
XXXII-26-5	p-Me-Ph	H	H	CH ₂ Ph	^t Pr	H	H	F	OH
XXXII-26-6	p-Me-Ph	H	H	CH ₂ -indol-3-yl	^t Pr	H	H	F	OH
XXXII-26-7	p-Me-Ph	H	H	CH ₂ CH ₂ SCH ₃	^t Pr	H	H	F	OH
XXXII-26-8	p-Me-Ph	*	H	*	^t Pr	H	H	F	OH

*R² and R^{3b} joined together by (CH₂)₃ to form five-membered ring.

Table XXXII-27.

№	R ¹	R ²	R ^{3a}	R ^{3b}	R ⁴	R ⁵	R ⁶	X	Y
XXXII-27-1	p-F-Ph	H	H	H	^t Pr	H	H	F	OH
XXXII-27-2	p-F-Ph	H	H	CH ₃	^t Pr	H	H	F	OH
XXXII-27-3	p-F-Ph	H	H	CH(CH ₃) ₂	^t Pr	H	H	F	OH
XXXII-27-4	p-F-Ph	H	H	CH ₂ CH(CH ₃) ₂	^t Pr	H	H	F	OH
XXXII-27-5	p-F-Ph	H	H	CH ₂ Ph	^t Pr	H	H	F	OH
XXXII-27-6	p-F-Ph	H	H	CH ₂ -indol-3-yl	^t Pr	H	H	F	OH
XXXII-27-7	p-F-Ph	H	H	CH ₂ CH ₂ SCH ₃	^t Pr	H	H	F	OH
XXXII-27-8	p-F-Ph	*	H	*	^t Pr	H	H	F	OH

*R² and R^{3b} joined together by (CH₂)₃ to form five-membered ring.

Table XXXII-28.

№	R ¹	R ²	R ^{3a}	R ^{3b}	R ⁴	R ⁵	R ⁶	X	Y
XXXII-28-1	p-Cl-Ph	H	H	H	^t Pr	H	H	F	OH
XXXII-28-2	p-Cl-Ph	H	H	CH ₃	^t Pr	H	H	F	OH
XXXII-28-3	p-Cl-Ph	H	H	CH(CH ₃) ₂	^t Pr	H	H	F	OH
XXXII-28-4	p-Cl-Ph	H	H	CH ₂ CH(CH ₃) ₂	^t Pr	H	H	F	OH
XXXII-28-5	p-Cl-Ph	H	H	CH ₂ Ph	^t Pr	H	H	F	OH
XXXII-28-6	p-Cl-Ph	H	H	CH ₂ -indol-3-yl	^t Pr	H	H	F	OH
XXXII-28-7	p-Cl-Ph	H	H	CH ₂ CH ₂ SCH ₃	^t Pr	H	H	F	OH
XXXII-28-8	p-Cl-Ph	*	H	*	^t Pr	H	H	F	OH

*R² and R^{3b} joined together by (CH₂)₃ to form five-membered ring.

Table XXXII-29.

N ^o	R ¹	R ²	R ^{3a}	R ^{3b}	R ⁴	R ⁵	R ⁶	X	Y
XXXII-29-1	p-Br-Ph	H	H	H	ⁱ Pr	H	H	F	OH
XXXII-29-2	p-Br-Ph	H	H	CH ₃	ⁱ Pr	H	H	F	OH
XXXII-29-3	p-Br-Ph	H	H	CH(CH ₃) ₂	ⁱ Pr	H	H	F	OH
XXXII-29-4	p-Br-Ph	H	H	CH ₂ CH(CH ₃) ₂	ⁱ Pr	H	H	F	OH
XXXII-29-5	p-Br-Ph	H	H	CH ₂ Ph	ⁱ Pr	H	H	F	OH
XXXII-29-6	p-Br-Ph	H	H	CH ₂ -indol-3-yl	ⁱ Pr	H	H	F	OH
XXXII-29-7	p-Br-Ph	H	H	CH ₂ CH ₂ SCH ₃	ⁱ Pr	H	H	F	OH
XXXII-29-8	p-Br-Ph	*	H	*	ⁱ Pr	H	H	F	OH

*R² and R^{3b} joined together by (CH₂)₃ to form five-membered ring.

Table XXXII-30.

N ^o	R ¹	R ²	R ^{3a}	R ^{3b}	R ⁴	R ⁵	R ⁶	X	Y
XXXII-30-1	p-I-Ph	H	H	H	ⁱ Pr	H	H	F	OH
XXXII-30-2	p-I-Ph	H	H	CH ₃	ⁱ Pr	H	H	F	OH
XXXII-30-3	p-I-Ph	H	H	CH(CH ₃) ₂	ⁱ Pr	H	H	F	OH
XXXII-30-4	p-I-Ph	H	H	CH ₂ CH(CH ₃) ₂	ⁱ Pr	H	H	F	OH
XXXII-30-5	p-I-Ph	H	H	CH ₂ Ph	ⁱ Pr	H	H	F	OH
XXXII-30-6	p-I-Ph	H	H	CH ₂ -indol-3-yl	ⁱ Pr	H	H	F	OH
XXXII-30-7	p-I-Ph	H	H	CH ₂ CH ₂ SCH ₃	ⁱ Pr	H	H	F	OH
XXXII-30-8	p-I-Ph	*	H	*	ⁱ Pr	H	H	F	OH

*R² and R^{3b} joined together by (CH₂)₃ to form five-membered ring.

Table XXXII-31.

N ^o	R ¹	R ²	R ^{3a}	R ^{3b}	R ⁴	R ⁵	R ⁶	X	Y
XXXII-31-1	CH ₃	H	H	H	ⁿ Bu	H	H	F	OH
XXXII-31-2	CH ₃	H	H	CH ₃	ⁿ Bu	H	H	F	OH
XXXII-31-3	CH ₃	H	H	CH(CH ₃) ₂	ⁿ Bu	H	H	F	OH
XXXII-31-4	CH ₃	H	H	CH ₂ CH(CH ₃) ₂	ⁿ Bu	H	H	F	OH
XXXII-31-5	CH ₃	H	H	CH ₂ Ph	ⁿ Bu	H	H	F	OH
XXXII-31-6	CH ₃	H	H	CH ₂ -indol-3-yl	ⁿ Bu	H	H	F	OH
XXXII-31-7	CH ₃	H	H	CH ₂ CH ₂ SCH ₃	ⁿ Bu	H	H	F	OH
XXXII-31-8	CH ₃	*	H	*	ⁿ Bu	H	H	F	OH

*R² and R^{3b} joined together by (CH₂)₃ to form five-membered ring.

Table XXXII-32.

N ^o	R ¹	R ²	R ^{3a}	R ^{3b}	R ⁴	R ⁵	R ⁶	X	Y
XXXII-32-1	Et	H	H	H	ⁿ Bu	H	H	F	OH
XXXII-32-2	Et	H	H	CH ₃	ⁿ Bu	H	H	F	OH
XXXII-32-3	Et	H	H	CH(CH ₃) ₂	ⁿ Bu	H	H	F	OH
XXXII-32-4	Et	H	H	CH ₂ CH(CH ₃) ₂	ⁿ Bu	H	H	F	OH
XXXII-32-5	Et	H	H	CH ₂ Ph	ⁿ Bu	H	H	F	OH
XXXII-32-6	Et	H	H	CH ₂ -indol-3-yl	ⁿ Bu	H	H	F	OH
XXXII-32-7	Et	H	H	CH ₂ CH ₂ SCH ₃	ⁿ Bu	H	H	F	OH
XXXII-32-8	Et	*	H	*	ⁿ Bu	H	H	F	OH

*R² and R^{3b} joined together by (CH₂)₃ to form five-membered ring.

Table XXXII-33.

N ^o	R ¹	R ²	R ^{3a}	R ^{3b}	R ⁴	R ⁵	R ⁶	X	Y
XXXII-33-1	ⁱ Pr	H	H	H	ⁿ Bu	H	H	F	OH
XXXII-33-2	ⁱ Pr	H	H	CH ₃	ⁿ Bu	H	H	F	OH
XXXII-33-3	ⁱ Pr	H	H	CH(CH ₃) ₂	ⁿ Bu	H	H	F	OH
XXXII-33-4	ⁱ Pr	H	H	CH ₂ CH(CH ₃) ₂	ⁿ Bu	H	H	F	OH
XXXII-33-5	ⁱ Pr	H	H	CH ₂ Ph	ⁿ Bu	H	H	F	OH
XXXII-33-6	ⁱ Pr	H	H	CH ₂ -indol-3-yl	ⁿ Bu	H	H	F	OH
XXXII-33-7	ⁱ Pr	H	H	CH ₂ CH ₂ SCH ₃	ⁿ Bu	H	H	F	OH
XXXII-33-8	ⁱ Pr	*	H	*	ⁿ Bu	H	H	F	OH

*R² and R^{3b} joined together by (CH₂)₃ to form five-membered ring.

Table XXXII-34.

N ^o	R ¹	R ²	R ^{3a}	R ^{3b}	R ⁴	R ⁵	R ⁶	X	Y
XXXII-34-1	ⁱ Bu	H	H	H	ⁿ Bu	H	H	F	OH
XXXII-34-2	ⁱ Bu	H	H	CH ₃	ⁿ Bu	H	H	F	OH
XXXII-34-3	ⁱ Bu	H	H	CH(CH ₃) ₂	ⁿ Bu	H	H	F	OH
XXXII-34-4	ⁱ Bu	H	H	CH ₂ CH(CH ₃) ₂	ⁿ Bu	H	H	F	OH
XXXII-34-5	ⁱ Bu	H	H	CH ₂ Ph	ⁿ Bu	H	H	F	OH
XXXII-34-6	ⁱ Bu	H	H	CH ₂ -indol-3-yl	ⁿ Bu	H	H	F	OH
XXXII-34-7	ⁱ Bu	H	H	CH ₂ CH ₂ SCH ₃	ⁿ Bu	H	H	F	OH
XXXII-34-8	ⁱ Bu	*	H	*	ⁿ Bu	H	H	F	OH

*R² and R^{3b} joined together by (CH₂)₃ to form five-membered ring.

Table XXXII-35.

N ^o	R ¹	R ²	R ^{3a}	R ^{3b}	R ⁴	R ⁵	R ⁶	X	Y
XXXII-35-1	Ph	H	H	H	ⁿ Bu	H	H	F	OH
XXXII-35-2	Ph	H	H	CH ₃	ⁿ Bu	H	H	F	OH
XXXII-35-3	Ph	H	H	CH(CH ₃) ₂	ⁿ Bu	H	H	F	OH
XXXII-35-4	Ph	H	H	CH ₂ CH(CH ₃) ₂	ⁿ Bu	H	H	F	OH
XXXII-35-5	Ph	H	H	CH ₂ Ph	ⁿ Bu	H	H	F	OH
XXXII-35-6	Ph	H	H	CH ₂ -indol-3-yl	ⁿ Bu	H	H	F	OH
XXXII-35-7	Ph	H	H	CH ₂ CH ₂ SCH ₃	ⁿ Bu	H	H	F	OH
XXXII-35-8	Ph	*	H	*	ⁿ Bu	H	H	F	OH

*R² and R^{3b} joined together by (CH₂)₃ to form five-membered ring.

Table XXXII-36.

N ^o	R ¹	R ²	R ^{3a}	R ^{3b}	R ⁴	R ⁵	R ⁶	X	Y
XXXII-36-1	p-Me-Ph	H	H	H	ⁿ Bu	H	H	F	OH
XXXII-36-2	p-Me-Ph	H	H	CH ₃	ⁿ Bu	H	H	F	OH
XXXII-36-3	p-Me-Ph	H	H	CH(CH ₃) ₂	ⁿ Bu	H	H	F	OH
XXXII-36-4	p-Me-Ph	H	H	CH ₂ CH(CH ₃) ₂	ⁿ Bu	H	H	F	OH
XXXII-36-5	p-Me-Ph	H	H	CH ₂ Ph	ⁿ Bu	H	H	F	OH
XXXII-36-6	p-Me-Ph	H	H	CH ₂ -indol-3-yl	ⁿ Bu	H	H	F	OH
XXXII-36-7	p-Me-Ph	H	H	CH ₂ CH ₂ SCH ₃	ⁿ Bu	H	H	F	OH
XXXII-36-8	p-Me-Ph	*	H	*	ⁿ Bu	H	H	F	OH

*R² and R^{3b} joined together by (CH₂)₃ to form five-membered ring.

Table XXXII-37.

N ^o	R ¹	R ²	R ^{3a}	R ^{3b}	R ⁴	R ⁵	R ⁶	X	Y
XXXII-37-1	p-F-Ph	H	H	H	ⁿ Bu	H	H	F	OH
XXXII-37-2	p-F-Ph	H	H	CH ₃	ⁿ Bu	H	H	F	OH
XXXII-37-3	p-F-Ph	H	H	CH(CH ₃) ₂	ⁿ Bu	H	H	F	OH
XXXII-37-4	p-F-Ph	H	H	CH ₂ CH(CH ₃) ₂	ⁿ Bu	H	H	F	OH
XXXII-37-5	p-F-Ph	H	H	CH ₂ Ph	ⁿ Bu	H	H	F	OH
XXXII-37-6	p-F-Ph	H	H	CH ₂ -indol-3-yl	ⁿ Bu	H	H	F	OH
XXXII-37-7	p-F-Ph	H	H	CH ₂ CH ₂ SCH ₃	ⁿ Bu	H	H	F	OH
XXXII-37-8	p-F-Ph	*	H	*	ⁿ Bu	H	H	F	OH

*R² and R^{3b} joined together by (CH₂)₃ to form five-membered ring.

Table XXXII-38.

N ^o	R ¹	R ²	R ^{3a}	R ^{3b}	R ⁴	R ⁵	R ⁶	X	Y
XXXII-38-1	p-Cl-Ph	H	H	H	ⁿ Bu	H	H	F	OH
XXXII-38-2	p-Cl-Ph	H	H	CH ₃	ⁿ Bu	H	H	F	OH
XXXII-38-3	p-Cl-Ph	H	H	CH(CH ₃) ₂	ⁿ Bu	H	H	F	OH
XXXII-38-4	p-Cl-Ph	H	H	CH ₂ CH(CH ₃) ₂	ⁿ Bu	H	H	F	OH
XXXII-38-5	p-Cl-Ph	H	H	CH ₂ Ph	ⁿ Bu	H	H	F	OH
XXXII-38-6	p-Cl-Ph	H	H	CH ₂ -indol-3-yl	ⁿ Bu	H	H	F	OH
XXXII-38-7	p-Cl-Ph	H	H	CH ₂ CH ₂ SCH ₃	ⁿ Bu	H	H	F	OH
XXXII-38-8	p-Cl-Ph	*	H	*	ⁿ Bu	H	H	F	OH

*R² and R^{3b} joined together by (CH₂)₃ to form five-membered ring.

Table XXXII-39.

N ^o	R ¹	R ²	R ^{3a}	R ^{3b}	R ⁴	R ⁵	R ⁶	X	Y
XXXII-39-1	p-Br-Ph	H	H	H	ⁿ Bu	H	H	F	OH
XXXII-39-2	p-Br-Ph	H	H	CH ₃	ⁿ Bu	H	H	F	OH
XXXII-39-3	p-Br-Ph	H	H	CH(CH ₃) ₂	ⁿ Bu	H	H	F	OH
XXXII-39-4	p-Br-Ph	H	H	CH ₂ CH(CH ₃) ₂	ⁿ Bu	H	H	F	OH
XXXII-39-5	p-Br-Ph	H	H	CH ₂ Ph	ⁿ Bu	H	H	F	OH
XXXII-39-6	p-Br-Ph	H	H	CH ₂ -indol-3-yl	ⁿ Bu	H	H	F	OH
XXXII-39-7	p-Br-Ph	H	H	CH ₂ CH ₂ SCH ₃	ⁿ Bu	H	H	F	OH
XXXII-39-8	p-Br-Ph	*	H	*	ⁿ Bu	H	H	F	OH

*R² and R^{3b} joined together by (CH₂)₃ to form five-membered ring.

Table XXXII-40.

N ^o	R ¹	R ²	R ^{3a}	R ^{3b}	R ⁴	R ⁵	R ⁶	X	Y
XXXII-40-1	p-I-Ph	H	H	H	ⁿ Bu	H	H	F	OH
XXXII-40-2	p-I-Ph	H	H	CH ₃	ⁿ Bu	H	H	F	OH
XXXII-40-3	p-I-Ph	H	H	CH(CH ₃) ₂	ⁿ Bu	H	H	F	OH
XXXII-40-4	p-I-Ph	H	H	CH ₂ CH(CH ₃) ₂	ⁿ Bu	H	H	F	OH
XXXII-40-5	p-I-Ph	H	H	CH ₂ Ph	ⁿ Bu	H	H	F	OH
XXXII-40-6	p-I-Ph	H	H	CH ₂ -indol-3-yl	ⁿ Bu	H	H	F	OH
XXXII-40-7	p-I-Ph	H	H	CH ₂ CH ₂ SCH ₃	ⁿ Bu	H	H	F	OH
XXXII-40-8	p-I-Ph	*	H	*	ⁿ Bu	H	H	F	OH

*R² and R^{3b} joined together by (CH₂)₃ to form five-membered ring.

Table XXXII-41.

N ^o	R ¹	R ²	R ^{3a}	R ^{3b}	R ⁴	R ⁵	R ⁶	X	Y
XXXII-41-1	CH ₃	H	H	H	Bz	H	H	F	OH
XXXII-41-2	CH ₃	H	H	CH ₃	Bz	H	H	F	OH
XXXII-41-3	CH ₃	H	H	CH(CH ₃) ₂	Bz	H	H	F	OH
XXXII-41-4	CH ₃	H	H	CH ₂ CH(CH ₃) ₂	Bz	H	H	F	OH
XXXII-41-5	CH ₃	H	H	CH ₂ Ph	Bz	H	H	F	OH
XXXII-41-6	CH ₃	H	H	CH ₂ -indol-3-yl	Bz	H	H	F	OH
XXXII-41-7	CH ₃	H	H	CH ₂ CH ₂ SCH ₃	Bz	H	H	F	OH
XXXII-41-8	CH ₃	*	H	*	Bz	H	H	F	OH

*R² and R^{3b} joined together by (CH₂)₃ to form five-membered ring.

Table XXXII-42.

N ^o	R ¹	R ²	R ^{3a}	R ^{3b}	R ⁴	R ⁵	R ⁶	X	Y
XXXII-42-1	Et	H	H	H	Bz	H	H	F	OH
XXXII-42-2	Et	H	H	CH ₃	Bz	H	H	F	OH
XXXII-42-3	Et	H	H	CH(CH ₃) ₂	Bz	H	H	F	OH
XXXII-42-4	Et	H	H	CH ₂ CH(CH ₃) ₂	Bz	H	H	F	OH
XXXII-42-5	Et	H	H	CH ₂ Ph	Bz	H	H	F	OH
XXXII-42-6	Et	H	H	CH ₂ -indol-3-yl	Bz	H	H	F	OH
XXXII-42-7	Et	H	H	CH ₂ CH ₂ SCH ₃	Bz	H	H	F	OH
XXXII-42-8	Et	*	H	*	Bz	H	H	F	OH

*R² and R^{3b} joined together by (CH₂)₃ to form five-membered ring.

Table XXXII-43.

N ^o	R ¹	R ²	R ^{3a}	R ^{3b}	R ⁴	R ⁵	R ⁶	X	Y
XXXII-43-1	ⁱ Pr	H	H	H	Bz	H	H	F	OH
XXXII-43-2	ⁱ Pr	H	H	CH ₃	Bz	H	H	F	OH
XXXII-43-3	ⁱ Pr	H	H	CH(CH ₃) ₂	Bz	H	H	F	OH
XXXII-43-4	ⁱ Pr	H	H	CH ₂ CH(CH ₃) ₂	Bz	H	H	F	OH
XXXII-43-5	ⁱ Pr	H	H	CH ₂ Ph	Bz	H	H	F	OH
XXXII-43-6	ⁱ Pr	H	H	CH ₂ -indol-3-yl	Bz	H	H	F	OH
XXXII-43-7	ⁱ Pr	H	H	CH ₂ CH ₂ SCH ₃	Bz	H	H	F	OH
XXXII-43-8	ⁱ Pr	*	H	*	Bz	H	H	F	OH

*R² and R^{3b} joined together by (CH₂)₃ to form five-membered ring.

Table XXXII-44.

N ^o	R ¹	R ²	R ^{3a}	R ^{3b}	R ⁴	R ⁵	R ⁶	X	Y
XXXII-44-1	^t Bu	H	H	H	Bz	H	H	F	OH
XXXII-44-2	^t Bu	H	H	CH ₃	Bz	H	H	F	OH
XXXII-44-3	^t Bu	H	H	CH(CH ₃) ₂	Bz	H	H	F	OH
XXXII-44-4	^t Bu	H	H	CH ₂ CH(CH ₃) ₂	Bz	H	H	F	OH
XXXII-44-5	^t Bu	H	H	CH ₂ Ph	Bz	H	H	F	OH
XXXII-44-6	^t Bu	H	H	CH ₂ -indol-3-yl	Bz	H	H	F	OH
XXXII-44-7	^t Bu	H	H	CH ₂ CH ₂ SCH ₃	Bz	H	H	F	OH
XXXII-44-8	^t Bu	*	H	*	Bz	H	H	F	OH

*R² and R^{3b} joined together by (CH₂)₃ to form five-membered ring.

Table XXXII-45.

N ^o	R ¹	R ²	R ^{3a}	R ^{3b}	R ⁴	R ⁵	R ⁶	X	Y
XXXII-45-1	Ph	H	H	H	Bz	H	H	F	OH
XXXII-45-2	Ph	H	H	CH ₃	Bz	H	H	F	OH
XXXII-45-3	Ph	H	H	CH(CH ₃) ₂	Bz	H	H	F	OH
XXXII-45-4	Ph	H	H	CH ₂ CH(CH ₃) ₂	Bz	H	H	F	OH
XXXII-45-5	Ph	H	H	CH ₂ Ph	Bz	H	H	F	OH
XXXII-45-6	Ph	H	H	CH ₂ -indol-3-yl	Bz	H	H	F	OH
XXXII-45-7	Ph	H	H	CH ₂ CH ₂ SCH ₃	Bz	H	H	F	OH
XXXII-45-8	Ph	*	H	*	Bz	H	H	F	OH

*R² and R^{3b} joined together by (CH₂)₃ to form five-membered ring.

Table XXXII-46.

N ^o	R ¹	R ²	R ^{3a}	R ^{3b}	R ⁴	R ⁵	R ⁶	X	Y
XXXII-46-1	p-Me-Ph	H	H	H	Bz	H	H	F	OH
XXXII-46-2	p-Me-Ph	H	H	CH ₃	Bz	H	H	F	OH
XXXII-46-3	p-Me-Ph	H	H	CH(CH ₃) ₂	Bz	H	H	F	OH
XXXII-46-4	p-Me-Ph	H	H	CH ₂ CH(CH ₃) ₂	Bz	H	H	F	OH
XXXII-46-5	p-Me-Ph	H	H	CH ₂ Ph	Bz	H	H	F	OH
XXXII-46-6	p-Me-Ph	H	H	CH ₂ -indol-3-yl	Bz	H	H	F	OH
XXXII-46-7	p-Me-Ph	H	H	CH ₂ CH ₂ SCH ₃	Bz	H	H	F	OH

N ₂	R ¹	R ²	R ^{3a}	R ^{3b}	R ⁴	R ⁵	R ⁶	X	Y
XXXII-46-8	p-Me-Ph	*	H	*	Bz	H	H	F	OH

*R² and R^{3b} joined together by (CH₂)₃ to form five-membered ring.

Table XXXII-47.

N ₂	R ¹	R ²	R ^{3a}	R ^{3b}	R ⁴	R ⁵	R ⁶	X	Y
XXXII-47-1	p-F-Ph	H	H	H	Bz	H	H	F	OH
XXXII-47-2	p-F-Ph	H	H	CH ₃	Bz	H	H	F	OH
XXXII-47-3	p-F-Ph	H	H	CH(CH ₃) ₂	Bz	H	H	F	OH
XXXII-47-4	p-F-Ph	H	H	CH ₂ CH(CH ₃) ₂	Bz	H	H	F	OH
XXXII-47-5	p-F-Ph	H	H	CH ₂ Ph	Bz	H	H	F	OH
XXXII-47-6	p-F-Ph	H	H	CH ₂ -indol-3-yl	Bz	H	H	F	OH
XXXII-47-7	p-F-Ph	H	H	CH ₂ CH ₂ SCH ₃	Bz	H	H	F	OH
XXXII-47-8	p-F-Ph	*	H	*	Bz	H	H	F	OH

*R² and R^{3b} joined together by (CH₂)₃ to form five-membered ring.

Table XXXII-48.

N ₂	R ¹	R ²	R ^{3a}	R ^{3b}	R ⁴	R ⁵	R ⁶	X	Y
XXXII-48-1	p-Cl-Ph	H	H	H	Bz	H	H	F	OH
XXXII-48-2	p-Cl-Ph	H	H	CH ₃	Bz	H	H	F	OH
XXXII-48-3	p-Cl-Ph	H	H	CH(CH ₃) ₂	Bz	H	H	F	OH
XXXII-48-4	p-Cl-Ph	H	H	CH ₂ CH(CH ₃) ₂	Bz	H	H	F	OH
XXXII-48-5	p-Cl-Ph	H	H	CH ₂ Ph	Bz	H	H	F	OH
XXXII-48-6	p-Cl-Ph	H	H	CH ₂ -indol-3-yl	Bz	H	H	F	OH
XXXII-48-7	p-Cl-Ph	H	H	CH ₂ CH ₂ SCH ₃	Bz	H	H	F	OH
XXXII-48-8	p-Cl-Ph	*	H	*	Bz	H	H	F	OH

*R² and R^{3b} joined together by (CH₂)₃ to form five-membered ring.

Table XXXII-49.

N ₂	R ¹	R ²	R ^{3a}	R ^{3b}	R ⁴	R ⁵	R ⁶	X	Y
XXXII-49-1	p-Br-Ph	H	H	H	Bz	H	H	F	OH
XXXII-49-2	p-Br-Ph	H	H	CH ₃	Bz	H	H	F	OH
XXXII-49-3	p-Br-Ph	H	H	CH(CH ₃) ₂	Bz	H	H	F	OH
XXXII-49-4	p-Br-Ph	H	H	CH ₂ CH(CH ₃) ₂	Bz	H	H	F	OH
XXXII-49-5	p-Br-Ph	H	H	CH ₂ Ph	Bz	H	H	F	OH

No	R ¹	R ²	R ^{3a}	R ^{3b}	R ⁴	R ⁵	R ⁶	X	Y
XXXII-49-6	p-Br-Ph	H	H	CH ₂ -indol-3-yl	Bz	H	H	F	OH
XXXII-49-7	p-Br-Ph	H	H	CH ₂ CH ₂ SCH ₃	Bz	H	H	F	OH
XXXII-49-8	p-Br-Ph	*	H	*	Bz	H	H	F	OH

*R² and R^{3b} joined together by (CH₂)₃ to form five-membered ring.

Table XXXII-50.

No	R ¹	R ²	R ^{3a}	R ^{3b}	R ⁴	R ⁵	R ⁶	X	Y
XXXII-50-1	p-I-Ph	H	H	H	Bz	H	H	F	OH
XXXII-50-2	p-I-Ph	H	H	CH ₃	Bz	H	H	F	OH
XXXII-50-3	p-I-Ph	H	H	CH(CH ₃) ₂	Bz	H	H	F	OH
XXXII-50-4	p-I-Ph	H	H	CH ₂ CH(CH ₃) ₂	Bz	H	H	F	OH
XXXII-50-5	p-I-Ph	H	H	CH ₂ Ph	Bz	H	H	F	OH
XXXII-50-6	p-I-Ph	H	H	CH ₂ -indol-3-yl	Bz	H	H	F	OH
XXXII-50-7	p-I-Ph	H	H	CH ₂ CH ₂ SCH ₃	Bz	H	H	F	OH
XXXII-50-8	p-I-Ph	*	H	*	Bz	H	H	F	OH

*R² and R^{3b} joined together by (CH₂)₃ to form five-membered ring.

DOSAGE, ADMINISTRATION, AND USE

- 5 A sixth embodiment of the present invention is directed to a composition for the treatment of any of the viral agents disclosed herein said composition comprising a pharmaceutically acceptable medium selected from among an excipient, carrier, diluent, and equivalent medium and a compound, that is intended to include its salts (acid or basic addition salts), hydrates, solvates, and crystalline forms can be obtained, represented by
- 10 formula I.

It is contemplated that the formulation of the sixth embodiment can contain any of the compounds contemplated in any of the aspects of the first, second, third, fourth, and fifth embodiments or those specifically recited in the tables above or exemplified herein, either alone or in combination with another compound of the present invention.

- 15 The compounds of the present invention may be formulated in a wide variety of oral administration dosage forms and carriers. Oral administration can be in the form of tablets, coated tablets, hard and soft gelatin capsules, solutions, emulsions, syrups, or

suspensions. Compounds of the present invention are efficacious when administered by suppository administration, among other routes of administration. The most convenient manner of administration is generally oral using a convenient daily dosing regimen which can be adjusted according to the severity of the disease and the patient's response to the
5 antiviral medication.

A compound or compounds of the present invention, as well as their pharmaceutically acceptable salts, together with one or more conventional excipients, carriers, or diluents, may be placed into the form of pharmaceutical compositions and unit dosages. The pharmaceutical compositions and unit dosage forms may be comprised
10 of conventional ingredients in conventional proportions, with or without additional active compounds and the unit dosage forms may contain any suitable effective amount of the active ingredient commensurate with the intended daily dosage range to be employed. The pharmaceutical compositions may be employed as solids, such as tablets or filled capsules, semisolids, powders, sustained release formulations, or liquids such as
15 suspensions, emulsions, or filled capsules for oral use; or in the form of suppositories for rectal or vaginal administration. A typical preparation will contain from about 5% to about 95% active compound or compounds (w/w). The term "preparation" or "dosage form" is intended to include both solid and liquid formulations of the active compound and one skilled in the art will appreciate that an active ingredient can exist in different
20 preparations depending on the desired dose and pharmacokinetic parameters.

The term "excipient" as used herein refers to a compound that is used to prepare a pharmaceutical composition, and is generally safe, non-toxic and neither biologically nor otherwise undesirable, and includes excipients that are acceptable for veterinary use as well as human pharmaceutical use. The compounds of this invention can be administered
25 alone but will generally be administered in admixture with one or more suitable pharmaceutical excipients, diluents or carriers selected with regard to the intended route of administration and standard pharmaceutical practice.

A "pharmaceutically acceptable salt" form of an active ingredient may also initially confer a desirable pharmacokinetic property on the active ingredient which were

absent in the non-salt form, and may even positively affect the pharmacodynamics of the active ingredient with respect to its therapeutic activity in the body. The phrase "pharmaceutically acceptable salt" of a compound as used herein means a salt that is pharmaceutically acceptable and that possesses the desired pharmacological activity of the parent compound. Such salts include: (1) acid addition salts, formed with inorganic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, and the like; or formed with organic acids such as glycolic acid, pyruvic acid, lactic acid, malonic acid, malic acid, maleic acid, fumaric acid, tartaric acid, citric acid, 3-(4-hydroxybenzoyl)benzoic acid, cinnamic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, 1,2-ethane-disulfonic acid, 2-hydroxyethanesulfonic acid, benzenesulfonic acid, 4-chlorobenzenesulfonic acid, 2-naphthalenesulfonic acid, 4-toluenesulfonic acid, camphorsulfonic acid, lauryl sulfuric acid, gluconic acid, glutamic acid, salicylic acid, muconic acid, and the like or (2) basic addition salts formed with the conjugate bases of any of the inorganic acids listed above, wherein the conjugate bases comprise a cationic component selected from among Na^+ , K^+ , Mg^{2+} , Ca^{2+} , and NH_4R^{g+} , in which R^g is a C_{1-3} alkyl and g is a number selected from among 0, 1, 2, 3, or 4. It should be understood that all references to pharmaceutically acceptable salts include solvent addition forms (solvates) or crystal forms (polymorphs) as defined herein, of the same acid addition salt.

Solid form preparations include powders, tablets, pills, capsules, suppositories, and dispersible granules. A solid carrier may be one or more substances which may also act as diluents, flavoring agents, solubilizers, lubricants, suspending agents, binders, preservatives, tablet disintegrating agents, or an encapsulating material. In powders, the carrier generally is a finely divided solid which is a mixture with the finely divided active component. In tablets, the active component generally is mixed with the carrier having the necessary binding capacity in suitable proportions and compacted in the shape and size desired. Suitable carriers include but are not limited to magnesium carbonate, magnesium stearate, talc, sugar, lactose, pectin, dextrin, starch, gelatin, tragacanth, methylcellulose, sodium carboxymethylcellulose, a low melting wax, cocoa butter, and the like. Solid form preparations may contain, in addition to the active component, colorants, flavors, stabilizers, buffers, artificial and natural sweeteners, dispersants,

thickeners, solubilizing agents, and the like.

Liquid formulations also are suitable for oral administration include liquid formulation including emulsions, syrups, elixirs and aqueous suspensions. These include solid form preparations which are intended to be converted to liquid form preparations shortly before use. Emulsions may be prepared in solutions, for example, in aqueous propylene glycol solutions or may contain emulsifying agents such as lecithin, sorbitan monooleate, or acacia. Aqueous suspensions can be prepared by dispersing the finely divided active component in water with viscous material, such as natural or synthetic gums, resins, methylcellulose, sodium carboxymethylcellulose, and other well known suspending agents.

The compounds of the present invention may be formulated for administration as suppositories. A low melting wax, such as a mixture of fatty acid glycerides or cocoa butter is first melted and the active component is dispersed homogeneously, for example, by stirring. The molten homogeneous mixture is then poured into convenient sized molds, allowed to cool, and to solidify.

The compounds of the present invention may be formulated for vaginal administration. Pessaries, tampons, creams, gels, pastes, foams or sprays containing in addition to the active ingredient such carriers as are known in the art to be appropriate.

Suitable formulations along with pharmaceutical carriers, diluents and excipients are described in *Remington: The Science and Practice of Pharmacy* **1995**, edited by E. W. Martin, Mack Publishing Company, 19th edition, Easton, Pennsylvania, which is hereby incorporated by reference. The compounds of the present invention can also be encapsulated in liposomes, such as those disclosed in U.S. Patent Nos. 6,180,134, 5,192,549, 5,376,380, 6,060,080, 6,132,763, each of which is incorporated by reference. A skilled formulation scientist may modify the formulations within the teachings of the specification to provide numerous formulations for a particular route of administration without rendering the compositions of the present invention unstable or compromising their therapeutic activity.

The modification of the present compounds to render them more soluble in water or other vehicle, for example, may be easily accomplished by minor modifications (e.g., salt formulation), which are well within the ordinary skill in the art. It is also well within the ordinary skill of the art to modify the route of administration and dosage regimen of a particular compound in order to manage the pharmacokinetics of the present compounds for maximum beneficial effect in patients.

A seventh embodiment of the present invention is directed to a use of the compound represented by formula I in the manufacture of a medicament for the treatment of any condition the result of an infection by any one of the following viral agents:

hepatitis C virus, West Nile virus, yellow fever virus, dengue virus, rhinovirus, polio virus, hepatitis A virus, bovine viral diarrhea virus and Japanese encephalitis virus.

The term "medicament" means a substance used in a method of treatment and/or prophylaxis of a subject in need thereof, wherein the substance includes, but is not limited to, a composition, a formulation, a dosage form, and the like, comprising the compound of formula I. It is contemplated that the compound of the use of the compound represented by formula I in the manufacture of a medicament for the treatment of any of the antiviral conditions disclosed herein of the seventh embodiment can be any of the compounds contemplated in any of the aspects of the first, second, third, fourth, fifth embodiments or those specifically recited in the tables above or exemplified herein, either alone or in combination with another compound of the present invention. A medicament includes, but is not limited to, any one of the compositions contemplated by the sixth embodiment of the present invention.

A eighth embodiment of the present invention is directed to a method of treatment and/or prophylaxis in a subject in need thereof said method comprises administering a therapeutically effective amount of the compound represented by formula I to the subject.

A first aspect of the eighth embodiment is directed to a method of treatment and/or prophylaxis in a subject in need thereof said method comprises administering a therapeutically effective of at least two or more different compounds falling within the scope of the compound represented by formula I to the subject.

A second aspect of the eighth embodiment is directed to a method of treatment and/or prophylaxis in a subject in need thereof said method comprises alternatively or concurrently administering a therapeutically effective of at least two compounds falling within the scope of the compound represented by formula I to the subject.

5 It is intended that a subject in need thereof is one that has any condition the result of an infection by any of the viral agents disclosed herein, which includes, but is not limited to, hepatitis C virus, West Nile virus, yellow fever virus, dengue virus, rhinovirus, polio virus, hepatitis A virus, bovine viral diarrhea virus or Japanese encephalitis virus, flaviviridae viruses or pestiviruses or hepaciviruses or a viral agent causing symptoms
10 equivalent or comparable to any of the above-listed viruses.

The term "subject" means a mammal, which includes, but is not limited to, cattle, pigs, sheep, chicken, turkey, buffalo, llama, ostrich, dogs, cats, and humans, preferably the subject is a human. It is contemplated that in the method of treating a subject thereof of the sixth embodiment can be any of the compounds contemplated in any of the aspects
15 of the first, second, and third embodiments or those specifically recited in the tables above, either alone or in combination with another compound of the present invention.

The term "therapeutically effective amount" as used herein means an amount required to reduce symptoms of the disease in an individual. The dose will be adjusted to the individual requirements in each particular case. That dosage can vary within wide
20 limits depending upon numerous factors such as the severity of the disease to be treated, the age and general health condition of the patient, other medicaments with which the patient is being treated, the route and form of administration and the preferences and experience of the medical practitioner involved. For oral administration, a daily dosage of between about 0.1 and about 10 g, including all values in between, such as 0.25, 0.5,
25 0.75, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, 6, 6.5, 7, 7.5, 8, 8.5, 9, and 9.5, per day should be appropriate in monotherapy and/or in combination therapy. A preferred daily dosage is between about 0.5 and about 7.5 g per day, more preferred 1.5 and about 6.0 g per day. Generally, treatment is initiated with a large initial "loading dose" to rapidly reduce or eliminate the virus following by a decreasing the dose to a level sufficient to prevent

resurgence of the infection. One of ordinary skill in treating diseases described herein will be able, without undue experimentation and in reliance on personal knowledge, experience and the disclosures of this application, to ascertain a therapeutically effective amount of the compounds of the present invention for a given disease and patient.

5 Therapeutic efficacy can be ascertained from tests of liver function including, but not limited to protein levels such as serum proteins (e.g., albumin, clotting factors, alkaline phosphatase, aminotransferases (e.g., alanine transaminase, aspartate transaminase), 5'-nucleosidase, γ -glutamyltranspeptidase, etc.), synthesis of bilirubin, synthesis of cholesterol, and synthesis of bile acids; a liver metabolic function, including,
10 but not limited to, carbohydrate metabolism, amino acid and ammonia metabolism. Alternatively the therapeutic effectiveness may be monitored by measuring HCV-RNA. The results of these tests will allow the dose to be optimized.

 A third aspect of the eighth embodiment, is directed to a method of treatment and/or prophylaxis in a subject in need thereof said method comprises administering to
15 the subject a therapeutically effective of a compound represented by formula I and a therapeutically effective amount of another antiviral agent; wherein the administration is concurrent or alternative. It is understood that the time between alternative administration can range between 1-24 hours, which includes any sub-range in between including, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, and 23
20 hours. Examples of "another antiviral agents" include, but are not limited to: HCV NS3 protease inhibitors (see WO 2008010921, WO 2008010921, EP 1881001, WO 2007015824, WO 2007014925, WO 2007014926, WO 2007014921, WO 2007014920, WO 2007014922, US 2005267018, WO 2005095403, WO 2005037214, WO 2004094452, US 2003187018, WO 200364456, WO 2005028502, and WO
25 2003006490); HCV NS5B Inhibitors (see US 2007275947, US20072759300, WO2007095269, WO 2007092000, WO 2007076034, WO 200702602, US 2005-98125, WO 2006093801, US 2006166964, WO 2006065590, WO 2006065335, US 2006040927, US 2006040890, WO 2006020082, WO 2006012078, WO 2005123087, US 2005154056, US 2004229840, WO 2004065367, WO 2004003138, WO
30 2004002977, WO 2004002944, WO 2004002940, WO 2004000858, WO 2003105770,

WO 2003010141, WO 2002057425, WO 2002057287, WO 2005021568, WO
 2004041201, US 20060293306, US 20060194749, US 20060241064, US 6784166, WO
 2007088148, WO 2007039142, WO 2005103045, WO 2007039145, WO 2004096210,
 and WO 2003037895); HCV NS4 Inhibitors (see WO 2007070556 and WO
 5 2005067900); HCV NS5a Inhibitors (see US 2006276511, WO 2006120252, WO
 2006120251, WO 2006100310, WO 2006035061); Toll-like receptor agonists (see WO
 2007093901); and other inhibitors (see WO 2004035571, WO 2004014852, WO
 2004014313, WO 2004009020, WO 2003101993, WO 2000006529).

A fourth aspect of the eighth embodiment, is directed to a method of treatment in
 10 a subject in need thereof said method comprises alternatively or concurrently
 administering a therapeutically effective of a compound represented by formula I and
 another antiviral agent to the subject. It is understood that the time between alternative
 administration can range between 1-24 hours, which includes any sub-range in between
 including, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, and 23
 15 hours.

A fifth aspect of the eighth embodiment, is directed to a method of treatment
 and/or prophylaxis in a subject in need thereof said method comprises administering to
 the subject a therapeutically effective of at least one compound represented by formula I
 and a therapeutically effective amount of another antiviral agent; wherein the
 20 administration is concurrent or alternative. It is understood that the time between
 alternative administration can range between 1-24 hours, which includes any sub-range in
 between including, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22,
 and 23 hours.

A sixth aspect of the eighth embodiment, is directed to a method of treatment in a
 25 subject in need thereof said method comprises alternatively or concurrently administering
 a therapeutically effective of at least one compound represented by formula I and another
 antiviral agent to the subject. It is understood that the time between alternative
 administration can range between 1-24 hours, which includes any sub-range in between


including, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, and 23 hours.

It is contemplated that the another antiviral agent includes, but is not limited to interferon - α , interferon- β , pegylated interferon- α , ribavirin, levovirin, viramidine,
 5 another nucleoside HCV polymerase inhibitor, a HCV non-nucleoside polymerase inhibitor, a HCV protease inhibitor, a HCV helicase inhibitor or a HCV fusion inhibitor. When the active compound or its derivative or salt are administered in combination with another antiviral agent the activity may be increased over the parent compound. When
 10 the treatment is combination therapy, such administration may be concurrent or sequential with respect to that of the nucleoside derivatives. "Concurrent administration" as used herein thus includes administration of the agents at the same time or at different times. Administration of two or more agents at the same time can be achieved by a single formulation containing two or more active ingredients or by substantially simultaneous administration of two or more dosage forms with a single active agent.

15 It will be understood that references herein to treatment extend to prophylaxis as well as to the treatment of existing conditions. Furthermore, the term "treatment" of a HCV infection, as used herein, also includes treatment or prophylaxis of a disease or a condition associated with or mediated by HCV infection, or the clinical symptoms thereof.

20 PROCESS FOR PREPARATION


An ninth embodiment of the present invention is directed to a process for preparing the compound of formula I, which comprises reacting a suitably substituted phosphochloridate compound **4** with a nucleoside analog **5**



wherein the substituents R^1 , R^2 , R^{3a} , R^{3b} , R^4 , R^5 , X , Y , R^6 , and base have their meanings as disclosed in the Detailed Description of the Invention and X' is a leaving group, such as Cl, Br, I, tosylate, mesylate, trifluoroacetate, trifluorosulfonate, pentafluorophenoxide, p-NO₂-phenoxide, or other commonly used leaving groups as disclosed in *Advanced Organic Chemistry* by March, Fourth Edition. Leaving groups and methods that can be used to effect the formation of a phosphoramidate nucleoside conjugate are found in US 20060142238 and WO 2007095269. Preferably, the leaving group is Cl.

This reaction is performed in an anhydrous aprotic solvent such tetrahydrofuran, dioxane, or both tetrahydrofuran and dioxane, or any functional equivalent thereof, with tetrahydrofuran being the preferred solvent. The reaction is typically initiated at a temperature range from -78°C to 40°C with the preferred reaction temperature being between 0°C and room temperature. The nucleoside is first stirred with a base (5 to 12 equivalents) such as N-methylimidazole, collidine, pyridine, 2,6-lutidine, 2, 6-*t*-Bu-pyridine, etc. a tertiary amine base, such as triethylamine, diisopropylethylamine, etc., or an alkyl Grignard reagent, such as *t*BuMgCl, *t*BuMgBr, MeMgCl, MeMgBr, etc. The phosphorochloridate (3-10 equivalents) is dissolved in the reaction solvent and added to the mixture of the nucleoside and base. The reaction is then allowed to stir over a period of time at a temperature between room temperature and 40°C for a period of 30 min to 24 hr. with the preferred reaction temperature being room temperature and time being 24 hr. The solvent is removed from the reaction mixture and the product is purified by chromatography on silica gel.

A tenth embodiment of the present invention is directed to a product obtained by a process which comprises reacting a suitably substituted phosphochloridate compound **4** with a nucleoside analog **5**



wherein the substituents R^1 , R^2 , R^{3a} , R^{3b} , R^4 , R^5 , X , Y , R^6 , X' , and base have their meanings as disclosed in the Detailed Description of the Invention.

This reaction can be performed in an anhydrous aprotic solvent or other suitable solvent, such as tetrahydrofuran, dioxane, or a mixture of tetrahydrofuran and dioxane, with tetrahydrofuran being the preferred solvent. The reaction is typically initiated at a temperature range from -78°C to 40°C with the preferred reaction temperature being between 0°C and room temperature. The nucleoside is first stirred with a base (5 to 12 equivalents) such as N-methylimidazole, a tertiary amine base or tButyl Magnesium Chloride. A phosphorochloridate (3-10 equivalents (or suitable "phosphoro-(leaving group)-date")) is dissolved in the reaction solvent and added to the mixture of the nucleoside and base. The reaction is then allowed to stir over a period of time at a temperature between room temperature and 40°C for a period of 30 min to 24 hr. with the preferred reaction temperature being room temperature and time being 24 hr. The solvent is removed from the reaction mixture and the product is purified by chromatography on silica gel.


Compounds and Preparation

Phosphoramidate compounds of the present invention can be prepared by condensation of a nucleoside analog **5** with a suitably substituted phosphochloridate compound **4** (Scheme 1). The nucleoside analog is made by conventional procedures disclosed in any one of U.S. Published Application Nos. 2005/0009737, 2006/0199783, 2006/0122146, and 2007/0197463, each of which is incorporated by reference in its entirety.

Disclosed $^1\text{H-NMR}$ values were recorded on a Varian AS-400 instrument. Mass spectral data were obtain using either a Micromass-Quattromicro API or a Waters Acquity.

Thus, by way of example only, a suitably substituted phenol can be reacted with phosphorus oxychloride (**1**) to afford an aryloxy phosphorodichloridate **2** (see Example 1) which is subsequently treated with an acid addition salt of an α -amino acid ester in the presence of TEA to afford an aryloxy phosphorochloridate **4**. This arylalkoxy-amino acid phosphoramidate is reacted with the nucleoside analog to provide the product **I** (for procedure see, e.g., C. McGuigan et al. Antiviral Res. 1992 17:311-321; D. Curley et al. Antiviral Res. 1990 14:345-356; McGuigan et al. Antiviral Chem. Chemother 1990 1(2):107-113).

Scheme 1



The preparation of nucleoside phosphoramidates requires reacting an appropriately substituted phosphochloridate with a nucleoside containing a free 5'-hydroxyl moiety. In cases where only one hydroxyl group is present, preparation of the phosphoramidate usually proceeds smoothly when the phosphochloridate is reacted with


the desired nucleoside. In cases where the nucleoside contains more than one free hydroxyl group, preparation of the appropriately protected nucleoside might be required. Silyl, acetonide or other alcohol protecting groups known in the art might be warranted for protection of the sugar moiety. For protection of the nucleoside base, protecting a
 5 free amino group may require amidine protection strategy.

Condensation of the phosphochloridate can be carried out on the unprotected nucleoside. Since the 5'-OH group of a nucleoside is much less hindered than the 3'-OH group, selective phosphoramidation is possible under carefully controlled conditions. After condensation to form a protected phosphoramidate nucleoside, deprotection to
 10 obtain the free phosphoramidate nucleoside can be carried out using standard protocols for nucleic acid chemistry. In many cases, the desired product is readily separated from the starting material using column chromatography on silica gel. The synthetic scheme is summarized in Scheme 1.

A further understanding of the disclosed embodiments will be appreciated by
 15 consideration of the following examples, which are only meant to be illustrative, and not limit the disclosed invention.

EXAMPLE 1

General Procedure for Preparation of phosphorodichloridates




20 A solution of the appropriate phenol **R¹-OH** (1eq) and triethylamine (1 eq.) in anhydrous ether was added dropwise to a stirred solution of phosphoryl trichloride **1** (1eq) at 0 °C over a period of 3 hours under nitrogen. Then the temperature was warmed to room temperature, and the reaction was stirred overnight. The triethylamine salt was

quickly removed with suction filtration and the filtrate concentrated *in vacuo* to dryness to afford **2** as an oil which was used without further purification.

EXAMPLE 2


General Procedure for Preparation of phosphorochloridates



A solution of triethylamine (2eq) in anhydrous dichloromethane was added dropwise to a solution of aryloxy-phosphodichloridate **2** (1 eq) and the appropriate amino ester **3** (1 eq) in anhydrous dichloromethane with vigorous stirring at -78 °C over a period of 30 to 120 minutes. Then the reaction temperature was allowed to warm to room temperature and stirred over night. Solvent was removed. The residue was washed with ethyl ether and filtered, the filtrate was dried over reduced pressure to give **4**.

EXAMPLE 3


General Procedures for nucleoside phosphoramidate derivatives



A solution of the appropriate phosphorochloridate **4** (6.5 equivalents) in anhydrous tetrahydrofuran (THF) was added to a mixture of nucleoside **5** (1 equivalent) and N-methylimidazole (8 equivalents) in anhydrous THF with vigorous stirring at room temperature and the reaction mixture was stirred overnight. The solvent was removed *in vacuo* and the crude was purified by column chromatography and/or preparative thin layer chromatography to give **I**.

EXAMPLE 4

Preparation of 2'-deoxy-2'-fluoro-2'-C-methyluridine




2'-Deoxy-2'-fluoro-2'-C-methylcytidine (1.0g, 1 eq) (Clark, J., et al., J. Med. Chem., 2005, 48, 5504-5508) was dissolved in 10 ml of anhydrous pyridine and concentrated to dryness in *vacuo*. The resulting syrup was dissolved in 20 ml of anhydrous pyridine under nitrogen and cooled to 0°C with stirring. The brown solution was treated with benzoyl chloride (1.63g, 3eq) dropwise over 10 min. The ice bath was removed and stirring continued for 1.5h whereby thin-layer chromatography (TLC) showed no remaining starting material. The mixture was quenched by addition of water


(0.5 ml) and concentrated to dryness. The residue was dissolved in 50 mL of dichloromethane (DCM) and washed with saturated NaHCO₃ aqueous solution and H₂O. The organic phase was dried over NaSO₄ and filtered, concentrated to dryness to give N⁴,3',5'-tribenzoyl-2'-Deoxy-2'-fluoro-2'-C-methylcytidine (2.0 g, Yield: 91%).

5 N⁴,3',5'-tribenzoyl-2'-Deoxy-2'-fluoro-2'-C-methylcytidine (2.0g, 1 eq) was refluxed in 80% aqueous AcOH overnight. After cooling and standing at room temperature (15 °C), most of the product precipitated and then was filtered through a sintered funnel. White precipitate was washed with water and co-evaporated with toluene to give a white solid. The filtrate was concentrated and co-evaporated with
10 toluene to give additional product which was washed with water to give a white solid. Combining the two batches of white solid gave 1.50g of 3',5'-dibenzoyl-2'-Deoxy-2'-fluoro-2'-C-methyluridine (Yield: 91%).

 To a solution of 3',5'-dibenzoyl-2'-Deoxy-2'-fluoro-2'-C-methyluridine (1.5 g, 1eq) in MeOH (10 mL) was added a solution of saturated ammonia in MeOH (20mL).
15 The reaction mixture was stirred at 0 °C for 30 min, and then warmed to room temperature slowly. After the reaction mixture was stirred for another 18 hours, the reaction mixture was evaporated under reduced pressure to give the residue, which was purified by column chromatography to afford pure compound 2'-deoxy-2'-fluoro-2'-C-methyluridine (500 mg, Yield: 60 %).

EXAMPLE 5**Preparation of 2'-Deoxy-2'-fluoro-2'-C-methyluridine 5'-(phenyl methoxy-alanyl phosphate)**


- 5 Phenyl methoxyalanyl phosphorochloridate (1 g, 6.5 eq) dissolved in 3 mL of THF was added to a mixture of 2'-Deoxy-2'-fluoro-2'-C-methyluridine (0.15 g, 1 eq) and N-methylimidazole (0.3 g, 8 eq) in 3 mL THF with vigorous stirring at room temperature, then the reaction was stirred overnight. Solvent was removed by reduced pressure. The resulting crude product was dissolved in methanol purified by prep-HPLC on a YMC
- 10 25x30X2 mm column using a water / acetonitrile gradient elution mobile phase. The acetonitrile and water were removed under reduced pressure to give the desired product (50.1 mg, 15.6%). ¹H NMR (DMSO-*d*₆) δ 1.20-1.27 (m, 6H), 3.58 (d, *J* = 16.0 Hz, 3H), 3.75-3.92 (m, 2H), 4.015-4.379 (m, 2H), 5.54 (t, *J* = 10.2 Hz, 1H), 5.83-5.91 (m, 1H), 6.00-6.16 (m, 1H), 7.18 (d, *J* = 8.0 Hz, 2H), 7.22 (s, 1H), 7.35 (t, *J* = 4.4 Hz, 2H), 7.55 (s,
- 15 1H), 11.52 (s, 1H); MS, *m/e* 502 (M+1)⁺.

EXAMPLE 6**Preparation of 2'-Deoxy-2'-fluoro-2'-C-methyluridine 5'-(phenyl methoxy-valyl phosphate)**

Phenyl methoxy-valyl phosphorochloridate (0.6 g, 3.6 eq) dissolved in 3 mL of THF was added to a mixture of 2'-Deoxy-2'-fluoro-2'-C-methyluridine (0.15 g, 1 eq) and N-methylimidazole (0.44 g, 9 eq) in 3 mL THF with vigorous stirring at room temperature, then the reaction was stirred overnight. Solvent was removed by reduced pressure. The resulting crude product was dissolved in methanol purified by prep-HPLC on a YMC 25x30X2 mm column using a water / acetonitrile gradient elution mobile phase. The acetonitrile and water were removed under reduced pressure to give the desired product (60 mg, 20%). ¹H NMR (DMSO-*d*₆) δ 0.74-0.847 (m, 6H), 1.20-1.28 (m, 3H), 1.89-1.92 (m, 1H), 3.50-3.54 (m, 1H), 3.58 (d, *J* = 10.4 Hz, 3H), 3.72-3.95 (m, 1H), 4.03-4.05 (m, 1H), 4.23-4.43 (m, 2H), 5.56 (t, *J* = 16.0 Hz, 1H), 5.85-5.92 (m, 1H), 6.01-6.07 (m, 1H), 7.16-7.21 (m, 3H), 7.37 (t, *J* = 8 Hz, 2H), 7.55-7.60 (m, 1H), 11.52 (s, 1H); MS, *m/e* 530 (M+1)⁺.

EXAMPLE 7

Preparation of 2'-Deoxy-2'-fluoro-2'-C-methyluridine 5'-(4-bromophenyl methoxy-valyl phosphate)




4-Bromophenyl methoxy-valyl phosphorochloridate (1 g, 3.4 eq) dissolved in 3 mL of THF was added to a mixture of 2'-deoxy-2'-fluoro-2'-C-methyluridine (0.2 g, 1 eq) and N-methylimidazole (0.35 g, 6 eq) in 3 mL THF with vigorous stirring at room temperature, then the reaction was stirred overnight. Solvent was removed by reduced


pressure. The resulting crude product was dissolved in methanol purified by prep-HPLC on a YMC 25x30X2 mm column using a water / acetonitrile gradient elution mobile phase. The acetonitrile and water were removed reduced pressure to give the desired product (120 mg, 26%). ^1H NMR ($\text{DMSO}-d_6$) δ 0.72-0.82 (m, 6H), 1.19-1.26 (m, 3H), 1.86-1.92 (m, 1H), 3.48-3.50 (m, 1H), 3.56 (d, $J = 12.0$ Hz, 3H), 3.72-3.89 (m, 1H), 3.96-4.03 (m, 1H), 4.22-4.37 (m, 2H), 5.54-5.60 (m, 1H), 5.85-5.91 (m, 1H), 5.98-6.13 (m, 1H), 7.15 (d, $J = 8.0$ Hz, 2H), 7.49-7.56 (m, 3H), 11.53 (s, 1H); MS, m/e 608 ($\text{M}+1$) $^+$.

EXAMPLE 8


Preparation of 2'-Deoxy-2'-fluoro-2'-C-methyluridine 5'-(4-bromophenyl methoxy-alanyl phosphate)



4-Bromophenyl methoxy-alanyl phosphorochloridate (0.6 g, 5 eq) dissolved in 3 mL of THF was added to a mixture of 2'-deoxy-2'-fluoro-2'-C-methyluridine (0.15 g, 1 eq) and N-methylimidazole (0.3 g, 7.8 eq) in 3 mL THF with vigorous stirring at room temperature, then the reaction was stirred overnight. Solvent was removed by reduced pressure. The resulting crude product was dissolved in methanol purified by prep-HPLC on a YMC 25x30X2 mm column using a water / acetonitrile gradient elution mobile phase. The acetonitrile and water were removed under reduced pressure to give the desired product (40 mg, 12 %); ^1H NMR ($\text{DMSO}-d_6$) δ 1.20-1.26 (m, 6H), 3.57 (d, $J = 2.8$ Hz, 3H), 3.84 (s, 1H), 3.97-4.03 (m, 1H), 4.21-4.25 (m, 1H), 4.33-4.37 (m, 2H), 5.54-5.60 (m, 1H), 5.83-5.89 (m, 1H), 5.98-6.19 (m, 1H), 7.16 (t, $J = 10.2$ Hz, 2H), 7.52-7.57 (m, 3H), 11.52 (s, 1 H); MS, m/e 580 ($\text{M}+1$) $^+$.

EXAMPLE 9**Preparation of N⁴-(*N,N*-dimethylformamidinyl)-2'-deoxy-2'-fluoro-2'-*C*-methylcytidine**

5 2'-Deoxy-2'-fluoro-2'-*C*-methylcytidine (500 mg, 1.9 mmol) was stirred with dimethylformamide dimethyl acetal in DMF (10 mL). The resulting mixture was stirred at room temperature overnight. After solvent removal the crude product was used for next step without further purification.

EXAMPLE 10**Preparation of 2'-Deoxy-2'-fluoro-2'-*C*-methylcytidine 5'-(phenyl methoxy-alanyl phosphate)**


Phenyl methoxyalanyl phosphorochloridate (0.6 g, 6 eq) dissolved in 3 mL of THF was added to a mixture of N⁴-(*N,N*-dimethylformamidinyl)-2'-deoxy-2'-fluoro-2'-*C*-methylcytidine (0.15 g, 1 eq) and *N*-methylimidazole (0.3 g, 7.8 eq) in 3 mL THF with vigorous stirring at room temperature, then the reaction was stirred overnight. Solvent was removed by reduced pressure. The resulting crude product was dissolved in methanol purified by prep-HPLC on a YMC 25x30X2 mm column using a water / acetonitrile gradient elution mobile phase. The acetonitrile and water were removed under reduced pressure to give the desired product (62 mg, 20.6%). ¹H NMR (DMSO-*d*₆) δ 1.16 (d, *J* = 23.2 Hz, 3H), 1.22 (d, *J* = 7.2 Hz, 3H), 3.56 (s, 3H), 3.69-3.75 (d, *J* = 25.6 Hz, 1H), 3.82-3.86 (m, 1H), 3.96-3.98 (m, 1H), 4.21-4.34 (m, 2H), 5.68 (d, *J* = 7.2

Hz, 1H), 5.75-5.77 (m, 1H), 6.07-6.16 (m, 1H), 7.15-7.19 (m, 3H), 7.2 (d, $J = 9.2$ Hz, 2H), 7.39 (t, $J = 7.8$ Hz, 2H), 7.48 (d, $J = 9.2$ Hz, 1H); MS, m/e 501(M+1)⁺.


EXAMPLE 11

Preparation of 2'-Deoxy-2'-fluoro-2'-C-methylcytidine 5'-(4-bromophenyl methoxy-valyl phosphate)

5



4-Bromophenyl methoxy-valyl phosphorochloridate (1.0 g, 3.4 eq.) dissolved in 3 mL of THF was added to a mixture of N⁴-(N,N-dimethylformamidinyl)-2'-deoxy-2'-fluoro-2'-C-methylcytidine (0.2 g, 1 eq.) and N-methylimidazole (0.35 g, 6 eq.) in 3 mL THF with vigorous stirring at room temperature, then the reaction was stirred overnight. Solvent was removed by reduced pressure. The resulting crude product was dissolved in methanol purified by prep-HPLC on a YMC 25x30X2 mm column using a water / acetonitrile gradient elution mobile phase. The acetonitrile and water were removed under reduced pressure to give the desired product as a white solid (59 mg, 13%); ¹H NMR (DMSO-*d*₆) δ 0.74-0.83 (m, 6H), 1.12-1.20 (m, 3H), 1.89-1.92 (m, 1H), 3.49-3.51 (m, 1H), 3.55 (s, 3H), 3.59-3.68 (m, 1H), 3.72-3.83 (m, 1H), 4.21-4.39 (m, 2H), 5.70-5.72 (m, 1H), 5.76-5.83 (m, 1H), 6.04-6.16 (m, 1H), 7.15 (d, $J = 13.0$ Hz, 2H), 7.26 (s, 1H), 7.33 (s, 1H), 7.46-7.55 (m, 1H), 7.56 (d, $J = 4.4$ Hz, 2H) ; MS, m/e 607 (M+1)⁺.

EXAMPLE 12**Preparation of 2'-deoxy-2'-fluoro-2'-C-methylcytidine 5'-(phenyl methoxy-valyl phosphate)**

Phenyl methoxy-valyl phosphorochloridate (0.6 g, 6 eq) dissolved in 3 mL of THF was added to a mixture of N⁴-(*N,N*-dimethylformamidinyl)-2'-deoxy-2'-fluoro-2'-C-methylcytidine (0.15 g, 1 eq) and N-methylimidazole (0.3 g, 7.8 eq) in 3 mL THF with vigorous stirring at room temperature, then the reaction was stirred overnight. Solvent was removed by reduced pressure. The resulting crude product was dissolved in methanol purified by prep-HPLC on a YMC 25x30X2 mm column using a water / acetonitrile gradient elution mobile phase. The acetonitrile and water were removed under reduced pressure to give the desired product as a white solid (86 mg, 42.9 %). ¹H NMR (DMSO-*d*₆) δ 0.72-0.80 (m, 6H), 1.09-1.18 (m, 3H), 1.87-1.92 (m, 1H), 3.47-3.51 (m, 1H), 3.58 (s, 3H), 3.71-3.75 (m, 1H), 3.97 (t, *J* = 11.2 Hz, 1H), 4.22-4.37 (m, 2H), 5.70 (d, *J* = 8.0 Hz, 1H), 5.76-5.84 (m, 1H), 6.01-6.15 (m, 1H), 7.13-7.18 (m, 3H), 7.27 (s, 2H), 7.34 (d, *J* = 4.0 Hz, 2H), 7.46-7.50 (m, 1H); MS, *m/e* 529 (M+1)⁺.


10

15

EXAMPLES

Example numbers **13-54** and **56-66** are prepared using similar procedures described for examples **5-8**. The example number, compound identification, and NMR/MS details are shown below:

20



Ex.	R ¹	R ²	R ^{3a}	R ^{3b}	R ⁴	NMR/MS
13	Ph	H	H	Me	Et	¹ H NMR (DMSO- <i>d</i> ₆) δ 1.12-1.16 (m, 3H), 1.20-1.28(m,6H), 3.70-3.90 (m, 2H), 4.00-4.08 (m, 3H), 4.18-4.45 (m, 2H), 5.52-5.58 (m, 1H), 5.85-5.98 (m, 1H), 6.00-6.20 (m, 2H), 7.16-7.23 (m, 3H), 7.37-7.40 (m, 2H), 7.54-7.60 (m, 1H), 11.54 (s,1H) ; MS, m/e 516.1 (M+1) ⁺
14	1-Naph	H	H	Me	Bn	¹ H NMR (DMSO- <i>d</i> ₆) δ 1.18-1.30 (m, 6H), 3.78-4.10 (m, 3H), 4.38-4.49 (m, 2H), 4.99-5.11 (m, 2H), 5.28-5.40 (m, 1H), 5.85-6.10 (m, 2H), 6.30-6.41 (m, 1H), 7.28-7.32 (m, 5H), 7.41-7.60 (m, 5H), 7.73-7.76(m, 1H), 7.94-8.11(m, 1H), 8.13-8.15(m, 1H), 11.50 (s,1H) ; MS, m/e 628.4 (M+1) ⁺
15	Ph	H	H	H	Me	¹ H NMR (DMSO- <i>d</i> ₆) δ 1.22 (d, J=22.4 Hz, 3H), 3.59(s, 3H), 3.63-3.69 (m, 2H), 3.74-3.8(m, 1H), 4.02(d, J=11.2 Hz, 1H), 4.23-4.28(m, 1H), 4.40-4.43 (m, 1H), 5.57-5.60 (m, 1H), 5.89(d, J=6.8 Hz, 1H), 6.00-6.06(m, 2H), 7.15-7.23 (m, 3H), 7.35-7.39 (m, 2H), 7.52(d, J=8 Hz, 1H), 11.52(s, 1H) ; MS, m/e 487.97 (M+1) ⁺
16	2,4-Cl-Ph	H	H	Me	Me	¹ H NMR (DMSO- <i>d</i> ₆) δ 1.22-1.28 (m, 6H), 3.57-3.60 (m, 3H), 3.84-3.92 (m, 2H), 4.00-4.04 (m, 1H), 4.31-4.44 (m, 2H), 5.54-5.61 (m, 1H), 5.85-6.10 (m, 2H), 6.32-6.43 (m, 1H), 7.44-7.54 (m, 3H), 7.72-7.75 (m, 1H), 11.54 (s,1H) ; MS, m/e 570.2 (M+1) ⁺
17	1-Naph	H	H	Me	Me	¹ H NMR (DMSO- <i>d</i> ₆) δ 1.15-1.27 (m, 6H), 3.51-3.55 (d, 3H), 3.85-3.96 (m, 2H), 4.00-4.10(m, 1H), 4.30-4.46 (m, 2H), 5.31-5.39 (m, 1H), 5.89-6.05 (m, 2H), 6.22-6.34 (m, 1H), 7.44-7.60 (m, 5H), 7.73-7.77 (m, 1H), 7.93-7.96 (m, 1H), 8.12-8.14 (m, 1H), 11.50(s,1H) ; MS, m/e 552.1 (M+1) ⁺
18	Ph	*	H	*	Me	¹ H NMR (DMSO- <i>d</i> ₆) δ 1.19 (d, J=22.8 Hz, 3H), 1.69-1.84 (m, 3H), 1.99-2.04 (m, 1H), 3.16-3.21 (m, 2H), 3.58 (s, 3H), 3.68-3.8 (m, 1H), 4.00 (m, 1H), 4.01-4.13 (m, 1H), 4.22-4.25 (m, 1 H), 4.5 (d, J = 11.2 Hz, 1H), 5.54 (d, J = 8.0 Hz, 1H), 5.86 (s, 1H), 5.6 (d, J = 19.6 Hz, 1H), 7.15-7.2 (m, 3H), 7.34 (t, J = 8.0 Hz, 2H), 7.51 (d, J = 8.0 Hz, 1H), 11.38 (s, 1H) ; MS, m/e 527.93(M+1) ⁺
19	Ph	H	H	Me	n-Bu	¹ H NMR (DMSO- <i>d</i> ₆) δ 0.80-0.90 (m, 3H), 1.20-1.35 (m, 8H), 1.48-1.55 (m, 2H), 3.78-3.88 (m, 2H), 3.95-4.08 (m, 3H), 4.22-4.45 (m, 2H), 5.55-5.57(t, 1H), 5.85-6.18 (m, 3H), 7.14-7.23 (m, 3H), 7.35-7.40 (m, 2H), 7.51-7.60 (d, 1H), 11.50 (s,1H) ; MS, m/e 544.2 (M+1) ⁺
20	Ph	H	H	Me	Bn	¹ H NMR (DMSO- <i>d</i> ₆) δ 1.20-1.30 (m, 6H), 3.72-4.05 (m, 3H), 4.23-4.27 (m, 1H), 4.32-4.45 (m, 1H), 5.07-5.10(t, 2H), 5.52-5.56(t, 1H), 5.86-6.10 (m, 2H), 6.13-6.21(m,1H), 7.15-7.21 (m, 3H), 7.29-7.40 (m, 7H), 7.51-7.56 (d, 1H), 11.50 (s,1H) ; MS, m/e 578.2 (M+1) ⁺
21	4-F-Ph	H	H	Me	Me	¹ H NMR (DMSO- <i>d</i> ₆) δ 1.28-1.34 (m, 6H), 3.65(d, J= 4 Hz, 3H), 3.85-3.96 (m, 2H), 4.06-4.12 (m, 1H), 4.30-4.34 (m,1H), 4.40-4.47 (m, 1H),

Ex.	R ¹	R ²	R ^{3a}	R ^{3b}	R ⁴	NMR/MS
						5.62-5.67 (m, 1H), 5.94-6.01(m, 1H), 6.09 (d, J=18.8 Hz, 1H), 6.17-6.26 (m, 1H), 7.27-7.33(m, 4H), 7.62 (d, J = 7.6 Hz, 1H), 11.61 (s, 1H) ; MS, m/e 519.94(M+1)+
22	4-Cl-Ph	H	H	Me	Me	1H NMR (DMSO- <i>d</i> ₆) δ 1.22-1.28 (m, 6H), 3.58 (d, 2H), 3.70-3.95(m,2H), 3.95-4.08 (m,1H), 4.23-4.45 (m, 2H), 5.55-5.61(t, 1H), 5.85-6.10 (m, 2H), 6.15-6.23(m,1H), 7.20-7.26 (m, 2H), 7.43-7.46 (m, 2H), 7.54-7.57 (d, 1H), 11.50 (s.1H) ; MS, m/e 536.1 (M+1)+
23	3,4-Cl-Ph	H	H	Me	Me	1H NMR (DMSO- <i>d</i> ₆) δ 1.13 (m, 6H), 3.49 (s, 3H), 3.61-3.85 (m, 2H), 3.90-3.93 (m, 1H), 4.16-4.22 (m, 1H), 4.27-4.31 (m, 1H), 5.47-5.52 (m, 1H), 5.82 (d, J = 11.6 Hz, 1H), 5.93(d, J = 19.2 Hz, 1H), 6.15-6.25 (m, 1H), 7.13 (t, J = 9.6 Hz, 1H), 7.43 (d, J = 12Hz, 2H), 7.57 (d, J = 6.0 Hz, 1H), 11.43(s, 1H) ; MS, m/e 569.85 (M+1)+
24	Ph	H	H	Me	2-Bu	1H NMR (DMSO- <i>d</i> ₆) δ 0.83 (d, J = 6.8 Hz, 6H), 1.20-1.26 (m, 6H), 1.79-1.86 (m, 1H), 3.73-3.90 (m, 4H), 4.01 (t, J = 11.2 Hz, 1H), 4.21-4.28 (m, 1H), 4.33-4.42 (m, 1H), 5.54 (t, J = 7.6 Hz, 1H), 5.85-5.92 (m, 1H), 5.99-6.13 (m, 2H), 7.19 (t, J = 8 Hz, 3H), 7.36 (t, J = 7.6 Hz, 2H), 7.53 (d, J = 7.6 Hz, 1H), 11.52 (s, 1H) ; MS, m/e 544.00 (M+1)+
25	Ph	H	H	Me	i-Pr	1H NMR (DMSO- <i>d</i> ₆) δ 1.13-1.28 (m, 12H), 3.74-3.81 (m, 2H), 3.95-4.08 (m,1H), 4.20-4.45 (m, 2H), 4.83-4.87 (m, 1H), 5.52-5.58 (m, 1H), 5.84-6.15 (m, 3H), 7.17-7.23 (m, 3H), 7.35-7.39 (m, 2H), 7.54-7.57 (m, 1H), 11.50 (s.1H) ; MS, m/e 530.2 (M+1)+
26	4-MeO-Ph	H	H	Me	n-Bu	1HNMR (400MHz, DMSO- <i>d</i> ₆): δ =0.78-0.82 (m, 3H), 1.29-1.47 (m, 8H), 1.49-1.54 (m, 2H), 3.66-3.87 (m, 5H), 3.96-4.02 (m, 3H), 4.21-4.39 (m, 2H), 5.57 (t, J= 12.0Hz, 1H), 5.84-6.05 (m, 3H), 6.90 (dd, J1 =8.0Hz, J2=4.0Hz, 2H), 7.09-7.14 (dd, J1=16.0Hz, J2=4.0Hz, 2H), 7.55 (d, J =8.0Hz, 1H), 11.48-11.62 (s, 1H)
27	4-F-Ph	H	H	Me	Et	1H NMR (DMSO- <i>d</i> ₆) δ 1.12-1.28 (m, 9H), 3.72-3.94(m,2H) ,3.98-4.10 (m,3H), 4.21-4.42(m,2H), 5.55-5.61 (t, 1H), 5.85-6.20 (m, 3H), 7.18-7.25 (m,4H), 7.55-7.58 (d, 1H), 11.50 (s.1H) ; MS, m/e 533.90 (M+1)+
28	4-F-Ph	H	H	Me	i-Pr	1H NMR (DMSO- <i>d</i> ₆) δ 1.13-1.30 (m, 12H), 3.74-3.85(m,2H) ,3.98-4.06 (m,1H), 4.23-4.41(m,2H), 4.83-4.87 (m, 1H), 5.55-5.61 (t, 1H), 5.85-6.12 (m, 3H), 7.18-7.24 (m,4H), 7.55-7.58 (d, 1H), 11.50 (s.1H) ; MS, m/e 547.91 (M+1)+
29	4-F-Ph	H	H	Me	Bn	1H NMR (DMSO- <i>d</i> ₆) δ 1.10-1.23 (m, 6H), 3.65-3.89(m,3H) ,4.10-4.30 (m,2H), 4.96-5.00(m,2H), 5.46-5.50 (t, 1H), 5.75-5.96 (m, 2H), 6.04-6.12(m,1H), 7.05-7.11 (m,4H), 7.20-7.24 (d, 5H), 7.42-7.45(d,1H), 11.50 (s.1H) ; MS, m/e 595.94 (M+1)+
30	4-MeO-Ph	H	H	Me	i-Pr	1HNMR (400MHz, DMSO- <i>d</i> ₆): δ=1.15-1.27 (m, 12H), 3.71-3.89 (m, 5H), 3.98-4.02 (m, 1H), 4.22-4.25 (m, 1H), 4.33-4.39 (m, 1H), 4.84-4.87 (m, 1H), 5.57 (t, J= 12.0Hz, 1H), 5.91-6.03 (m, 3H), 6.90 (d, J= 8.0Hz, 2H), 7.09-7.14 (m, 2H), 7.55 (d, J= 8.0Hz, 1H), 11.51 (s, 1H)
31	2-Cl-Ph	H	H	Me	Bn	1H NMR (DMSO- <i>d</i> ₆) δ 1.23 (m, 6 H), 3.93-4.00 (m, 3 H), 4.27-4.40 (m, 2H), 5.0(t, J= 7.2 Hz, 2 H), 5.53 (m ,1 H), 5.80-6.0(m , 2 H), 6.30(m, 1H), 7.15 (d, J= 2.4 Hz, 1 H), 7.27 (m, 6 H), 7.51 (m, 3 H), 11.5 (s, 1 H) ; MS, m/e 579.87(M+1)+ / 596.78 (M+18)+

Ex.	R ¹	R ²	R ^{3a}	R ^{3b}	R ⁴	NMR/MS
32	2,4-Cl-Ph	H	H	Me	n-Bu	¹ H NMR (DMSO- <i>d</i> ₆) δ=0.82 (m, 3 H), 1.23 (m, 8 H), 1.47 (m, 2 H), 3.86 (m, 2 H), 3.84 (m, 3 H), 4.27-4.43 (m, 2H), 5.5 (m, 1 H), 6.02 (m, 2 H), 6.35(m, 1H), 7.44 (m, 3 H), 7.77 (m, 1 H), 11.5 (s, 1 H) ; MS, m/e 611.87(M+1)+
33	4-Me-Ph	H	H	Me	i-Pr	¹ H NMR (DMSO- <i>d</i> ₆) δ 1.14-1.27 (m, 12H), 2.17-2.26 (m, 3H), 3.73-3.82 (m, 1H), 3.99-4.02 (m, 1H), 4.23-4.26 (m, 1H), 4.37-4.40 (m, 1H), 4.82-4.88 (m, 1H), 5.52-5.58 (m, 1H), 5.85-6.07 (m, 3H), 7.01-7.20 (m, 4H), 7.55 (d, J = 16Hz, 1H), 11.51 (s, 1H) ; MS, m/e 543.98 (M+1)+; 1108.86 (2M+23)+
34	4-F-Ph	H	H	Me	n-Bu	¹ H NMR (DMSO- <i>d</i> ₆) δ 0.82-0.89 (m, 3H), 1.20-1.31 (m, 8H), 1.48-1.53 (m, 2H), 3.77-3.90 (m, 2H), 3.95-4.10 (m, 3H), 4.21-4.45(m, 2H), 5.56-5.61 (t, 1H), 5.83-6.20 (m, 3H), 7.18-7.25 (m, 4H), 7.55-7.58 (d, 1H), 11.50 (s, 1H) ; MS, m/e 584.1 (M+23)+
35	3,4-diCl-Ph	H	H	Me	Et	¹ H NMR (DMSO- <i>d</i> ₆) δ 1.12-1.31 (m, 9H), 3.77-3.92 (m, 2H), 3.95-4.08 (m, 3H), 4.21-4.45(m, 2H), 5.56-5.62 (t, 1H), 5.80-6.11 (m, 2H), 6.18-6.33(m, 1H), 7.18-7.25 (m, 1H), 7.49-7.56 (d, 2H), 7.62-7.67(m, 1H), 11.50 (s, 1H) ; MS, m/e 606.1 (M+23)+
36	2-Cl-Ph	H	H	Me	i-Pr	¹ H NMR (400MHz, DMSO- <i>d</i> ₆): δ =1.12-1.16 (m, 6H), 1.21-1.27 (m, 6H), 3.79-3.85 (m, 2H), 4.00-4.07 (m, 1H), 4.28-4.32 (m, 1H), 4.38-4.43 (m, 1H), 4.83-4.87 (m, 1H), 5.56 (dd, J1=16.0Hz, J2=8.0Hz, 1H), 5.85-6.12 (m, 2H), 6.20-6.33 (m, 1H), 7.19-7.22 (m, 1H), 7.33 (t, J=16.0Hz, 1H), 7.48-7.55 (m, 3H), 11.55 (s, 1H)
37	4-MeO-Ph	H	H	Me	Bn	¹ H NMR (400MHz, DMSO- <i>d</i> ₆): δ=1.19-1.26 (m, 6H), 3.69-3.70 (s, 3H), 3.87 (m, 2H), 3.99 (m, 1H), 4.20-4.21 (m, 1H), 4.35 (m, 1H), 5.07-5.09 (m, 2H), 5.54 (t, J = 16.0Hz, 1H), 5.85-5.92 (m, 1H), 6.04-6.10 (m, 2H), 6.86 (d, J= 8.0Hz, 2H), 7.09 (dd, J1=16.0Hz, J2=4.0Hz, 2H), 7.30-7.34 (m, 5H), 7.53 (s, 1H), 11.52 (s, 1H)
38	Ph	H	H	Me	n-Pen	¹ H NMR (DMSO- <i>d</i> ₆) δ 0.79-0.81 (m, 3H), 1.17-1.23 (m, 10H), 3.74-3.81 (m, 2H), 3.94-3.96 (m, 3H), 4.19-4.36 (m, 2H), 5.49-5.54 (m, 1H), 5.87-6.08 (m, 3H), 7.14-7.33 (m, 3H), 7.31-7.35 (m, 2H), 7.51 (d, J = 8Hz, 1H), 11.51 (s, 1H) ; MS, m/e 557.9 (M+1)+; 1136.88 (2M+23)+
39	4-Cl-Ph	H	H	Me	i-Pr	¹ H NMR (DMSO- <i>d</i> ₆) δ 1.04-1.19 (m, 12H), 3.76-3.80 (m, 2H), 3.98-4.08 (m, 1H), 4.42-4.42 (m, 2H), 4.82-4.85 (m, 1H), 5.55-5.60 (m, 1H), 5.80-6.20 (m, 3H), 7.20-7.25 (m, 2H), 7.43 (d, J = 8.8Hz, 1H), 7.54 (d, J = 8Hz, 1H), 11.51 (s, 1H) ; MS, m/e 563.88 (M+1)+; 1148.73 (2M+23)+
40	4-Cl-Ph	H	H	Me	n-Bu	¹ H NMR (DMSO- <i>d</i> ₆) δ 0.85 (t, J = 7.2 Hz, 3H), 1.22-1.33 (m, 8H), 1.45-1.53 (m, 2H), 3.80-3.87 (m, 2H), 3.96-4.04 (m, 3H), 4.24-4.27 (m, 1H), 4.35-4.39 (m, 1H), 5.56-5.61 (m, 1H), 5.82-6.11 (m, 2H), 6.15-6.18 (m, 1H), 7.20-7.56 (m, 4H), 7.51-7.57 (m, 1H) , 11.54 (s, 1H); MS, m/e 577.95(M+1)+
41	4-Cl-Ph	H	H	Me	Et	¹ H NMR (DMSO- <i>d</i> ₆) δ 1.14 (t, J = 7.0Hz, 3H), 1.20-1.28 (m, 6H), 3.77-3.88 (m, 2H), 3.99-4.07 (m, 3H), 4.24-4.28 (m, 1H), 4.34-4.43 (m, 1H), 5.56-5.61 (m, 1H), 5.86-6.13 (m, 2H), 6.15-6.24 (m, 1H), 7.20-7.26 (m, 2H), 7.44 (d, J = 7.6Hz, 2H) , 7.55 (d, J = 7.6Hz,

Ex.	R ¹	R ²	R ^{3a}	R ^{3b}	R ⁴	NMR/MS
42	4-Me-Ph	H	H	Me	n-Bu	1H, 11.55 (s, 1H); MS, m/e 549.11(M+1)+ 1H NMR (DMSO- <i>d</i> ₆) δ 0.79-0.83 (m, 3H), 1.17-1.28 (m, 8H), 1.45-1.47 (m, 2H), 2.22 (d, J = 2.8Hz, 1H), 3.70-3.90 (m, 2H), 3.95-3.98 (m, 3H), 4.10-4.40 (m, 2H), 5.51 (t, 1H), 5.80-5.90 (m, 1H), 5.95-6.05 (m, 2H), 7.02-7.06 (m, 2H), 7.51 (t, J = 4.2Hz, 4H), 7.51 (d, 1H), 11.51 (s, 1H); MS, m/e 557.99(M+1)+; 1136.84(2M+23)+
43	4-Me-Phe	H	H	Me	Bn	1H NMR (DMSO- <i>d</i> ₆) δ 1.16-1.24 (m, 6H), 2.22 (s, 3H), 3.65-4.03 (m, 3H), 4.11-4.38 (m, 2H), 5.04-5.05 (m, 2H), 5.48-5.50 (m, 1H), 5.77-5.87 (m, 1H), 5.90-6.11 (m, 2H), 6.98-7.10 (m, 4H), 7.28-7.32 (m, 5H), 7.50 (t, 1H), 11.48 (s, 1H); MS, m/e 592.00 (M+1)+.
44	Ph	H	H	Et	Me	1H NMR (DMSO- <i>d</i> ₆) δ 0.70-0.80 (m, 3H), 1.11-1.26 (m, 3H), 1.42-1.61 (m, 2H), 3.50-3.54 (m, 3H), 3.58-3.80 (m, 2H), 3.91-4.02 (m, 1H), 4.12-4.38 (m, 2H), 5.47-5.52 (m, 1H), 5.90-6.03 (m, 2H), 7.08-7.16 (m, 3H), 7.26-7.35 (m, 2H), 7.48 (t, 1H), 11.45 (s, 1H); MS, m/e 515.95 (M+1)+; 1052.82 (2M+23)+
45	Ph	H	H	Me	4-F-Bn	¹ H NMR (400MHz, DMSO- <i>d</i> ₆): δ 1.20-1.26 (m, 6H), 3.80-3.93 (m, 2H), 3.98 (s, 1H), 4.25-4.26 (m, 1H), 4.36-4.37 (m, 1H), 5.07 (s, 2H), 5.52-5.55 (m, 1H), 5.86-5.87 (m, 1H), 5.98-6.04 (m, 1H), 6.14-6.17 (m, 1H), 7.15-7.20 (m, 5H), 7.36 (dd, J = 20.0, 8.0 Hz, 4H), 7.54 (s, 1H), 11.55 (s, 1H)
46	4-Cl-Ph	H	H	Me	n-Bu	¹ H NMR (400MHz, DMSO- <i>d</i> ₆): δ 1.21-1.28 (m, 6H), 3.71-3.88 (m, 1H), 3.91-3.98 (m, 1H), 4.00-4.01 (m, 1H), 4.23-4.27 (m, 1H), 4.35-4.38 (m, 1H), 5.08 (d, J = 4.0Hz, 2H), 5.57 (dd, J = 12.0, 8.0 Hz, 1H), 5.91 (d, J = 8.0 Hz, 1H), 6.01 (d, J = 8.0 Hz, 1H), 6.22-6.24 (m, 1H), 7.17-7.23 (m, 2H), 7.31-7.40 (m, 7H), 7.53 (s, 1H), 11.50 (s, 1H)
47	Ph	H	H	Me	3-Me-1-Bu	¹ H NMR (DMSO- <i>d</i> ₆) δ 0.80-0.82 (m, 6H), 1.18-1.40 (m, 8H), 1.50-1.58 (m, 1H), 3.71-3.82 (m, 3H), 3.97-3.4.01 (m, 3H), 4.21-4.40 (m, 2H), 5.30(t, J = 8.6 Hz, 1H), 5.81-6.10 (m, 3H), 7.15-7.20 (m, 3H), 7.32-7.36 (m, 2H), 7.48 (d, J = 8.4 Hz, 1H), 11.38 (s, 1H); MS, m/e 557.98 (M+1)+; 1136.88 (2M+23)+
48	3,4-diCl-Ph	H	H	Me	Bn	¹ H NMR (DMSO- <i>d</i> ₆) δ 1.05-1.37 (m, 6H), 3.71-3.82 (m, 1H), 3.87-4.02 (m, 2H), 4.28-4.29 (m, 1H), 4.36-4.38 (m, 1H), 5.04 (d, J = 5.2Hz, 2H), 5.55-5.64 (m, 1H), 5.85-5.94 (m, 1H), 6.00-6.05 (m, 1H), 6.29-6.40 (m, 1H), 7.17-7.24 (m, 1H), 7.30-7.41 (m, 5H), 7.45-7.58 (m, 2H), 7.61 (d, J = 4.0Hz, 1H), 11.53 (s, 1H); MS, m/e 545.80(M+1)+;
49	Ph	H	H	Me	c-Hex	¹ H NMR (DMSO- <i>d</i> ₆) δ 1.18-1.41 (m, 12H), 1.59-1.67 (m, 4H), 3.74-13.80 (m, 1H), 3.96-4.02 (m, 1H), 4.19-4.26 (m, 1H), 4.31-4.39 (m, 1H), 4.60 (s, 1H), 5.52 (t, J = 7.8 Hz, 1H), 5.80-6.09 (m, 3H), 7.15-7.20 (m, 3H), 7.32-7.36 (m, 2H), 7.52 (d, J = 8 Hz, 1H), 11.50 (s, 1H); MS, m/e 569.98 (M+1)+; 592.14 (M+23)+
50	Ph	H	Me	H	n-Bu	1H NMR (DMSO- <i>d</i> ₆) δ 0.76 (t, J = 7.2Hz, 3H), 1.10-1.22 (m, 8H), 1.38-1.43 (m, 2H), 3.72-3.75 (m, 2H), 3.87-3.93 (m, 3H), 4.14-4.21 (m, 1H), 4.23-4.33 (m, 1H), 5.46-5.54 (m, 1H), 5.84-6.11 (m, 3H), 7.09-7.14 (m, 2H), 7.27-7.32 (m, 2H), 7.34-7.51 (m, 1H), 11.47 (s, 1H); MS, m/e 543.98(M+1)+
51	Ph	H	Me	H	i-Pr	1H NMR (DMSO- <i>d</i> ₆) δ 1.39 (d, J = 7.2Hz, 6H), 1.19-1.29 (m, 6H),

Ex.	R ¹	R ²	R ^{3a}	R ^{3b}	R ⁴	NMR/MS
						3.65-3.75 (m, 2H), 3.95-4.05 (m, 1H), 4.20-4.22 (m, 1H), 4.31-4.33 (m, 1H), 4.79-4.82 (m, 1H), 5.48-5.57 (m, 1H), 5.84-5.91 (m, 1H), 5.96-6.07 (m, 2H), 7.12-7.35 (m, 5H), 7.44-7.54 (m, 1H), 11.49 (s, 1H); MS, <i>m/e</i> 529.96 (M+1) ⁺
52	Ph	H	Me	H	Bn	¹ H NMR (DMSO- <i>d</i> ₆) δ 1.18-1.28 (m, 6H), 3.70-3.83 (m, 1H), 3.87-3.94 (m, 1H), 3.99-4.01 (m, 1H), 4.23-4.26 (m, 1H), 4.33-4.37 (m, 1H), 5.03-5.12 (m, 2H), 5.51-5.59 (m, 1H), 5.87-5.90 (m, 1H), 5.95-6.07 (m, 1H), 6.10-6.27 (m, 1H), 7.15-7.23 (m, 3H), 7.31-7.38 (m, 7H), 7.47-7.56 (m, 1H), 11.50 (s, 1H); MS, <i>m/e</i> 577.99 (M+1) ⁺
53	2-Cl-Ph	H	H	Me	n-Bu	¹ H NMR (400MHz, DMSO- <i>d</i> ₆): δ 0.81-0.86 (m, 3H), 1.21-1.31 (m, 8H), 1.46-1.52 (m, 2H), 3.84-3.90 (m, 2H), 3.97-4.04 (m, 3H), 4.27-4.41 (m, 2H), 5.53-5.58 (m, 1H), 5.82-5.95 (m, 1H), 5.96-6.10 (m, 1H), 6.27-6.31 (m, 1H), 7.19-7.22 (m, 1H), 7.34 (dd, <i>J</i> = 8.0, 4.0 Hz, 1H), 7.47-7.55 (m, 3H), 11.55 (s, 1H)
54	4-Br-Ph	H	H	Me	i-Pr	¹ H NMR (400MHz, DMSO- <i>d</i> ₆): δ 1.10-1.14 (m, 6H), 1.20-1.27 (m, 6H), 3.74-3.81 (m, 2H), 3.99-4.01 (m, 1H), 4.21-4.25 (m, 1H), 4.37-4.38 (m, 1H), 4.81-4.85 (m, 1H), 5.58 (dd, <i>J</i> = 8.0, 4.0 Hz, 1H), 5.82-5.95 (m, 1H), 5.96-6.09 (m, 1H), 6.10-6.13 (m, 1H), 7.18 (dd, <i>J</i> = 12.0, 8.0 Hz, 2H), 7.53-7.57 (m, 3H), 11.52 (s, 1H)
55	4-F-Ph	H	H	Me	c-Hex	¹ H NMR (DMSO- <i>d</i> ₆) δ 1.20-1.44 (m, 12H), 1.60-1.71 (m, 4H), 3.75-4.02 (m, 2H), 3.94-4.02 (m, 1H), 4.19-4.26 (m, 2H), 4.59-4.61 (m, 1H), 5.57 (t, <i>J</i> = 8.4 Hz, 1H), 5.85-6.06 (m, 3H), 7.17-7.23 (m, 4H), 7.54 (d, <i>J</i> = 8.4 Hz, 1H), 11.50 (s, 1H); MS, <i>m/e</i> 587.92 (M+1) ⁺
56	4-Br-Ph	H	H	Me	c-Hex	¹ H NMR (400MHz, DMSO- <i>d</i> ₆): δ 1.18-1.46 (m, 12H), 1.61-1.69 (m, 4H), 3.75-3.82 (m, 2H), 3.95-4.08 (m, 1H), 4.25-4.28 (m, 1H), 4.38 (s, 1H), 4.60-4.62 (m, 1H), 5.56-5.60 (m, 1H), 5.82-5.95 (m, 1H), 6.02-6.20 (m, 2H), 7.09-7.20 (m, 2H), 7.53-7.57 (m, 3H), 11.52 (s, 1H); MS, <i>m/e</i> 650.0 (M+3) ⁺
57	Ph	H	H	Et	i-Pr	¹ H NMR (400MHz, DMSO- <i>d</i> ₆): δ 0.75-0.82 (m, 3H), 1.12-1.26 (m, 9H), 1.52-1.59 (m, 2H), 3.55-3.68 (m, 1H), 3.72-3.85 (m, 1H), 3.95-4.08 (m, 1H), 4.18-4.28 (m, 1H), 4.32-4.41 (m, 1H), 4.83-4.86 (m, 1H), 5.55 (m, <i>J</i> = 7.6Hz, 1H), 5.99-6.04 (m, 2H), 6.05-6.10 (m, 1H), 7.14-7.21 (m, 3H), 7.33-7.37 (m, 2H), 7.52-7.54 (m, 1H), 11.53 (s, 1H); MS, <i>m/e</i> 566.07 (M+23) ⁺
58	Ph	H	H	Et	c-Hex	¹ H NMR (400MHz, DMSO- <i>d</i> ₆): δ 0.75-0.88 (m, 3H), 1.26-1.46 (m, 9H), 1.52-1.69 (m, 6H), 3.60-3.63 (m, 1H), 3.72-3.90 (m, 1H), 4.02-4.03 (m, 1H), 4.24-4.27 (m, 1H), 4.37-4.38 (m, 1H), 4.63-4.65 (m, 1H), 5.55 (dd, <i>J</i> = 8.0Hz, 4.4Hz, 1H), 5.80-5.95 (m, 1H), 6.00-6.07 (m, 2H), 7.15-7.22 (m, 3H), 7.34-7.38 (m, 2H), 7.54 (d, <i>J</i> = 8.0Hz, 1H), 11.55 (s, 1H); MS, <i>m/e</i> 584.01 (M+1) ⁺ , 606.17 (M+23) ⁺
59	4-F-Ph	H	H	Et	c-Hex	¹ H NMR (DMSO- <i>d</i> ₆) δ 0.75-0.84 (m, 3H), 1.24 (d, <i>J</i> = 22.8Hz, 3H), 1.29-1.47 (m, 6H), 1.51-1.70 (m, 6H), 3.59-3.66 (m, 1H), 3.77-3.84 (m, 1H), 3.98-4.04 (m, 1H), 4.21-4.27 (m, 1H), 4.34-4.41 (m, 1H), 4.60-4.65 (m, 1H), 5.56-5.60 (m, 1H), 5.84-5.90 (m, 1H), 6.00-6.08

Ex.	R ¹	R ²	R ^{3a}	R ^{3b}	R ⁴	NMR/MS
						(m, 2H), 7.20-7.24 (m, 4H), 7.56(d, <i>J</i> = 8.0Hz, 1H), 11.49 (s, 1H); MS, <i>m/e</i> 602.00(M+1) ⁺
60	Ph	H	H	Me	F-CH ₂ -CH ₂ -	¹ H NMR (DMSO- <i>d</i> ₆) δ 1.18-1.25(m, 6H), 3.71-3.89 (m, 2H), 3.92-3.99 (m, 1H), 4.19-4.27 (m, 4H), 4.48-4.61 (m, 2H), 3.94-3.98 (m, 2H), 4.11-4.23 (m, 4H), 5.47-5.52 (m, 1H), 6.01-6.11 (m, 1H), 5.90-6.14 (m, 2H), 7.15-7.21 (m, 3H), 7.32-7.36 (m, 2H), 7.46-7.57 (m, 1H), 11.49 (s, 1H); MS, <i>m/e</i> 533.86 (M+1) ⁺
61	Ph	H	H	Me	F ₂ CH-CH ₂ -	¹ H NMR (DMSO- <i>d</i> ₆) δ 1.17-1.24 (m, 6H), 3.67-3.81 (m, 1H), 3.89-3.98 (m, 2H), 4.21-4.36 (m, 4H), 5.48-5.53 (m, 1H), 5.82-6.05 (m, 2H), 6.18-6.22 (m, 2H), 7.15-7.20 (m, 3H), 7.32-7.36 (m, 2H), 7.51 (s, 1H), 11.50 (s, 1H); MS, <i>m/e</i> 551.92 (M+1) ⁺
62	Ph	H	H	Me	(CF ₃) ₂ -CH-	¹ H NMR (DMSO- <i>d</i> ₆) δ 1.13-1.29 (m, 6H), 3.67-3.81 (m, 1H), 3.94-4.32 (m, 4H), 5.47 (t, <i>J</i> = 8 Hz 1H), 5.82-6.01 (m, 2H), 6.33-6.36 (m, 1H), 6.70-6.78 (m, 1H), 7.09-7.15 (m, 3H), 7.28-7.32 (m, 2H), 7.43-7.46 (m, 1H), 11.44 (s, 1H); MS, <i>m/e</i> 637.90 (M+1) ⁺
63	Ph	H	H	Me	(CH ₂ F) ₂ -CH-	¹ H NMR (DMSO- <i>d</i> ₆) δ 1.20-1.29 (m, 6H), 3.70-3.90 (m, 1H), 3.91-4.12 (m, 2H), 4.20-4.33 (m, 1H), 4.35-4.48 (m, 1H), 4.52-4.55 (m, 2H), 4.63-4.67 (m, 2H), 5.20-5.35 (m, 1H), 5.56 (t, <i>J</i> = 8.4 Hz, 1H), 5.80-5.95 (m, 1H), 5.95-6.10 (m, 1H), 6.18-6.21 (m, 1H), 7.18-7.23 (m, 3H), 7.35-7.39 (m, 2H), 7.54 (s, 1H), 11.55 (s, 1H); MS, <i>m/e</i> 565.98 (M+1) ⁺
64	Ph	H	H	Me	c-Pr-CH ₂ -	¹ H NMR (DMSO- <i>d</i> ₆) δ 0.20-0.24(m, 2H), 0.47-0.48(m, 2H), 0.76-0.84(m, 3H), 1.03-1.05(m, 1H), 1.23(dd, <i>J</i> = 22.4 6.8 Hz 3H), 1.55-1.60(m, 2H), 3.61-3.68(m, 1H), 3.81-3.89 (m, 3H), 3.98-4.03(m, 1H), 4.23-4.29(m, 1H), 4.35-4.41(m, 1H), 5.56-6.00(m, 1H), 5.88-5.91(m, 1H), 6.04-6.10(m, 2H), 7.20-7.24(m, 4H), 7.55 (d, <i>J</i> = 7.6 Hz 1H), 11.53 (s, 1H); MS, <i>m/e</i> 573.17 (M+1) ⁺
65	Ph	H	H	Et	c-Pen	¹ H NMR (DMSO- <i>d</i> ₆) δ 0.75-0.83 (m, 3H), 1.20-1.28 (m, 3H), 1.49-1.63 (m, 8H), 1.76-1.80 (m, 2H), 3.58-3.60 (m, 1H), 3.70-3.82 (m, 1H), 3.98-4.05 (m, 1H), 4.24-4.26 (m, 1H), 4.37-4.42 (m, 1H), 5.03 (s, 1H), 5.54-5.57 (m, 1H), 5.90-6.00 (m, 1H), 6.02-6.07 (m, 2H), 7.15-7.22 (m, 3H), 7.35-7.39 (m, 2H), 7.55 (d, <i>J</i> = 8.0 Hz, 1H), 11.55 (s, 1H); MS, <i>m/e</i> 570.03 (M+1) ⁺

*R² and R^{3b} together are -(CH₂)₃- as derived from L-proline

The purification procedure by Prep-HPLC:

Crude products were dissolved in methanol. Injection volumes of these solutions
5 were 5 mL.

The preparative HPLC system including 2 sets of Gilson 306 pumps, a Gilson 156 UV/Vis detector, a Gilson 215 injector & fraction collector, with Unipoint control software. A Ymc 25×30×2 mm column was used. The mobile phase was HPLC grade water (A), and HPLC grade acetonitrile (B). Fractions were collected into 100*15mm glass tubes.


HPLC gradient is shown in Table 1. Once the gradient was selected, acetonitrile solution was injected into HPLC system, and then fractions collected according to UV peaks. After the separation, each glass tubes were run MS test to collect the desired compounds. The fractions with target MS were combined in a well-weighted flask. Most of acetonitrile was removed under reduce pressure and the remaining solution was freeze-dried to give desired compound.

Table 1:

Preparative HPLC gradient			
Time (min)	Flow rate (mL/min)	% A	% B
0	15	90	10
30	15	60	40

Preparation of Example 66

Scheme



Preparation of compound (b)

- 5 To a solution of compound **a** (1 g, 2.69 mmol) in anhydrous THF (30 mL) was added dropwise 1 M solution of $\text{LiAl}(\text{OBu-}t)_3\text{H}$ in THF (2.69 mL, 2.69 mmol) at -20°C . The reaction mixture was stirred for 2-3 h at the same temperature. EtOAc (100 mL) was added followed by saturated NH_4Cl solution (10 mL) and reaction mixture was slowly brought to room temperature. Reaction mixture was extracted with EtOAc and washed
- 10 with 1N HCl and water. Combined organic phase was evaporated to give 0.8 g of crude compound **b** as transparent oil, which was used directly for next reaction.

Preparation of compound (d)

- To a solution of compound **b** (0.8 g, 2.1 mmol), compound **c** (0.45 g, 2.5 mmol) and Ph_3P (0.56 g, 2.1 mmol) in anhydrous THF (20 mL) under nitrogen atmosphere was
- 15 added DEAD (1.8 mL). The reaction mixture was stirred at room temperature overnight.

The reaction solution was concentrated under reduce pressure. The residue was separated by preparative layer chromatography (hexanes:EtOAc = 3:1) to give crude compound **d** (0.8 g). The crude compound **d** was used to the next step without further purification.

Preparation of compound (e)

5 Compound **d** (0.8 g, 1.57 mmol) was dissolved in THF (2 mL) and THF saturated with ammonia (5 mL) was then added to this solution. The reaction mixture was heated to 90 °C overnight. After 18 hours, the solution was cooled to room temperature by ice water, then the solvent was removed under reduced pressure and the residue was purified by column to give compound **e** (0.75 g) for the next step.

10 **Preparation of compound (f)**

 Compound **e** (0.5 g, 1.01 mmol) was dissolved in methanol (2 mL) and methanol was saturated with ammonia (5 mL) was then added to this solution. The reaction mixture was stirred at room temperature overnight. After 18 hours, the solvent was removed under reduced pressure and the residue was purified by column to give crude compound **f**
15 (0.15 g) for the next step.

Preparation of compound (i)

 A solution of triethylamine (1.07 g, 10.6 mmol) in anhydrous dichloromethane (15 mL) was added dropwise to a solution of compound **g** (1.16 g, 5.3 mmol) and compound **h** (1.31 g, 5.3 mmol) in dichloromethane (10 mL) with vigorous stirring at -78 °C over a
20 period of 2 hours. After completion of addition, the reaction temperature was allowed to warm to room temperature gradually and stirred over night. Then the solvent was removed under vacuum and anhydrous ether 20 mL was added and the precipitated salt was filtered and the precipitate was washed with ether. The combined organic phase was concentrated to give the colorless oil of compound **i** (1.0 g).


25

Preparation of Compound 66


 To a solution of compound **j** (0.1 g, 0.35 mmol) dissolved in 10 mL of anhydrous THF, stirred and added 0.4g NMI till the solution became clear, added compound **i** (0.8 g, 2.89 mmol) in 10 mL THF dropwise, stirred at r.t. overnight. Compound purity and
30 identification was confirmed by LCMS. The solvent was evaporated and purified by Prep-HPLC to afford **66**. (25 mg, Yield: 13.6%). ¹H NMR (DMSO-*d*₆) δ 1.08 (d, *J* =

22.8 Hz, 3H), 1.17-1.24 (m, 3H), 3.50-3.52 (m, 3H), 3.78-3.83 (m, 1H), 4.10-4.13 (m, 1H), 4.24-4.44 (m, 2H), 5.85-5.92 (m, 1H), 6.01-6.11 (m, 1H), 6.2-6.27 (m, 1H), 7.08-7.19 (m, 4H), 7.31-7.38 (m, 3H), 8.15 (s, 1H), 8.26 (s, 1H); MS, m/e 525 (M+1)⁺.


- 5 Example numbers **67-74**, identified below, were prepared using similar procedures disclosed for Example **66**, above.





Example	R ¹¹	R ¹⁰	NMR/MS
67	OH	NH ₂	¹ H NMR (DMSO- <i>d</i> ₆) δ 1.06-1.13 (m, 3H), 1.20-1.24 (m, 3H), 3.27-3.33(m, 3H), 3.56 (s, 1H), 3.82-3.88 (m, 1H), 4.07-4.13 (m, 1H), 4.25-4.40 (m, 2H), 5.85-5.87 (m, 1H), 5.98-6.09 (m, 2H), 6.59 (s, 32H), 7.14-7.37 (m, 3H), 7.35-7.37 (m, 2H), 7.79 (d, <i>J</i> =7.2 Hz, 1H), 10.69 (s, 1H); MS, m/e 541 (M+1) ⁺ ;
68	NH ₂	NH ₂	¹ H NMR (DMSO- <i>d</i> ₆) δ 1.07 (d, <i>J</i> =22.8 Hz, 3H), 1.19 (d, <i>J</i> =7.2 Hz, 3H), 3.51 (s, 3H), 3.62 (s, 1H), 3.75-3.81 (m, 1H), 4.05-4.11 (m, 1H), 4.27-4.42 (m, 2H), 5.79-5.83 (m, 1H), 5.92 (s, 2H), 6.00-6.09 (m, 2H), 6.75 (s, 2H), 7.08-7.17 (m, 3H), 7.31-7.35 (m, 2H), 7.78 (s, 1H); MS, m/e 540 (M+1) ⁺ ;
69	NH ₂	c-Pentyl-NH-	¹ H NMR (DMSO- <i>d</i> ₆) δ 1.05 (d, <i>J</i> =22.8 Hz, 3H), 1.09-1.19 (m, 3H), 1.48 (s, 4H), 1.66 (s, 1H), 1.86 (s, 1H), 3.54 (d, <i>J</i> =14 Hz, 3H), 3.65 (s, 1H), 4.25-4.43 (m, 4H), 5.71-5.82 (m, 1H), 5.94-6.04 (m, 4H), 7.11-7.24 (m, 3H), 7.26-7.34 (m, 2H), 7.77(d, <i>J</i> =3.6 Hz, 1H); MS, m/e 608(M+1) ⁺
70	NH ₂		¹ H NMR (DMSO- <i>d</i> ₆) δ 1.07 (d, <i>J</i> =22.4 Hz, 3H), 2.35-2.38 (m, 2H), 3.54 (d, <i>J</i> =9.2 Hz, 3H), 3.59-3.62 (m, 2H), 3.65 (s, 1H), 3.75-3.82 (m, 1H), 4.01-4.13 (m, 2H), 4.22-4.40 (m, 6H), 5.75-5.85 (m, 1H), 6.00-6.07 (m, 4H), 7.15-7.21 (m, 3H), 7.32-7.35 (m, 2H), 7.79 (d, <i>J</i> =4.0 Hz, 1H); MS, m/e 580 (M+1) ⁺
71	NH ₂	Et ₂ N-	¹ H NMR (DMSO- <i>d</i> ₆) δ 1.06-1.28 (m, 12H), 3.55 (d, <i>J</i> =4.8

Example	R ¹¹	R ¹⁰	NMR/MS
			Hz, 3H), 3.79-3.87 (m, 4H), 4.07-4.12 (m, 2H), 4.29-4.42 (m, 3H), 5.75-5.82 (m, 1H), 5.94 (s, 2H), 6.04-6.10 (m, 2H), 7.14-7.22 (m, 3H), 7.31-7.37 (m, 2H), 7.82 (d, <i>J</i> =4.4 Hz, 1H); MS, <i>m/e</i> 596 (M+1) ⁺
72	NH ₂	n-Propyl-NH-	¹ H NMR (DMSO- <i>d</i> ₆) δ 0.84 (t, <i>J</i> =7.2 Hz, 3H), 1.01-1.01 (m, 3H), 1.09-1.12 (m, 3H), 1.51-1.56 (m, 2H), 3.48 (d, <i>J</i> =15.2 Hz, 3H), 3.79-3.82 (m, 1H), 4.04-4.05 (m, 1H), 4.27-4.38 (m, 3H), 5.72-5.79 (m, 1H), 5.98-6.04 (m, 4H), 7.13-7.20 (m, 3H), 7.26-7.32 (m, 2H), 7.76 (d, <i>J</i> =5.2 Hz, 1H); MS, <i>m/e</i> 582 (M+1) ⁺
73	NH ₂	c-Butyl-NH-	¹ H NMR (DMSO- <i>d</i> ₆) δ 1.02-1.08 (m, 3H), 1.18 (d, <i>J</i> =4.8 Hz, 3H), 1.44-1.61 (m, 2H), 2.02-2.17 (m, 4H), 3.51 (d, <i>J</i> =10.8 Hz, 3H), 3.78-3.83 (m, 1H), 4.03-4.06 (m, 1H), 4.27-4.38 (m, 2H), 4.53-4.62 (m, 1H), 5.68-5.79 (m, 1H), 5.95-6.04 (m, 4H), 7.11-7.18 (m, 3H), 7.29-7.35 (m, 2H), 7.51-7.58 (m, 1H), 7.78 (d, <i>J</i> =5.2 Hz, 1H); MS, <i>m/e</i> 594 (M+1) ⁺
74	NH ₂		¹ H NMR (DMSO- <i>d</i> ₆) δ 0.97-1.20 (m, 6H), 2.18 (s, 3H), 2.19 (s, 4H), 3.43-3.47 (m, 3H), 3.75 (s, 1H), 4.01-4.06 (m, 4H), 4.22-4.35 (m, 3H), 5.69-5.75 (m, 1H), 5.98-6.05 (m, 3H), 7.09-7.15 (m, 3H), 7.25-7.29 (m, 2H), 7.77 (d, <i>J</i> =3.6 Hz, 1H); MS, <i>m/e</i> 623 (M+1) ⁺

Example numbers 75-80 are prepared using similar procedures disclosed for Example **66**, above.



Example	R ¹¹	R ¹⁰
75	H	n-propyl-NH-
76	H	c-Butyl-NH-
77	H	c-Pentyl-NH-
78	H	
79	H	
80	H	

EXAMPLE 81

Certain exemplified compounds were obtained as mixture of diastereomers because of the chirality at phosphorous. The diastereomers were separated on a Chiralpak-AS-H (2 X 25 cm) column under Supercritical Fluid Chromatography (SFC) conditions using 20% methanol in carbon dioxide as solvent. The absolute stereochemistry of the P-chiral center of the diastereomers were not determined. However, chromatographic resolution of these two diastereomers provides for isomers that are characterized as fast eluting and slow eluting isomers. Some examples are shown below.

Compound	EC90 (uM)
Example 15 (Diastereomeric mixture)	0.86
Fast Moving isomer of Example 15	1.35
Slow Moving isomer of Example 15	0.26
Example 39 (Diastereomeric mixture)	0.47
Fast Moving isomer of Example 39	0.78
Slow Moving isomer of Example 39	0.02

Compound	EC90 (uM)
Example 49 (Diastereomeric mixture)	0.126
Fast Moving isomer of Example 49	0.03
Slow Moving isomer of Example 49	5.78








EXAMPLE 82







HCV replicon assay. HCV replicon RNA-containing Huh7 cells (clone A cells; Apath, LLC, St. Louis, Mo.) were kept at exponential growth in Dulbecco's modified Eagle's medium (high glucose) containing 10% fetal bovine serum, 4 mM L-glutamine and 1 mM sodium pyruvate, 1× nonessential amino acids, and G418 (1,000 µg/ml). Antiviral assays were performed in the same medium without G418. Cells were seeded in a 96-well plate at 1,500 cells per well, and test compounds were added immediately after seeding. Incubation time 4 days. At the end of the incubation step, total cellular RNA was isolated (RNeasy 96 kit; Qiagen). Replicon RNA and an internal control (TaqMan rRNA control reagents; Applied Biosystems) were amplified in a single-step multiplex RT-PCR protocol as recommended by the manufacturer. The HCV primers and probe were designed with Primer Express software (Applied Biosystems) and covered highly conserved 5'-untranslated region (UTR) sequences (sense, 5'-







AGCCATGGCGTTAGTA(T)GAGTGT-3', and antisense, 5'-TTCCGCAGACCACTATGG-3'; probe, 5'-FAM-CCTCCAGGACCCCCCTCCC-TAMRA-3').

To express the antiviral effectiveness of a compound, the threshold RT-PCR cycle of the test compound was subtracted from the average threshold RT-PCR cycle of the no-drug control (ΔC_{tHCV}). A ΔC_t of 3.3 equals a 1-log 10 reduction (equal to the 90% effective concentration [EC_{90}]) in replicon RNA levels. The cytotoxicity of the test compound could also be expressed by calculating the ΔC_{tRNA} values. The $\Delta \Delta C_t$ specificity parameter could then be introduced ($\Delta C_{tHCV} - \Delta C_{tRNA}$), in which the levels of

HCV RNA are normalized for the rRNA levels and calibrated against the no-drug control.

Ex #	Compound	Log10 Reduction at 50µM	EC90 (µM)
5		-1.21	3.0
6		-0.45	ND
7		0.31	ND
8		-1.48	2.11
10		-1.25	19.15
11		-0.55	ND
12		0.31	ND

Ex #	Compound	Log10 Reduction at 50µM	EC90 (µM)
15		ND	0.86
25		-2.22	0.39
27		-2.25	0.66
28		-2.16	0.75
36		-1.64	21.9
39		-1.78	0.47

Ex #	Compound	Log10 Reduction at 50µM	EC90 (µM)
49		-2.69	0.126
53		-1.33	<0.3
54		-1.55	0.57
55		-2.38	<0.3
69		-2.25	< 0.3
70		-2.25	<0.3

¹(4-BrPh): 4-bromo-phenyl.

The entire contents of U.S. Provisional Application Nos. 60/909,315, filed March 30, 2007, and 60/982,309, filed October 24, 2007, are hereby incorporated by reference in the present application so far as needed to supplement the present disclosure and/or rectify any errors. Moreover, the patent and non-patent references disclosed herein are

5 incorporated by reference. In the event that the incorporated patent and non-patent reference contains a term that conflicts with a term disclosed in either one of the two Provisional Applications or the present application text, the meaning of the term contained in the present application text and the two Provisional Applications controls provided that the overall meaning of the incorporated subject matter is not lost.

10



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	ISSUE DATE	PATENT NO.	ATTORNEY DOCKET NO.	CONFIRMATION NO.
17/077,267	05/09/2023	11642361	37JD-199059-US13	4237

117796 7590 04/19/2023
Gilead Sciences, Inc.
c/o Sheppard Mullin Richter & Hampton LLP
650 Town Center Drive, 10th Floor
Costa Mesa, CA 92626

ISSUE NOTIFICATION

The projected patent number and issue date are specified above. The patent will issue electronically. The electronically issued patent is the official patent grant pursuant to 35 U.S.C. § 153. The patent may be accessed on or after the issue date through Patent Center at <https://patentcenter.uspto.gov/>. The patent will be available in both the public and the private sides of Patent Center. Further assistance in electronically accessing the patent, or about Patent Center, is available by calling the Patent Electronic Business Center at 1-888-217-9197.

The USPTO is implementing electronic patent issuance with a transition period, during which period the USPTO will mail a ceremonial paper copy of the electronic patent grant to the correspondence address of record. Additional copies of the patent (i.e., certified and presentation copies) may be ordered for a fee from the USPTO's Certified Copy Center at <https://certifiedcopycenter.uspto.gov/index.html>. The Certified Copy Center may be reached at (800)972-6382.

Determination of Patent Term Adjustment under 35 U.S.C. 154 (b) (application filed on or after May 29, 2000)

The Patent Term Adjustment is 31 day(s). Any patent to issue from the above-identified application will include an indication of the adjustment on the front page.

If a Continued Prosecution Application (CPA) was filed in the above-identified application, the filing date that determines Patent Term Adjustment is the filing date of the most recent CPA.

Applicant will be able to obtain more detailed information by accessing the Patent Application Information Retrieval (PAIR) WEB site (<http://pair.uspto.gov>).

Any questions regarding the Patent Term Extension or Adjustment determination should be directed to the Office of Patent Legal Administration at (571)-272-7702. Questions relating to issue and publication fee payments should be directed to the Application Assistance Unit (AAU) of the Office of Patents Stakeholder Experience (OPSE), Stakeholder Support Division (SSD) at (571)-272-4200.

INVENTOR(s) (Please see PAIR WEB site <http://pair.uspto.gov> for additional inventors):

Jinfa Du, Redwood City, CA;
Dhanapalan Nagarathnam, Bethany, CT;
Michael Joseph Sofia, Doylestown, PA;
Peiyuan Wang, San Mateo, CA;

APPLICANT(s) (Please see PAIR WEB site <http://pair.uspto.gov> for additional applicants):

Gilead Sciences, Inc., Foster City, CA;

The United States represents the largest, most dynamic marketplace in the world and is an unparalleled location for business investment, innovation, and commercialization of new technologies. The USA offers tremendous resources and advantages for those who invest and manufacture goods here. Through SelectUSA, our nation works to encourage and facilitate business investment. To learn more about why the USA is the best country in the world to develop technology, manufacture products, and grow your business, visit SelectUSA.gov.



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE

United States Patent and Trademark Office

Address : COMMISSIONER FOR PATENTS

P.O. Box 1450

Alexandria, VA 22313-1450

www.uspto.gov

APPLICATION NO.	ISSUE DATE	PATENT NO.
17/077,267	09-MAY-23	11642361

Gilead Sciences, Inc. c/o Sheppard Mullin Richter & Hampton LLP
650 Town Center Drive, 10th Floor
Costa Mesa, CA 92626

EGRANT NOTIFICATION

Your electronic patent grant (eGrant) is now available, which can be accessed via Patent Center at <https://patentcenter.uspto.gov>

The electronic patent grant is the official patent grant under 35 U.S.C. 153. For more information, please visit <https://www.uspto.gov/electronicgrants>



ELECTRONIC PAYMENT RECEIPT

APPLICATION #
17/077,267

RECEIPT DATE / TIME
07/12/2023 04:28:14 PM ET

ATTORNEY DOCKET #
37J D-199059-US13

Title of Invention

NUCLEOSIDE PHOSPHORAMIDATE PRODRUGS

Application Information

APPLICATION TYPE	Utility - Nonprovisional Application under 35 USC 111(a)	PATENT #	11642361
CONFIRMATION #	4237	FILED BY	J oannah Laluces
PATENT CENTER #	62426823	AUTHORIZED BY	Lorna Tanner
CUSTOMER #	117796	FILING DATE	10/22/2020
CORRESPONDENCE ADDRESS	-	FIRST NAMED INVENTOR	J infa Du

Payment Information

PAYMENT METHOD DA / 504561	PAYMENT TRANSACTION ID E20237BG30285810	PAYMENT AUTHORIZED BY J oannah Laluces
PRE-AUTHORIZED ACCOUNT 504561	PRE-AUTHORIZED CATEGORY 37 CFR 1.17 (Patent application and reexamination processing fees); 37 CFR 1.21 (Miscellaneous fees and charges)	

FEE CODE	DESCRIPTION	ITEM PRICE(\$)	QUANTITY	ITEM TOTAL(\$)
1251	EXTENSION FOR RESPONSE WITHIN FIRST MONTH	220.00	1	220.00
1455	FILING AN APPLICATION FOR PATENT TERM ADJUSTMENT	210.00	1	210.00
TOTAL AMOUNT:				\$430.00

This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.

New Applications Under 35 U.S.C. 111

If a new application is being filed and the application includes the necessary components for filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application

National Stage of an International Application under 35 U.S.C. 371

If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.

New International Application Filed with the USPTO as a Receiving Office

If a new international application is being filed and the international application includes the necessary components for an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of the application.



ELECTRONIC ACKNOWLEDGEMENT RECEIPT

APPLICATION #
17/077,267

RECEIPT DATE / TIME
07/12/2023 04:28:14 PM ET

ATTORNEY DOCKET #
37J D-199059-US13

Title of Invention

NUCLEOSIDE PHOSPHORAMIDATE PRODRUGS

Application Information

APPLICATION TYPE	Utility - Nonprovisional Application under 35 USC 111(a)	PATENT #	11642361
CONFIRMATION #	4237	FILED BY	J oannah Laluces
PATENT CENTER #	62426823	FILING DATE	10/22/2020
CUSTOMER #	117796	FIRST NAMED INVENTOR	J infa Du
CORRESPONDENCE ADDRESS	-	AUTHORIZED BY	Lorna Tanner

Documents

TOTAL DOCUMENTS: 1

DOCUMENT	PAGES	DESCRIPTION	SIZE (KB)
37J D-199059-US13_Petition_for_Reconsideration_of_PTA.pdf	5	Patent Term Adjustment Petition	113 KB

Digest

DOCUMENT	MESSAGE DIGEST(SHA-512)
37J D-199059-US13_Petition_for_Reconsideration_of_PTA.pdf	E 797D9A1E39784F53582B23BE95D8913854500F222E936534528C23E4930C566338EEEF920FAAFD453039366014EECE48CC950C6BB01571FD97D1E83FAF22AB

This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.

New Applications Under 35 U.S.C. 111

If a new application is being filed and the application includes the necessary components for filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application

National Stage of an International Application under 35 U.S.C. 371

If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.

New International Application Filed with the USPTO as a Receiving Office

If a new international application is being filed and the international application includes the necessary components for an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of the application.

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:
Gilead Sciences, Inc.

Application No.: 17/077,267

Patent No.: 11,642,361

Confirmation No.: 4237

Filed: October 22, 2020

Art Unit: 1623

For: NUCLEOSIDE
PHOSPHORAMIDATE PRODRUGS

Examiner: Patrick T. Lewis

REQUEST FOR RECONSIDERATION OF PATENT TERM ADJUSTMENT
UNDER 37 C.F.R. §1.705

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Commissioner:

Petitioner respectfully requests reconsideration of the Patent Term Adjustment (“PTA”) determined for the above-identified patent. The patent issued on May 9, 2023, and as such, this request for reconsideration of PTA is timely filed, together with a one month extension before its due date of August 9, 2023.

In the present case, the Office determined that the instant patent was entitled to 31 days of PTA. Petitioner believes that the PTA determination is based on an incorrect calculation under newly amended 37 C.F.R. §1.704(c)(10), wherein 70 days of Applicant delay was assessed for an Amendment after Notice of Allowance.

85 Fed. Reg. 36335 (effective on July 16, 2020) provides: “The changes in this final rule apply to original utility and plant patents issuing from applications filed on or after May 29, 2000, in which a notice of allowance was mailed on or after July 16, 2020.”

The instant application was filed on October 22, 2020, and a Notice of Allowance was mailed on December 7, 2022. Accordingly, the changes in 85 Fed. Reg. 36335 apply to the instant application.

Pursuant to 85 Fed. Reg. 36335, 37 C.F.R. §1.704(c)(10) has been “amended to *exclude* ‘an amendment under §1.312 or other paper *expressly requested* by the Office’ from the amendments under §1.312 or other papers filed after a notice of allowance that will result in a reduction of patent term adjustment under §1.704(c)(10)” (emphasis added).

85 Fed. Reg. 36335 further provides that an “amendment under § 1.312 or other paper going beyond what was requested by the USPTO . . . would not be considered ‘an amendment under § 1.312 or other paper expressly requested by the Office’ under § 1.704(c)(10).” Still further, 85 Fed. Reg. 36335 provides that “the phrase ‘expressly requested by the Office’ requires a specific request in an Office action or notice . . . for the amendment under § 1.312 or other paper.”

After a Notice of Allowance was mailed on December 7, 2022, a Notice to File Corrected Application Papers (hereinafter “Notice”) was mailed by the Office on January 20, 2023. On February 15, 2023 (i.e. before the Notice’s two month due date of March 20, 2023), Petitioner timely filed a Response to the Notice to File Corrected Application Papers (“February 15 Response”), correcting the alleged deficiencies expressly requested by the Office in the Notice. The Office entered the amendments on March 6, 2023.

Thus, the February 15 Response was an amendment or other paper *expressly requested* by the Office in its Notice and did not go beyond what was requested by the Office. Pursuant to the newly amended Section 1.704(c)(10), the February 15 response should be *excluded* from amendments under § 1.312 or other papers filed after a notice of allowance that will result in a reduction of patent term adjustment under § 1.704(c)(10). As such, no Applicant delay should be incurred from the filing of the February 15 Response.

Accordingly, the Office’s determination of 70 days of Applicant delay as calculated from December 7, 2022 (the mailing date of the Notice of Allowance) and ending on February 15, 2023 (the entry date of the amendments) is incorrect.

Instead, after a Notice of Allowance was mailed on December 7, 2022, Petitioner filed a Request under 37CFR1.46(c) to correct, update, change applicant on December 22, 2022 to change applicant (“December 22 Request”). Pursuant to the newly amended Section 1.704(c)(10), “papers that will be *considered* a failure to engage in reasonable efforts to conclude processing or examination of an application include: ... (3) a request for a corrected filing receipt; ... (7) a request to change or correct inventorship; ...”(emphasis added). If the December 22 Request constitutes either of a request for a corrected filing receipt or a request to change or correct inventorship, it will result in a reduction of patent term adjustment by 15 days. As such, 15 days of Applicant delay should be incurred from the issuance of Notice of Allowance.

Petitioner has recalculated PTA for the instant patent and has determined that the patent is entitled to 86 days of PTA.

The attached sheets detail the relevant dates and time periods for PTA under 37 C.F.R. §1.702 and §1.703 and time periods for deductions under 37 C.F.R. §1.704. The correct PTA is determined as follows:

Total of non-overlapping PTO delay under §154(b)(1)(A), (B) & (C):	117 days
Total Applicant delay under §154(b)(2)(C):	31 days
Final PTA Determination under 37 C.F.R. §1.703(f):	86 days

The patent is not subject to a terminal disclaimer.

Petitioner therefore requests that the patent be accorded **86** days PTA.

The requisite fee is submitted herewith.

The Commissioner is hereby authorized to charge any additional fees which may be required regarding this application under 37 C.F.R. §1.705, or credit any overpayment, to Deposit Account No. 50-4561. If any extensions of time are needed for timely acceptance of papers submitted herewith, Petitioner hereby petitions for such extension under 37 C.F.R. §1.136 and authorizes payment of any such extension fees to Deposit Account No. 50-4561.

Respectfully submitted,

Dated: July 12, 2023

By /Lorna L. Tanner/

Lorna L. Tanner

Registration No.: 50,782

Attorney for Applicant

SHEPPARD MULLIN RICHTER & HAMPTON LLP

650 Town Center Drive, 10th Floor

Costa Mesa, CA 92626

(650) 815-2658

Customer Number: 117796

RELEVANT DATES AND EVENTS TO DETERMINE PTA UNDER 35 U.S.C. §154

Date	Contents Description	PTO (Days)	APPL (Days)
10/22/2020	Filing date		
12/03/2020	Notice to File Missing Parts		
03/19/2021	Response to Notice to File Missing Parts		16
04/12/2022	Non-Final Rejection	111	
07/12/2022	Response to Non-Final Rejection		
09/22/2022	Final Rejection		
11/15/2022	Response to Final Rejection		
12/07/2022	Notice of Allowance		
12/22/2022	Request to change applicant		15
01/03/2023	Issue Fee Payment		
01/20/2023	Notice to File Corrected Application Papers		
02/15/2023	Response to Notice to File Corrected Application Papers		
03/06/2023	Entry Date of Response to Notice to File Corrected Application Papers		
05/09/2023	Issue Date of Patent	6	
Total of non-overlapping PTO delay under §154(b)(1)(A), (B) & (C):		117	
Total Applicant delay under §154(b)(2)(C):			31
Final PTA Determination:		86	